{"nbformat":4,"nbformat_minor":0,"metadata":{"colab":{"provenance":[],"gpuType":"A100","authorship_tag":"ABX9TyPPaWn+UB7lc1hJIlx/EVN9"},"kernelspec":{"name":"python3","display_name":"Python 3"},"language_info":{"name":"python"},"accelerator":"GPU","widgets":{"application/vnd.jupyter.widget-state+json":{"c581d6cccc764596a4dc8e476d8dc646":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_2ca6fea734cb43a3b3de54a8092a3d3e","IPY_MODEL_311a0773d2784f93bdf64ad7e3659cfc","IPY_MODEL_19fc02281334497f86578362e9fba86b"],"layout":"IPY_MODEL_3107b5c9b33f4c74ac73be2165d2a90d"}},"2ca6fea734cb43a3b3de54a8092a3d3e":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_9643a28c3a6f473fa0b61634b89bc37a","placeholder":"​","style":"IPY_MODEL_58927dac28e541a58bbe3fb6b8cbd844","value":"modules.json: 100%"}},"311a0773d2784f93bdf64ad7e3659cfc":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_5b776ec9e80b49b3a008876f6b874ce4","max":349,"min":0,"orientation":"horizontal","style":"IPY_MODEL_59e848950953483598fcfc11f91e74dd","value":349}},"19fc02281334497f86578362e9fba86b":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_b905cc1168fd46e287a0995669ac5c1f","placeholder":"​","style":"IPY_MODEL_58da92637c4c40cea32fed3aa076176c","value":" 349/349 [00:00&lt;00:00, 40.4kB/s]"}},"3107b5c9b33f4c74ac73be2165d2a90d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9643a28c3a6f473fa0b61634b89bc37a":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"58927dac28e541a58bbe3fb6b8cbd844":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"5b776ec9e80b49b3a008876f6b874ce4":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"59e848950953483598fcfc11f91e74dd":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"b905cc1168fd46e287a0995669ac5c1f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"58da92637c4c40cea32fed3aa076176c":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"f0850f47f2fc4e518cfcc6d271fe1088":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_70a2c966f117415a9220ffeac58d012e","IPY_MODEL_fc524f27e5f844d98e56013191f24e49","IPY_MODEL_a241cebdb61848a192530e67416b5e2e"],"layout":"IPY_MODEL_6d67d2eb06774e0d930935844720f37e"}},"70a2c966f117415a9220ffeac58d012e":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_fa2aa1e9cb2e4db1bf983010eb4c4def","placeholder":"​","style":"IPY_MODEL_90fbdfd27afa4f5781ec0b9a5df29349","value":"config_sentence_transformers.json: 100%"}},"fc524f27e5f844d98e56013191f24e49":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_c1e94f47ea554f2b8b93831e71a78c24","max":116,"min":0,"orientation":"horizontal","style":"IPY_MODEL_12beef7fdfea4ece9dcffc94ab9db35f","value":116}},"a241cebdb61848a192530e67416b5e2e":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_6938a369f6ac443ca655a7c777eb618f","placeholder":"​","style":"IPY_MODEL_327798400c994832b56ead6a41bb2ded","value":" 116/116 [00:00&lt;00:00, 16.3kB/s]"}},"6d67d2eb06774e0d930935844720f37e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"fa2aa1e9cb2e4db1bf983010eb4c4def":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"90fbdfd27afa4f5781ec0b9a5df29349":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"c1e94f47ea554f2b8b93831e71a78c24":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"12beef7fdfea4ece9dcffc94ab9db35f":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"6938a369f6ac443ca655a7c777eb618f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"327798400c994832b56ead6a41bb2ded":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"114f210a213d459589797a1b75ffe133":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_040cb1b5dbc94d62afa74626c9e7d663","IPY_MODEL_f96a846e2035482ea2b4c685abb995cf","IPY_MODEL_ab7ac9c15042410aa1bdd1c974a9beba"],"layout":"IPY_MODEL_130b05799eeb42788bfc6880a7c99c74"}},"040cb1b5dbc94d62afa74626c9e7d663":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_c8e1d3653c754e7da4d0c18c8741ba44","placeholder":"​","style":"IPY_MODEL_c64e9b0e5b8a4d8286c70ed82ac74f2d","value":"README.md: "}},"f96a846e2035482ea2b4c685abb995cf":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_119ef5a1534047b09d2760f71a1e1426","max":1,"min":0,"orientation":"horizontal","style":"IPY_MODEL_85dfb84c053c47f5a06392b35fb6c105","value":1}},"ab7ac9c15042410aa1bdd1c974a9beba":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_179890a8004e4a3ba53960c3fe97d636","placeholder":"​","style":"IPY_MODEL_dbdfe7496e2c428fa5b952c3c2368ace","value":" 10.5k/? [00:00&lt;00:00, 1.20MB/s]"}},"130b05799eeb42788bfc6880a7c99c74":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"c8e1d3653c754e7da4d0c18c8741ba44":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"c64e9b0e5b8a4d8286c70ed82ac74f2d":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"119ef5a1534047b09d2760f71a1e1426":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":"20px"}},"85dfb84c053c47f5a06392b35fb6c105":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"179890a8004e4a3ba53960c3fe97d636":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"dbdfe7496e2c428fa5b952c3c2368ace":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"64e51c871c0a41efadefeb30ace2ac82":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_60a54202ae3a43e8b5cebc3befdda531","IPY_MODEL_6b2862ba1b0c4cc999de65d692b1134e","IPY_MODEL_4ddca68d5da44a07ac389c07328fbdf1"],"layout":"IPY_MODEL_d55e447a750d43c0b4ffbcaac05cd0d6"}},"60a54202ae3a43e8b5cebc3befdda531":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_c7667631b419441995480ff5f96fb2b9","placeholder":"​","style":"IPY_MODEL_93c533473f6144cba0f0ce23b5301ca0","value":"sentence_bert_config.json: 100%"}},"6b2862ba1b0c4cc999de65d692b1134e":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_b1d6b97394c34effb84dcd50eb2ab0e9","max":53,"min":0,"orientation":"horizontal","style":"IPY_MODEL_d4efedf6e82b41a3a6dc8d656ab838f8","value":53}},"4ddca68d5da44a07ac389c07328fbdf1":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_4250a038548f4a58a19de7a3ae150545","placeholder":"​","style":"IPY_MODEL_ea1d9182f3f54c048afb9b32ce788975","value":" 53.0/53.0 [00:00&lt;00:00, 7.43kB/s]"}},"d55e447a750d43c0b4ffbcaac05cd0d6":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"c7667631b419441995480ff5f96fb2b9":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"93c533473f6144cba0f0ce23b5301ca0":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"b1d6b97394c34effb84dcd50eb2ab0e9":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d4efedf6e82b41a3a6dc8d656ab838f8":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"4250a038548f4a58a19de7a3ae150545":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"ea1d9182f3f54c048afb9b32ce788975":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"2141152f3b0d47c0914877dbe68f5683":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_00e3672e46db465e925a325ecb794ada","IPY_MODEL_e2ec64240109441d9c83547524f73f8d","IPY_MODEL_170e9a1ab659414383ae43ecb2afa7cc"],"layout":"IPY_MODEL_066af936d15f4dc7b8740283c2345adf"}},"00e3672e46db465e925a325ecb794ada":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_61f7e08cfba642dabfa5112be5b1ce27","placeholder":"​","style":"IPY_MODEL_e672a0b5deb94be7b8664a2772169947","value":"config.json: 100%"}},"e2ec64240109441d9c83547524f73f8d":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_eda698b0b1ef40f7ac8eee66d347c38c","max":612,"min":0,"orientation":"horizontal","style":"IPY_MODEL_af7170f24ce349ba942b0cfce8f0cbf3","value":612}},"170e9a1ab659414383ae43ecb2afa7cc":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_75130df35e3540c6825bc8e8b139d6ae","placeholder":"​","style":"IPY_MODEL_d3d674accced41e0a4d3e973067328d8","value":" 612/612 [00:00&lt;00:00, 76.5kB/s]"}},"066af936d15f4dc7b8740283c2345adf":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"61f7e08cfba642dabfa5112be5b1ce27":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"e672a0b5deb94be7b8664a2772169947":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"eda698b0b1ef40f7ac8eee66d347c38c":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"af7170f24ce349ba942b0cfce8f0cbf3":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"75130df35e3540c6825bc8e8b139d6ae":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d3d674accced41e0a4d3e973067328d8":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"528bb1b624ca44c681d81f39bf17253f":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_2ba01a7c877547c59d773a9dd81c4175","IPY_MODEL_1040fa54a4c44e2682b2f85b47502567","IPY_MODEL_98ac846dbc8a47f2ae4b249bd53681bd"],"layout":"IPY_MODEL_18634264229445eaade5ffaff3ad9922"}},"2ba01a7c877547c59d773a9dd81c4175":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_2a7df9ef7c1640729316a0d36ba1e9aa","placeholder":"​","style":"IPY_MODEL_e63c7d9d38734d2e839bf54ac2d39a20","value":"model.safetensors: 100%"}},"1040fa54a4c44e2682b2f85b47502567":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_ad7015a8b33945789864d5f9dff81d2e","max":90868376,"min":0,"orientation":"horizontal","style":"IPY_MODEL_d4c77016f2604eaca329c115471d74b5","value":90868376}},"98ac846dbc8a47f2ae4b249bd53681bd":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_74be82c6fa77419083a87242bf39fe06","placeholder":"​","style":"IPY_MODEL_06519ad398e24cbbb0624be39bac17ac","value":" 90.9M/90.9M [00:00&lt;00:00, 113MB/s]"}},"18634264229445eaade5ffaff3ad9922":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"2a7df9ef7c1640729316a0d36ba1e9aa":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"e63c7d9d38734d2e839bf54ac2d39a20":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"ad7015a8b33945789864d5f9dff81d2e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d4c77016f2604eaca329c115471d74b5":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"74be82c6fa77419083a87242bf39fe06":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"06519ad398e24cbbb0624be39bac17ac":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"5650ba831fb44f5a80c78f07e26ebe17":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_7b8871a557954703af748c7dd9089d74","IPY_MODEL_8fd6000e28d74ac288cf0e3e07ca2db5","IPY_MODEL_37d615b956bc45e2a8a9b6f3af77f182"],"layout":"IPY_MODEL_ad34017fecca48b0a61e9d91930e4ca8"}},"7b8871a557954703af748c7dd9089d74":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_6a5e29491af54f84b84b87ff54716645","placeholder":"​","style":"IPY_MODEL_0bc7364ebdb34e25afdbaa244953839c","value":"tokenizer_config.json: 100%"}},"8fd6000e28d74ac288cf0e3e07ca2db5":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_fafe4eca5bdc44df8cb27284435ea86c","max":350,"min":0,"orientation":"horizontal","style":"IPY_MODEL_a572d8c16cc04d4089fb9421238619bf","value":350}},"37d615b956bc45e2a8a9b6f3af77f182":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_55bc0a89540641c7bfe6a058d0c4d6f2","placeholder":"​","style":"IPY_MODEL_8f00cb7417be4d70b1c89f5b69deca83","value":" 350/350 [00:00&lt;00:00, 42.6kB/s]"}},"ad34017fecca48b0a61e9d91930e4ca8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"6a5e29491af54f84b84b87ff54716645":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"0bc7364ebdb34e25afdbaa244953839c":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"fafe4eca5bdc44df8cb27284435ea86c":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a572d8c16cc04d4089fb9421238619bf":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"55bc0a89540641c7bfe6a058d0c4d6f2":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"8f00cb7417be4d70b1c89f5b69deca83":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"83687cfe05cc4e4c8e3cd7208c1732d5":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_f1523b966cd34eaaafe76d0bfc1f4d39","IPY_MODEL_8818cb8ac7a74cb3bf528ded155ffb4a","IPY_MODEL_012e1843a1c343dd8de20b069f28efad"],"layout":"IPY_MODEL_45ba7418d7504a188bc9a814b6c02a36"}},"f1523b966cd34eaaafe76d0bfc1f4d39":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_a77dd730080c4d369042f25a35db3afc","placeholder":"​","style":"IPY_MODEL_48899951fc224832bd3ee13e89d6bfba","value":"vocab.txt: "}},"8818cb8ac7a74cb3bf528ded155ffb4a":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_a703125b07bf49e5872f0c8eb2b24338","max":1,"min":0,"orientation":"horizontal","style":"IPY_MODEL_74df5a72bec44f048dcfebaf5bd189ef","value":1}},"012e1843a1c343dd8de20b069f28efad":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_667a656e96744393991f4eeb65cef83a","placeholder":"​","style":"IPY_MODEL_365e1a8d7dee4f59ba4675cff00a2656","value":" 232k/? [00:00&lt;00:00, 4.27MB/s]"}},"45ba7418d7504a188bc9a814b6c02a36":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a77dd730080c4d369042f25a35db3afc":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"48899951fc224832bd3ee13e89d6bfba":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"a703125b07bf49e5872f0c8eb2b24338":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":"20px"}},"74df5a72bec44f048dcfebaf5bd189ef":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"667a656e96744393991f4eeb65cef83a":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"365e1a8d7dee4f59ba4675cff00a2656":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"d4f3ca7c45fd493f8111994b2de00857":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_017d021b531344058246895e0fed8559","IPY_MODEL_08c024a7b46c47dca7e5ecac43645e84","IPY_MODEL_45eac7108ae44d3ebfaa6ea2c7a3327a"],"layout":"IPY_MODEL_961e3b4841154fa0ae176ffe34cc018d"}},"017d021b531344058246895e0fed8559":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_a5bf903c2ed144dea825c83f2acd5f47","placeholder":"​","style":"IPY_MODEL_5fed7505b67b4b16bb376849936154e1","value":"tokenizer.json: "}},"08c024a7b46c47dca7e5ecac43645e84":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_6e256646fd894ae2a0abfbf7b3ad3398","max":1,"min":0,"orientation":"horizontal","style":"IPY_MODEL_e7093523f01e4fc1bdae4ee916545402","value":1}},"45eac7108ae44d3ebfaa6ea2c7a3327a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_1ab0a70eb35d46f4a0070b013d2e86cc","placeholder":"​","style":"IPY_MODEL_37731d45b2914a1d9cf4fe39e1676d6f","value":" 466k/? [00:00&lt;00:00, 13.6MB/s]"}},"961e3b4841154fa0ae176ffe34cc018d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a5bf903c2ed144dea825c83f2acd5f47":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"5fed7505b67b4b16bb376849936154e1":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"6e256646fd894ae2a0abfbf7b3ad3398":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":"20px"}},"e7093523f01e4fc1bdae4ee916545402":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"1ab0a70eb35d46f4a0070b013d2e86cc":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"37731d45b2914a1d9cf4fe39e1676d6f":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"2253a5d9a05145c98d7851a494d50b13":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_92abaf33c56241dcb4e7b91a744a87af","IPY_MODEL_afd6ff7d657941ec91fc171dcf3d6b0e","IPY_MODEL_4db3ce0dbd4b4448b2ddc1794b909c52"],"layout":"IPY_MODEL_777923e640894f84aeea953373b29d79"}},"92abaf33c56241dcb4e7b91a744a87af":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_4e5446c57c5f495ab7fd50680237a8c7","placeholder":"​","style":"IPY_MODEL_9448df7e8c12451cbd866ff1ede20083","value":"special_tokens_map.json: 100%"}},"afd6ff7d657941ec91fc171dcf3d6b0e":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_2f0dc6cbf74f4cf49536a100fe8885eb","max":112,"min":0,"orientation":"horizontal","style":"IPY_MODEL_3cb07e8d1ab4445b9fe2f7db874d61a0","value":112}},"4db3ce0dbd4b4448b2ddc1794b909c52":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_2ded608cf63443d19c1d939e96c7c969","placeholder":"​","style":"IPY_MODEL_b3dc17e6f3ef462da2bed208a7076e4d","value":" 112/112 [00:00&lt;00:00, 14.8kB/s]"}},"777923e640894f84aeea953373b29d79":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"4e5446c57c5f495ab7fd50680237a8c7":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9448df7e8c12451cbd866ff1ede20083":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"2f0dc6cbf74f4cf49536a100fe8885eb":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"3cb07e8d1ab4445b9fe2f7db874d61a0":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"2ded608cf63443d19c1d939e96c7c969":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"b3dc17e6f3ef462da2bed208a7076e4d":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"42cd8963c06940a6aaf6ec1910e9588f":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_f2448cbb6b734678854d5ad3a74b4f91","IPY_MODEL_8eb5fcda1b184c8299408d6e0a460877","IPY_MODEL_247bcf027f5449cdb6f000b133c4c062"],"layout":"IPY_MODEL_27cd5199384246f5a5a9c9912eb143d8"}},"f2448cbb6b734678854d5ad3a74b4f91":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_352e993adfea4ca285c758edff676988","placeholder":"​","style":"IPY_MODEL_269512d8a6d44dc3aa8e86fa16b691dc","value":"config.json: 100%"}},"8eb5fcda1b184c8299408d6e0a460877":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_b512af23be654fa6ab841df94ff96d4f","max":190,"min":0,"orientation":"horizontal","style":"IPY_MODEL_6bbacfad3c2d43a783f5488921db7d68","value":190}},"247bcf027f5449cdb6f000b133c4c062":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_6cf9265f357143a7b93a335660dba983","placeholder":"​","style":"IPY_MODEL_4dcda8c4401c4e7db277743e703ede64","value":" 190/190 [00:00&lt;00:00, 26.2kB/s]"}},"27cd5199384246f5a5a9c9912eb143d8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"352e993adfea4ca285c758edff676988":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"269512d8a6d44dc3aa8e86fa16b691dc":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"b512af23be654fa6ab841df94ff96d4f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"6bbacfad3c2d43a783f5488921db7d68":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"6cf9265f357143a7b93a335660dba983":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"4dcda8c4401c4e7db277743e703ede64":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"f36095740a2f4f1d905fedc550e4c2f7":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_0f363034114c4676819fbd07f9fcedd6","IPY_MODEL_4ca5a20793434e1a9d3747d791dd78cc","IPY_MODEL_0660cb0c35b64e198c88c53cb3c72821"],"layout":"IPY_MODEL_edb665f82db64a32b5456f032213ee6f"}},"0f363034114c4676819fbd07f9fcedd6":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_297fd996825a430b905f27b5bcc05cf7","placeholder":"​","style":"IPY_MODEL_ce3e0bc01aee41e2876180caea71e786","value":"tokenizer_config.json: 100%"}},"4ca5a20793434e1a9d3747d791dd78cc":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_21d5be861b63420184373a6d002d3338","max":1618,"min":0,"orientation":"horizontal","style":"IPY_MODEL_1171f7c0c83f44549038ccf8f2ec1e08","value":1618}},"0660cb0c35b64e198c88c53cb3c72821":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_7c9ebc5872ca4b5a8f3b2bc5b8ae67f8","placeholder":"​","style":"IPY_MODEL_a552dd69d85b42cab179f9a7bcecf2a6","value":" 1.62k/1.62k [00:00&lt;00:00, 169kB/s]"}},"edb665f82db64a32b5456f032213ee6f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"297fd996825a430b905f27b5bcc05cf7":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"ce3e0bc01aee41e2876180caea71e786":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"21d5be861b63420184373a6d002d3338":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"1171f7c0c83f44549038ccf8f2ec1e08":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"7c9ebc5872ca4b5a8f3b2bc5b8ae67f8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a552dd69d85b42cab179f9a7bcecf2a6":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"b281ee0e1664428b81d80b30b75a2f40":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_f7ae1036c08045b391e5216052376634","IPY_MODEL_5d219f2e1d1740719c6e314300fb4a56","IPY_MODEL_4783ac5d2e5e46638e93973a19e7abd7"],"layout":"IPY_MODEL_909fbfb4d43542a09d46f564085d862e"}},"f7ae1036c08045b391e5216052376634":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_0d08b7510f914ba99896f27b2068ad0e","placeholder":"​","style":"IPY_MODEL_38048455f27d465daef2fecac5517e0a","value":"tokenizer.model: 100%"}},"5d219f2e1d1740719c6e314300fb4a56":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_13960bf238b04d99bea57d50d026ed26","max":499723,"min":0,"orientation":"horizontal","style":"IPY_MODEL_45b63b50686d4b00ac25ba0c96d78ed9","value":499723}},"4783ac5d2e5e46638e93973a19e7abd7":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_b5a889e26ef04e37afaacef66e4269cd","placeholder":"​","style":"IPY_MODEL_1172cf1917d941cbab1538fc89a8072e","value":" 500k/500k [00:00&lt;00:00, 3.89MB/s]"}},"909fbfb4d43542a09d46f564085d862e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"0d08b7510f914ba99896f27b2068ad0e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"38048455f27d465daef2fecac5517e0a":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"13960bf238b04d99bea57d50d026ed26":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"45b63b50686d4b00ac25ba0c96d78ed9":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"b5a889e26ef04e37afaacef66e4269cd":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"1172cf1917d941cbab1538fc89a8072e":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"6ab7f97fe9d142119e382c20926b8762":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_891d963ce7514ce3bdb1b2a8a3fa72c4","IPY_MODEL_74eda0ccb23c49a49ea61e5abc917861","IPY_MODEL_c44ff6e0fe8c4b46b0b41f4df8269740"],"layout":"IPY_MODEL_405e66d0b12642219a5564b2ec500b51"}},"891d963ce7514ce3bdb1b2a8a3fa72c4":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_13cc9478e00a4f4eb1c7787170945ad7","placeholder":"​","style":"IPY_MODEL_a7cbbc38ef684515b7637c70cfad4240","value":"special_tokens_map.json: 100%"}},"74eda0ccb23c49a49ea61e5abc917861":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_a6776d724ecd43c1b743b4699632255d","max":414,"min":0,"orientation":"horizontal","style":"IPY_MODEL_8dc356baae994ffe85a7f963d0919701","value":414}},"c44ff6e0fe8c4b46b0b41f4df8269740":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_e04c4a3d6c5340a0844f7aec4e939a42","placeholder":"​","style":"IPY_MODEL_8f94a20cce9e44d88572c156d9db3e63","value":" 414/414 [00:00&lt;00:00, 49.9kB/s]"}},"405e66d0b12642219a5564b2ec500b51":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"13cc9478e00a4f4eb1c7787170945ad7":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a7cbbc38ef684515b7637c70cfad4240":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"a6776d724ecd43c1b743b4699632255d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"8dc356baae994ffe85a7f963d0919701":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"e04c4a3d6c5340a0844f7aec4e939a42":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"8f94a20cce9e44d88572c156d9db3e63":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"a3fe3d1fccbc46b597984ed44294bd37":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_0682ff6bc837406e8715c23856c86632","IPY_MODEL_f91ab92797ff47cbaf8dda112d47b0ba","IPY_MODEL_081a3e40a5df441dac5c9dd437bd9092"],"layout":"IPY_MODEL_3206fd36a93d4ec58b7b9b9bea16474c"}},"0682ff6bc837406e8715c23856c86632":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_dd89f58adf54423285d6759535975ccd","placeholder":"​","style":"IPY_MODEL_73ae0d522fc84ad7a24fbc7b8a7c05d2","value":"tokenizer.json: 100%"}},"f91ab92797ff47cbaf8dda112d47b0ba":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_547a5dd61e404d08abeb6bb4ad9eb0f5","max":1842767,"min":0,"orientation":"horizontal","style":"IPY_MODEL_fff84553f7d84418bbc90b66b3e551f8","value":1842767}},"081a3e40a5df441dac5c9dd437bd9092":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_60e8b4815d8a4a0ba0ebc34cfdb0196b","placeholder":"​","style":"IPY_MODEL_36bea899963c464ab6bcc7b125b6d88a","value":" 1.84M/1.84M [00:00&lt;00:00, 22.3MB/s]"}},"3206fd36a93d4ec58b7b9b9bea16474c":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"dd89f58adf54423285d6759535975ccd":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"73ae0d522fc84ad7a24fbc7b8a7c05d2":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"547a5dd61e404d08abeb6bb4ad9eb0f5":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"fff84553f7d84418bbc90b66b3e551f8":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"60e8b4815d8a4a0ba0ebc34cfdb0196b":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"36bea899963c464ab6bcc7b125b6d88a":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"adc8f9d954664089a6418c828eef063d":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_9c682533ca2844378fc6eb02a1e4ff48","IPY_MODEL_4561672e505c4543b7e0301546ba551f","IPY_MODEL_1b80e5533cd049829eb1cd78c445f024"],"layout":"IPY_MODEL_b88af45f70e747c2bd1b7ebb39bfd0c3"}},"9c682533ca2844378fc6eb02a1e4ff48":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_753f3cb87bbc46e7aba66a25e7569634","placeholder":"​","style":"IPY_MODEL_0154c19c900f497a9363cf2cf766f6c1","value":"config.json: 100%"}},"4561672e505c4543b7e0301546ba551f":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_caf9c745b63243f285e6c94d98af9ccb","max":587,"min":0,"orientation":"horizontal","style":"IPY_MODEL_853431afa3824f52bfaad0faba330729","value":587}},"1b80e5533cd049829eb1cd78c445f024":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_d3cfa56c0e1b45bb8633394e1d0e4a6f","placeholder":"​","style":"IPY_MODEL_3405eb2dd86c43a089fa4142f844d8d1","value":" 587/587 [00:00&lt;00:00, 81.8kB/s]"}},"b88af45f70e747c2bd1b7ebb39bfd0c3":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"753f3cb87bbc46e7aba66a25e7569634":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"0154c19c900f497a9363cf2cf766f6c1":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"caf9c745b63243f285e6c94d98af9ccb":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"853431afa3824f52bfaad0faba330729":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"d3cfa56c0e1b45bb8633394e1d0e4a6f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"3405eb2dd86c43a089fa4142f844d8d1":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"99e9fe4cf7a340bda8009a479c000b87":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_2cb29ed52e1d4648afb3a4adae11e229","IPY_MODEL_9dd15afea6334f299f6e003f1208769d","IPY_MODEL_33c0f77634434a508d01e9dda2a6b6fc"],"layout":"IPY_MODEL_0eb8b9c077324973bb430af19d0488a4"}},"2cb29ed52e1d4648afb3a4adae11e229":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_a987e94e44df4b07b202da6b0e3f2441","placeholder":"​","style":"IPY_MODEL_3f77711f84f740b1a78f4db242d5cbd6","value":"model.safetensors.index.json: 100%"}},"9dd15afea6334f299f6e003f1208769d":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_366e64a4fb514760b777288d648ae72c","max":33444,"min":0,"orientation":"horizontal","style":"IPY_MODEL_1be1b33f5a6241c3b0b5031aa6909273","value":33444}},"33c0f77634434a508d01e9dda2a6b6fc":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_62202b930d9d423595524be963b9ba5f","placeholder":"​","style":"IPY_MODEL_eb2e1684eff341b8989efac792b8cfce","value":" 33.4k/33.4k [00:00&lt;00:00, 4.25MB/s]"}},"0eb8b9c077324973bb430af19d0488a4":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a987e94e44df4b07b202da6b0e3f2441":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"3f77711f84f740b1a78f4db242d5cbd6":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"366e64a4fb514760b777288d648ae72c":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"1be1b33f5a6241c3b0b5031aa6909273":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"62202b930d9d423595524be963b9ba5f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"eb2e1684eff341b8989efac792b8cfce":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"b7f4ecc7a59448cd9405ba3542197de0":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_92be8cd23469454fb9c41db29d8376cc","IPY_MODEL_3a3370e841bc404297d577c01678ba5c","IPY_MODEL_ac56975b6cf945ff95110decfac72acd"],"layout":"IPY_MODEL_8bb35e562027447ca18463a9d5099f2b"}},"92be8cd23469454fb9c41db29d8376cc":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_31fac4e7622444c6a96ece8f6778289d","placeholder":"​","style":"IPY_MODEL_cd74f513a2ef436089ef91f7cb5b27c4","value":"Fetching 3 files: 100%"}},"3a3370e841bc404297d577c01678ba5c":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_66b84a3838ba44ec8414d2d7a289197e","max":3,"min":0,"orientation":"horizontal","style":"IPY_MODEL_9217945e15d54064969cf58481e4cf58","value":3}},"ac56975b6cf945ff95110decfac72acd":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_7ae772fc6edf4ec790e201ef1ad0d8b7","placeholder":"​","style":"IPY_MODEL_2cc7ac395a364612a919f35db58c16fb","value":" 3/3 [01:43&lt;00:00, 103.50s/it]"}},"8bb35e562027447ca18463a9d5099f2b":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"31fac4e7622444c6a96ece8f6778289d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"cd74f513a2ef436089ef91f7cb5b27c4":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"66b84a3838ba44ec8414d2d7a289197e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9217945e15d54064969cf58481e4cf58":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"7ae772fc6edf4ec790e201ef1ad0d8b7":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"2cc7ac395a364612a919f35db58c16fb":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"1e853ec8714547e282dd9f0bd0319610":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_e03a48476bb74daa90d337a868bbf27d","IPY_MODEL_9359f6c76222495594a0631283e95108","IPY_MODEL_f509c704b8ad429baf821f95c9673846"],"layout":"IPY_MODEL_438cde7a33c144ff9086b460d95499fc"}},"e03a48476bb74daa90d337a868bbf27d":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_3a558d4945294bfea4e2727e5ac15e6e","placeholder":"​","style":"IPY_MODEL_bfafb887b03545f69da00e93e21b21b6","value":"model-00002-of-00003.safetensors: 100%"}},"9359f6c76222495594a0631283e95108":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_892998a6d9a1438187bb37ec9ed3c968","max":9904129368,"min":0,"orientation":"horizontal","style":"IPY_MODEL_56758b30f43148f8b8ed3408e9c3edc1","value":9904129368}},"f509c704b8ad429baf821f95c9673846":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_f93fc73c214649eca1212fb1880fab36","placeholder":"​","style":"IPY_MODEL_6fdfebbeb8614a079be8a20c632b6329","value":" 9.90G/9.90G [01:42&lt;00:00, 231MB/s]"}},"438cde7a33c144ff9086b460d95499fc":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"3a558d4945294bfea4e2727e5ac15e6e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"bfafb887b03545f69da00e93e21b21b6":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"892998a6d9a1438187bb37ec9ed3c968":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"56758b30f43148f8b8ed3408e9c3edc1":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"f93fc73c214649eca1212fb1880fab36":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"6fdfebbeb8614a079be8a20c632b6329":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"6cd0eb0848a94aaaa04d0c537a025438":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_47831cfc8b8744f7a0072807b805d4d7","IPY_MODEL_9a3e8ca0a0b04d4baa7b3d00fdaa62cc","IPY_MODEL_270eb39d2c6f4cf995e6de91b3afabb2"],"layout":"IPY_MODEL_dc81b31f435c4e0e8520d3cf8f1c81b8"}},"47831cfc8b8744f7a0072807b805d4d7":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_d188392935194e13a67a5e5a57ed6594","placeholder":"​","style":"IPY_MODEL_d4f9b177991d415b9e09d168de5eccc5","value":"model-00003-of-00003.safetensors: 100%"}},"9a3e8ca0a0b04d4baa7b3d00fdaa62cc":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_358ba890bbcd463e8557fe7dc8c71619","max":6178962272,"min":0,"orientation":"horizontal","style":"IPY_MODEL_9d4d197312b3442fba1c1d35eb9b1745","value":6178962272}},"270eb39d2c6f4cf995e6de91b3afabb2":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_5d3053e6db0640e39293b367d085f3a3","placeholder":"​","style":"IPY_MODEL_590789da25d746ad909bb25aa2b4f7c7","value":" 6.18G/6.18G [01:19&lt;00:00, 70.2MB/s]"}},"dc81b31f435c4e0e8520d3cf8f1c81b8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d188392935194e13a67a5e5a57ed6594":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d4f9b177991d415b9e09d168de5eccc5":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"358ba890bbcd463e8557fe7dc8c71619":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9d4d197312b3442fba1c1d35eb9b1745":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"5d3053e6db0640e39293b367d085f3a3":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"590789da25d746ad909bb25aa2b4f7c7":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"497e7daf56314ec79a43b0cc91332250":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_202d7d80e5b2407781a6e9bb75ad343a","IPY_MODEL_75607cb534354951b34cf11d47ed1a8a","IPY_MODEL_c2534c22476644c8bcb8041c7c6af32f"],"layout":"IPY_MODEL_59395ab656984953be8f28802e45a741"}},"202d7d80e5b2407781a6e9bb75ad343a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_4eb03449e6484fbdae1dd57410699914","placeholder":"​","style":"IPY_MODEL_92a5984bd2984b2b878f60a8b0d4071d","value":"model-00001-of-00003.safetensors: 100%"}},"75607cb534354951b34cf11d47ed1a8a":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_db3d051a23e04fd09e7d28301f6ad251","max":9948693272,"min":0,"orientation":"horizontal","style":"IPY_MODEL_de01f3db1ffb447f85cad94ef4b93938","value":9948693272}},"c2534c22476644c8bcb8041c7c6af32f":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_065597c4dbc34623b9332e1d825c9dcc","placeholder":"​","style":"IPY_MODEL_2d193865af744bacb78ed6a2145b5b8b","value":" 9.95G/9.95G [01:43&lt;00:00, 360MB/s]"}},"59395ab656984953be8f28802e45a741":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"4eb03449e6484fbdae1dd57410699914":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"92a5984bd2984b2b878f60a8b0d4071d":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"db3d051a23e04fd09e7d28301f6ad251":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"de01f3db1ffb447f85cad94ef4b93938":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"065597c4dbc34623b9332e1d825c9dcc":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"2d193865af744bacb78ed6a2145b5b8b":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"6660d6448f724446bac6d97a27ad1516":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_a57efa1943524fbd9cec57f0203dab7a","IPY_MODEL_dcbbfb79ce314a3fb3ee2adad1935b7e","IPY_MODEL_877e1da4240248e09a251b3dd0153b32"],"layout":"IPY_MODEL_a0e0090e533046309ff335265b0712bb"}},"a57efa1943524fbd9cec57f0203dab7a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_1f8f5416add44417a8d0097b4245a92b","placeholder":"​","style":"IPY_MODEL_5b48dc65352f4bcb911075cc2cbdc4e5","value":"Loading checkpoint shards: 100%"}},"dcbbfb79ce314a3fb3ee2adad1935b7e":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_6b315f7e1b84455b90029765d3470186","max":3,"min":0,"orientation":"horizontal","style":"IPY_MODEL_fb078fe2bfd846eaa42a7222648f2492","value":3}},"877e1da4240248e09a251b3dd0153b32":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_b37812d4d88b4072a56a8566fdffd90c","placeholder":"​","style":"IPY_MODEL_dc3ec13188ca4a2eafd9a006d5c61285","value":" 3/3 [00:30&lt;00:00,  9.66s/it]"}},"a0e0090e533046309ff335265b0712bb":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"1f8f5416add44417a8d0097b4245a92b":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"5b48dc65352f4bcb911075cc2cbdc4e5":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"6b315f7e1b84455b90029765d3470186":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"fb078fe2bfd846eaa42a7222648f2492":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"b37812d4d88b4072a56a8566fdffd90c":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"dc3ec13188ca4a2eafd9a006d5c61285":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"ab46b8f4a5ae4484bec348fbc30201e1":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_69745973c64940f8984e542c0f0b0365","IPY_MODEL_a287bdb0fd774d57a0fdc6638abf7c6d","IPY_MODEL_11c25430a48b4b139ce03d5004747e1f"],"layout":"IPY_MODEL_94c68bc43b3e45098119090734e68c18"}},"69745973c64940f8984e542c0f0b0365":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_35f23e5c15754adcb26b3ca153b9ec05","placeholder":"​","style":"IPY_MODEL_1fa9f1b1fca14450953406796285d584","value":"generation_config.json: 100%"}},"a287bdb0fd774d57a0fdc6638abf7c6d":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_f62de3e2f53d48b2b5fda06261ec9724","max":188,"min":0,"orientation":"horizontal","style":"IPY_MODEL_cd1b1b65d606417389a140187d8f483d","value":188}},"11c25430a48b4b139ce03d5004747e1f":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_07e626f2295345f0a9f353ba28fb0283","placeholder":"​","style":"IPY_MODEL_205f986c9feb41c88b0de05dfb028f21","value":" 188/188 [00:00&lt;00:00, 23.2kB/s]"}},"94c68bc43b3e45098119090734e68c18":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"35f23e5c15754adcb26b3ca153b9ec05":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"1fa9f1b1fca14450953406796285d584":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"f62de3e2f53d48b2b5fda06261ec9724":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"cd1b1b65d606417389a140187d8f483d":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"07e626f2295345f0a9f353ba28fb0283":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"205f986c9feb41c88b0de05dfb028f21":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}}}}},"cells":[{"cell_type":"code","execution_count":1,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"-vYu2U5XquPG","executionInfo":{"status":"ok","timestamp":1764632204830,"user_tz":300,"elapsed":47092,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"fae3d42b-998a-4e52-8fc3-12794d08e88e"},"outputs":[{"output_type":"stream","name":"stdout","text":["Looking in indexes: https://download.pytorch.org/whl/cu126\n","Requirement already satisfied: torch in /usr/local/lib/python3.12/dist-packages (2.9.0+cu126)\n","Requirement already satisfied: torchvision in /usr/local/lib/python3.12/dist-packages (0.24.0+cu126)\n","Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from torch) (3.20.0)\n","Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.12/dist-packages (from torch) (4.15.0)\n","Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch) (75.2.0)\n","Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch) (1.14.0)\n","Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch) (3.6)\n","Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch) (3.1.6)\n","Requirement already satisfied: fsspec>=0.8.5 in /usr/local/lib/python3.12/dist-packages (from torch) (2025.3.0)\n","Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.77)\n","Requirement already satisfied: nvidia-cuda-runtime-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.77)\n","Requirement already satisfied: nvidia-cuda-cupti-cu12==12.6.80 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.80)\n","Requirement already satisfied: nvidia-cudnn-cu12==9.10.2.21 in /usr/local/lib/python3.12/dist-packages (from torch) (9.10.2.21)\n","Requirement already satisfied: nvidia-cublas-cu12==12.6.4.1 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.4.1)\n","Requirement already satisfied: nvidia-cufft-cu12==11.3.0.4 in /usr/local/lib/python3.12/dist-packages (from torch) (11.3.0.4)\n","Requirement already satisfied: nvidia-curand-cu12==10.3.7.77 in /usr/local/lib/python3.12/dist-packages (from torch) (10.3.7.77)\n","Requirement already satisfied: nvidia-cusolver-cu12==11.7.1.2 in /usr/local/lib/python3.12/dist-packages (from torch) (11.7.1.2)\n","Requirement already satisfied: nvidia-cusparse-cu12==12.5.4.2 in /usr/local/lib/python3.12/dist-packages (from torch) (12.5.4.2)\n","Requirement already satisfied: nvidia-cusparselt-cu12==0.7.1 in /usr/local/lib/python3.12/dist-packages (from torch) (0.7.1)\n","Requirement already satisfied: nvidia-nccl-cu12==2.27.5 in /usr/local/lib/python3.12/dist-packages (from torch) (2.27.5)\n","Requirement already satisfied: nvidia-nvshmem-cu12==3.3.20 in /usr/local/lib/python3.12/dist-packages (from torch) (3.3.20)\n","Requirement already satisfied: nvidia-nvtx-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.77)\n","Requirement already satisfied: nvidia-nvjitlink-cu12==12.6.85 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.85)\n","Requirement already satisfied: nvidia-cufile-cu12==1.11.1.6 in /usr/local/lib/python3.12/dist-packages (from torch) (1.11.1.6)\n","Requirement already satisfied: triton==3.5.0 in /usr/local/lib/python3.12/dist-packages (from torch) (3.5.0)\n","Requirement already satisfied: numpy in /usr/local/lib/python3.12/dist-packages (from torchvision) (2.0.2)\n","Requirement already satisfied: pillow!=8.3.*,>=5.3.0 in /usr/local/lib/python3.12/dist-packages (from torchvision) (11.3.0)\n","Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch) (1.3.0)\n","Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch) (3.0.3)\n","Requirement already satisfied: transformers in /usr/local/lib/python3.12/dist-packages (4.57.2)\n","Collecting transformers\n","  Downloading transformers-4.57.3-py3-none-any.whl.metadata (43 kB)\n","\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m44.0/44.0 kB\u001b[0m \u001b[31m2.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hRequirement already satisfied: accelerate in /usr/local/lib/python3.12/dist-packages (1.12.0)\n","Collecting bitsandbytes\n","  Downloading bitsandbytes-0.48.2-py3-none-manylinux_2_24_x86_64.whl.metadata (10 kB)\n","Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from transformers) (3.20.0)\n","Requirement already satisfied: huggingface-hub<1.0,>=0.34.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.36.0)\n","Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2.0.2)\n","Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (25.0)\n","Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.12/dist-packages (from transformers) (6.0.3)\n","Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2025.11.3)\n","Requirement already satisfied: requests in /usr/local/lib/python3.12/dist-packages (from transformers) (2.32.4)\n","Requirement already satisfied: tokenizers<=0.23.0,>=0.22.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.22.1)\n","Requirement already satisfied: safetensors>=0.4.3 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.7.0)\n","Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.12/dist-packages (from transformers) (4.67.1)\n","Requirement already satisfied: psutil in /usr/local/lib/python3.12/dist-packages (from accelerate) (5.9.5)\n","Requirement already satisfied: torch>=2.0.0 in /usr/local/lib/python3.12/dist-packages (from accelerate) (2.9.0+cu126)\n","Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (2025.3.0)\n","Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (4.15.0)\n","Requirement already satisfied: hf-xet<2.0.0,>=1.1.3 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (1.2.0)\n","Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (75.2.0)\n","Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (1.14.0)\n","Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.6)\n","Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.1.6)\n","Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.77)\n","Requirement already satisfied: nvidia-cuda-runtime-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.77)\n","Requirement already satisfied: nvidia-cuda-cupti-cu12==12.6.80 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.80)\n","Requirement already satisfied: nvidia-cudnn-cu12==9.10.2.21 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (9.10.2.21)\n","Requirement already satisfied: nvidia-cublas-cu12==12.6.4.1 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.4.1)\n","Requirement already satisfied: nvidia-cufft-cu12==11.3.0.4 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (11.3.0.4)\n","Requirement already satisfied: nvidia-curand-cu12==10.3.7.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (10.3.7.77)\n","Requirement already satisfied: nvidia-cusolver-cu12==11.7.1.2 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (11.7.1.2)\n","Requirement already satisfied: nvidia-cusparse-cu12==12.5.4.2 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.5.4.2)\n","Requirement already satisfied: nvidia-cusparselt-cu12==0.7.1 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (0.7.1)\n","Requirement already satisfied: nvidia-nccl-cu12==2.27.5 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (2.27.5)\n","Requirement already satisfied: nvidia-nvshmem-cu12==3.3.20 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.3.20)\n","Requirement already satisfied: nvidia-nvtx-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.77)\n","Requirement already satisfied: nvidia-nvjitlink-cu12==12.6.85 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.85)\n","Requirement already satisfied: nvidia-cufile-cu12==1.11.1.6 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (1.11.1.6)\n","Requirement already satisfied: triton==3.5.0 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.5.0)\n","Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.4.4)\n","Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.11)\n","Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2.5.0)\n","Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2025.11.12)\n","Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch>=2.0.0->accelerate) (1.3.0)\n","Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch>=2.0.0->accelerate) (3.0.3)\n","Downloading transformers-4.57.3-py3-none-any.whl (12.0 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m12.0/12.0 MB\u001b[0m \u001b[31m124.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading bitsandbytes-0.48.2-py3-none-manylinux_2_24_x86_64.whl (59.4 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m59.4/59.4 MB\u001b[0m \u001b[31m41.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hInstalling collected packages: transformers, bitsandbytes\n","  Attempting uninstall: transformers\n","    Found existing installation: transformers 4.57.2\n","    Uninstalling transformers-4.57.2:\n","      Successfully uninstalled transformers-4.57.2\n","Successfully installed bitsandbytes-0.48.2 transformers-4.57.3\n","\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m67.3/67.3 kB\u001b[0m \u001b[31m3.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25h  Installing build dependencies ... \u001b[?25l\u001b[?25hdone\n","  Getting requirements to build wheel ... \u001b[?25l\u001b[?25hdone\n","  Preparing metadata (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.0/1.0 MB\u001b[0m \u001b[31m22.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.5/2.5 MB\u001b[0m \u001b[31m42.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m21.4/21.4 MB\u001b[0m \u001b[31m36.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m329.5/329.5 kB\u001b[0m \u001b[31m32.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m278.2/278.2 kB\u001b[0m \u001b[31m28.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.0/2.0 MB\u001b[0m \u001b[31m98.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m450.8/450.8 kB\u001b[0m \u001b[31m40.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m103.3/103.3 kB\u001b[0m \u001b[31m9.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m17.4/17.4 MB\u001b[0m \u001b[31m131.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m72.5/72.5 kB\u001b[0m \u001b[31m6.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m132.3/132.3 kB\u001b[0m \u001b[31m13.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m65.9/65.9 kB\u001b[0m \u001b[31m6.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m208.0/208.0 kB\u001b[0m \u001b[31m22.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m105.4/105.4 kB\u001b[0m \u001b[31m9.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m71.6/71.6 kB\u001b[0m \u001b[31m6.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m64.7/64.7 kB\u001b[0m \u001b[31m6.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m517.7/517.7 kB\u001b[0m \u001b[31m43.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m50.9/50.9 kB\u001b[0m \u001b[31m5.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m128.4/128.4 kB\u001b[0m \u001b[31m13.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m4.4/4.4 MB\u001b[0m \u001b[31m123.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m456.8/456.8 kB\u001b[0m \u001b[31m43.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m46.0/46.0 kB\u001b[0m \u001b[31m4.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m86.8/86.8 kB\u001b[0m \u001b[31m9.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25h  Building wheel for pypika (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n","\u001b[31mERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.\n","google-colab 1.0.0 requires requests==2.32.4, but you have requests 2.32.5 which is incompatible.\n","google-adk 1.19.0 requires opentelemetry-api<=1.37.0,>=1.37.0, but you have opentelemetry-api 1.38.0 which is incompatible.\n","google-adk 1.19.0 requires opentelemetry-sdk<=1.37.0,>=1.37.0, but you have opentelemetry-sdk 1.38.0 which is incompatible.\n","langgraph-prebuilt 1.0.5 requires langchain-core>=1.0.0, but you have langchain-core 0.3.80 which is incompatible.\n","opentelemetry-exporter-otlp-proto-http 1.37.0 requires opentelemetry-exporter-otlp-proto-common==1.37.0, but you have opentelemetry-exporter-otlp-proto-common 1.38.0 which is incompatible.\n","opentelemetry-exporter-otlp-proto-http 1.37.0 requires opentelemetry-proto==1.37.0, but you have opentelemetry-proto 1.38.0 which is incompatible.\n","opentelemetry-exporter-otlp-proto-http 1.37.0 requires opentelemetry-sdk~=1.37.0, but you have opentelemetry-sdk 1.38.0 which is incompatible.\u001b[0m\u001b[31m\n","\u001b[0m"]}],"source":["!pip install torch torchvision --index-url https://download.pytorch.org/whl/cu126\n","!pip install --upgrade transformers accelerate bitsandbytes\n","!pip install -q \"langchain>=0.2.10,<1.0.0\" \"langchain-community>=0.2.10\" \\\n","                \"langchain-text-splitters>=0.2.0\" \"chromadb>=0.5.5\" \\\n","                \"sentence-transformers>=2.2.2\" \"pypdf>=4.2.0\""]},{"cell_type":"code","source":["!pip install faiss-cpu pdfplumber"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"2xERNe14tfNx","executionInfo":{"status":"ok","timestamp":1764632212202,"user_tz":300,"elapsed":7371,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"de26ed88-2701-4d51-933a-ea468dbb349c"},"execution_count":2,"outputs":[{"output_type":"stream","name":"stdout","text":["Collecting faiss-cpu\n","  Downloading faiss_cpu-1.13.0-cp39-abi3-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl.metadata (7.7 kB)\n","Collecting pdfplumber\n","  Downloading pdfplumber-0.11.8-py3-none-any.whl.metadata (43 kB)\n","\u001b[?25l     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/43.6 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m43.6/43.6 kB\u001b[0m \u001b[31m1.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hRequirement already satisfied: numpy<3.0,>=1.25.0 in /usr/local/lib/python3.12/dist-packages (from faiss-cpu) (2.0.2)\n","Requirement already satisfied: packaging in /usr/local/lib/python3.12/dist-packages (from faiss-cpu) (25.0)\n","Collecting pdfminer.six==20251107 (from pdfplumber)\n","  Downloading pdfminer_six-20251107-py3-none-any.whl.metadata (4.2 kB)\n","Requirement already satisfied: Pillow>=9.1 in /usr/local/lib/python3.12/dist-packages (from pdfplumber) (11.3.0)\n","Collecting pypdfium2>=4.18.0 (from pdfplumber)\n","  Downloading pypdfium2-5.1.0-py3-none-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (67 kB)\n","\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m67.7/67.7 kB\u001b[0m \u001b[31m5.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hRequirement already satisfied: charset-normalizer>=2.0.0 in /usr/local/lib/python3.12/dist-packages (from pdfminer.six==20251107->pdfplumber) (3.4.4)\n","Requirement already satisfied: cryptography>=36.0.0 in /usr/local/lib/python3.12/dist-packages (from pdfminer.six==20251107->pdfplumber) (43.0.3)\n","Requirement already satisfied: cffi>=1.12 in /usr/local/lib/python3.12/dist-packages (from cryptography>=36.0.0->pdfminer.six==20251107->pdfplumber) (2.0.0)\n","Requirement already satisfied: pycparser in /usr/local/lib/python3.12/dist-packages (from cffi>=1.12->cryptography>=36.0.0->pdfminer.six==20251107->pdfplumber) (2.23)\n","Downloading faiss_cpu-1.13.0-cp39-abi3-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl (23.6 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m23.6/23.6 MB\u001b[0m \u001b[31m95.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading pdfplumber-0.11.8-py3-none-any.whl (60 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m60.0/60.0 kB\u001b[0m \u001b[31m4.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading pdfminer_six-20251107-py3-none-any.whl (5.6 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m5.6/5.6 MB\u001b[0m \u001b[31m111.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading pypdfium2-5.1.0-py3-none-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (3.0 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m3.0/3.0 MB\u001b[0m \u001b[31m85.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hInstalling collected packages: pypdfium2, faiss-cpu, pdfminer.six, pdfplumber\n","Successfully installed faiss-cpu-1.13.0 pdfminer.six-20251107 pdfplumber-0.11.8 pypdfium2-5.1.0\n"]}]},{"cell_type":"markdown","source":["# Imports"],"metadata":{"id":"Fu74LY-3q46X"}},{"cell_type":"code","source":["from transformers import AutoTokenizer, AutoModelForCausalLM, BitsAndBytesConfig\n","import torch\n","import random\n","import numpy as np\n","import os\n","from langchain_community.document_loaders import PyPDFLoader, TextLoader\n","from langchain_text_splitters import RecursiveCharacterTextSplitter\n","from langchain_community.vectorstores import Chroma\n","from langchain_community.embeddings import HuggingFaceEmbeddings\n","from sentence_transformers import SentenceTransformer\n","import faiss\n","import pdfplumber\n","import math\n","import re\n","import json"],"metadata":{"id":"3-XmC_9Sq6Oe","executionInfo":{"status":"ok","timestamp":1764632234469,"user_tz":300,"elapsed":22265,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":3,"outputs":[]},{"cell_type":"markdown","source":["# Getting the documents and make a vector DB\n","Make sure you have the data folder in your drive"],"metadata":{"id":"ONyoS_MysFN_"}},{"cell_type":"code","source":["from google.colab import drive\n","drive.mount('/content/drive')\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"vNYmqwjIso0L","executionInfo":{"status":"ok","timestamp":1764632250893,"user_tz":300,"elapsed":16413,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"efec5303-f55e-4171-feea-73890a144741"},"execution_count":4,"outputs":[{"output_type":"stream","name":"stdout","text":["Mounted at /content/drive\n"]}]},{"cell_type":"code","source":["DATA_DIR = \"/content/extracted\""],"metadata":{"id":"5_aR7wsHuKxM","executionInfo":{"status":"ok","timestamp":1764632250908,"user_tz":300,"elapsed":2,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":5,"outputs":[]},{"cell_type":"code","source":["import zipfile\n","\n","zip_path = \"/content/drive/MyDrive/data.zip\"        # path to your zip file\n","extract_path = DATA_DIR  # where to extract\n","\n","with zipfile.ZipFile(zip_path, 'r') as zip_ref:\n","    zip_ref.extractall(extract_path)"],"metadata":{"id":"qEiOjYBnsuTP","executionInfo":{"status":"ok","timestamp":1764632252755,"user_tz":300,"elapsed":1846,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":6,"outputs":[]},{"cell_type":"markdown","source":["## Create the Vector DB"],"metadata":{"id":"Ul1gdZhQuTLf"}},{"cell_type":"code","source":["DATA_DIR = os.path.join(DATA_DIR, \"data/files/no_take_home\")\n","print(os.listdir(DATA_DIR))"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"JnY5ZkH7uW_M","executionInfo":{"status":"ok","timestamp":1764632252762,"user_tz":300,"elapsed":6,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"6b475b9f-0a84-4a3d-a60e-94577553e306"},"execution_count":7,"outputs":[{"output_type":"stream","name":"stdout","text":["['doc7.pdf', 'doc2.pdf', 'doc1.pdf', 'doc8.pdf', 'doc5.pdf', 'doc6.pdf', 'doc9.pdf', 'doc4.pdf', 'doc10.pdf', 'doc3.pdf']\n"]}]},{"cell_type":"code","source":["QA_DIR = \"/content/extracted/data/qa_pairs\""],"metadata":{"id":"eumygzwiCPSE","executionInfo":{"status":"ok","timestamp":1764632252764,"user_tz":300,"elapsed":1,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":8,"outputs":[]},{"cell_type":"code","source":["PERSIST_DIR = \"./RAG_CARDIOLOGY\"\n","COLLECTION = \"hallucination_eval\"\n","CHUNK_SIZE = 500\n","CHUNK_OVERLAP = 20"],"metadata":{"id":"RGKnllhbu7lF","executionInfo":{"status":"ok","timestamp":1764632252766,"user_tz":300,"elapsed":1,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":9,"outputs":[]},{"cell_type":"markdown","source":["Gather all the documents and merge the pages of a document into 1."],"metadata":{"id":"neVzySkj16Mk"}},{"cell_type":"code","source":["from langchain_community.document_loaders import PyPDFLoader\n","from langchain.schema import Document\n","\n","documents = []\n","for d in os.listdir(DATA_DIR):\n","    path = os.path.join(DATA_DIR, d)\n","    loader = PyPDFLoader(path)\n","    pages = loader.load()\n","\n","    # merge pages into one big Document\n","    full_text = \"\\n\".join([p.page_content for p in pages])\n","    documents.append(Document(page_content=full_text, metadata={\"source\": path}))\n","\n","print(len(documents), \"combined documents\")\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"6BX3L3_NvVSG","executionInfo":{"status":"ok","timestamp":1764632295917,"user_tz":300,"elapsed":43151,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"d05f0cb1-7225-42d0-dc88-6e3f6ab1919a"},"execution_count":10,"outputs":[{"output_type":"stream","name":"stdout","text":["10 combined documents\n"]}]},{"cell_type":"markdown","source":["split the document into chunks"],"metadata":{"id":"wglXJASq2AEY"}},{"cell_type":"code","source":["splitter = RecursiveCharacterTextSplitter(\n","    chunk_size=CHUNK_SIZE,\n","    chunk_overlap=CHUNK_OVERLAP,\n","    add_start_index=True,\n",")\n","chunks = splitter.split_documents(documents)\n","print(f\"Created {len(chunks)} chunks\")"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"0KIDfe24wqTL","executionInfo":{"status":"ok","timestamp":1764632296140,"user_tz":300,"elapsed":199,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"9899c636-b3af-4052-edea-0908fcbfe79c"},"execution_count":11,"outputs":[{"output_type":"stream","name":"stdout","text":["Created 8380 chunks\n"]}]},{"cell_type":"code","source":["emb = HuggingFaceEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\")"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":528,"referenced_widgets":["c581d6cccc764596a4dc8e476d8dc646","2ca6fea734cb43a3b3de54a8092a3d3e","311a0773d2784f93bdf64ad7e3659cfc","19fc02281334497f86578362e9fba86b","3107b5c9b33f4c74ac73be2165d2a90d","9643a28c3a6f473fa0b61634b89bc37a","58927dac28e541a58bbe3fb6b8cbd844","5b776ec9e80b49b3a008876f6b874ce4","59e848950953483598fcfc11f91e74dd","b905cc1168fd46e287a0995669ac5c1f","58da92637c4c40cea32fed3aa076176c","f0850f47f2fc4e518cfcc6d271fe1088","70a2c966f117415a9220ffeac58d012e","fc524f27e5f844d98e56013191f24e49","a241cebdb61848a192530e67416b5e2e","6d67d2eb06774e0d930935844720f37e","fa2aa1e9cb2e4db1bf983010eb4c4def","90fbdfd27afa4f5781ec0b9a5df29349","c1e94f47ea554f2b8b93831e71a78c24","12beef7fdfea4ece9dcffc94ab9db35f","6938a369f6ac443ca655a7c777eb618f","327798400c994832b56ead6a41bb2ded","114f210a213d459589797a1b75ffe133","040cb1b5dbc94d62afa74626c9e7d663","f96a846e2035482ea2b4c685abb995cf","ab7ac9c15042410aa1bdd1c974a9beba","130b05799eeb42788bfc6880a7c99c74","c8e1d3653c754e7da4d0c18c8741ba44","c64e9b0e5b8a4d8286c70ed82ac74f2d","119ef5a1534047b09d2760f71a1e1426","85dfb84c053c47f5a06392b35fb6c105","179890a8004e4a3ba53960c3fe97d636","dbdfe7496e2c428fa5b952c3c2368ace","64e51c871c0a41efadefeb30ace2ac82","60a54202ae3a43e8b5cebc3befdda531","6b2862ba1b0c4cc999de65d692b1134e","4ddca68d5da44a07ac389c07328fbdf1","d55e447a750d43c0b4ffbcaac05cd0d6","c7667631b419441995480ff5f96fb2b9","93c533473f6144cba0f0ce23b5301ca0","b1d6b97394c34effb84dcd50eb2ab0e9","d4efedf6e82b41a3a6dc8d656ab838f8","4250a038548f4a58a19de7a3ae150545","ea1d9182f3f54c048afb9b32ce788975","2141152f3b0d47c0914877dbe68f5683","00e3672e46db465e925a325ecb794ada","e2ec64240109441d9c83547524f73f8d","170e9a1ab659414383ae43ecb2afa7cc","066af936d15f4dc7b8740283c2345adf","61f7e08cfba642dabfa5112be5b1ce27","e672a0b5deb94be7b8664a2772169947","eda698b0b1ef40f7ac8eee66d347c38c","af7170f24ce349ba942b0cfce8f0cbf3","75130df35e3540c6825bc8e8b139d6ae","d3d674accced41e0a4d3e973067328d8","528bb1b624ca44c681d81f39bf17253f","2ba01a7c877547c59d773a9dd81c4175","1040fa54a4c44e2682b2f85b47502567","98ac846dbc8a47f2ae4b249bd53681bd","18634264229445eaade5ffaff3ad9922","2a7df9ef7c1640729316a0d36ba1e9aa","e63c7d9d38734d2e839bf54ac2d39a20","ad7015a8b33945789864d5f9dff81d2e","d4c77016f2604eaca329c115471d74b5","74be82c6fa77419083a87242bf39fe06","06519ad398e24cbbb0624be39bac17ac","5650ba831fb44f5a80c78f07e26ebe17","7b8871a557954703af748c7dd9089d74","8fd6000e28d74ac288cf0e3e07ca2db5","37d615b956bc45e2a8a9b6f3af77f182","ad34017fecca48b0a61e9d91930e4ca8","6a5e29491af54f84b84b87ff54716645","0bc7364ebdb34e25afdbaa244953839c","fafe4eca5bdc44df8cb27284435ea86c","a572d8c16cc04d4089fb9421238619bf","55bc0a89540641c7bfe6a058d0c4d6f2","8f00cb7417be4d70b1c89f5b69deca83","83687cfe05cc4e4c8e3cd7208c1732d5","f1523b966cd34eaaafe76d0bfc1f4d39","8818cb8ac7a74cb3bf528ded155ffb4a","012e1843a1c343dd8de20b069f28efad","45ba7418d7504a188bc9a814b6c02a36","a77dd730080c4d369042f25a35db3afc","48899951fc224832bd3ee13e89d6bfba","a703125b07bf49e5872f0c8eb2b24338","74df5a72bec44f048dcfebaf5bd189ef","667a656e96744393991f4eeb65cef83a","365e1a8d7dee4f59ba4675cff00a2656","d4f3ca7c45fd493f8111994b2de00857","017d021b531344058246895e0fed8559","08c024a7b46c47dca7e5ecac43645e84","45eac7108ae44d3ebfaa6ea2c7a3327a","961e3b4841154fa0ae176ffe34cc018d","a5bf903c2ed144dea825c83f2acd5f47","5fed7505b67b4b16bb376849936154e1","6e256646fd894ae2a0abfbf7b3ad3398","e7093523f01e4fc1bdae4ee916545402","1ab0a70eb35d46f4a0070b013d2e86cc","37731d45b2914a1d9cf4fe39e1676d6f","2253a5d9a05145c98d7851a494d50b13","92abaf33c56241dcb4e7b91a744a87af","afd6ff7d657941ec91fc171dcf3d6b0e","4db3ce0dbd4b4448b2ddc1794b909c52","777923e640894f84aeea953373b29d79","4e5446c57c5f495ab7fd50680237a8c7","9448df7e8c12451cbd866ff1ede20083","2f0dc6cbf74f4cf49536a100fe8885eb","3cb07e8d1ab4445b9fe2f7db874d61a0","2ded608cf63443d19c1d939e96c7c969","b3dc17e6f3ef462da2bed208a7076e4d","42cd8963c06940a6aaf6ec1910e9588f","f2448cbb6b734678854d5ad3a74b4f91","8eb5fcda1b184c8299408d6e0a460877","247bcf027f5449cdb6f000b133c4c062","27cd5199384246f5a5a9c9912eb143d8","352e993adfea4ca285c758edff676988","269512d8a6d44dc3aa8e86fa16b691dc","b512af23be654fa6ab841df94ff96d4f","6bbacfad3c2d43a783f5488921db7d68","6cf9265f357143a7b93a335660dba983","4dcda8c4401c4e7db277743e703ede64"]},"id":"36o4hVcTwsDl","executionInfo":{"status":"ok","timestamp":1764632299593,"user_tz":300,"elapsed":3450,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"bc649fef-d96d-4734-f02b-b31d4505707a"},"execution_count":12,"outputs":[{"output_type":"stream","name":"stderr","text":["/tmp/ipython-input-1019173367.py:1: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n","  emb = HuggingFaceEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\")\n","/usr/local/lib/python3.12/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n","The secret `HF_TOKEN` does not exist in your Colab secrets.\n","To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n","You will be able to reuse this secret in all of your notebooks.\n","Please note that authentication is recommended but still optional to access public models or datasets.\n","  warnings.warn(\n"]},{"output_type":"display_data","data":{"text/plain":["modules.json:   0%|          | 0.00/349 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"c581d6cccc764596a4dc8e476d8dc646"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["config_sentence_transformers.json:   0%|          | 0.00/116 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"f0850f47f2fc4e518cfcc6d271fe1088"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["README.md: 0.00B [00:00, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"114f210a213d459589797a1b75ffe133"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["sentence_bert_config.json:   0%|          | 0.00/53.0 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"64e51c871c0a41efadefeb30ace2ac82"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["config.json:   0%|          | 0.00/612 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"2141152f3b0d47c0914877dbe68f5683"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["model.safetensors:   0%|          | 0.00/90.9M [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"528bb1b624ca44c681d81f39bf17253f"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["tokenizer_config.json:   0%|          | 0.00/350 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"5650ba831fb44f5a80c78f07e26ebe17"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["vocab.txt: 0.00B [00:00, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"83687cfe05cc4e4c8e3cd7208c1732d5"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["tokenizer.json: 0.00B [00:00, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"d4f3ca7c45fd493f8111994b2de00857"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["special_tokens_map.json:   0%|          | 0.00/112 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"2253a5d9a05145c98d7851a494d50b13"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["config.json:   0%|          | 0.00/190 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"42cd8963c06940a6aaf6ec1910e9588f"}},"metadata":{}}]},{"cell_type":"markdown","source":["create the vector DB"],"metadata":{"id":"wCt8Oz_42DNl"}},{"cell_type":"code","source":["vs = Chroma.from_documents(\n","    documents=chunks,\n","    embedding=emb,\n","    persist_directory=PERSIST_DIR,\n","    collection_name=COLLECTION,\n","    collection_metadata={\"hnsw:space\": \"cosine\"}\n",")\n","vs.persist()\n","print(\"Persisted at:\", os.path.abspath(PERSIST_DIR))\n","print(\"Vector count:\", vs._collection.count())"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"OEoTrPUgws5E","executionInfo":{"status":"ok","timestamp":1764632315254,"user_tz":300,"elapsed":15660,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"8760ba30-ee57-46ee-c00a-ca597bc9c43d"},"execution_count":13,"outputs":[{"output_type":"stream","name":"stdout","text":["Persisted at: /content/RAG_CARDIOLOGY\n","Vector count: 8380\n"]},{"output_type":"stream","name":"stderr","text":["/tmp/ipython-input-1184809567.py:8: LangChainDeprecationWarning: Since Chroma 0.4.x the manual persistence method is no longer supported as docs are automatically persisted.\n","  vs.persist()\n"]}]},{"cell_type":"markdown","source":["# Evaluation 1: Baseline model\n","## Step 1: Load the model\n","After experimentation with 1B, 3B, 7B models we found that for our experiments a 13B model is necessary to create good answers for the baseline. We will use Llama-2-13b-chat-hf model as the main model and the 3B as student."],"metadata":{"id":"0aKoLcec2FD9"}},{"cell_type":"code","source":["from google.colab import userdata\n","key = userdata.get('hf_key')\n","model_name = \"meta-llama/Llama-2-13b-chat-hf\"\n","\n","bnb_config = BitsAndBytesConfig(\n","    load_in_4bit=True,\n","    bnb_4bit_quant_type=\"nf4\",\n","    bnb_4bit_compute_dtype=\"bfloat16\"\n",")\n","\n","# Explicitly tell the tokenizer to use the SentencePiece model\n","tokenizer = AutoTokenizer.from_pretrained(model_name, use_fast=False, use_auth_token=key)\n","\n","model = AutoModelForCausalLM.from_pretrained(\n","    model_name,\n","    quantization_config=bnb_config,\n","    device_map=\"auto\",\n","    use_auth_token=key\n",")\n","\n","print(model.device)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":592,"referenced_widgets":["f36095740a2f4f1d905fedc550e4c2f7","0f363034114c4676819fbd07f9fcedd6","4ca5a20793434e1a9d3747d791dd78cc","0660cb0c35b64e198c88c53cb3c72821","edb665f82db64a32b5456f032213ee6f","297fd996825a430b905f27b5bcc05cf7","ce3e0bc01aee41e2876180caea71e786","21d5be861b63420184373a6d002d3338","1171f7c0c83f44549038ccf8f2ec1e08","7c9ebc5872ca4b5a8f3b2bc5b8ae67f8","a552dd69d85b42cab179f9a7bcecf2a6","b281ee0e1664428b81d80b30b75a2f40","f7ae1036c08045b391e5216052376634","5d219f2e1d1740719c6e314300fb4a56","4783ac5d2e5e46638e93973a19e7abd7","909fbfb4d43542a09d46f564085d862e","0d08b7510f914ba99896f27b2068ad0e","38048455f27d465daef2fecac5517e0a","13960bf238b04d99bea57d50d026ed26","45b63b50686d4b00ac25ba0c96d78ed9","b5a889e26ef04e37afaacef66e4269cd","1172cf1917d941cbab1538fc89a8072e","6ab7f97fe9d142119e382c20926b8762","891d963ce7514ce3bdb1b2a8a3fa72c4","74eda0ccb23c49a49ea61e5abc917861","c44ff6e0fe8c4b46b0b41f4df8269740","405e66d0b12642219a5564b2ec500b51","13cc9478e00a4f4eb1c7787170945ad7","a7cbbc38ef684515b7637c70cfad4240","a6776d724ecd43c1b743b4699632255d","8dc356baae994ffe85a7f963d0919701","e04c4a3d6c5340a0844f7aec4e939a42","8f94a20cce9e44d88572c156d9db3e63","a3fe3d1fccbc46b597984ed44294bd37","0682ff6bc837406e8715c23856c86632","f91ab92797ff47cbaf8dda112d47b0ba","081a3e40a5df441dac5c9dd437bd9092","3206fd36a93d4ec58b7b9b9bea16474c","dd89f58adf54423285d6759535975ccd","73ae0d522fc84ad7a24fbc7b8a7c05d2","547a5dd61e404d08abeb6bb4ad9eb0f5","fff84553f7d84418bbc90b66b3e551f8","60e8b4815d8a4a0ba0ebc34cfdb0196b","36bea899963c464ab6bcc7b125b6d88a","adc8f9d954664089a6418c828eef063d","9c682533ca2844378fc6eb02a1e4ff48","4561672e505c4543b7e0301546ba551f","1b80e5533cd049829eb1cd78c445f024","b88af45f70e747c2bd1b7ebb39bfd0c3","753f3cb87bbc46e7aba66a25e7569634","0154c19c900f497a9363cf2cf766f6c1","caf9c745b63243f285e6c94d98af9ccb","853431afa3824f52bfaad0faba330729","d3cfa56c0e1b45bb8633394e1d0e4a6f","3405eb2dd86c43a089fa4142f844d8d1","99e9fe4cf7a340bda8009a479c000b87","2cb29ed52e1d4648afb3a4adae11e229","9dd15afea6334f299f6e003f1208769d","33c0f77634434a508d01e9dda2a6b6fc","0eb8b9c077324973bb430af19d0488a4","a987e94e44df4b07b202da6b0e3f2441","3f77711f84f740b1a78f4db242d5cbd6","366e64a4fb514760b777288d648ae72c","1be1b33f5a6241c3b0b5031aa6909273","62202b930d9d423595524be963b9ba5f","eb2e1684eff341b8989efac792b8cfce","b7f4ecc7a59448cd9405ba3542197de0","92be8cd23469454fb9c41db29d8376cc","3a3370e841bc404297d577c01678ba5c","ac56975b6cf945ff95110decfac72acd","8bb35e562027447ca18463a9d5099f2b","31fac4e7622444c6a96ece8f6778289d","cd74f513a2ef436089ef91f7cb5b27c4","66b84a3838ba44ec8414d2d7a289197e","9217945e15d54064969cf58481e4cf58","7ae772fc6edf4ec790e201ef1ad0d8b7","2cc7ac395a364612a919f35db58c16fb","1e853ec8714547e282dd9f0bd0319610","e03a48476bb74daa90d337a868bbf27d","9359f6c76222495594a0631283e95108","f509c704b8ad429baf821f95c9673846","438cde7a33c144ff9086b460d95499fc","3a558d4945294bfea4e2727e5ac15e6e","bfafb887b03545f69da00e93e21b21b6","892998a6d9a1438187bb37ec9ed3c968","56758b30f43148f8b8ed3408e9c3edc1","f93fc73c214649eca1212fb1880fab36","6fdfebbeb8614a079be8a20c632b6329","6cd0eb0848a94aaaa04d0c537a025438","47831cfc8b8744f7a0072807b805d4d7","9a3e8ca0a0b04d4baa7b3d00fdaa62cc","270eb39d2c6f4cf995e6de91b3afabb2","dc81b31f435c4e0e8520d3cf8f1c81b8","d188392935194e13a67a5e5a57ed6594","d4f9b177991d415b9e09d168de5eccc5","358ba890bbcd463e8557fe7dc8c71619","9d4d197312b3442fba1c1d35eb9b1745","5d3053e6db0640e39293b367d085f3a3","590789da25d746ad909bb25aa2b4f7c7","497e7daf56314ec79a43b0cc91332250","202d7d80e5b2407781a6e9bb75ad343a","75607cb534354951b34cf11d47ed1a8a","c2534c22476644c8bcb8041c7c6af32f","59395ab656984953be8f28802e45a741","4eb03449e6484fbdae1dd57410699914","92a5984bd2984b2b878f60a8b0d4071d","db3d051a23e04fd09e7d28301f6ad251","de01f3db1ffb447f85cad94ef4b93938","065597c4dbc34623b9332e1d825c9dcc","2d193865af744bacb78ed6a2145b5b8b","6660d6448f724446bac6d97a27ad1516","a57efa1943524fbd9cec57f0203dab7a","dcbbfb79ce314a3fb3ee2adad1935b7e","877e1da4240248e09a251b3dd0153b32","a0e0090e533046309ff335265b0712bb","1f8f5416add44417a8d0097b4245a92b","5b48dc65352f4bcb911075cc2cbdc4e5","6b315f7e1b84455b90029765d3470186","fb078fe2bfd846eaa42a7222648f2492","b37812d4d88b4072a56a8566fdffd90c","dc3ec13188ca4a2eafd9a006d5c61285","ab46b8f4a5ae4484bec348fbc30201e1","69745973c64940f8984e542c0f0b0365","a287bdb0fd774d57a0fdc6638abf7c6d","11c25430a48b4b139ce03d5004747e1f","94c68bc43b3e45098119090734e68c18","35f23e5c15754adcb26b3ca153b9ec05","1fa9f1b1fca14450953406796285d584","f62de3e2f53d48b2b5fda06261ec9724","cd1b1b65d606417389a140187d8f483d","07e626f2295345f0a9f353ba28fb0283","205f986c9feb41c88b0de05dfb028f21"]},"id":"R4tI_lPUxnTP","executionInfo":{"status":"ok","timestamp":1764632456463,"user_tz":300,"elapsed":141209,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"da31e9fb-3b4d-49cf-cc95-e84b05ed0d6b"},"execution_count":14,"outputs":[{"output_type":"stream","name":"stderr","text":["/usr/local/lib/python3.12/dist-packages/transformers/models/auto/tokenization_auto.py:1041: FutureWarning: The `use_auth_token` argument is deprecated and will be removed in v5 of Transformers. Please use `token` instead.\n","  warnings.warn(\n"]},{"output_type":"display_data","data":{"text/plain":["tokenizer_config.json:   0%|          | 0.00/1.62k [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"f36095740a2f4f1d905fedc550e4c2f7"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["tokenizer.model:   0%|          | 0.00/500k [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"b281ee0e1664428b81d80b30b75a2f40"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["special_tokens_map.json:   0%|          | 0.00/414 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"6ab7f97fe9d142119e382c20926b8762"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["tokenizer.json:   0%|          | 0.00/1.84M [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"a3fe3d1fccbc46b597984ed44294bd37"}},"metadata":{}},{"output_type":"stream","name":"stderr","text":["/usr/local/lib/python3.12/dist-packages/transformers/models/auto/auto_factory.py:492: FutureWarning: The `use_auth_token` argument is deprecated and will be removed in v5 of Transformers. Please use `token` instead.\n","  warnings.warn(\n"]},{"output_type":"display_data","data":{"text/plain":["config.json:   0%|          | 0.00/587 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"adc8f9d954664089a6418c828eef063d"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["model.safetensors.index.json:   0%|          | 0.00/33.4k [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"99e9fe4cf7a340bda8009a479c000b87"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["Fetching 3 files:   0%|          | 0/3 [00:00<?, ?it/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"b7f4ecc7a59448cd9405ba3542197de0"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["model-00002-of-00003.safetensors:   0%|          | 0.00/9.90G [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"1e853ec8714547e282dd9f0bd0319610"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["model-00003-of-00003.safetensors:   0%|          | 0.00/6.18G [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"6cd0eb0848a94aaaa04d0c537a025438"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["model-00001-of-00003.safetensors:   0%|          | 0.00/9.95G [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"497e7daf56314ec79a43b0cc91332250"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["Loading checkpoint shards:   0%|          | 0/3 [00:00<?, ?it/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"6660d6448f724446bac6d97a27ad1516"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["generation_config.json:   0%|          | 0.00/188 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"ab46b8f4a5ae4484bec348fbc30201e1"}},"metadata":{}},{"output_type":"stream","name":"stdout","text":["cuda:0\n"]}]},{"cell_type":"markdown","source":["## Step 2: setup RAG pipeline"],"metadata":{"id":"tRkyx0my4CT7"}},{"cell_type":"code","source":["def get_RAG(vector_db, query, k=3):\n","  rag_docs = vector_db.similarity_search(query, k=k)\n","  return rag_docs\n","\n","def format_RAG_docs(docs):\n","  return \"\\n\\n\".join([\n","    f\"Source: {doc.metadata['source']}\\n{doc.page_content}\"\n","    for doc in docs\n","  ])\n","\n","def create_prompt(question, k, vector_db):\n","  rag_docs = get_RAG(vector_db, question, k=k)\n","  formatted_rag_docs = format_RAG_docs(rag_docs)\n","  prompt = f\"\"\"Using the following retrieved passages, answer the medical question concisely (1-2 sentences).\n","Format your answer exactly as:\n","\n","Answer: <your concise answer>\n","Confidence: <X%>\n","Citation: <document/source>\n","\n","Question: {question}\n","\n","Passages:\n","{formatted_rag_docs}\n","\n","Answer:\n","  \"\"\"\n","  return prompt\n",""],"metadata":{"id":"N69qv-e34Eyn","executionInfo":{"status":"ok","timestamp":1764632456502,"user_tz":300,"elapsed":1,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":15,"outputs":[]},{"cell_type":"markdown","source":["# Step 3: Setup experiment for baseline"],"metadata":{"id":"-f7ibEKK91a3"}},{"cell_type":"code","source":["from transformers import GenerationConfig\n","def get_answer_and_token_probs(model, tokenizer, prompt):\n","  # Encode prompt\n","  inputs = tokenizer(prompt, return_tensors=\"pt\").to(model.device)\n","\n","  # Generation configuration\n","  gen_config = GenerationConfig(\n","      min_new_tokens=30,\n","      max_new_tokens=150,\n","      do_sample=False,  # Greedy to make logprobs deterministic\n","\n","  )\n","  # Generate tokens step by step to capture probabilities\n","  generated_ids = inputs[\"input_ids\"]\n","  logprobs_list = []\n","\n","  with torch.no_grad():\n","      for _ in range(gen_config.max_new_tokens):\n","          # Get model logits\n","          outputs = model(generated_ids)\n","          logits = outputs.logits  # shape: [batch, seq_len, vocab_size]\n","          next_token_logits = logits[:, -1, :]  # last token\n","\n","          # Compute probabilities\n","          probs = torch.softmax(next_token_logits, dim=-1)\n","          topk_probs, _ = torch.topk(probs, k=10, dim=-1)\n","\n","          # Store top-10 token probabilities and ids\n","          logprobs_list.append(topk_probs.cpu().tolist())\n","\n","          # Greedy: choose the highest probability token\n","          next_token = torch.argmax(next_token_logits, dim=-1, keepdim=True)\n","          generated_ids = torch.cat([generated_ids, next_token], dim=-1)\n","\n","          # Stop if EOS token\n","          if next_token.item() == tokenizer.eos_token_id:\n","              break\n","\n","  # Decode final answer\n","  generated_text = tokenizer.decode(generated_ids[0, inputs[\"input_ids\"].shape[1]:], skip_special_tokens=True)\n","  return generated_text, logprobs_list"],"metadata":{"id":"IsnJKyt896WB","executionInfo":{"status":"ok","timestamp":1764632456504,"user_tz":300,"elapsed":1,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":16,"outputs":[]},{"cell_type":"code","source":["qa_objects = os.listdir(QA_DIR)\n","qa_object = [qa for qa in qa_objects if \"doc1.json\" in qa][0]\n","print(qa_object)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"vPJT4MNeCuiu","executionInfo":{"status":"ok","timestamp":1764632456509,"user_tz":300,"elapsed":4,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"3cfc3da9-93da-4ec0-c50c-df9194db1e56"},"execution_count":17,"outputs":[{"output_type":"stream","name":"stdout","text":["qa_doc1.json\n"]}]},{"cell_type":"code","source":["import pandas as pd\n","def experiment_1(model, tokenizer, vector_db, doc_dir, k):\n","  results = []\n","  doc_names = os.listdir(doc_dir)\n","  doc_names = [doc.split(\".\")[0] for doc in doc_names]\n","\n","  qa_objects = os.listdir(QA_DIR)\n","  for doc in doc_names:\n","    print(doc)\n","    qa_object = [qa for qa in qa_objects if doc + \".json\" in qa][0]\n","    with open(os.path.join(QA_DIR, qa_object), \"r\") as f:\n","      data = json.load(f)\n","\n","    questions = data[\"questions\"]\n","    answers = data[\"answers\"]\n","\n","    for i, question in enumerate(questions):\n","      print(f\"Question {i+1}/{len(questions)}\")\n","      prompt = create_prompt(question, k, vector_db)\n","      generated_text, logprobs_list = get_answer_and_token_probs(model, tokenizer, prompt)\n","\n","      results.append({\n","          \"id\": f\"{doc}_question_{i}\",\n","          \"response\" : generated_text,\n","          \"answer\": answers[i],\n","          \"logprobs\": logprobs_list\n","      })\n","\n","  df = pd.DataFrame(results).set_index(\"id\")\n","  return df\n","\n","print(DATA_DIR)\n","print(os.listdir(DATA_DIR))\n","df = experiment_1(model, tokenizer, vs, DATA_DIR, 3)\n","\n","\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"JSyrLb42A4ZE","executionInfo":{"status":"ok","timestamp":1764633691902,"user_tz":300,"elapsed":1235393,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"2ec68ba3-1f12-4ef7-b4b9-aa3fc9ff1f33"},"execution_count":18,"outputs":[{"output_type":"stream","name":"stdout","text":["/content/extracted/data/files/no_take_home\n","['doc7.pdf', 'doc2.pdf', 'doc1.pdf', 'doc8.pdf', 'doc5.pdf', 'doc6.pdf', 'doc9.pdf', 'doc4.pdf', 'doc10.pdf', 'doc3.pdf']\n","doc7\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc2\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc1\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc8\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc5\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc6\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc9\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc4\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc10\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc3\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n"]}]},{"cell_type":"code","source":["df.to_csv(\"/content/drive/MyDrive/baseline_results.csv\")"],"metadata":{"id":"sRaIcA9awLJL","executionInfo":{"status":"ok","timestamp":1764633692044,"user_tz":300,"elapsed":139,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":19,"outputs":[]},{"cell_type":"markdown","source":["# Experiment 2: RAG with document held out\n","\n","It is basically the same experiment as 1 but with the document from which we retrieve the question held out"],"metadata":{"id":"oUUi0LdHSIO0"}},{"cell_type":"code","source":["def delete_doc_from_vector_db(vector_db, doc):\n","  path = os.path.join(DATA_DIR, doc)\n","  chunks = vector_db.get(where={\"source\": path})\n","  vector_db.delete(where={\"source\": path})\n","  return chunks\n","\n","def insert_chunks_into_vector_db(vector_db, chunks):\n","  docs_to_add = [\n","    Document(page_content=text, metadata=meta)\n","    for text, meta in zip(chunks['documents'], chunks['metadatas'])\n","  ]\n","  vector_db.add_documents(\n","      documents=docs_to_add,\n","      ids=chunks['ids']  # your existing IDs\n","  )"],"metadata":{"id":"R25MprMrSU4O","executionInfo":{"status":"ok","timestamp":1764634255323,"user_tz":300,"elapsed":9,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":25,"outputs":[]},{"cell_type":"code","source":["docs_to_add = [\n","    Document(page_content=text, metadata=meta)\n","    for text, meta in zip(chunks['documents'], chunks['metadatas'])\n","]\n","\n","# Add them to your vector store with the corresponding IDs\n","vs.add_documents(\n","    documents=docs_to_add,\n","    ids=chunks['ids']  # your existing IDs\n",")\n","\n","print(vs.get(where={\"source\": path_test}))"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"KJJh5f4cYE3G","executionInfo":{"status":"ok","timestamp":1764634069556,"user_tz":300,"elapsed":1095,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}},"outputId":"5988aeb6-ed7d-4f4c-c992-496ff98a2cb3"},"execution_count":24,"outputs":[{"output_type":"stream","name":"stdout","text":["{'ids': ['a98aaa8b-5b05-4d54-bce9-066e90c65e1c', 'a21b6a6d-fd4e-4e1d-a66a-b190ab91bb13', 'e4ac4b6f-7029-48ce-b955-d6ce745610f5', 'c8a83112-a66a-468a-9304-2d246541e154', '69a464b5-62c8-4fae-9dc8-de9d5ed5f39e', '84d3e2c2-53a9-41d6-b93e-a61769111d17', 'a5cdd279-de39-4cb8-88a7-6161cd760c24', '87fd6917-353c-4e2d-a97b-fa0c656aec7f', 'e8f1ccdd-e902-4600-ae21-787aefa13d5d', '770f2e02-8dac-428b-a467-891330277be0', '33c8bd17-e005-444e-8cde-f4d430e8757b', '68ea313a-1b6b-4602-9755-db34c5242080', '80163133-dbdc-41ce-993e-94ca445fcdf9', '9020b080-fdac-480d-9cca-497528571827', '84c13bc8-4fdd-421f-9e2c-39a56f66cb19', 'b70c7d2f-579f-43b9-8dc0-d46036350fb4', '7926c253-5a06-4128-9d6e-132b121aecdc', '48e5ffe6-436e-4c57-9f95-e5dbb8cfbe50', '8c4dad1c-36a2-40a2-88af-185e843cf118', '8f82859f-78ee-4acf-987b-c2d05050713a', 'db525a97-601c-46fd-bbf8-cfe4628b130d', '41a028bc-763f-4192-b5ff-60457f8fdd61', 'a94a5e06-e6ab-46d1-96c6-b36585c932aa', 'd7bbf5f4-6bde-448e-9992-2a93f3f9fb2f', '8017c2ab-2663-4891-9b8d-a04e569b95c7', 'cd085aca-b98a-4900-9ae8-8dff9093fc9d', 'ba206e18-3ea4-4de0-8140-4e85e2396c70', 'a398b093-a869-41df-a852-cc312fa7a9e3', 'd59dec21-3168-4520-8835-5f7a805d33d2', '0508be46-b18e-4d4c-a68f-5ac66326d080', 'a68526de-c46b-43ec-8dbb-4b6e0bcb04da', 'b61ada51-a72f-406d-b9ac-24d4aa5a6bac', 'ab0e1af6-e76c-44d2-abbf-45775d25fbeb', '1ea74dab-b9e0-43df-ae57-a0f9e49822a6', 'a2187f9a-e7db-4261-bfbf-582cd5506a2f', 'a3163b59-ae06-42b4-9a3e-5c9a5ecf67c5', '76e13611-1540-4d05-98a6-fdd54744ac90', '5bc382b3-6131-47d9-949b-f179e875101f', '00b4742a-caaf-4799-aaeb-aee45810b8a1', '3e0468f4-bf35-4008-816d-a675ec3a78fe', '3af519fe-3c61-4503-9fd9-165823c12446', '84c59488-1646-4631-9cb7-6fad73a0624d', 'a1fee48c-54c3-43f9-bd57-857b42be74fc', '40bceba1-d371-4199-ae9e-bc6918120ae9', 'd0cd8f46-7cc4-4dd6-abab-9beb5cda14ad', '62385537-c9db-4429-9add-f49b980cd21b', '875a0c6b-3800-4b4e-9136-86fbda9cb51b', 'd6d43d0e-dc53-43a9-b238-009e5d70bfab', '6d4d22f9-ad1d-4c11-9ccb-46cc0ae99ecb', '4e668d62-24d7-454f-999b-6383b2824abd', '4513195e-2126-46bb-a305-96deb201d66e', 'e026d887-1d57-4edd-a7c7-2a3c4f6bf58d', 'd54cf824-b6a3-46a0-9d7b-d2afa4440978', 'a24dcb84-95ac-48ff-986f-6941a383354a', '8bea0a09-85d4-4b19-b626-7d8399c5340b', 'd5ec38b2-d190-4c96-8e0b-67c55fa22f2e', '89ca6b56-0a30-4500-9564-7bb7394d60c7', '221d5f47-9680-43a8-b938-4a75dd4c347a', '4f8a5216-c67d-4600-afe0-03637a5a2a10', 'de48cbc8-7979-4d75-bfbb-e7e5eb2b9c4b', '1d96ff44-703b-48d3-8eb6-65b9f35a98ee', 'e166a1c9-686f-48d0-a898-a83af1af9d57', '2628903a-deab-407c-94fa-96a71815c23f', '16ea57da-03bc-42e3-a122-4a14f95132ce', '35452aae-39c6-4210-9722-201ee0194668', '46e8d41f-384b-4a1a-ba94-6beb0cd3eb36', '21ce88b9-2be6-44ea-9aae-1a1465551324', 'f0589443-d05d-46b3-9a6a-c8cd11789752', '1982e6a8-730f-4589-b362-2b75e21981c1', 'a0354691-d490-466b-80cb-d084a3bc92d3', 'dcc6e5a1-379b-4148-ad11-81fce081154f', 'ce287b2d-d7d2-4b1e-a8d8-cdf0dbe453f6', '7259b452-8148-4032-b20f-ab09be8acc5f', '8f2909ef-194b-4990-b8fa-725922dc7749', '742cf5e2-862e-4f97-88fb-2a41fe6bb3ee', '002a6d0f-e623-4d98-9371-845cbd41f7b9', '2fd6cf82-06e3-4a4b-b3bf-79cbfa14bf13', '20ebdc8e-dc9d-4893-b853-1d22af24e36a', '471c124b-1dee-493b-9ea1-928021b431da', '14c6b934-229c-4ecd-8314-1748bcfbf863', '8e5e769e-a97d-48f5-a50f-d038b9b8370b', '911bf2d3-44a4-4141-9915-00f030218d3a', '35453bba-43f8-4c29-be80-15c65c33c99b', 'df6405fa-a13e-44d1-bac5-db3015e238b5', 'ec21deed-8b95-4fa3-8c6e-32f4ab1b1805', 'ed363b23-75e4-42f6-af8c-73780a4f1aaf', 'eba55238-53b4-480b-9078-25aa1cc0ad24', '7a1beafb-6b4e-4a28-b3d7-a704a9d6b583', '75682b79-94ed-4b75-b2eb-b512c159bf77', '4dd28204-946c-4e3e-9f94-011e7cfe2a71', '9e1b97a7-70c1-4a9c-b7e4-24d502d1d354', '2821dbe3-eada-4697-9bf8-6d2231bcb3ab', '773eb39d-37bc-46bf-bb97-e7255e4cd14a', '385cf176-a16c-4b3a-8da9-3068c90b7270', 'f99e50a5-1f03-4db3-9b06-70e6ed617e72', '80c7ae79-c60e-4f24-adff-67cc37c669b0', 'bc148bef-fa81-4381-a896-093ae780a61f', '15d2d249-2d69-46bf-94fa-fc88c1ed236b', '02ac4d9c-05d5-439b-a7a1-295d63b681d3', '8ff57fdf-61ba-45b7-9fc4-da37bae3d51d', 'da2b92ce-b681-426a-a22b-a273b73fb202', '5a426620-0b61-4c43-9766-59d25fd517ff', '4f3bd077-efa5-4fec-bff1-678eac17f575', '0d5c8c88-b52e-422c-be51-cc5ab23b3caf', '9771ac34-7213-4038-a0df-75d7c27090e9', 'a0816ea3-5c3f-493f-beba-eaccb62b23fc', 'cea9dbf2-269a-4d18-b4e7-622549027fb3', 'a69fddc1-fe99-4f80-b762-11426f89300d', 'c917aca6-2a46-43d7-bc07-b79f806d0161', '5c17b724-cf30-420a-a48c-39f3ad4273c5', 'f4a9263c-ac51-420a-bf67-96d40a36a3f9', '92615459-d326-411a-96c4-9dece035518d', '43b69a2d-f0c5-40d8-8522-843963078c6f', '768e2b68-4aa9-4d9d-a428-2c862d0be8bd', '0a031e44-a2b0-4b5b-8cb1-9bc1246d3bb1', 'fca91d02-798d-48c5-8400-3e4ca16079e2', '65989ab9-ceef-4582-8161-ce65f5fe16cf', '417b2fa9-f278-4a3e-ba44-cc34a0d78113', 'e3da74a0-6e05-4c1e-91ea-124bef5aa45b', '315ae817-c5f3-4909-8832-6654607a0f48', 'd541921f-3e3f-4df1-8d52-2ba57c748c36', 'fe7c8af8-a090-43d4-837b-2ac0e828bcbc', '0dcfcf07-9e88-4a6e-a3bb-0443c7b8953b', '245f5c47-9f58-4d33-8e81-f02878f6020c', '9447c46d-a7e6-4f6e-a4dc-79c3f7388ec2', '86d7825c-8e8c-4344-b61b-00ac9aa1ef01', '04c0005b-5dcf-4cac-937e-f631a34c58a2', '29d79794-3b12-4e94-87d8-b3a13a782d9c', '5ecf6234-a3c7-4bc7-a0eb-906ebc8b2d1e', '58142539-dc6d-4acc-9124-e70ee7a837f7', '00f2b9bf-85b8-49f0-888f-43e464dd0687', '0ffe336a-fa96-4a5e-b2dc-7c9a71bf965f', 'd4097453-9e49-4a8f-8707-315471818fa7', 'd32bc7f4-bc39-4329-8c04-4a698e5b201d', 'b07cc8a2-6adc-4d03-ba5e-285021d96013', 'c032b694-977b-412f-b534-9eddc505c373', 'b63ad7de-7f54-4e6d-8b5c-80bce0b9bacf', '52cb7aa9-374b-483f-a64d-7c0744c7f553', '24cbb60a-886a-42e5-9ef1-4c7bfd3007e8', '815d3eb7-ec5f-4bfa-b7a4-df40cc42c9e3', '1332f622-2d66-4d64-a17b-6613686d93ff', 'c6faee63-1e66-4e14-aa63-f48db6fd33d3', 'ac4e198a-dfd8-4318-90c1-2f261746f376', '9ab98590-ee81-4022-90c8-aa04aeb8c936', '92a92f03-aee9-4e35-8629-aa76692ea018', '7684c133-9a80-49e3-ac96-b0ed8f25dfed', 'f138e944-7dc2-4751-b531-5cd11784edff', 'cb85dd2c-8725-4589-a2f2-aec85d77d6ca', '9c19c2a6-866e-4c82-9e05-6979fce38aae', 'ea333932-0b15-4b31-a8de-a0552402009b', 'ba3c0086-3444-4951-9154-6124e17aa325', '0c2f87de-d384-4609-9630-2992403526ac', '5b8476c3-c958-4b2b-9f8c-228d880dfe9e', '01f4e9e6-4120-4309-af34-0cd5523ef74a', '2e473d1c-207b-45b7-821c-d4f2023d42db', '1358f01c-92ca-4258-bc25-7d375137d075', '1e0cb312-50d8-45d2-9080-530ea866757b', 'c52ebade-ee57-4ea3-a33d-d0054fc6357c', 'd58f5a61-497d-4f5b-b39d-e58eea39e012', '3710a9c2-be73-4ae1-8663-fba78c111ac4', '83562bad-6dfc-48ce-8dfd-9d59e22c44fa', '3ad1b862-1ca2-439e-b170-9868c8cfeb86', '1ed0a4a4-9ce6-4bf3-8449-e8ca553eba2c', '9320646e-33c0-4b30-8893-e7f63fe56f60', '7b5b8a2a-7ca7-4d55-837d-b7e2eefcbf2e', 'b8bbabbb-28b2-4305-b5d7-ac45443fb634', '491905af-18ad-4dda-bbb5-8795894a00c9', '182d6206-9a6f-42da-b098-69c6971cfde8', '90e020cd-cd95-4fcd-ad5a-215533a77d68', '0202f223-e3db-41b6-84a9-7993b8a55560', '63625bc1-03a8-4f75-b89a-5da98258b564', 'aae4c106-6cfe-4d33-9bc2-bf757d3cac6c', '37dc8f7f-7c3a-49d7-a787-1cc7616250a0', '6f7e1432-e6b0-4d88-ad3d-d2641a92e3d8', 'f60d683a-cfec-4fa7-abbb-962eff748fdb', 'a6a9734f-8711-4662-bba8-9fbb5344cb30', 'c631da85-1fd1-4f86-8b8f-3a5f2fa8a5c7', 'a5868081-8f90-4925-be1c-9bf3d5513fa3', 'c6cb923b-791d-43ce-a822-2dd5ec01f48a', 'd06bc771-76df-43e8-b424-b25eb9129aa2', '5ddcae38-bfac-4a9f-9a18-a11062b469fc', 'd5bdfab7-9a10-4309-8c82-a0948a3ef324', 'cda157e2-7056-4b70-b4a5-67e1ca9dc73a', '45e619e4-75a4-42bb-9e08-b7d5b88a2d8e', '4a165066-dc37-4b26-89eb-719a91df77c1', '15486c3d-d6d7-424f-85ab-b0fe1b575d0f', '22cde2eb-1463-4394-b6ea-ba091344cf4a', '3bd342cc-14ba-4542-af13-760b306d636a', '5ce56978-7e60-48f7-9643-bbab548fc361', 'bc37bf42-4a51-45d0-bf26-6c4f1b34553d', '899933e4-8e04-4504-8a81-03cfdfe9bad6', '1a16f34a-64bd-40a2-b0ad-db2eacb71d92', 'b88327c1-839c-4751-9f63-33a0b1dde324', '9301501d-f0e6-470a-85ed-f1cfe9af52c2', 'b9eb929a-d1a9-4ea5-93f3-a51bb0cdc63c', 'd40a852f-8fa2-47ec-8bcc-57d4f707f3f7', 'f15be979-2918-4be7-9566-2ed254ec0606', 'e7a0994b-6c77-43b7-be03-b1aca15d225a', 'a59eba65-0cf7-4a13-906c-0ec4d4c63c67', '32b62869-f485-4082-8636-d7ea5fd8989d', '97479555-2f01-4c5e-b78c-a443c738a412', 'aa45a9b1-7e71-4868-ad10-c5511dfa8087', '372898be-d385-4b61-a2da-b2aa9b46e10d', '827d463f-6227-493c-b908-f5766f2763af', '8f102534-309b-437d-b50b-632f2c2aabf7', '74ee779f-9927-43cc-96ae-9e6981c41fbf', '2b3de212-f026-46cd-bf05-75fa9d2fa6f5', 'a624db64-6e92-4c02-821b-f0ba5bd6b43a', 'a6af2a80-4239-485a-af44-f57ff84bf462', 'b603102b-6f30-44bb-92d6-a59b46ce1004', '73a00483-dc2c-4bdf-bd24-ebcf094818ab', 'd1daa921-6d17-49c9-a8c6-7add05b46927', '5269915a-d99f-4a2c-83e4-2feb48cb9314', '474eb326-ff33-42b2-a083-32d7ffbbfbbb', '4527f7cf-f445-4f69-bd54-8ff58abb6213', 'd1453cc6-4409-414d-88ea-7f34c030b8d4', '45efeb31-5e40-4866-9182-80a97e0b3ff8', '14b77624-d550-492b-b777-b4d741a5743c', 'fb012ba0-6907-47e3-abee-014f7afae5b4', 'caed7980-118f-447c-8416-12244ba57422', '69a15fcc-143e-4a3d-90e1-184a6ec102f8', '5b5dce2a-ec7c-4653-9b30-68b2f1242148', '512fb817-b21c-40ab-8ba5-711de5b19589', '62fef8b5-64a1-4ff9-b6d1-bc252fd34502', 'ee3e44c5-15b4-4095-b337-0392ec6eacc9', '285c2a09-6154-49c9-ba44-6a0890d74982', '3cc2954a-401f-4969-97f8-e76d4dc26e30', 'd7760fb9-12e1-46b4-a19f-841e7ae7f4a8', '7f2865cf-1ee9-4d3a-ad16-1a89d813f00f', '85667692-6909-4b84-ab58-8283a5d0e8df', '77dcc202-d459-4b19-8946-5c92614883d3', '4502f80d-676e-481a-b59f-b10835da361b', 'ff390e61-143e-4c10-8e14-cee621e6b548', '7aa736b7-df08-4e95-993e-f9dfc71de79b', '00f8f8ac-537b-403b-844f-ff2eef566183', '7caa9984-fd1a-423b-9d37-d5bd9f9fd4f7', '12895726-af47-4e69-ab7a-2855d22d30d2', 'e5e31a5d-3a99-4b2d-a950-675399ea7593', '3d95b88b-0ea2-4f3d-b665-8b452dde329e', '869ed62e-f1d7-47eb-aa19-0d0fd4f48b76', '055d1e76-b9f5-44c4-96a6-21b4584b1cb9', 'a0025028-0b95-4f7f-ac59-292da1cf462c', '215485d0-d231-4a15-9a30-a95426ec12c2', '979a5c69-fb20-42b3-a5d2-92c643fb5405', '80f50076-d0ef-4183-8759-e8020e4ffed5', '629788b6-8f5b-48bc-9c38-db92c5936162', 'a11c65fa-34a9-4a24-8f70-7dedfe991be5', '94d09b2a-c214-4598-9a1f-0860101c5ebf', '0d1449f8-6d84-4d39-859e-2012af40363a', 'a3a4bd36-e83f-44ff-844b-49df846bb517', '3d69ff83-01d9-43f5-a2a0-6fc0ae12af63', '3ca7731a-8b6d-42ff-91cc-7c15d10d422c', '6a422216-3293-409c-bbc7-4e5744f6897b', 'd9563294-e0b0-4894-b7f8-8ddb306ab685', 'a9bbf784-ea20-4b6f-a3c8-8f45ac0d733f', '0d4d706a-d6ca-43a1-a190-b451d288c3d3', '4988d69c-ccd5-4dfc-9798-0f0b41eee624', '009c6c6c-020a-4177-993f-c88d8c6a036b', '471d7610-09af-42b0-9dd9-30cfaa253671', '13aefb12-599b-4316-9ad4-d6d367ef9f6c', '5d8e504c-2674-48c7-8bdb-03ab572ab915', '8fc53c8b-7bf0-4eb6-b189-4bcb34277622', 'b8f29d9f-d866-4d8a-8555-7057f20de1f1', '41349908-3bc2-4571-9811-cc6fb844069d', '9ff2fbaa-1271-463f-adc3-6180a558e32b', '5b857a89-2024-44aa-a4f3-e67b8b850caa', 'eb6f7f70-494f-473a-9cfd-444d933690a3', '73116615-5768-4eca-8e8b-f15ba608f4f8', '9bded9d4-a229-44f1-8d19-252e8cac5bd4', 'e3026c88-891d-42b0-a856-89af63adf964', '43d89c5c-539e-40a9-be88-c287e210a3fc', '5e447b03-dff7-45d6-bc5b-3a8576e64aec', '75ab8a8f-d207-4aaa-bcb1-e5d9b9196732', '0c432292-c3b5-4360-9dd7-fc551118d7b4', '22ff4a3b-34b9-44d8-9247-884ad83402cb', '1db321fa-8bac-44c3-a78a-90e40767b85b', '0f652c30-31d8-4c98-a848-df60f6110bff', '29f02974-d11f-4cec-82ef-66d24187c68f', 'bdd63ebf-c467-44d5-8828-3a04e49ece1b', '49ae31a4-e29a-4196-b6c9-4e5798b9546b', '8f45f58a-5dca-47fd-bf75-89e1f5c76e8d', 'fd225edd-c043-4c88-b71d-a1cd88df77c6', '9ab99138-9d3d-48ca-928e-d08059deb062', 'c06eecd1-c9ea-4c2d-8995-e705586e83df', '25eea6c2-64a3-4160-85d7-2cb974f2ce66', '51ae8dad-6105-4984-8594-dbed1a022a88', 'f69b1881-3ccd-4daa-8c90-c28ae2393ef0', 'b103358f-87e4-49e0-95f6-8d99147e0517', 'f8c324ab-464f-4d5d-875b-a1d32ae45ac7', '6e52eb91-e3a6-4777-aa2e-5afc0484e63d', 'b2dcc6a9-34c8-4900-9fe9-c93b712e064c', '7d8cdedf-61c1-4c48-a4dd-10780edd2d22', 'e614642a-553e-4712-91aa-a15270959b03', '7bcafd4a-0ecf-496f-827a-0bdc99e2338c', '3dcf29f3-29c0-4335-9890-44b21864da60', '94d0c124-22a9-4c39-97ab-b43da7bd8848', '7fb3f8c3-8e1a-4e2e-9066-2502394e907d', 'bcbd24aa-10e4-4106-9872-be0cbf5645a9', '6822afba-1462-4dda-b4ea-dfb9dc917c2f', '0d9ae645-d17d-4143-be97-020ecdf736b2', 'f242b619-50c6-47c6-a364-0f144c88bbdd', '2d37c459-1c8f-4330-83f2-908f0c5171bc', '6e0b6f9d-bc53-420a-a127-ccd868d5c199', '58816b97-f71c-4666-b961-5cb3b79f3370', '28032201-e70c-4298-afea-5c87e35d54f4', '19cf7903-1e49-4c5a-b7fe-67be04d423fd', 'ae50ff57-5c78-40e5-a27d-15d511b0ba9b', 'aa8b79e6-f4b0-4dc4-b393-3ae2afe521ad', '536ea313-5215-47b2-894e-969247cedb26', '3f75d817-9ddc-4273-bc5c-afa14d90e1f0', '578f856a-93ca-4dba-bfe4-edf07b6f0f4a', '843e0900-40de-487f-be23-95b85e3643fe', '65090f04-9255-45c5-bfd9-08fe1a6998c7', '2eb36251-60f1-4445-a099-05197a393c1b', '6d302a62-9929-4eda-baf7-5f6349992ccc', '2d150975-ab94-43ec-8e72-8376ffaf8af8', '0a5b30e5-9a3c-4813-9b30-044aebabd973', 'b08e3150-75da-4368-acb1-2affd80167cc', 'f161ed61-97cb-4ec3-9eb6-90b83677456f', '9fbcbcc6-b988-4650-94c7-c161460b1c66', 'db6e7f65-63e6-4efc-b546-16bd57f2eb55', '61b4cb83-2796-4b80-a19d-f6185e44c25c', 'b4a08b3e-ec08-41ab-ade9-607e599d6ce9', '541381e0-3748-4782-aa72-4fe41f871ebe', '3f4eddac-daa2-45d1-a3ed-c56a47ed20ff', '0b860141-902f-493c-b7d9-93f9d2b0f796', '0bd26648-4c99-47f4-a258-cf66cd044934', 'ee832277-d8ea-41f7-b4af-1b167a8cd5ba', '57f1eb13-4dec-46db-9a76-9b4881a51a68', 'e5fbaa8a-997f-4be3-84c3-7c16f10d6338', '64a464e8-1d0e-4f4c-848f-22fb425fa743', '488453c3-2194-4696-9e06-81bc562c9bcf', 'c77bcd16-4e54-486d-9bd7-4a10957bca59', '97d2fd19-7d35-49a1-92bb-cfb8379653cd', 'a494d2d1-f650-42cb-bd91-89be4e8b2deb', '2fc6ccef-914a-47f6-8486-0e854b18bcfd', '3ff72914-8231-4e1d-b66b-400175938627', '22aff74f-a0dc-4d7a-961a-f5f60a226418', '97baa0bc-3bc9-42b4-8f77-f3639542c094', '2e0683e6-a8bf-445b-a540-4d85e7ee74d0', 'b47e37dd-10bf-4757-855b-c49277687c4a', '63cb62e2-c9c8-4798-be49-1ab8f3f5c871', '0a0295c7-28f5-4ee3-a443-329250104793', 'b1dff655-014a-4274-bf14-0ef09657e8a6', 'be31337a-e888-4d37-b642-0636ae494450', '49cee6f9-ce35-4e30-adb1-4ce45b11c4c0', 'f441f95e-a6eb-45c8-99e5-064bec6da040', 'f8d797d8-303a-475c-acf7-8b5a32ae384e', '7c294229-d795-4f08-b807-457a880f8935', '3177689d-21d2-4276-8dc5-b3c64c17ff19', '6c67ff6f-a5db-47ed-ab38-3ff3fa4b7fa0', '34b1a152-be8b-4b40-a3ff-a72815220d90', '4ae7e311-7e62-4969-b0dc-33803d009be3', '9510d7e4-b6c2-4ff7-aa9a-a3c855e8e662', '0573b992-68ed-4ad5-b90c-a1f0e5da697c', '9eabeb2a-a513-4868-8d06-8c448e7b6327', 'e7084a56-4b06-447e-a110-29343349d194', 'a5223f68-ac29-4b93-952a-e4fae6c7d8b9', 'a9d2453b-e4e4-4ac8-a3c7-61a1573cc9df', 'a6a21b34-d26a-4fae-9cc1-b44936832c8c', '7d879d4b-219e-49bd-92c7-6f2d29b247ac', 'a923ce25-2de0-4e88-9851-2a1c9e49b4d9', 'e87e0ef0-7874-429c-8622-1627983f456b', '4dba6e2a-8053-4d23-a280-6f9eb5f6ad94', '14ccf8af-783b-4364-bff8-ef0de7936681', '30aed616-d1f6-4e46-b02c-2ee8c2be9904', '999e2ea2-38df-4227-9b43-3501bbca7830', 'fc5f0fb3-5fde-4b3b-9c46-8cd444ccf802', '397c3d8c-5194-4d99-8a33-d1f86f30d951', '72afadf7-246a-4df4-866c-34968ae6e0af', '9af727cd-d19a-4b95-8fa2-47bd230baa29', 'eecd1c39-32cb-4fb8-ab7f-58529637840e', 'af9cde53-c183-44ae-b8bd-d77f52114d99', '62df0cd2-5886-4364-9305-80a99dde6b18', 'ac08e400-7357-4cc2-8e22-909c3f321064', '14403bb2-0ab8-40e9-8a51-c187a3e5fe52', '1296989d-b4a1-4d7a-b398-365b851c2066', '1e410e05-de54-463f-8684-daa1947f98f1', '0405b13d-7700-4e10-b9e6-253480b99032', 'c61765ed-7d34-490f-a52a-0fe2f8ee0851', '8db0bb69-6748-4ca2-8323-67ea378b4fc1', 'ddbe2cd9-3d21-42d7-bd28-211a2c933969', '0ea53748-7216-4296-8bff-9f56d5578467', '5b1d0d54-fc0e-4734-bfcc-ff49ae95c0f7', 'bdd29177-2f67-40f0-951a-84431769885c', '9b96d352-2f18-48f8-b569-69714c9f0377', '8c6eed4d-7770-4616-a714-0844bc0e926b', '8107f55e-d8c0-40b6-b035-d4ed0d164b24', '4a47376f-9c38-468e-b8fc-15f3337fcb26', '6bba8e21-9893-41eb-971b-6d6d334168dc', '8287330b-5d2f-4a2e-99ee-3c442eeafd1e', '7e2229c3-b7cd-4b2f-85db-49178ad36e3d', 'c5d4914f-79ef-4b77-b4ff-ab458a6bbed4', 'a65f6c7d-2424-41b8-bd15-b3a9e0a5c140', 'db2246db-049b-42bd-bcbf-caf0f7190f53', 'cdc02432-874b-481d-a771-3fb08e6d778c', '554da233-44d9-456f-a58c-1a9edcdea248', '354d77ec-b133-4550-8b5a-d742c16be9e5', 'b2811002-f758-4063-bb2b-f783c689dfe0', '30dcb9a0-b2fd-4b3e-a474-f9208d8347a6', '4378d92e-3356-4187-9685-29d6fe43a5cb', 'cbe42ad6-d3c6-4a56-834e-d95bc555468d', 'ba1969c2-107b-4b48-8477-3fdd5a0f0fb5', 'aad00405-2ee0-4e80-8a7c-4c6ca275df23', '10e020c2-410f-4f9e-8887-8d087dffe48e', '87d6c1ba-0876-4dd9-a6c9-cd742d483f0c', '00dda89e-7c36-4fd8-9a12-f654db12720f', '74909de0-7f8c-4c24-a24c-45a3c70a870b', '3619a03a-5f97-4210-979e-c705adb589da', 'd8e706fd-8596-4bfb-a824-ea3a030a8391', '3cf1af89-d3ce-42e8-a090-6c473d5368b1', '6ea60335-eb97-48d8-a49c-29fcbce9c8d6', '9d3c341c-4df2-440a-ae8f-98722de78744', 'aeb08931-d7f1-49d9-8986-47a1468b4850', '6a223f64-2700-4ad6-802a-36c3cd560862', 'e8d4179a-b8e6-4fad-bcbe-51c40fe82862', '91498c1b-9a3f-4749-8465-c3930ae82519', '19c108fb-f00f-4a54-a6ba-98d7704dd8ff', '7a76a7bc-991f-4483-ac76-6f8aa20ea6e4', 'ebe45ec3-6bcc-4139-ae12-ee17df1f0c0c', 'b3cff664-e421-4565-9975-7a8a02992ae0', '284afc25-b911-444d-92e8-e4f620489e02', '8d8d2ed9-00ad-48a9-98c5-063bcd647b3b', 'e6e4ee61-814a-4f75-9642-6aab98b3cc54', 'f96eba41-ec23-4b28-bad4-1436d131974b', '675d3ae8-5727-451c-8864-bfad555ec4b5', 'abf693c2-bc89-4191-b208-8335ae36a2a8', '628a5a15-591e-4623-a433-1e1169c11bd9', 'c57fb3bf-686e-44fa-b80e-df43c9b9b737', 'be38c11d-acd3-4d65-b4b1-98a58486ac82', '039d27f3-e243-48ab-8bd5-5b54c853a6ca', '77070a23-2f6c-4b06-8f25-ead59e8d9215', '47b1b09b-774e-4999-94bb-7e5e240e41e4', '13d6d718-d85d-4c4e-b395-c8ce79ed460e', 'e892ea4b-0527-4358-a525-cafd609b6dc5', '01fdef50-08bb-44a5-9220-65a2c099601d', '61763a9a-da42-4c2f-9d54-2e86cab6f735', '78fbc704-d06e-473a-b0cf-5331598a86c6', 'e18c0ccf-3cea-4708-9ab1-e7b99d990658', '60960903-f7b0-4913-b767-9f1cbc0727c7', '0d516e7d-1444-427c-9972-2696fdd69484', '9e54341a-9d97-4f9b-88fd-0d9291d47c61', '7ec830da-b598-4122-a956-38be2d9131d3', '386a49fd-4a60-40dd-8fe3-31aff02d4283', '00e280a4-5647-49b7-96a3-9fefad890cea', 'f1259368-1d58-4e5d-9599-5f07a9167613', 'd9201d29-3b35-425d-b0b5-e74fc287335e', '46c6b65a-2065-4c53-b600-c3abc1ae1f08', '0c2e4836-f1fd-441c-8daf-60db4685a0dc', '9dfb181c-03fc-44f3-af30-61f08d2c1e74', 'eef38a57-ed67-498d-ae7f-4dc9369d7b9e', 'f5181a20-0c6c-4c20-bcd9-ce69cd4b5c95', '153a4dda-a6e6-4911-a9bd-65e518f217a1', '46a5cf87-8541-4c1f-a999-6bbdfec061cd', '6125d412-a54c-4266-b7d1-0f2fc835e6bb', '84a4edc6-53c6-4ddb-a8be-60b8c3a0f74f', 'f274cc46-0df5-4b64-94e7-43d16b87b36e', '0ddb2415-7aeb-4c2b-b9cd-ffb4e8e2ba86', '918785f7-da46-42b8-8f6d-e0b920561102', 'a16c2b94-1c6c-4784-93aa-6e8e1675fb4b', '5dfbdfb5-221e-421d-9f18-f17d870728a8', '76f44065-8547-4237-953b-81d737c59261', 'cfd44cc3-64b3-42e2-85ca-f274064328bc', 'edea9b7a-495f-4aec-9870-4f42ada6ae16', '18f94211-37db-4608-b7eb-eda0aa3560ce', '1cd585c7-a82b-45eb-81af-ccbf2e370cab', 'af580333-2e0d-44c3-972f-93d422e09ffb', '020cc272-ae95-42ee-8584-594d4eb40e1d', 'b3f82124-b907-4282-97a7-d3088313d578', '27609f35-1f27-4a8a-9112-e2f2f15f9ef6', 'bc068b0d-3044-4538-8b77-decda7c5da90', '6c8cfd3a-3dcf-4d33-adaf-241c7af7288a', '300f8b07-c3d0-4ccb-8e8d-e726f795fe6d', 'f8d5034b-2753-498f-acfc-9dc50e7f3334', 'bdd40088-e0ab-4b0f-b490-df4fa686a697', '7d95d40d-8274-46fe-8867-ea7a600f41e2', 'd6877a9e-5cc1-4711-8c0f-993b2f506be6', '1afb67c9-600e-410b-82f6-c39e9ee5836e', '94053708-5ba2-4729-9190-6028d8fe9c9a', '0f916a1b-a623-464c-89f2-50f2ddc0c1a1', '992fc5c6-ca6b-4ccb-a241-6a96d797c117', '1887c4d4-4216-4f9d-8520-978fec5d6127', 'f3649b9d-e9b0-4732-a8da-11be6e752a5a', '7809295c-5590-4d15-9da1-d4ea7bc7843f', 'ea50e4bb-de04-4bdd-94ad-d3f904071aa0', 'd94dd49c-7cd5-4102-bc49-bbbda152146f', '6b7f23b3-f523-4b52-a81d-f0a6470ecc7a', '96db6441-99fd-4d44-a081-96a587fa9bad', '92625270-b7dd-4f86-ac65-48a864b541b6', 'ef794a71-375d-4e21-bb39-fa3484b62f41', '5255d2c9-a767-4c14-8f6d-d79972c00131', 'b4be876f-1e5f-4a68-94b4-199842fc2e6a', 'f2fc174b-e63b-44da-9d8f-d5547c4a3c4f', '456c9f67-b3dc-4037-a8ff-98ea6766e64e', 'a04b0f29-68d8-498a-8eb5-59aa7fad2a80', '914b1643-caf7-4fd8-862f-a2bce287f773', '0c7a1290-ef03-4f11-9b9f-10b309711805', '2291161f-bfd4-4839-a9bd-f87a8fda8cd5', 'bdb1a209-e81d-429c-b27e-5e22629c1ebb', '742cdd7e-b554-4dfa-9c41-b5a6e0f27558', 'abceeb34-e239-4887-8b81-104c39f07cbd', 'd8177cca-bc63-4aac-aa43-bde77256013c', 'e02103c3-8f44-4ab0-bc94-5f1e13aab895', '1750c2ba-c7f8-42b6-9a1d-5a09b7f6c6ea', '320961b1-1a4e-40eb-a125-5cf83d594f74', '97848783-dec8-4c54-84be-384e8f11bb37', 'faa7f6d8-5245-4a46-be99-90a39b294216', '3529e83d-8734-4a45-b9d8-d89234aea99b', '04becf5e-c2a3-40bc-a083-f0f9f4d94ed6', '8439c321-484c-4a13-8f80-327d62c677d1', '82bea87f-57cb-42cb-b6a1-81c292340582', '65345ee1-a6b4-42a1-b6e1-4946466b431a', '9d52ed2b-1c92-484f-9fcb-f89222480413', 'b70b5066-d748-4d14-a159-b21ac26fa0a3', 'f49d3abc-c0e0-410f-b2d0-99ca91db3d39', 'a33055bf-263b-4764-a5af-8b370310d3f9', '17afbe04-4c13-43dc-8bba-42cdc9f4dacf', '7ee83e41-1243-438b-9223-581a698aca46', '8c3abd74-b636-4483-b546-af2e26853804', 'fa8bd63c-0577-48c4-b6b8-2e1ee86376c4', 'da9ae857-6b73-46a8-b19a-0161bb4b855c', 'b0e2cb10-954a-4815-9d79-b661a9f83600', '0165cff8-21b3-4c64-bc92-17998fdcbc21', 'b07cb0f2-e1d0-4800-b99f-cb10f3e0ae77', '495d81cc-1b59-46e9-a3da-3d3d675e70bb', 'ec61d646-9f07-4e97-a993-32863a900786', '6310ce44-3a8f-489b-be51-2548b748857e', '260d2cdd-5adf-4cc3-a2db-6191d07c26eb', 'f50a7979-f116-414a-8c9a-d80811cead59', '2b9c559e-d840-4b4f-b38f-49da384fd099', '6a58d5a3-8021-4869-801d-809f31d9caa3', '755bb06d-058a-4735-bd8f-dd53752159b2', 'd4019569-6b72-4d53-a590-5efc2e00e19a', '84815a04-672d-497d-9bc3-261cf3a266d7', '506c4aa8-aca3-4e87-bff5-f61ab8f06f66', '65dfbb67-48ad-4f5b-9d0b-6b3340340794', '4bc31f79-3612-4d80-847b-e72041c9c212', '918143b0-ff4e-47e7-9c8b-cad90d3fa5ed', '6db22fe2-82fb-43e8-aefa-60eb62dc34e5', 'dd2005f2-3688-4f3f-a982-f7956383e45a', '7e199da9-38bd-4c71-90b1-be846f54a33f', 'cb78ecd1-b606-4898-a730-03bf26976d89', '9284d38f-c07b-43a7-aae8-8732a937c350', 'a1d1920e-20e0-49ae-84eb-446452ada8d3', 'e978cc2c-34d6-4091-9ac9-24c3ba7259ef', '72c81dd5-c2fe-4b62-a955-54cbbff415be', 'e17b88b6-ffb0-4893-ac72-97a575172e40', 'd57be22b-6d3e-4d47-8e87-ed0526882f0d', '0f3db2ef-5ef2-48ba-861e-acde112a9d69', 'f3cb5cbd-c69c-4b93-a782-0f8f3587344f', '96c31e0f-5b9a-4a07-b4eb-f0d231141f29', 'ce1982b2-3dc4-4af0-898f-fe015cf19a84', '55ee7626-b5cb-4e53-842d-ebd508315533', '1c43f7b7-d18e-4be5-a9af-36f4fe3aefae', 'e026e076-0196-479a-9910-c490b16cc601', '7ba1342d-e80b-4271-833a-b3ed162cbc1e', 'fcebeb98-daa6-40a2-bf91-cb8b91b6886f', '3ebea57f-b7a4-4644-99a5-d390860d485e', 'f897b7eb-d2df-4a4e-83c3-ed2d6133cd2d', '61a6eb43-1400-409e-8e98-c43af8101c3f', '208522b4-eb8e-4d0c-b20e-d3d3b93dec22', 'a6d8288e-9ed8-469e-b08c-fa9b3ce8e2fa', '6d29e35d-c92e-4ba4-80e5-16dd37619389', '32a2c1f7-de12-4844-9a1c-8e4d5b74420c', '2f4b8561-e4ac-475f-9940-504abdd210ac', '98fc8344-e833-4d97-a876-ac0064af2e34', '23f68ada-42de-42e0-87b1-e39d68f725af', 'fd8a9958-adc1-4079-8ef9-6c815fe7b01a', '3aefe3f9-3eea-47f4-a596-33f1da7a5ef2', '21ba7cd8-4d64-4a87-8f9c-a4fd187dcd64', 'ddb0b049-bad0-40a7-8b18-2e9f9e3b1b06', '60757bdf-1f14-4ecb-b0ce-88ceec5e24b3', '2630f206-ce78-48fe-89d6-0a6a63dde05a', '79b29086-55ac-4d45-a111-2fdaf1e7e552', '729305f2-2bf5-4d8a-969a-e588fe025e38', 'ecca1201-07fe-4c71-8050-a92841490e15', '4a0e4968-2d9b-41b4-9bf2-b9944f1bc0f9', '374489b5-3d76-4978-b672-60fcbaa90506', 'a4cd7cf9-098a-4e32-8f61-840e7593a0bf', 'b32cbff6-a275-4b21-b01d-6bccf421ef98', 'd9702508-26e3-4093-a5f2-5cda647a327f', '69f46b86-9bc4-4188-bcc7-001916a06514', '2bc86192-a5dd-490c-8e2c-5ca985686d35', 'bfdae63e-59bc-444a-8c3e-3512e255d66a', '656e2f59-7969-4652-9211-be92fd078916', 'ee7c4767-305b-4098-8906-a8ec8187b4c7', '2b6dfa98-0e45-4d5d-a2f4-165cfbc76fcc', '85728ac1-4dee-42ee-bb2c-68e63d5dfc31', 'bca885da-d164-47bd-b50a-d832fecb3290', 'ce518a22-34c1-4c69-a1c6-2974f34735b5', '3c2ce546-8b71-4282-b43a-46bfb27729fb', 'fbf496f6-0592-454b-b341-72d1af78d81a', 'afc5511f-ab46-42a8-a8f0-3411e6d5eca7', 'fd990504-60da-451f-82e8-c7ffab27ab7f', 'cbfdfa09-5559-43e3-b6ba-896c6356a26e'], 'embeddings': None, 'documents': ['myocardial infarction (NSTEMI); percutaneous coronary\\nintervention (PCI); prehospital; revascularization; risk;\\nST-segment elevation myocardial infarction (STEMI);\\ntime factors; treatment outcome.\\nAdditional relevant studies, which were published\\nthrough April 2024 during the guideline writing process,\\nwere also considered by the writing committee and added\\nto the evidence tables when appropriate. The ﬁnal evi-\\ndence tables summarize the evidence used by the writing', 'committee to formulate recom mendations. References\\nselected and published in the present document are\\nrepresentative and not all-inclusive.\\n1.2. Composition of the Writing Committee\\nThe writing committee consisted of general cardiologists,\\ninterventional cardiologists, cardiovascular surgeons,\\ncritical care cardiologists, emergency physicians, cardiac\\nimaging experts, advanced practice nurses, clinical phar-\\nmacists, and lay/patient representatives. The writing', 'committee included representatives from the AHA, ACC,\\nAmerican College of Emergency Physicians (ACEP), Na-\\ntional Association of EMS Physicians (NAEMSP), and So-\\nciety for Cardiovascular Angi ography and Interventions\\n(SCAI). Appendix 1 of the current document lists writing\\ncommittee members ’ comprehensive and relevant RWI.\\n1.3. Guideline Review and Approval\\nThe Joint Committee appointed a peer review committee\\nto review the document. The peer review committee', 'comprised individuals nominated by the ACC, AHA, and\\nthe collaborating orga nizations. Reviewers ’ RWI infor-\\nmation was distributed to the writing committee and is\\npublished in this document (Appendix 2). This document\\nwas approved for publication by the governing bodies of\\nthe ACC and the AHA and was endorsed by ACEP,\\nNAEMSP, and SCAI.\\n1.4. Scope of the Guideline\\nThe scope of the “2025 ACC/AHA/ACEP/NAEMSP/SCAI\\nGuideline for the Management of Patients With Acute', 'Coronary Syndromes ” (referred to hereafter as the “2025\\nACS guideline ”) is to incorporate new evidence since the\\npublication of the “2013 ACCF/AHA Guideline for the\\nManagement of ST-Elevation Myocardial Infarction, ”\\n1 the\\ncorresponding “2014 AHA/ACC Guideline for the Man-\\nagement of Patients With Non–ST-Elevation Acute Coro-\\nnary Syndromes, ”2 and the “2015 ACC/AHA/SCAI Focused\\nUpdate on Primary Percutaneous Coronary Intervention\\nfor Patients With ST-Elevation Myocardial Infarction. ”\\n3', '3\\nThe 2025 ACS guideline and the “2021 ACC/AHA/SCAI\\nGuideline for Coronary Artery Revascularization ”4 retire\\nand replace, respectively, the “2016 ACC/AHA Guideline\\nFocused Update on Duration of Dual Antiplatelet Therapy\\nin Patients With Coronary Artery Disease.”5 This guideline\\nprimarily focuses on the management of type 1 acute\\nmyocardial infarction (AMI). It can be challenging to\\ndifferentiate type 1 versus type 2 MI. In cases of uncer-', 'tainty and depending on the bene ﬁts/risks of a speci ﬁc\\ndiagnostic or therapeutic intervention, it may be appro-\\npriate to err on the side of considering an event a type 1\\nacute coronary syndrome (ACS) event until established to\\nbe otherwise.\\nIn the United States, an estimated 805,000 AMIs occur\\nannually of which 605,000 are ﬁrst MI events and\\n200,000 are recurrent.\\n6-8 Although signi ﬁcant morbidity\\na n dm o r t a l i t ya r ea s s o c i a t e dw i t hM I ,3 0 - d a ya n di n -', 'hospital mortality rates after STEMI have declined\\nin part as a result of timely reperfusion and\\nimplementation of evidence-based secondary preven-\\ntion.\\n9 From 2011 to 2021 in the United States, the annual\\ndeath rate attributable to coronary heart disease declined\\nby 15.0%.\\n6 The economic impact of MI is also substantial,\\nwith the total annual cost estimated at $84.9 billion,\\nincluding direct medical expe nditures and indirect lost\\nproductivity and wages. 10,11 The incidence of MI is', 'higher among Black males compared with non-Hispanic\\nWhite males for reasons that are believed to be multi-\\nfactorial.\\n12,13 Potential factors th at may contribute to\\nthis disparity include a higher prevalence of risk factors\\nfor CAD, less use of guideline-recommended medica-\\ntions post-MI, and socioeconomic factors.\\n14-19 In addi-\\ntion to racial disparities, there are sex-related\\ndisparities in the prevalence, presentation, treatment,\\nand outcomes of ACS even after adjusting for con-', 'founding factors such as income, geography, and edu-\\ncation.\\n20 W o m e nt e n dt op r e s e n tw i t hA C So na v e r a g e\\n10 years later than men and with a greater burden of\\nCVD risk factors. Although chest pain remains the most\\ncommon symptom of AMI, women are more likely than\\nmen to present with accompanying non –chest pain\\nsymptoms.\\n21-24 A delay in recognition of these symp-\\ntoms can result in delays in presentation, diagnosis, and\\ntimely treatment of women with ACS. Studies have also', 'shown that women presenting with ACS are less likely\\nto be correctly diagnosed with an ACS, receive\\nguideline-directed medical therapy,\\n25-27 and/or undergo\\ncoronary revascularization when indicated. 28,29 Bridging\\nthese racial and sex gaps will require continued pro-\\nvider education, better understanding of barriers to\\naccessing quality care and guideline-directed medical\\ntherapy, and changes at the community and legislative\\nlevel to address social dete rminants of health such as', 'income, employment status, neighborhood safety, and\\naccess to healthy foods.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2141\\nIn developing the 2025 ACS guideline, the writing\\ncommittee reviewed previously published guidelines and\\nrelated scienti ﬁc statements. Table 1 contains a list of\\nthese publications deemed pertinent to this writing\\neffort. It is intended for use as a resource, obviating the', 'need to repeat existing guideline recommendations.\\nSome recommendations have been carried forward from\\npreviously published guidelines. If unchanged, those\\nrecommendations remain current. Any changes to the\\nformatting or content of these recommendations are\\ndeﬁned as:\\nn Modiﬁed: formatting changes (eg, minor verbiage\\nmodiﬁcations such as PICO[TS] structure)\\nn Adapted: substantive changes (eg, major adaptations,\\nsuch as a change in Class of Recommendation [COR],', 'Level of Evidence [LOE], drug, or device classiﬁcation).\\nChanges are depicted in a footnote below the recom-\\nmendation tables.\\n1.5. Class of Recommendation and Level of Evidence\\nThe COR indicates the strength of recommendation,\\nencompassing the estimated magnitude and certainty of\\nbeneﬁt in proportion to risk. The LOE rates the quality of\\nscienti ﬁc evidence supporting the intervention on the\\nbasis of the type, quantity, and consistency of data from\\nclinical trials and other sources (Table 2).', '1\\nTABLE 1 Associated Publications\\nTitle Organization\\nPublication Year\\n(Reference)\\nGuidelines\\nManagement of blood cholesterol AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/\\nAPhA/ASPC/NLA/PCNA\\n201830\\nPrevention, detection, evaluation, and management of high blood pressure in adults ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/\\nASPC/NMA/PCNA\\n201831\\nPrimary prevention of cardiovascular disease ACC/AHA 2019 32\\nCoronary artery revascularization ACC/AHA/SCAI 2021 4', 'Evaluation and diagnosis of chest pain AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR 2021 33\\nPrevention of stroke in patients with stroke and transient ischemic attack AHA/ASA 2021 34\\nManagement of heart failure AHA/ACC/HFSA 2022 35\\nManagement of patients with chronic coronary disease AHA/ACC/ACCP/ASPC/NLA/PCNA 2023 36\\nDiagnosis and management of atrialﬁbrillation ACC/AHA/ACCP/HRS 2023 37\\nOther Relevant Documents\\nHome-based cardiac rehabilitation AHA/ACC/AACVPR 2019 38', 'Classiﬁcation of cardiogenic shock SCAI, endorsed by ACC/AHA/SCCM/STS 2019 39\\nContemporary diagnosis and management of patients with myocardial infarction in the\\nabsence of obstructive coronary artery disease\\nAHA 2019 40\\nInvasive management of acute myocardial infarction complicated by cardiogenic shock AHA 2021 41\\nMechanical complications of acute myocardial infarction AHA 2021 42\\nSHOCK stage classiﬁcation update SCAI, endorsed by ACC/ACEP/AHA/ESC/ACVC/\\nISHLT/ SCCM/STS\\n202143', '202143\\nManagement of patients at risk for and with left ventricular thrombus AHA 2022 44\\nCardiac catheterization laboratory management of the comatose adult patient with an\\nout-of-hospital cardiac arrest\\nAHA 2024 45\\nAACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American Academy of Physician Associates (formerlyAmerican Academy of Physician', 'Assistants); ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACCP, American College of Clinical Pharmacy; ACEP, American College of Emergency\\nPhysicians; ACPM, American College of Preventive Medicine; ACVC, Association for Acute Cardiovascular Care; ADA, American Diabetes Association;AGS, American Geriatrics Society;', 'AHA, American Heart Association; APhA, American Pharmacists Association; ASA, American Stroke Association; ASCVD, atherosclerotic cardiovascular disease; ASE, American Society of\\nEchocardiography; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; CHEST, American College of Chest Physicians; ESC, European Society of', 'Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm Society; ISHLT, International Society for Heart and Lung Transplantation; NLA, National Lipid Association; NMA,\\nNational Medical Association; PCNA, Preventive Cardiovascular Nurses Association; SAEM, Society for Academic Emergency Medicine; SCAI, Societyfor Cardiovascular Angiography and', 'Interventions; SCCM, Society of Critical Care Medicine; SCCT, Society of Cardiovascular Computed Tomography; SCMR, Society for Cardiovascular Magnetic Resonance; SHOCK, Should\\nWe Emergently Revascularize Occluded Coronaries for Cardiogenic Shock trial; and STS, Society of Thoracic Surgery.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2142', '2142\\nTABLE 2 Applying the American College of Cardiology/American Heart Association Class of Recommendation and Level of Evidence to\\nClinical Strategies, Interventions, Treatments, or Di agnostic Testing in Patient Care* (Updated May 2019)\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2143\\n1.6. Abbreviations\\n2. OVERVIEW OF ACS\\n2.1. Deﬁnition and Classiﬁcation of ACS\\nACS are typically caused by th e disruption (rupture or', 'erosion) of an unstable corona ry artery atherosclerotic\\nplaque with associated partial or complete coronary ar-\\ntery thrombosis and/or microemboli, resulting in dimin-\\nished blood ﬂow to the myocardium and subsequent\\nmyocardial ischemia ( Figure 1).\\n1,2 ACS includes 3 related\\nclinical conditions that exist along a continuum of\\nseverity: (1) unstable angina, (2) non –ST-segment eleva-\\ntion myocardial infarction (NSTEMI), and (3) STEMI. The', 'initial diagnosis and classiﬁcation of ACS should be based\\non the clinical history and symptomatology, interpreta-\\ntion of the ECG ( Table 3 ), and assessment of cardiac\\ntroponin (cTn). Unstable angina is de ﬁned by transient\\nmyocardial ischemia leading to diminished ﬂow in the\\nabsence of signi ﬁcant myonecrosis detected by circu-\\nlating troponin. In contrast,patients with more prolonged\\nor severe myocardial ischemia are diagnosed with MI and', 'have elevated biomarkers of myonecrosis. Patients with\\nNSTEMI may have a partially occluded coronary artery\\nleading to subendocardial ischemia, while those with\\nSTEMI typically have a completely occluded vessel lead-\\ning to transmural myocardia li s c h e m i aa n di n f a r c t i o n\\n(Figure 2).\\n3,4 The pathophysiology of ACS can be dynamic\\nand thus patients can rapidly progress from one clinical\\ncondition (eg, unstable angina, NSTEMI, STEMI) to', 'another during the course of their presentation and initial\\nevaluation and treatment. Other, less common causes of\\nmyocardial ischemia, among others, include coronary ar-\\ntery spasm, embolism, and dissection.\\n3\\nThis guideline will focus on the acute management of\\nACS, including unstable angina, NSTEMI, and STEMI,\\nwhich are presumed to result from atherosclerotic plaque\\nrupture or plaque erosion and subsequent thrombosis. 4\\nUnder the Universal De ﬁnition of MI, these MI events', 'would be classi ﬁed as type 1 MI events (Table 4).4 The\\ndiagnostic evaluation of chest pain and the management\\nof type 2 MI, spontaneous coronary artery dissection, and\\nMINOCA (MI with nonobstructive coronary artery disease)\\nare covered in separate documents.\\n5-8 Ad e t a i l e d\\ndescription of the approach to the evaluation of patients\\nwith chest pain can be found in the 2021 AHA/ACC/ASE/\\nCHEST/SAEM/SCCT/SCMR Chest Pain Guideline.\\n5\\nAbbreviation Meaning/Phrase', 'ACEi angiotensin-converting enzyme inhibitor\\nACS acute coronary syndromes\\nAF atrial ﬁbrillation\\nAMI acute myocardial infarction\\nARB angiotensin receptor blocker\\nASCVD atherosclerotic cardiovascular disease\\nCABG coronary artery bypass grafting\\nCAD coronary artery disease\\nCCD chronic coronary disease\\nCDP clinical decision pathway\\nCICU cardiac intensive care unit\\nCR cardiac rehabilitation\\ncTn cardiac troponin\\nCVD cardiovascular disease\\nDAPT dual antiplatelet therapy\\nDOAC direct oral anticoagulant', 'ECG electrocardiogram\\nFDA U.S. Food and Drug Administration\\nFFR fractional ﬂow reserve\\nFMC ﬁrst medical contact\\nGLP-1 glucagon-like peptide-1\\nHF heart failure\\nhs-cTn high-sensitivity cardiac troponin\\nIABP intra-aortic balloon pump\\nICD implantable cardioverter-de ﬁbrillator\\nIVUS intravascular ultrasound\\nLDL low-density lipoprotein\\nLDL-C low-density lipoprotein cholesterol\\nLV left ventricular\\nLVEF left ventricular ejection fraction\\nMACE major adverse cardiovascular event', 'MCS mechanical circulatory support\\nMI myocardial infarction\\nMINOCA MI with nonobstructive coronary artery disease\\nMVD multivessel disease\\nNSTE-ACS non –ST-segment elevation ACS\\nNSTEMI non –ST-segment elevation myocardial infarction\\nOCT optical coherence tomography\\nOR odds ratio\\nPCI percutaneous coronary intervention\\nPCSK9 proprotein convertase subtilisin/kexin type 9\\nPPCI primary percutaneous coronary intervention\\nPPI proton pump inhibitor\\nQOL quality of life\\nRCT randomized controlled trial', 'ROSC return of spontaneous circulation\\n(continued in the next column)\\nAbbreviation Meaning/Phrase\\nSGLT-2 sodium-glucose cotransporter-2\\nSTEMI ST-segment elevation myocardial infarction\\nUFH unfractionated heparin\\nVA-ECMO venoarterial extracorporeal membrane oxygenation\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2144\\nProgressive lipid accumulation and in ﬂammation\\nwithin an atherosclerotic plaque may lead to plaque', 'instability.\\n1 Rupture of the atherosclerotic plaque and\\nexposure of plaque contents to the circulation may then\\nculminate in activation of the coagulation cascade and\\nsubsequent thrombosis. The presence of thrombus may\\ncompromise ﬂow to the myocardium, leading to myocar-\\ndial ischemia and eventual myonecrosis. Since early\\ninitiation of therapy is imperative for patients with ACS, a\\nhigh index of suspicion is warranted for those who pre-\\nsent with signs and symptoms that could be consistent', 'with myocardial ischemia.\\nPatients with ACS are at the highest risk for cardio-\\nvascular complications acutely, including prior to hos-\\npital presentation and during the early hospital phase.\\nWith appropriate management, this risk begins to\\nattenuate; however, patients remain at increased risk of\\nrecurrent cardiovascular events for several months to\\nyears after an ACS.\\n9 This may in part be related to the\\nacute inﬂammatory milieu that exists after ACS that may', 'contribute to a heightened risk of recurrent events.\\nAlthough the point at which a patient transitions from\\nbeing a patient with an acute ACS to one with more\\nstable or chronic coronary disease (CCD) is incompletely\\ndeﬁned, many of the medications indicated at discharge\\nin patients with an ACS are similar to those for the\\nmanagement of a patient with CCD and should be\\nextended more than a year beyond ACS. The long-term\\nmanagement of patients with ACS who are presumed to', 'now have more stable coronary disease has been\\ndescribed in the 2023 AHA/ ACC/ACCP/ASPC/NLA/PCNA\\nChronic Coronary Disease Guideline.\\n10\\nFIGURE 1 Pathobiology of a Type 1 Myocardial Infarction Due to Atherosclerotic Plaque Disruption\\nProgressive lipid accumulation and inﬂammation within an atherosclerotic plaque may lead to plaque instability. Rupture or erosion of the atherosclerotic', 'plaque and exposure of plaque contents to the circulation may then culminate in activation of the coagulation cascade and subsequent thrombosis. When this\\noccurs in the epicardial vessels of the coronary circulation, the presence of thrombus may compromiseﬂow to the myocardium, leading to myocardial\\nischemia and eventual myonecrosis. Illustration by Patrick Lane, ScEYEnce Studios. Copyright 2025 American College of Cardiology Foundation, and\\nAmerican Heart Association, Inc.', 'TABLE 3 Electrocardiographic Interpretation for Pati ents With Suspected Acute Coronary Syndromes\\nNSTE-ACS STEMI\\nElectrocardiographic\\nevidence of ischemia\\nNew or presumed new and usually dynamic horizontal or down-\\nsloping ST-segment depression$0.5 mm in$2 contiguous leads\\nand/or T-wave inversion>1m mi n$2 contiguous leads with\\nprominent R wave or R/S ratio>1 or transient ST-segment\\nelevation.\\nNew or presumed new ST-segment elevation of$1m mi n$2', 'anatomically contiguous leads (measured at the J-point) in all\\nleads other than V2-V3 and $2 mm in men$40 y,$2.5 mm in\\nmen <40 y, and$1.5 mm in women regardless of age in leads\\nV2-V3.*\\nOther observed\\nelectrocardiographic\\nchanges\\nMany patients with NSTE-ACS have either nonspeciﬁc ST-segment\\nor T-wave changes or a normal ECG. The absence of\\nelectrocardiographic evidence of ischemia does not exclude ACS.\\nPosterior leads (V7-V9) should be obtained in patients with suspected', 'left circumﬂex occlusion particularly in the setting of isolated\\nST-segment depression$0.5 mm in leads V1-V3.\\nAdapted with permission from Thygesen et al.4 Copyright 2018 The European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, Inc., and\\nthe World Heart Federation. Adapted from Kontos et al.11 Copyright 2022 American College of Cardiology Foundation.', '*ST-segment changes may be observed in other conditions including acute pericarditis, left ventricular hypertrophy, LBBB, Brugada syndrome, right ventricular pacing, Takotsubo\\nsyndrome, and early repolarization that may obscure the diagnosis of STEMI.12 New or presumably new LBBB at presentation occurs infrequently and should not be considered\\ndiagnostic of AMI in isolation; clinical correlation is required.13 A new LBBB in an asymptomatic patient does not constitute a STEMI equivalent.11', 'ACS indicates acute coronary syndromes; AMI, acute myocardial infarction, LBBB, left bundle branch block; NSTE-ACS, non–ST-segment elevation ACS; and STEMI, ST-segment\\nelevation MI.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2145\\nFIGURE 2 Types and Classiﬁcation of Acute Coronary Syndromes', 'NSTEMI indicates non–ST-segment elevation myocardial infarction; and STEMI, ST-segment elevation myocardial infarction. Illustration by Patrick Lane, ScEYEnce\\nStudios. Copyright 2025 American College of Cardiology Foundation, and the American Heart Association, Inc.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2146\\n3. INITIAL EVALUATION AND MANAGEMENT OF\\nSUSPECTED ACS\\n3.1. Initial Assessment of Suspected ACS', '3.1.1. Prehospital Assessment and Management Considerations\\nfor Suspected ACS\\nSynopsis\\nR a p i da n dc o o r d i n a t e dp r e h o s p i t a lc a r ep l a y sac r i t i c a l\\nrole in the optimal management of patients with sus-\\npected ACS. 11 Patients with suspected ACS should be\\ntransported to the emergency department (ED) by emer-\\ngency medical services (EMS).\\n12 In contrast to transport by\\nprivate vehicle, EMS transport allows for assessment,', 'monitoring, and treatment of potentially life-threatening\\nconditions such as arrhythmias or cardiac arrest during\\ntransport to the ED.\\n13 In patients with suspected ACS,\\ntrained prehospital personnel should obtain a focused\\nTABLE 4 Types of Acute Myocardial Infarction According to the Universal De ﬁnition of Myocardial Infarction\\nType 1* Caused by acute coronary atherothrombosis, usually precipitated by atherosclerotic plaque disruption (rupture or erosion) and often associated', 'with partial or complete vessel thrombosis.\\nType 2 Caused by an imbalance between myocardial oxygen supply and demand unrelated to acute coronary atherothrombosis.\\nType 3 Cardiac death, with symptoms of myocardial ischemia and presumed ischemic electrocardiographic changes or ventricular arrythmia, before bl ood\\nsamples for cardiac biomarkers can be obtained or increases in cardiac biomarkers can be identiﬁed and/or in whom MI is identiﬁed by autopsy.', 'Type 4 4a: Peri-PCI MI caused by a procedural complication and detected #48 h after PCI.\\n4b: Post-PCI MI caused by coronary stent or stent scaffold thrombosis.\\n4c: Post-PCI MI caused by coronary stent restenosis.\\nType 5 Peri-CABG MI caused by a procedural complication detected #48 h after CABG surgery.\\nAdapted with permission from Thygesen et al.4 Copyright 2018 The European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, Inc., and', 'the World Heart Federation.\\n*This guideline focuses on the management of type 1 AMI. The diagnostic evaluation of chest pain and the management of type 2 MI, SCAD, and MINOCA are covered in separate\\ndocuments.\\n5-8\\nAMI indicates acute myocardial infarction; CABG, coronary artery bypass grafting; MI, myocardial infarction; MINOCA, MI with nonobstructive coronary artery disease; PCI,\\npercutaneous coronary intervention; and SCAD, spontaneous coronary artery dissection.', 'Recommendations for Prehospital Assessment and\\nManagement Considerations for Suspected ACS\\nReferenced studies that support recommendations\\nare summarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\nSuspected ACS\\n1 B-NR\\n1. In patients with suspected ACS, a\\n12-lead ECG should be acquired\\nand interpreted within 10\\nminutes of ﬁrst medical contact\\n(FMC) * to identify patients with\\nSTEMI.\\n1,2\\n1 C-LD\\n2. In patients with suspected ACS in\\nwhich the initial ECG is non-', 'diagnostic of STEMI, serial ECGs\\nto detect potential ischemic\\nchanges should be performed,\\nespecially when clinical suspicion\\nof ACS is high, symptoms are\\npersistent, or the clinical condi-\\ntion deteriorates. †\\n3,4\\n(continued in the next column)\\nContinued\\nCOR LOE RECOMMENDATIONS\\nSTEMI\\n1 B-NR\\n3. In patients with suspected\\nSTEMI, immediate emergency\\nmedical services (EMS) transport\\nto a PCI-capable hospital for\\nprimary PCI (PPCI‡ )i st h er e c -\\nommended triage strategy, with', 'an FMC–to-ﬁrst-device time sys-\\ntem goal of £90 minutes.\\n5-7\\n1 B-NR\\n4. In patients with suspected\\nSTEMI, early advance notiﬁcation\\nof the receiving PCI-capable\\nhospital by EMS personnel and\\nactivation of the cardiac cathe-\\nterization team is recommended\\nto reduce time to\\nreperfusion.\\n1,8,9\\n*FMC indicates the time point when the patient is initially assessed by a health care\\nprofessional who can obtain and interpret the ECG and deliver initial interventions (eg,', 'deﬁbrillation). †Modiﬁed from the “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR\\nGuideline for the Evaluation and Diagnosis of Chest Pain.”10 ‡PPCI refers to emergency\\nPCI in the setting of STEMI to achieve reperfusion in patients without previousﬁbri-\\nnolytic treatment.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2147\\nhistory and physical examination (including assessment\\nof vital signs) and obtain at least one 12-lead ECG so', 'that the electrocardiographic ﬁndings can facilitate next\\nsteps in patient triage. Speci ﬁcally, patients should be\\nmanaged based on the presence or absence of ST-\\nsegment elevation (or suspected equivalent) on the 12-\\nlead ECG ( Table 3 for STEMI electrocardiographic\\ncriteria). When possible, electrocardiographic tracings\\ncan be transmitted to the PPCI center while en route to\\nhelp expedite coronary re perfusion upon arrival.\\nBecause patients with ACS and evidence of heart failure', '(HF), ventricular arrhythmias, or cardiogenic shock in\\nthe prehospital setting are at highest risk for death,\\nidenti ﬁcation of these complications is important with\\nsubsequent triage of these patients to a PCI-capable\\nfacility when possible ( Section 8 , “Cardiogenic Shock\\nManagement ”).\\n14,15\\nRecommendation-Speci ﬁc Supportive Text\\n1. The early acquisition and recording of prehospital 12-\\nlead ECGs by trained personnel is associated with\\nshorter reperfusion times and lower mortality rates', 'from STEMI if this diagnostic information is integrated\\nin patients ’ care.\\n1,2,16 Appropriately trained EMS\\npersonnel (ie, paramedics) can interpret 12-lead ECGs\\nfor the identi ﬁcation of STEMI with high accuracy.\\n17\\nWhen ST-segment elevation or an equivalent ﬁnding\\nis present on the initial ECG (Table 3), initial manage-\\nment and triage should follow the prescribed STEMI\\ntreatment algorithm. Electrocardiographic changes are\\nnot required to conﬁrm a diagnosis of non-ST-segment', 'elevation ACS (NSTE-ACS).\\n2. In patients for whom the initial ECG is nondiagnostic,\\nserial ECGs should be performed during transport to\\nthe hospital especially when clinical suspicion of ACS\\nis high, ischemic symptoms are persistent, or the\\nclinical condition deteriorates.\\n3,4 Acquisition of sub-\\nsequent ECGs should not delay transport to a hospi-\\ntal. A second and/or third ECG during EMS transport\\nmay identify up to 15% of additional STEMI cases not\\npresent on the ﬁrst ECG.', '3 In an observational study\\nof 728 patients with suspected ACS who underwent\\nserial prehospital ECGs, a STEMI diagnosis was sub-\\nsequently made in 8% of patients following an initial\\nnondiagnostic ECG with a median of 12 minutes after\\nthe ﬁrst study.\\n4 Posterior ECG leads (V7-V9)s h o u l db e\\napplied in patients with ongoing symptoms and a\\nnondiagnostic ECG and those with ST-segment de-\\npressions in leads V\\n1-V3 to assess for ST-segment\\nelevation in the posterior leads, which could indi-', 'cate a posterior STEMI.\\n3. PPCI is the preferred method of reperfusion for pa-\\ntients with STEMI. 18 Rapid reperfusion of the infarct-\\nrelated artery is associated with improved myocardial\\nsalvage and improved survival.\\n19,20 For those who are\\nmanaged by PPCI, each 30 minutes of delay is associ-\\nated with an increase in th e relative risk of 1-year\\nm o r t a l i t yb y7 . 5 % .\\n19 As such, evidence supports\\nsystem-level interventions to reduce time-to-device. 11', 'Patients with prehospital identi ﬁcation of STEMI\\nshould preferentially be transported to a PCI-capable\\nhospital with a goal of FMC –to–ﬁrst-device time\\nof #90 minutes.\\n20 For patients who are directly trans-\\nported to the hospital by EMS, the time to treatment\\ngoal is de ﬁned as the FMC by EMS until coronary\\nreperfusion. Direct transfer to a PCI-capable facility has\\nbeen associated with shor ter reperfusion times and\\nlower mortality compared with transport to the closest', 'non–PCI-capable hospital.\\n21 In prehospital settings\\nwhere a FMC–to–ﬁrst-device goal of#90 minutes is not\\nfeasible in patients with STEMI, direct transport to a\\nPCI-capable hospital may be considered if the antici-\\npated FMC-to-device time is #120 minutes.\\n22,23 See\\nSection 5.1 , “Regional Systems of STEMI Care, ” for\\nfurther details.\\n4. The implementation of several care processes has\\ndemonstrated signi ﬁcant reductions in reperfusion\\ntimes in patients with STEMI when implemented', 'within a regional medical system.\\n24 These include (1)\\nprehospital catheterization laboratory activation, (2)\\nsingle call transfer protocol for patients from a non-\\nPCI facility, and (3) ED bypass to transport patients\\ndirectly to the catheteriza tion laboratory for those\\npresenting by EMS to a PCI-capable hospital, and for\\ntransfers from other facilities. In particular, the pre-\\nhospital activation of catheterization laboratories has\\nbeen associated with lower short- and long-term', 'mortality in patients presenting with STEMI.\\n1,8,25\\nSee Section 5.1 , “Regional Systems of STEMI Care, ”\\nfor further details.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2148\\n3.1.2. Initial In-Hospital Assessment of Patients With Conﬁrmed\\nor Suspected ACS\\nSynopsis\\nChest pain is the second most common presenting\\ncomplaint to EDs in the United States and has a wide array\\nof potential causes, including ACS.\\n14 Although most pa-', 'tients with chest pain will not have an ultimate diagnosis\\nof ACS, a missed ACS event has signiﬁcant implications\\nfor the patient ’s morbidity and mortality. Patients pre-\\nsenting with signs or symptoms of ACS should undergo a\\nhistory and physical examination, have timely electro-\\ncardiographic acquisition and interpretation ( Table 3 ),\\nand assessment of cardiac troponin, because these tests\\nare central to the diagnosis of MI\\n15 a n dw i l lg u i d ep a t i e n t', 'management ( Figure 3 ). A thorough description of the\\nevaluation of patients with suspected ACS is provided in\\nthe “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR\\nGuideline for the Evaluation and Diagnosis of Chest\\nPain. ”\\n13 Initial medical treatment should begin immedi-\\nately for patients with presumed ACS. Urgent echocardi-\\nography, which may include an initial point-of-care\\nultrasound by trained clinicians, is indicated for patients\\nwith cardiogenic shock, hemodynamic instability, or for', 'suspected mechanical comp lications. For patients with\\nsuspected STEMI, rapid reperf usion is critical after diag-\\nnosis, and further diagnostic testing should not delay\\ncardiac catheterization or ﬁbrinolytic therapy unless it\\nwould immediately change patient management. For pa-\\ntients who warrant additional testing to con ﬁrm a diag-\\nnosis of ACS, selection of the method of assessment may\\nencompass several factors, including clinical history,', 'electrocardiographic ﬁndings, cardiac biomarkers, patient\\npreference, and patient exercise capacity. The use of\\nevidence-based clinical decision pathways (CDPs) has\\nbeen shown to improve outcomes and direct appropriate\\nuse of resources.\\n13 CDPs reduce unnecessary testing in\\n21% to 43% of patients while maintaining a high negative\\npredictive value for major adverse cardiovascular events\\n(MACE).\\n16-19\\nRecommendation-speci ﬁc Supportive Text', '1. A focused history and rapid evaluation are critical in\\nthe assessment of a patient with suspected ACS.13 Early\\nrecognition and initiation of therapy for ACS improves\\noutcomes. 2,20 Rapid electrocardiographic acquisition\\nand interpretation is required for identi ﬁcation of\\nSTEMI (Table 3). In patients with NSTE-ACS, the ECG\\nmay be normal or demonstrate transient ST-segment\\nelevation (a high-risk ﬁnding), ST-segment depres-\\nsion, T-wave inversions, or nonspeci ﬁcc h a n g e s .O f', 'note, ST-segment depression in the anteroseptal leads\\n(V\\n1-V3) could indicate an evolving posterior STEMI and\\ntherefore should be managed with a high index of\\nsuspicion with a posterior lead ECG if warranted\\n(Table 3 ).\\n21 Overall, timely acquisition of an ECG is\\nimperative in patients with a goal to obtain and inter-\\npret an ECG by a trained clinician within 10 minutes of\\npresentation.\\n1\\n2. An initial nondiagnostic 12-lead ECG does not “rule\\nout” or exclude ACS. Electrocardiographic abnormal-', 'ities may be dynamic. A nondiagnostic ECG should be\\ncompared to prior ECGs, and a repeat ECG should be\\nobtained during the ED course to assess for evolving\\nchanges.\\n3 Right-sided leads should be obtained in pa-\\ntients with a concern for inferior STEMI to evaluate for\\nright ventricular involvement.\\n22 Assessment for pos-\\nterior STEMI with an ECG is described inTable 3.T h e\\nRecommendations for Initial In-Hospital Assessment of\\nPatients With Con ﬁrmed or Suspected ACS', 'Referenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1 B-NR\\n1. In patients with suspected ACS,\\nacquisition and interpretation of\\nan ECG within 10 minutes is rec-\\nommended to help guide patient\\nmanagement. *\\n1,2\\n1 B-NR\\n2. In patients with suspected ACS in\\nwhom the initial ECG is non-\\ndiagnostic, serial 12-lead ECGs\\nshould be performed to detect\\npotential ischemic changes,\\nespecially when clinical suspicion\\nof ACS is high, symptoms are', 'persistent, or clinical condition\\ndeteriorates. *\\n3\\n1 B-NR\\n3. In patients with suspected ACS,\\nc T ns h o u l db em e a s u r e da ss o o n\\nas possible, preferably using a\\nhigh-sensitivity cTn (hs-cTn)\\nassay. *\\n4-7\\n1 B-NR\\n4. In patients with suspected ACS\\nwith an initial hs-cTn or cTn that\\nis nondiagnostic, the recom-\\nmended time intervals for repeat\\nmeasurements after the initial\\nsample collection (time zero) are\\n1 to 2 hours for hs-cTn and 3 to\\n6 hours for conventional cTn\\nassays. *\\n8-12', 'assays. *\\n8-12\\n*Adapted from the “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the\\nEvaluation and Diagnosis of Chest Pain.”13\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2149\\ntiming of repeat ECGs should be guided by the pa-\\ntient ’s symptoms, especially recurrent chest pain, and\\nany change in clinical condition. 15 In NCDR ACTION\\n(National Cardiovascular Data Registry and Acute Cor-', 'onary Treatment and Intervention Outcomes\\nNetwork), 11% of patients ultimately diagnosed with\\nSTEMI had an initial ECG that was nondiagnostic, and\\n72.4% of those patients had a follow-up ECG diagnostic\\nof STEMI within 90 minutes of their initial ECG.\\n3\\n3. cTn is the biomarker of choice for assessing patients for\\npossible cardiac injury, with hs-cTn assays being\\npreferred. cTn is central to the diagnosis of AMI.\\n15\\nGiven its high sensitivity and speci ﬁcity for myocar-', 'dial injury, cTn (I or T) should be utilized to detect or\\nexclude myocardial injury.\\n7 In the setting of electro-\\ncardiographic evidence of STEMI, reperfusion therapy\\nshould not be delayed pending biomarker results.\\nAc T nc o n c e n t r a t i o n>99th percentile upper reference\\nFIGURE 3 Initial Assessment of Patients With Suspected ACS\\nColors correspond to Class of Recommendation inTable 2. *Examples of evidence-based CDPs and deﬁnition of low, intermediate, and high risk as deﬁned in', 'the 2021 AHA/ACC/Multisociety Chest Pain Guideline. ACS indicates acute coronary syndromes; CDP, clinical decision pathway; cTn, cardiac troponin; hs-cTn,\\nhigh-sensitivity cardiac troponin; NSTEMI, non–ST-segment elevation myocardial infarction; and STEMI, ST-segment elevation myocardial infarction.\\nAdapted with permission from Gulati et al.13 Copyright 2021 American Heart Association, Inc., and American College of Cardiology Foundation.\\nRao et al JACC VOL. 85, NO. 22, 2025', '2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2150\\nlimit (a value unique to each assay) is an indicator of\\nmyocardial injury. 15,23,24 hs-cTn assays are preferred\\nover conventional cTn assays because the sensitivity\\nand negative predictive values of hs-cTn are\\ngreater.\\n4,15 In addition, the time interval from chest\\npain onset to detection of hs-cTn is shorter with hs-cTn\\ncompared with conventional cTn assays, leading to', 'more rapid “rule in” or “rule out” of ischemia.\\n25\\n4. AMI is characterized by a rising and/or falling pattern\\nof cTn values with at least 1 value above the 99th\\npercentile upper reference limit and believed caused\\nby myocardial ischemia.\\n21 With the development of hs-\\ncTn assays enabling detection of circulating cTn at\\nlower concentrations, CDPs using serial testing of hs-\\nc T na tp r e s e n t a t i o n( 0h o u r s )a n d1t o2h o u r sl a t e r', 'provide high negative predictive value, as well as\\naccelerated recognition of myocardial injury.\\n9,10,12\\nClinicians should be familiar with both the evidence-\\nbased CDPs and the analytical characteristics of the\\ncTn assay (ie, limit of quanti ﬁcation, 99th percentile\\nupper reference limit, and criteria for signi ﬁcant\\nchange) used in their practice.\\n24,26 Men and women\\nmay have different cutoff values with hs-cTn assays.\\nWith hs-cTn assays, changes in hs-cTn concentration', 'within the normal reference range but below the 99th\\npercentile upper reference limit can signal cardiac\\nischemia and may warrant further evaluation. CDPs\\nincorporating hs-cTn assays with repeat sampling at 1\\nor 2 hours from ED arrival with calculation of the\\nchange or “delta ” hs-cTn can identify patients at very\\nlow risk (eg, negative predictive value >99.5%) based\\non assay-speci ﬁcd i a g n o s t i ct h r e s h o l d s .\\n8,11,27-30 How-\\never, when using conventional cTn assays, the sam-', 'pling timeframe is extended to 3 to 6 hours from ED\\narrival.\\n31 cTn may be within normal range early after\\nsymptom onset especially when a high-sensitivity\\nassay is not used. When using a CDP that in-\\ncorporates a single hs-cTn value, the troponin should\\nbe obtained at least 3 hours after the onset of\\nsymptoms.\\n32\\n3.1.3. Risk Stratiﬁcation Tools for Patients With STEMI and\\nNSTE-ACS\\nSynopsis\\nSubstantial variability in short-term mortality and\\nMACE risk exists among patients with ACS. Individual', 'risk assessment can inform discussions with patients and\\ndecisions regarding therapeutic interventions. Several\\nrisk scores have been developed and validated to help\\nassess a patient’s short- and long-term risk in established\\nACS using commonly available clinical and laboratory\\nvariables. Although seve ral risk scores exist,\\n1-3 the\\nGRACE (Global Registry of Acute Coronary Events) and\\nTIMI (Thrombolysis In Myocardial Infarction) Risk Scores', 'for NSTE-ACS and STEMI (Table 5) are well validated and\\nmay be useful for helping to guide some therapeutic de-\\ncisions (Section 6.1., “Rationale and Timing for a Routine\\nInvasive or Selective Invasive Approach”).\\n4-7 These scores\\nare not to be used as diagnostic tools, because they\\nstratify patient risk in the setting of suspected or\\nconﬁrmed ACS. Risk assessment using the GRACE Risk\\nScore has been found to be superior to subjective physi-', 'cian assessment for the prediction of death or MI in pa-\\ntients with STEMI or inter mediate-risk NSTE-ACS.\\n8\\nHowever, there is insuf ﬁcient evidence that routine use\\nof risk scores in patients hospitalized for STEMI/NSTE-\\nACS translates into reduced risk of cardiovascular\\nevents.\\n9,10\\nEvidence of HF, such as pulmonary congestion detec-\\nted by physical examination, chest x-ray, or lung ultra-\\nsound, is an important risk marker and integral part of the', 'Killip classi ﬁcation (and thereby the GRACE Risk Score\\na n dT I M IR i s kS c o r ef o rS T E M I )i np a t i e n t sw i t hA C S .\\n11-15\\nSimilarly, elevated cardia c biomarkers provide prog-\\nnostic information and also are key elements of the\\nGRACE and TIMI Risk Scores. Higher cTn levels in patients\\nwith ACS are associated with an increased risk of death\\nand MACE\\n16,17 and similarly may be useful for helping\\nt og u i d es o m et r e a t m e n td e c i s i o n s .4,18 Several other', 'serum or plasma biomarkers may provide additional\\nprognostic information. In particular, natriuretic peptides\\n(including B-type natriuretic peptide and N-terminal pro-\\nB-type natriuretic peptide) may identify those patients\\nwith ACS at increased risk of death, HF, and recurrent\\nMACE.\\n19,20\\nEarly recognition of cardiogenic shock in patients\\npresenting with ACS on FMC by EMS or ED providers is\\nthe key to initial triage and risk strati ﬁcation. 21 Cardio-', 'genic shock related to AMI is present in 7% to 10% of\\nthe ACS population and carries a high mortality rate.\\n22\\nEarly and rapid revasculariza tion for cardiogenic shock\\nrelated to AMI is associated with increased survival, and\\ntriage to a PCI-capable hospital and ideally to hospitals\\nproviding advanced therapies (eg, mechanical circula-\\ntory support [MCS]) is preferred ( Section 8.1 , “Revas-\\ncularization in ACS With Cardiogenic Shock ” and\\nSection 8.2 , “MCS in Patients With ACS and Cardio-', 'genic Shock ”). Several scales are available to determine\\nthe severity of shock, and observational data have\\nshown associations between severity as assessed by\\nthese scales and outcomes.\\n23\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2151\\n3.2. Management of Patients Presenting With Cardiac Arrest Synopsis\\nApproximately 10% of patients with STEMI transferred\\nby EMS to the hospital are estimated to have an out-of-', 'hospital cardiac arrest. 15 Early recognition of STEMI in\\nresuscitated patients and direct transfer to a PCI-capable\\ncenter is associated with improved survival.\\n1,2 Survival-\\nto-hospital discharge in the patient who is comatose\\nwith out-of-hospital cardiac arrest is <10% regardless of\\netiology.\\n16 Those with a witnessed arrest and a shockable\\nrhythm have improved survival. Outcomes for patients\\nwith STEMI who are awake after resuscitated cardiac ar-', 'rest are comparable to patients with STEMI who were not\\nin cardiac arrest.\\n3 For this reason, patients with cardiac\\narrest who have achieved return of spontaneous circula-\\ntion (ROSC) and are awake with STEMI on ECG are can-\\ndidates for PPCI. However, care should be individualized\\nin the comatose patient with rapid assessment of the pa-\\ntient ’s clinical features and cardiac arrest characteristics\\nbefore proceeding with invasive angiography.\\n17-19 In', '17-19 In\\ncontrast, patients who are stable without ST-segment\\nelevation after out-of-hospital cardiac arrest do not\\nrequire immediate coronary angiography. Coronary angi-\\nography can be deferred pen ding further risk strati ﬁca-\\ntion.\\n8-13\\nRecommendation-Speci ﬁc Supportive Text\\n1. Observational studies have shown an association be-\\ntween triage of out-of-hospital cardiac arrest patients\\nto a PCI-capable facility with improved outcomes.\\n1,2,15\\nData from the CARES (Cardiac Arrest Registry to', 'Enhance Survival) registry showed that transfer to a\\nPCI-capable center was associated with improved sur-\\nvival in patients with cardiac arrest and STEMI on ECG.\\nEMS should preferentially transfer patients who are\\nRecommendations for Management of Patients\\nPresenting With Cardiac Arrest\\nReferenced studies that support recommendations\\na r es u m m a r i z e di nt h eEvidence Table .\\nCOR LOE RECOMMENDATIONS\\n1 C-LD\\n1. Patients with cardiac arrest and\\nSTEMI who have been resusci-', 'tated should preferentially be\\ntransferred by EMS to a PPCI-\\ncapable center.\\n1,2\\n1 B-NR\\n2. Patients who have been resusci-\\ntated after cardiac arrest and are\\nnoncomatose or who are coma-\\ntose with favorable prognostic\\nfeatures and with evidence of\\nSTEMI, should undergo PPCI to\\nimprove survival.\\n3-7\\n2b C-LD\\n3. In patients with cardiac arrest\\nwho are comatose, have unfa-\\nvorable prognostic features, and\\nevidence of STEMI, PPCI may be\\nreasonable after individualized\\nassessment.\\n4,7\\n3: No BeneﬁtA', '4,7\\n3: No BeneﬁtA\\n4. In resuscitated patients who are\\ncomatose after cardiac arrest,\\nelectrically and hemodynamically\\nstable, and without evidence of\\nSTEMI, immediate angiography is\\nnot recommended due to lack of\\nbeneﬁt.\\n8-14\\nTABLE 5 Selected Risk Strati ﬁcation Tools for Patients With ACS\\nGRACE Risk Score (2.0)6,7\\nTIMI Risk Score for\\nUnstable Angina/NSTEMI *4 TIMI Risk Score for STEMI5\\nTarget population ACS Unstable angina or NSTEMI STEMI\\nTarget outcome(s) In-hospital, 6-mo, 1-y,', '3-y, death or death/MI\\n14-d all-cause death, MI,\\nor urgent revascularization\\n30-d all-cause death\\nVariables used In-hospital risk score\\nAge\\nKillip class\\nSystolic blood pressure\\nHeart rate\\nST-segment deviation\\nCardiac arrest on admission\\nSerum creatinine\\nElevated cardiac biomarkers\\nAge $65 y\\n$3 risk factors for CAD\\nKnown coronary stenosis ($50%)\\nST-segment deviation$0.5 mm\\n$2 anginal events in prior 24 h\\nAspirin use in prior 7 d\\nElevated cardiac biomarkers (CK-MB or troponin)', 'Age (65-74 y/$75 y) (2-3 points)\\nKillip class II-IV (2 points)*\\nSystolic blood pressure\\n(<100 mm Hg, 3 points)\\nHeart rate>100 bpm (2 points)\\nAnterior ST-segment elevation or LBBB\\n(1 point)\\nDiabetes/hypertension/angina (1 point)\\nWeight (<67 kg, 1 point)\\nTime to treatment>4 h (1 point)\\n*Score 1 point for each characteristic that is present.', 'ACS indicates acute coronary syndromes; bpm, beats per minute; CAD, coronary artery disease; CK-MB, creatine kinase-myocardial band; GRACE, Global Registry of Acute Coronary\\nEvents; LBBB, left bundle branch block; MI, myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; and\\nTIMI, Thrombolysis In Myocardial Infarction.\\nRao et al JACC VOL. 85, NO. 22, 2025', '2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2152\\ncomatose after cardiac arrest, have achieved ROSC, and\\nhave STEMI on the ECG to a PPCI center.2 Although the\\nARREST (Advanced Reperfusi on Strategies for Patients\\nWith Out of Hospital Cardiac Arrest and Refractory\\nVentricular Fibrillation) trial did not show a beneﬁti n\\ntriaging patients to primary cardiac arrest centers, this\\nstudy evaluated patients without STEMI on the ECG.\\n20', '20\\n2. Nearly one-third of patients with cardiac arrest and\\nSTEMI on ECG have normal neurologic status on pre-\\nsentation to the ED.\\n3 Being alert or with partial/mini-\\nmal neurologic response on presentation with STEMI\\nafter cardiac arrest is an independent predictor of\\nsurvival. Observational studies have demonstrated\\ncomparable survival of the awake patient with STEMI\\nwith cardiac arrest to those patients with STEMI\\nwithout cardiac arrest.\\n3 For this reason, patients with', 'STEMI who have achieved ROSC and are awake should\\nundergo PPCI (Section 5.2.1, “PPCI in STEMI”).\\n3. In patients who are comatose after cardiac arrest and\\nhave achieved ROSC, but have STEMI on the ECG, an\\nindividualized patient assessment for survival and fu-\\ntility is essential before proceeding with PCI. Observa-\\ntional data have identiﬁed poor prognostic features that\\nhave been validated and incorporated into risk scores\\nfor this population. These include unwitnessed', 'arrest, no bystander cardio pulmonary resuscitation,\\nnonshockable rhythm, cardi opulmonary resuscitation\\n>30 minutes, time to ROSC >30 minutes, arterial\\npH <7.2, lactate >7 mmol/L, age >85 years, and end-\\nstage renal disease on dialysis.\\n4,21-30 Although these\\ndata suggest a lack of clear beneﬁt for invasive therapies\\nfor patients with STEMI and cardiac arrest who have\\nfeatures indicating an unfavorable neurologic prog-\\nnosis,\\n4,7 this has not been validated in prospective trials.', 'However, for those patients with favorabl ep r o g n o s t i c\\nf e a t u r e s ,P P C Ii sa s s o c i a t e dw i t hg r e a t e rs u r v i v a l .4,7,27\\n4. Six contemporary trials 9-14 have evaluated the role of\\nemergency angiography in patients who remain\\ncomatose after cardiac arrest, do not have ST-segment\\nelevation on a 12-lead ECG, and are electrically and\\nhemodynamically stable. These studies consistently\\ndemonstrated a lack of bene ﬁt to early angiography', 'when compared with delayed or no angiography in the\\nstudy population with comparable in-hospital and 6-\\nmonth survival, as well as neurologic recovery.\\n31 The\\nrelative utility of delayed coronary angiography in this\\npopulation is uncertain.\\n4. STANDARD MEDICAL THERAPIES FOR STEMI\\nAND NSTE-ACS\\n4.1. Oxygen Therapy\\nSynopsis\\nSupplemental oxygen has hi storically been adminis-\\ntered as part of routine care in the management of\\npatients with suspected ACS, although evidence to', 'suggest clinical bene ﬁti nt h ea b s e n c eo fh y p o x i ah a s\\nbeen lacking.\\n5 Randomized trials that have enrolled\\npatients with MI and without hypoxia have not\\ndemonstrated any clinical bene ﬁt from routine use of\\nsupplemental oxygen ( $6L / m i n )2-4,6 and have raised\\nsome concerns that it may increase myocardial injury by\\nincreasing vasoconstriction and increasing oxidative\\nstress.\\n3\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. Use of supplemental oxygen may provide bene ﬁtt o', 'patients who present with hypoxia (peripheral capil-\\nlary oxygen saturations <90%), including those who\\npresent with acute or chronic conditions that require\\nthe need for supplemental oxygen to achieve an oxy-\\ngen saturation $90%. A systematic review and meta-\\nanalysis of RCTs in acutely ill adults from various\\nRecommendations for Oxygen Therapy\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1 C-LD\\n1. In patients with ACS and', 'conﬁrmed hypoxia (oxygen satu-\\nration <90%), supplemental ox-\\nygen to increase oxygen\\nsaturations to ‡90% is recom-\\nmended to improve myocardial\\noxygen supply and decrease\\nanginal symptoms.\\n1\\n3: No BeneﬁtA\\n2. In patients with ACS and oxygen\\nsaturations ‡90%, routine\\nadministration of supplemental\\noxygen is not recommended\\nbecause it does not improve\\ncardiovascular outcomes.\\n2-4\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2153', '2153\\ncauses without hypoxia suggested worse short- and\\nlong-term mortality with liberal compared with con-\\nservative administration of supplemental oxygen.\\n7\\nThese studies were unable to deﬁne the optimal oxy-\\ngen saturation target range to minimize potential harm\\nand maximize clinical bene ﬁt. The observed relation-\\nship between oxygenation and outcomes appears to be\\nU-shaped with the lowest mortality rate described for\\nthose patients with an Sp\\nO2 of 94% to 96% at\\npresentation. 8', 'presentation. 8\\n2. Several randomized trials have now demonstrated a\\nlack of cardiovascular bene ﬁt with routine use of\\nsupplemental oxygen in patients presenting with\\nknown or suspected AMI and oxygen\\nsaturations $90%. Although exclus ion criteria varied\\namong studies, patients with a home oxygen\\nrequirement, active bronchospasm requiring supple-\\nmental oxygen, or with cardiac arrest at presentation\\nwere excluded.\\n2-4,6 The AVOID (Air Versus Oxygen in', 'ST-Segment-Elevation Myocardial Infarction) trial\\ninvestigated the effects of supplemental oxygen\\n(8 L/min) in patients with STEMI and oxygen\\nsaturations $94% and demonstrated a lack of beneﬁt\\nwith routine supplemental oxygen, including a\\npossible increase in myocardial injury and infarct\\nsize.\\n3 DETO2X-AMI (Ef ﬁcacy and Outcome Study of\\nSupplemental Oxygen Treatment in Patients With\\nSuspected Myocardial Infarction) evaluated the use of\\nroutine supplemental oxygen (6 L/min) in 6,629 pa-', 'tients with suspected MI and an oxygen\\nsaturation $90%.\\n2 The use of supplemental oxygen\\ndid not reduce all-cause mortality at 1 year and did\\nnot reduce rehospitalization with MI. 2,9 A consistent\\nlack of clinical beneﬁt was seen in the study for those\\nwith lower baseline oxygen saturations (90%-94%). 10\\n4.2. Analgesics\\nSynopsis\\nPatients presenting with known or suspected ACS often\\nexperience chest pain or other uncomfortable symptoms.\\nRapid and effective pain relief remains an important', 'treatment goal to prevent sy mpathetic activation and\\nadverse clinical sequelae ( Table 6 ). Analgesic therapies\\nmay provide symptomatic relief, but they have not been\\nshown to improve clinical outcomes in patients with\\nACS.\\n1,2 Nitrates and opiate medications remain effective\\ntreatment options for management of pain in ACS but\\nshould be thoughtfully ut ilized to prevent potential\\nharm.\\n3-6 In particular, rapid coronary revascularization\\nshould be pursued for patients with ongoing ischemic', 'symptoms that are not relieved with nitrates, and opiates\\nshould not be used solely to mask these symptoms.\\nConcerns have also been raised that the use of opiates\\nmay delay gastric and intestinal absorption of orally\\nadministered P2Y12 inhibit ors, thereby delaying their\\npharmacodynamic effects in patients undergoing PCI.\\n7-10\\nHowever, the clinical relevance of these pharmacody-\\nnamic ﬁndings remains disputed.\\n11-14 Use of nonaspirin\\nnonsteroidal anti-in ﬂammatory drugs should be avoided', 'for management of suspected or known ischemia pain\\nwhenever possible.\\n15-17 Use of nonsteroidal anti-\\ninﬂammatory drugs is associated with increased risk of\\nMACE in patients with and without prior cardiac disease,\\nwith no documented bene ﬁt to support routine use in\\npatients with ACS.\\n15-19\\nTABLE 6 Analgesic Treatment Options for Cardiac Chest Pain\\nMedication Route Suggested Dosing Considerations\\nNitroglycerin* SL (tablets,\\nspray)\\n0.3 or 0.4 mg every 5 min as needed\\nup to a total of 3 doses', 'Use in hemodynamically stable patients with SBP$90 mm Hg.\\nNitroglycerin* IV Start at 10 mg/min and titrate to pain\\nrelief and hemodynamic tolerability.\\nConsider for persistent anginal pain after oral nitrate therapy, or if ACS is accompanied by\\nhypertension or pulmonary edema.20-22 Avoid use in suspected RV infarction,\\nSBP <90 mm Hg or a change in SBP>30 mm Hg below baseline. Tachyphylaxis may\\noccur after approximately 24 h.\\nMorphine IV 2-4 mg; may repeat if needed every 5-15 min.', 'Doses up to 10 mg may be considered.\\nUse for relief of pain that is resistant to other maximally tolerated anti-ischemic\\nmedications. May delay the effects of oral P2Y12 therapy.7,9-12 Monitor closely for\\nadverse effects.\\nFentanyl IV 25-50 mg; may repeat if needed. Doses up to\\n100 mg may be considered.\\nUse for relief of pain that is resistant to other maximally tolerated anti-ischemic\\nmedications. May delay the effects of oral P2Y12 therapy.8 Monitor closely for\\nadverse effects.', 'adverse effects.\\n*Nitrates should not be administered after recent PDE5 inhibitor use. Avoid use of nitrates/nitroglycerin within 12 h of avanaﬁl, 24 h of sildenaﬁl/vardenaﬁl, or 48 h of tadalaﬁl.23-25\\nACS indicates acute coronary syndromes; PDE5, phosphodiesterase-5 inhibitor; RV, right ventricular; SBP, systolic blood pressure; and SL, sublingual.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2154\\n4.3. Antiplatelet Therapy', '4.3.1. Aspirin\\nSynopsis\\nAspirin has long been considered an integral part of\\nantiplatelet therapy to prevent recurrent athero-\\nthrombotic events among patients with ACS.\\n1-3,6 Aspirin\\nreduces the incidence of vascular death after AMI,3 and in\\nsecondary prevention trials (that include patients after\\nMI), it reduces the occurrence of vascular and coronary\\nevents, including MI and stroke. 2 Although aspirin use\\nafter ACS was traditionally considered lifelong, a strategy', 'of aspirin discontinuation, rather than P2Y12 inhibitor\\ndiscontinuation, may now be considered in the mainte-\\nnance phase after 1 to 3 months in selected patients to\\nreduce risk of bleeding (Section 11.1, “DAPT Strategies in\\nthe First 12 Months Postdischarge ”). Aspirin discontinu-\\nation after 1 to 4 weeks after PCI is also appropriate for\\npatients on a full-dose anticoagulant in combination with\\ncontinued use of a P2Y12 inhibitor (Section 11.1.1 , “Anti-', 'platelet Therapy in Patient s on Anticoagulation Post-\\ndischarge ”). For patients in whom a history of aspirin\\nhypersensitivity is reported, aspirin desensitization is\\npreferred whenever possible to allow for initial use of\\ndual antiplatelet therapy.\\n7-9 The use of a P2Y12 inhibitor is\\nrecommended in all patient s with ACS regardless of\\nwhether they have a history of aspirin hypersensitivity,\\nbut should be administered with a loading dose as early as', 'possible for those patients unable to take aspirin at\\npresentation.\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. Aspirin should be initiat ed with a loading dose (162-\\n3 2 5m g )i np a t i e n t sw i t hA C Sw i t h o u ta na b s o l u t e\\ncontraindication as soon as possible on presentation\\nirrespective of ﬁnal management strategy (invasive\\nor noninvasive), followed by a daily maintenance\\ndose (Table 7 in Section 4.3.2 , “Oral P2Y12 Inhibitors', 'During Hospitalization ”). In patients who cannot take\\noral medication, rectal or intravenous (where avail-\\nable) administration are options for administration.\\nCurrent evidence supports the use of uncoated low-\\ndose aspirin (75-100 mg) for daily maintenance\\nt h e r a p y .T h e7 5t o1 0 0m gd a i l yd o s eo fa s p i r i ne x -\\nceeds the minimal effective dose required for\\nplatelet thromboxane A\\n2 suppression, allowing for\\nsome interindividual variability in drug response. 10', 'Among patients with ACS referred for an invasive\\nstrategy, continued use of full-dose aspirin (300-325\\nmg daily) for 30 days (following an initial loading\\ndose) was not superior to low-dose aspirin (75-100\\nmg daily) for reduction of MACE but was associated\\nwith increased minor and gastrointestinal bleeding.\\n4\\nIn an open-label RCT of patients with established\\natherosclerotic cardiovas cular disease (ASCVD), 35%\\nof whom had a previous MI, no signi ﬁcant differ-', 'ences were observed in MACE or major bleeding for\\npatients treated with 81 mg of aspirin daily and\\nthose treated with 325 mg daily, although a high\\ndegree of crossover between study arms was\\nobserved.\\n5 Together, these data support the use of\\nlow-dose aspirin (75-100 mg daily) for maintenance\\ntherapy. Based on an association between aspirin\\ndosing and outcomes in a post hoc analysis of the\\nPLATO (Platelet Inhibition and Patient Outcomes)\\ntrial, aspirin doses of #100 mg daily should always', 'be used in patients treated with ticagrelor.\\n11\\nRecommendation for Aspirin\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n1A\\n1. In patients with ACS, an initial\\noral loading dose of aspirin, fol-\\nlowed by daily low-dose aspirin,\\nis recommended to reduce death\\nand MACE.\\n1-5\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2155', '2155\\n4.3.2. Oral P2Y12 Inhibitors During Hospitalization\\nSynopsis\\nOral inhibitors of the platelet P2Y12 receptor antago-\\nnize adenosine diphosphate –mediated activation of\\nplatelets. Across the spectrum of ACS, the addition of a\\nP2Y12 inhibitor to aspirin signi ﬁcantly reduces platelet\\na g g r e g a t i o na n dh a sb e e ns h o w nt or e d u c et h ei n c i d e n c e\\nof recurrent MACE but with an increased risk of\\nbleeding.\\n1-5,9,10 In addition to receiving aspirin, patients', 'w i t hA C Ss h o u l dt h e r e f o r eb et r e a t e dw i t hal o a d i n gd o s e\\nof an oral P2Y12 inhibitor followed by daily dosing\\n(Table 7). The selection of the speciﬁct y p eo fo r a lP 2 Y 1 2\\ninhibitor should involve several considerations, including\\nthe patient’s anticipated management strategy and their\\nrisk of bleeding (Figure 4).\\n1-5,9,10 Clinically available oral\\nP2Y12 inhibitors include clopidogrel, prasugrel, and tica-', 'grelor. Clopidogrel is the least potent oral P2Y12 inhibitor\\nand requires more time to reach its maximal platelet in-\\nhibition after a loading dose, because it requires\\nbiotransformation in the liver to form its active metabo-\\nlite. Pharmacodynamic variability in response in clopi-\\ndogrel has been well described,\\n14,15 and hyporesponders\\nmay be at increased risk of MACE and stent thrombosis\\nwhen treated with clopidogrel after PCI.\\n16,17 Ticagrelor', '16,17 Ticagrelor\\nRecommendations for Oral P2Y12 Inhibitors During\\nHospitalization\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\nAll Patients With ACS (STEMI and NSTE-ACS)\\n1A\\n1. In patients with ACS, an oral\\nP2Y12 inhibitor should be\\nadministered in addition to\\naspirin to reduce MACE.\\n1-5\\n3: Harm B-R\\n2. In patients with a history of\\nstroke or transient ischemic\\nattack, prasugrel should not be\\nadministered because of worse', 'net clinical outcomes. *†\\n4\\nIn-Hospital Management in Patients With NSTE-ACS\\n1 B-R\\n3. In patients with NSTE-ACS un-\\ndergoing PCI, prasugrel or tica-\\ngrelor is recommended to reduce\\nMACE and stent thrombosis.4-6\\n1 B-R\\n4. In patients with NSTE-ACS who\\nare managed without planned\\ninvasive evaluation, ticagrelor is\\nrecommended to reduce\\nMACE.\\n5,7\\n1 B-R\\n5. In patients with NSTE-ACS, clo-\\npidogrel is recommended to\\nreduce MACE when prasugrel or\\nticagrelor are unavailable,\\ncannot be tolerated, or are', 'contraindicated.\\n1\\n2b B-NR\\n6. In patients with NSTE-ACS plan-\\nned for an invasive strategy with\\ntiming of angiography antici-\\npated to be>24 hours, upstream\\ntreatment with clopidogrel or\\nticagrelor may be considered to\\nreduce MACE.\\n1,5,8\\n(continued in the next column)\\nContinued\\nCOR LOE RECOMMENDATIONS\\nIn-Hospital Management in Patients With STEMI\\n1 B-R\\n7. In patients with STEMI managed\\nwith PPCI, prasugrel or ticagrelor\\nshould be administered to reduce\\nMACE and stent\\nthrombosis.\\n4,5,9,10\\n1 C-LD', '4,5,9,10\\n1 C-LD\\n8. In patients with STEMI managed\\nwith PPCI, clopidogrel is recom-\\nmended to reduce MACE and\\nstent thrombosis when prasugrel\\nor ticagrelor are unavailable,\\ncannot be tolerated, or are\\ncontraindicated.\\n11\\n1A\\n9. In patients with STEMI managed\\nwith ﬁbrinolytic therapy, clopi-\\ndogrel should be administered\\nconcurrently to reduce death and\\nMACE.\\n2,3\\n*Modiﬁed from the“2021 ACC/AHA/SCAI Guideline for Coronary Artery Revasculariza-', 'tion”12 and the†”2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management\\nof Patients With Chronic Coronary Disease.”13\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2156\\nand prasugrel are more potent than clopidogrel and ach-\\nieve more rapid onset of inhibition of platelet activation\\nbut with increased risk of bleeding compared with clopi-\\ndogrel. Of note, ticagrelor may cause subjective transient', 'dyspnea in approximately 10% to 15% of patients after\\nACS.\\n5 The topic of duration of dual antiplatelet therapy is\\naddressed in Section 11.1, “DAPT Strategies in the First 12\\nMonths Postdischarge. ”\\nRecommendation-Speci ﬁc Supportive Text\\n1. Several trials have demonstrated the clinical beneﬁto f\\noral P2Y12 inhibitors in ACS for reducing MACE but\\nwith increased risk of bleeding. In randomized\\nplacebo-controlled trials in both NSTE-ACS and STEMI,', 'the addition of clopidogrel to aspirin reduced risk of\\nMACE irrespective of management strategy.\\n1-3 In pa-\\ntients with STEMI treated withﬁbrinolytic therapy, the\\naddition of clopidogrel to aspirin reduces 30-day\\nMACE, including recurrent MI, and improves sur-\\nvival.\\n2,3 Moreover, in randomized trials, the use of\\nprasugrel and ticagrelor further reduced risk of MACE,\\nas well as stent thrombosis, when compared with clo-\\npidogrel in patients with STEMI (not receiving con-', 'current ﬁbrinolytic therapy) or NSTE-ACS.\\n4,5 The\\nbeneﬁts of oral P2Y12 inhibitors have also been\\ndemonstrated in patients after coronary artery bypass\\nTABLE 7 Dosing Considerations for Oral Antiplatelet Therapy in Patients With ACS\\nAgent Setting Dosing Considerations\\nAspirin NSTE-ACS or STEMI Loading dose 162-325 mg orally. Aspirin (nonenteric coated) should be chewed, when possible, to achieve faster onset', 'of antiplatelet action. Loading dose should be administered for patients already on aspirin therapy.\\nMaintenance dose 75-100 mg orally daily (nonenteric coated)\\nClopidogrel NSTE-ACS or STEMI without\\nﬁbrinolytic\\nLoading dose 300 or 600 mg orally\\nMaintenance 75 mg orally daily\\nSTEMI withﬁbrinolytic Loading dose 300 mg orally if age #75 y; Initial dose 75 mg orally if age>75 y\\nMaintenance 75 mg orally daily\\nPrasugrel NSTE-ACS or STEMI without\\nﬁbrinolytic, and undergoing\\nPCI', 'PCI\\nLoading dose 60 mg orally\\nMaintenance dose 10 mg orally daily if body weight$60 kg and age<75 y\\nMaintenance dose 5 mg orally daily if body weight<60 kg or age$75 y (use caution)\\nTicagrelor NSTE-ACS or STEMI without\\nﬁbrinolytic\\nLoading dose 180 mg orally\\nMaintenance dose 90 mg orally twice daily\\nNSTE-ACS indicates non–ST-segment elevation acute coronary syndromes; PCI, percutaneous coronary intervention; and STEMI, ST-segment elevation myocardial infarction.', 'FIGURE 4 Initial Choice of P2Y12 Inhibitor in Patients Not Requiring an Oral Anticoagulant\\nColors correspond to Class of Recommendation inTable 2. ACS indicates acute coronary syndromes; ASA, aspirin; CABG, coronary artery bypass grafting; NSTE-ACS,\\nnon–ST-segment elevation ACS; PCI, percutaneous coronary intervention; and STEMI, ST-segment elevation myocardial infarction.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2157', '2157\\ngraft (CABG) surgery. 18-21 Guidance on dosing inter-\\nruption for patients referred for CABG is in Table 8.\\nDuration of administration after CABG is described in\\nSection 11.1 , “DAPT Strategies in the First 12 Months\\nPostdischarge. ”\\n2. In a secondary analysis of the randomized, double-\\nblind TRITON-TIMI 38 (Trial to Assess Improvement\\nin Therapeutic Outcomes by Optimizing Platelet In-\\nhibition with Prasugrel –Thrombolysis In Myocardial\\nInfarction 38) of prasugrel versus clopidogrel In', 'addition to aspirin among patients with ACS, sub-\\ngroup analyses using an outcome of net clinical\\nbeneﬁt (MACE events plus bleeding) demonstrated\\nnet harm with prasugrel versus clopidogrel among\\npatients with previous tr ansient ischemic attack or\\nstroke.\\n4 Dose reduction of prasugrel should be\\nconsidered in patients $75 years of age and in those\\nwith a body weight <60 kg (Table 7).\\n3. The randomized, double-blind TRITON-TIMI 38 and\\nPLATO trials demonstrated that prasugrel (TRITON-', 'T I M I3 8 )o rt i c a g r e l o r( P L A T O )r e d u c e dt h er a t eo ft h e\\ncomposite endpoint of cardiovascular death, MI, or\\nstroke by 16% to 20% when compared with clopidogrel,\\nas well as reduced the risk of stent thrombosis.\\n4,5 In the\\nPLATO trial, a nominal reduction in all-cause death\\nwith ticagrelor compared with clopidogrel was also\\nobserved.\\n5 In TRITON-TIMI 38, the P2Y12 inhibitor\\n(prasugrel or clopidogrel) was only administered in', 'patients with NSTE-ACS once the anatomy was deemed\\ns u i t a b l ef o rP C I .I nt h eP L A T Ot r i a l ,7 2 %w e r em a n a g e d\\nwith a planned invasive strategy and results in the\\ninvasively managed population were highly consistent\\nwith the overall trial for reducing MACE, as well as\\ncardiovascular and all-cause death individually.\\n6 Both\\nprasugrel and ticagrelor increase the risk of non-CABG\\nmajor bleeding compared with clopidogrel.\\n4,5 Prasugrel', '4,5 Prasugrel\\nhas been shown to increase life-threatening bleeds. 4\\nLimited data exist to compare the efﬁcacy and safety\\nof prasugrel versus ticagrelor head-to-head. One open-\\nlabel randomized trial reported a lower rate of MACE\\nwith similar bleeding with prasugrel administered at\\nthe time of PCI compared with ticagrelor used as up-\\nstream therapy in patients with ACS undergoing inva-\\nsive evaluation.\\n22\\n4. The randomized, double-blind PLATO trial of ticagrelor', 'versus clopidogrel included patients with ACS\\nmanaged with or without a planned invasive strategy.\\nAmong the 28% of patients (n ¼ 5,216) who were\\nmanaged without a planned invasive strategy, a 15%\\nreduction was observed in the primary endpoint of\\nvascular death, MI, or stroke with ticagrelor versus\\nclopidogrel that was highly consistent with the 16%\\nreduction in MACE in the overall trial. Similarly, the\\nﬁndings for bleeding were consistent with the overall\\ntrial result.\\n5,7', 'trial result.\\n5,7\\n5. In the randomized, double-blind, placebo-controlled\\nCURE (Clopidogrel in Unstable Angina to Prevent\\nRecurrent Events) trial, among patients with NSTE-ACS\\nreceiving aspirin and who were medically managed or\\nunderwent revascularizati on, the administration of\\nclopidogrel signi ﬁcantly reduced the composite of\\ncardiovascular death, MI, or stroke.\\n1 Although prasu-\\ngrel and ticagrelor further reduce major cardiovascular\\nevents compared with clopidogrel in patients with ACS', 'undergoing PCI, these more potent agents also further\\nincrease the risk of bleeding.\\n4,5 Clopidogrel is an\\neffective alternative P2Y12 inhibitor for use in patients\\nwith high bleeding risk or contraindications to prasu-\\ngrel or ticagrelor. In an open-label trial with a high\\ncrossover rate among older patients with ACS under-\\ngoing PCI, patients treated with clopidogrel had a\\nsimilar rate of ischemic events and less bleeding\\ncompared with ticagrelor.\\n23 Signi ﬁcant interpatient', 'variability in the pharmacodynamic response to clopi-\\ndogrel has been described.\\n15\\n6. In a prospective substudy among the patients who\\nunderwent PCI (n¼ 2,658) in the CURE trial, those who\\nwere pretreated with clopidogrel (median 6 days) prior\\nto PCI had a signi ﬁcantly lower rate of MACE both\\nbefore PCI and by 30 days.8 Clopidogrel is a prodrug\\nthat requires metabolism by the cytochrome P450\\nenzyme system to form its active metabolite and\\ntherefore may require several hours before signiﬁcant', 'antiplatelet effect is observed following a loading dose.\\nA meta-analysis of trials of clopidogrel in patients with\\nACS undergoing PCI found that pretreatment with\\nclopidogrel signi ﬁcantly reduced the risk for 30-day\\ncardiovascular death or MI.\\n11 However, less is known\\nregarding the need for pretreatment in the era of more\\npotent P2Y12 inhibitors with more rapid onset of anti-\\nplatelet action. In a randomized trial of prasugrel pre-\\ntreatment versus adminis tration at the time of PCI,', 'pretreatment (median of only 4.4 hours) did not\\nimprove ischemic outcomes, but signi ﬁcantly\\nTABLE 8 Management of Oral P2Y12 Inhibitors for\\nPatients Who Require CABG Surgery *\\nClopidogrel Elective CABG: Interrupt for 5 d before surgery.\\nUrgent CABG: Interruption for at least 24 h (ideally) and\\nproceeding earlier than 5 d may be reasonable.\\nPrasugrel Elective CABG: Interrupt for 7 d before surgery.\\nUrgent CABG: Interruption for at least 24 h (ideally) and', 'proceeding earlier than 7 d may be reasonable.\\nTicagrelor Elective CABG: Interrupt for 3-5 d before surgery.\\nUrgent CABG: Interruption for at least 24 h (ideally) and\\nproceeding earlier than 5 d may be reasonable.\\n*For all patients, oral P2Y12 inhibitor should be resumed after surgery when bleeding\\nrisk not excessive (typically 24-72 hours).\\nCABG indicates coronary artery bypass grafting.\\nRao et al JACC VOL. 85, NO. 22, 2025', '2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2158\\nincreased bleeding. 24 In the PLATO trial, knowledge of\\ncoronary anatomy prior to administration of the study\\ndrug was not required; however, upstream use of\\nticagrelor was not speciﬁcally compared with a strategy\\nof administration at time of PCI. Therefore, it remains\\nunknown whether a beneﬁt exists for administration of\\nticagrelor prior to PCI in patients with NSTE-ACS. For', 'this reason, routine pretre atment in patients under-\\ngoing an early invasive management strategy ( <24\\nhours) is not supported by clinical trial data. However,\\nit may be reasonable to consider pretreatment with\\nclopidogrel or ticagrelor in patients undergoing an\\ninvasive management strategy with the timing of\\nangiography anticipated to be $24 hours from admin-\\nistration of the loading dose.\\n7. The clinical ef ﬁcacy of prasugrel and ticagrelor\\ncompared with clopidogrel in TRITON-TIMI 38 and the', 'PLATO trial was consistent in patients undergoing PPCI\\nor delayed (ie, secondary) PCI after initial therapy for\\nSTEMI.\\n4,5 In the subgroup of patients with STEMI in\\nTRITON-TIMI 38 (n ¼ 3,534), prasugrel signi ﬁcantly\\nr e d u c e dM A C Eb y2 1 %a n ds t e n tt h r o m b o s i sb y4 2 %a t1 5\\nmonths without a clear excess in bleeding. 9 In the\\nP L A T Ot r i a l ,c o m p a r e dw i t hc l o p i d o g r e l ,t r e a t m e n to f\\npatients with STEMI undergoing PPCI (n¼ 7,544) with', 'ticagrelor was associated with a consistent trend toward\\nreduction in cardiovascular death, recurrent MI, or\\nstroke, as well as a signi ﬁcant reduction in stent\\nt h r o m b o s i sa n da n1 8 %r e d u c t i o ni na l l - c a u s ed e a t h .\\n10\\nBoth TRITON-TIMI 38 and the PLATO trial permitted\\nstudy drug administration prior to the initial angiogram\\nfor patients with STEMI undergoing primary PCI. In a\\nseparate randomized trial in PPCI for STEMI, allocation', 'to prehospital ticagrelor or hospital administration did\\nnot improve the primary endpoint of coronary reperfu-\\nsion prior to the PCI.\\n25 However, upstream administra-\\ntion of ticagrelor was associated with a reduction in\\nstent thrombosis with similar bleeding between treat-\\nment groups. Registry data have also not shown clear\\nclinical bene ﬁt for preloading a P2Y12 inhibitor in pa-\\ntients with STEMI,\\n26 but a meta-analysis that included\\npatients with STEMI showed that clopidogrel pretreat-', 'ment was associated with a lower risk for MACE without\\nan increase in bleeding.\\n27\\n8. Clopidogrel is effective for prevention of stent throm-\\nbosis and early recurrent ischemic events in patients\\nwith STEMI undergoing PCI. 11 As in patients with\\nNSTE-ACS, in patients with STEMI undergoing PPCI,\\nprasugrel and ticagrelor reduce the risk of recurrent\\nMACE compared with clopidogrel.\\n9,10 Administration\\nof clopidogrel is an alternative to prasugrel or tica-', 'grelor in patients with STEMI who are at high\\nbleeding risk or have other contraindications to those\\nagents.\\n9. In the CLARITY (Clopidogrel as Adjunctive Reperfu-\\nsions Therapy)-TIMI 28 trial, addition of clopidogrel\\nt oa s p i r i ni np a t i e n t sw i t hS T E M Iw h ow e r e<75 years\\nof age and received ﬁbrinolytic therapy reduced the\\nodds of an occluded infarct-related artery at angiog-\\nraphy, as well as the composite of cardiovascular\\ndeath, recurrent MI, or recurrent ischemia requiring', 'urgent revascularization by 30 days.\\n2 In the ran-\\ndomized, placebo-controlled COMMIT (Clopidogrel\\nand Metoprolol in Myocardia lI n f a r c t i o nT r i a l )s t u d y\\namong patients with suspected MI (93% STEMI, 54%\\nﬁbrinolytic-treated) receiving aspirin, clopidogrel 75\\nmg/day (without a loading dose), signi ﬁcantly low-\\nered the risk of the composite endpoint of death,\\nreinfarction, or stroke, as well as the endpoint of\\nmortality alone, with a consistent pattern in the', 'subgroup treated with ﬁbrinolytic.\\n3 No signi ﬁcant\\nexcess was observed in bleeding with clopidogrel\\nversus placebo. Based on the design of these 2 trials,\\nwhen administered concurrently with ﬁbrinolytic as\\nthe reperfusion strategy, clopidogrel is recommended\\nto be administered with a loading dose (300 mg, then\\n75 mg daily) for patients <75 years of age and start-\\ning without a loading dose (75 mg daily) for\\npatients $75 years of age. In patients treated with a', 'ﬁbrinolytic agent who are undergoing subsequent\\nPCI, either clopidogre lo rt i c a g r e l o r( a g e<75 years,\\nwithin 24 hours after a ﬁbrinolytic agent) or prasu-\\ngrel ( >24 hours after a ﬁbrinolytic agent) are alter-\\nnatives to support PCI.\\n9-12 ,28 In a trial of 3,799\\npatients with STEMI who were treated with a ﬁbri-\\nnolytic agent, 89% of whom also received clopidogrel\\nat the time of a ﬁbrinolytic agent, randomization to\\nticagrelor administered at a median of 11.4 hours', '(interquartile range, 5.8-18.2 hours) after ﬁbrinolytic\\ntherapy was noninferior to clopidogrel with respect\\nto major bleeding.\\n28\\n4.3.3. Intravenous P2Y12 Inhibition\\nRecommendation for Intravenous P2Y12 Inhibition\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n2b B-R\\n1. Among patients with ACS under-\\ngoing PCI who have not received\\na P2Y12 inhibitor, intravenous\\ncangrelor may be reasonable to\\nreduce periprocedural ischemic\\nevents. *', 'events. *\\n1-4\\n*Reproduced from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”5\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2159\\nSynopsis\\nCangrelor is a direct-acting, intravenous antagonist of\\nthe P2Y12 receptor characterized by rapid and potent\\nplatelet inhibitory effects w ith restoration of platelet\\nfunction occurring within 1 hour of drug discontinuation.\\n6', '6\\nThese pharmacological prop erties may be particularly\\nbeneﬁcial in clinical scenarios wherein absorption of\\norally administered P2Y12 inhibitors is impaired or not\\np o s s i b l e ,a sw e l la si np a t i e n t sr e q u i r i n gC A B Go ro t h e r\\nsurgery early after PCI when prolonged discontinuation of\\na P2Y12 inhibitor may not be safe.\\n7 The safety and efﬁcacy\\nof cangrelor has been compared with clopidogrel or\\nplacebo in 3 RCTs involving patients who are P2Y12', 'inhibitor-naïve and undergoing PCI for stable or acute\\nindications.\\n1-3 In a patient-level pooled analysis of these\\nstudies, cangrelor administered during PCI signi ﬁcantly\\nreduced periprocedural ischemic events albeit at the\\nexpense of more frequent minor bleeding.\\n4 The safety and\\nefﬁcacy of cangrelor versus ticagrelor or prasugrel with\\nrespect to ischemic events have not been established. The\\ntransition from intravenous to oral P2Y12 inhibition is an', 'important consideration to ensure adequate platelet inhi-\\nbition on completion of cangrelor infusion (Table 9).8\\nRecommendation-Speci ﬁc Supporting Text\\n1. CHAMPION PHOENIX (A Clinical Trial Comparing Can-\\ngrelor to Clopidogrel Standard Therapy in Subjects Who\\nRequire PCI) examined the effect of cangrelor versus\\nclopidogrel in patients undergoing PCI for acute or\\nstable coronary syndromes.\\n2 Cangrelor was adminis-\\ntered as an intravenous bolus prior to PCI followed by', 'an infusion for at least 2 hours or for the duration of the\\nprocedure, whichever was longer. In the control arm,\\nclopidogrel was administered as a 600- or 300-mg\\nloading dose immediately before or after PCI. At 48\\nhours, the primary endpoint of all-cause death, MI,\\nischemia-driven revascularization, or stent thrombosis\\nwas signiﬁcantly reduced with cangrelor with similar\\neffects observed among those presenting with NSTE-\\nACS (n ¼ 2,810) or STEMI (n ¼ 1,991). These results', 'contrast with the earlier neutral ﬁndings from the\\nCHAMPION PLATFORM (Cangrelor Versus Standard\\nTherapy to Achieve Optimal Management of Platelet\\nInhibition) trial and CHAMPION PCI (A Clinical Trial to\\nDemonstrate the Ef ﬁcacy of Cangrelor), which\\ncompared cangrelor with placebo and clopidogrel,\\nrespectively.\\n1,3 D i f f e r e n c e sa c r o s st r i a l si nt h et i m i n go f\\nclopidogrel administration and de ﬁnitions of MI and\\nstent thrombosis may in part account for variability in', 'the incidence of ischemic events and observed treat-\\nment effect. In a pooled analysis of these trials, can-\\ngrelor was associated with a signi ﬁcant reduction in\\nperiprocedural ischemic events compared with control\\nwith no evidence of heterogeneity across types of ACS\\npresentations.\\n4\\n4.3.4. Intravenous Glycoprotein IIb/IIIa Inhibitors\\nRecommendations for Intrave nous Glycoprotein IIb/IIIa\\nInhibitors\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .', 'COR LOE RECOMMENDATIONS\\n2a C-LD\\n1. In patients with ACS undergoing\\nPCI with large thrombus burden,\\nno-re ﬂow, or slow ﬂow, adjunc-\\ntive use of an intravenous or\\nintracoronary glycoprotein IIb/\\nIIIa inhibitor is reasonable to\\nimprove procedural success and\\nreduce infarct size. *\\n,1,2\\n3: Harm B-R\\n2. In patients with ACS, glycopro-\\ntein IIb/IIIa inhibitors should not\\nbe administered routinely due to\\nlack of ischemic beneﬁta n d\\nincreased risk of bleeding.\\n3-5', '3-5\\n*Adapted from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”6\\nTABLE 9 Transition From Intravenous Cangrelor Infusion\\nto Oral P2Y12 Inhibitor\\nOral P2Y12\\ninhibitor\\nLoading\\nDose Timing of Loading Dose Administration\\nClopidogrel 600 mg Immediately after discontinuation of cangrelor\\nPrasugrel 60 mg Immediately after discontinuation of cangrelor\\nTicagrelor 180 mg At any time during or immediately after\\ndiscontinuation of cangrelor', 'Recommendations in table obtained from U.S. Food and Drug Administration labeling\\nfor cangrelor.8\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2160\\nSynopsis\\nGlycoprotein IIb/IIIa receptor inhibitors are parenter-\\nally administered drugs that block platelet aggregation by\\npreventing platelet cross-linking via ﬁbrinogen or von\\nWillebrand factor binding to the glycoprotein IIb/IIIa re-', 'ceptor. These agents were ﬁrst evaluated before\\ncontemporary antiplatelet an d interventional strategies\\nw e r ei n t r o d u c e da n di na ne r aw h e nt h et i m et oc o r o n a r y\\nrevascularization was substantially longer than today.\\nThus, limited data are available for glycoprotein IIb/IIIa\\nreceptors in patients receiving more potent P2Y12 in-\\nhibitors and in those receiving earlier PCI with contem-\\nporary drug-eluting stents that have a lower risk for stent', 'thrombosis than prior generations of stents. In current\\npractice, the role of glycoprotein IIb/IIIa receptor in-\\nhibitors is largely limited to adjunctive use at the time of\\nPCI in patients with large thrombus burden or as“rescue ”\\nor “bailout ” therapy in patients with PCI complications\\nsuch as no-reﬂow or persistent or recurring thrombus at\\nthe lesion.\\n1\\nRecommendation-Speci ﬁc Supportive Text\\n1. In a study of 452 selected high-risk patients with', 'large anterior STEMI and a large thrombus burden,\\nadjunctive use of intracoronary abciximab reduced\\nthrombus burden and infarct size.\\n1 Other trials have\\nalso suggested that glycoprot ein IIb/IIIa inhibitors can\\nreduce intracoronary thrombus burden in patients\\nwith STEMI and NSTE-ACS.\\n7,8 Thus, glycoprotein IIb/\\nIIIa receptor inhibitors can be considered at the time\\nof PCI for patients with a large coronary thrombus\\nburden or no-re ﬂow or slow ﬂow that is believed to', 'be attributable to distal embolization of thrombus. In\\nclinical trials comparing intravenous and intra-\\ncoronary administration of glycoprotein IIb/IIIa in-\\nh i b i t o r s ,c l i n i c a la n db l e e d i n go u t c o m e s ,a sw e l la s\\nthrombus resolution and inf arct size, have generally\\nbeen similar.\\n2,9,10\\n2. Multiple strategies have been evaluated for use of\\nglycoprotein IIb/IIIa receptor inhibitors in patients\\nwith ACS. “Upstream ” administration of these agents', 'is deﬁned as administration of small molecule agents\\n(epti ﬁbatide or tiroﬁban) early after ACS diagnosis for\\nmedical stabilization prior to planned angiography\\na n dP C I .I nt h eE A R L Y - A C S( E a r l yG l y c o p r o t e i nI I b /\\nIIIa Inhibition in Patients with Non-ST-segment\\nElevation Acute Coronary Sy ndrome) trial, 9,406 pa-\\ntients with NSTE-ACS were randomized to routine\\nupstream use of epti ﬁbatide (within 8 hours after\\npresentation to the hospital) versus ad hoc adjunctive', 'use at the time of PCI among patients with NSTE-\\nACS.\\n4 Ischemic outcomes were not improved and\\nbleeding was increased in the routine upstream\\neptiﬁbatide arm. An alternative approach is routine\\nadjunctive use of a glycoprotein IIb/IIIa inhibitor at\\nt h et i m eo fP C If o rp a t i e n t sw i t hS T E M Io rN S T E - A C S .\\nAlthough early trials perfo rmed prior to use of potent\\nP2Y12 inhibitors suggested that this approach\\nimproved procedural outcomes and reduced peri-', 'procedural myocardial necrosis, studies performed\\namong patients receiving pretreatment with clopi-\\ndogrel have not con ﬁrmed reduction of ischemic\\nevents with routine adjunctive glycoprotein IIb/IIIa\\ninhibition and have increased bleeding\\ncomplications.\\n5,11\\n4.4. Parenteral Anticoagulation\\nRecommendations for Parenteral Anticoagulation\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\nNSTE-ACS: Upstream* Anticoagulant Therapy\\n1 B-R', '1 B-R\\n1. In patients with NSTE-ACS,\\nintravenous unfractionated hep-\\narin (UFH) is useful to reduce\\nischemic events. †\\n1-4\\n1 B-R\\n2. In patients with NSTE-ACS in\\nwhom an early invasive approach\\nis not anticipated, either enox-\\naparin or fondaparinux are rec-\\nommended alternatives to UFH\\nto reduce ischemic events.\\n5-11\\nAnticoagulant Therapy in Patients Undergoing\\nCoronary Revascularization\\n1 C-LD\\n3. In patients with ACS undergoing\\ncoronary revascularization (CABG', 'o rP C I )i nt h es a m ea d m i s s i o n ,\\nparenteral anticoagulation\\nshould be continued until revas-\\ncularization to reduce ischemic\\nevents.\\n12,13\\nAnticoagulant Therapy to Support PCI in ACS\\n(STEMI and NSTE-ACS)\\n1 C-EO\\n4. In patients with ACS undergoing\\nPCI, intravenous UFH is useful to\\nreduce ischemic events. †\\n(continued on the next page)\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2161\\nSynopsis', '2161\\nSynopsis\\nParenteral anticoagulation is recommended for all pa-\\ntients with ACS, irrespective of the initial treatment\\nstrategy, to treat the underlying pathophysiologic process\\n(coronary atherothrombosis) and reduce the risk of\\nrecurrent MACE (Table 10). Although eventual diagnostic\\nreclassi ﬁcation can occur (ie, to other non-\\natherothrombotic ACS diagn oses such as coronary spasm\\nor other conditions that can mimic ACS, such as stress', 'cardiomyopathy or myocarditis), initial parenteral anti-\\ncoagulation is intended to treat thrombus caused by\\natherosclerotic plaque disru ption (rupture or erosion) in\\npatients with presumed type 1 MI.\\n32 Anticoagulation\\ns t r a t e g i e sa r et ob ei n i t i a t e du p s t r e a m( a tt h et i m eo f\\ndiagnosis and prior to coronary angiography) and to\\nsupport PCI or other reperfusion therapy. In patients with\\nACS undergoing PCI, intraprocedural thrombin genera-', 'tion and platelet aggregation may occur, for which reason\\nparenteral anticoagulation is recommended to reduce the\\nrisk for thrombotic complications.\\n33 The choice of a\\nparenteral anticoagulant can be complex because it is\\ninﬂuenced by various factors, including vascular access\\nsite, renal function, and concomitant use of other anti-\\nplatelet or anticoagulant agents. Heparin-induced\\nthrombocytopenia can occur with both UFH and low-\\nmolecular-weight heparin; in this context, argatroban', 'and bivalirudin are direct thrombin inhibitors that are\\nacceptable alternative anticoagulants for patients with\\nknown heparin-induced thrombocytopenia.\\n34,35\\nRecommendation-Speci ﬁc Supportive Text\\n1. UFH has traditionally been the preferred anticoagu-\\nlant to treat patients with NSTE-ACS. 1-4 However,\\nlimitations to its use include the lack of a predictable\\ndose response and risk of heparin-induced thrombo-\\ncytopenia.\\n33 In unstable angina, a meta-analysis', 'including 1,353 patients enrolled from 6 randomized\\nstudies showed that, in comparison to patients\\nt r e a t e dw i t ha s p i r i na l o n e ,t h o s et r e a t e dw i t ha s p i r i n\\nand heparin were at lower, albeit nonstatistically\\nsigni ﬁcant, risk for MI or death during the randomized\\ntreatment period (relative risk, 0.67 [95% CI, 0.44-\\n1.02]).\\n3 Its efﬁcacy compared with placebo has not\\nbeen evaluated in the current era of dual antiplatelet\\ntherapy (DAPT) and early revascularization.\\n33', '33\\n2. Fondaparinux, a synthe tic pentasaccharide that\\nselectively binds antithrombin and causes rapid and\\npredictable inhibition of Factor Xa, was evaluated in\\nContinued\\nCOR LOE RECOMMENDATIONS\\n1 B-R\\n5. In patients with STEMI undergo-\\ning PCI, bivalirudin is useful as an\\nalternative to UFH to reduce\\nmortality and bleeding. † 14-19\\n2b B-R\\n6. In patients with NSTE-ACS un-\\ndergoing PCI, bivalirudin may be\\nreasonable as an alternative to\\nUFH to reduce bleeding.† 16,20-23\\n2b B-R', '2b B-R\\n7. In patients with ACS, intravenous\\nenoxaparin may be considered as\\nan alternative to UFH at the time\\nof PCI to reduce ischemic\\nevents. ‡\\n7,8,24-26\\n3: Harm B-R\\n8. In patients with ACS, fondapar-\\ninux should not be used to sup-\\nport PCI because of the risk of\\ncatheter thrombosis.\\n5,27\\nSTEMI: Anticoagulant Therapy Treated With Fibrinolytic Therapy\\n1A\\n9. In patients with STEMI treated\\nwith ﬁbrinolytic therapy, paren-\\nteral anticoagulation should be\\ncontinued for the duration of the', 'hospital stay (maximum of 8\\ndays) or until revascularization is\\nperformed to reduce ischemic\\nevents.\\n9,10,27-29\\n1A\\n10. In patients with STEMI treated\\nwith ﬁbrinolytic therapy who\\nare not intended to undergo an\\ninvasive approach, enoxaparin is\\nthe recommended anticoagu-\\nlant to reduce ischemic\\nevents.\\n9,10,28,29\\n1 B-R\\n11. In patients with STEMI treated\\nwith ﬁbrinolytic therapy who are\\nnot intended to undergo an\\ninvasive approach, fondaparinux\\nis a recommended alternative to', 'reduce ischemic events.\\n27,30\\n*At the time of diagnosis and prior to invasive coronary angiography if planned.\\n†Adapted or ‡modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”31\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2162\\npatients with high-risk NSTE-ACS in the OASIS-5\\n(Fifth Organization to Assess Strategies in Acute\\nIschemic Syndromes) trial.\\n5 Fondaparinux was similar', 'to enoxaparin in the risk for ischemic events at 9 days,\\nbut it reduced major bleeding. About 40% of the pa-\\ntients underwent PCI, and an increase was observed\\nin the rate of guiding-catheter thrombus formation\\nwith fondaparinux (0.9% versus 0.3%) compared with\\nenoxaparin. In NSTE-ACS, despite some data favoring\\nthe use of enoxaparin over UFH,\\n11 multiple meta-\\nanalyses have not demonstrated compelling superi-\\nority in ef ﬁcacy over UFH.\\n7,26,36 A meta-analysis', 'comparing low-molecular-weight heparin to UFH in\\n12,171 patients with ACS without ST-segment eleva-\\ntion across 5 randomized trials showed no signiﬁcant\\ndifference in death or MI (2.2% versus 2.3%) or in the\\nrisk of major bleeding.\\n36\\n3. For patients with ACS undergoing coronary revascu-\\nlarization (CABG or PCI), parenteral anticoagulation is\\nindicated until revascularization. The premature\\ndiscontinuation of anticoagulation is associated with', 'a transient rebound increase in thrombin activity and\\nactivated protein C and the reactivation of ischemic\\nevents,\\n12,13 with the greatest risk for reinfarction in\\nthe ﬁrst 4 to 8 hours after the discontinuation of\\nanticoagulation.\\n4. UFH has traditionally been the preferred anticoagu-\\nlant to support PCI in patients with NSTE-ACS. Acti-\\nvated clotting time is used to guide dosing during\\nPCI.\\n37 Although its pharmacokinetic effects are not\\nalways predictable, its anticoagulant effect is revers-', 'ible with the administration of protamine.\\n5. Bivalirudin is a direct thrombin inhibitor evaluated\\nin both NSTE-ACS and STEMI that can be used to\\nsupport PCI. In the BRIGHT- 4 (Bivalirudin with Pro-\\nlonged Full-Dose Infusion during PPCI versus Hepa-\\nrin) trial,\\n15 which enrolled patients with STEMI\\nundergoing PPCI using radial access (93%), bivalir-\\nudin was compared with heparin monotherapy in an\\nopen-label design. The bivalirudin regimen used', 'included the standard bolus and dosing (0.75 mg/kg,\\nthen 1.75 mg/kg per hour) plus a post-PCI infusion at\\nthe full dose (1.75 mg/kg per hour) for 2 to 4 hours.\\nBivalirudin with the full dose post-PCI infusion was\\nsuperior to UFH in reducing the 30-day composite of\\nall-cause death or BARC (Bleeding Academic\\nResearch Consortium) types 3-5 bleeding (4.39%\\nversus 3.06%; P ¼ 0.007).\\n15 All-cause death was also\\nreduced with bivalirudin (3.92% versus 2.96%; P ¼', '0.04), as well as 30-day stent thrombosis (0.37%\\nversus 1.1%; P ¼ 0.0015). Based on these results,\\nwhen bivalirudin is used to support PPCI for STEMI,\\na postprocedure 2- to 4-hour infusion at full dose is\\nrecommended.\\n15,38,39\\n6. Meta-analyses comparing bivalirudin versus UFH with\\nor without glycoprotein IIb /IIIa inhibitors in patients\\nwith ACS demonstrate that bivalirudin is associated\\nwith a lower risk for major bleeding.\\n16,17,40 In the\\nTABLE 10 Dosing of Parenteral Anticoagulation in ACS', 'Drug Dosing\\nUFH n Initial therapy: Loading dose 60 IU/kg (max 4,000 IU), with initial infusion12 IU/kg per h (max 1,000 IU/h) adjusted to therapeutic aPTT\\nrange of 60-80 s.\\nn To support PCI: In patients who have received prior anticoagulant therapy, additional UFH as needed to achieve an ACT 250-300 s.\\nIn patients who have not received prior anticoagulant therapy, 70-100 U/kg initial bolus to achieve target ACT of 250-300 s.', 'n With ﬁbrinolytic therapy: Loading dose 60 IU/kg (maximum 4,000 IU) with initial infusion 12 IU/kg per h (maximum 1,000 IU/h) adjusted to\\ntherapeutic aPTT range. *\\nBivalirudin n To support PCI: 0.75 mg/kg bolus, 1.75 mg/kg per h IV infusion during the PCI procedure.\\nn Post-PCI infusion for PPCI: 1.75 mg/kg per h for 2-4 h post-PCI.\\nn In patients with CrCl <30 mL/min, reduced infusion to 1 mg/kg per h.', 'Enoxaparin n Initial therapy: 1 mg/kg subcutaneous every 12 h. Reduce dose to 1 mg/kg per d subcutaneous if CrCl<30 mL/min.\\nn To support PCI: For previous treatment with enoxaparin, if the last subcutaneous dose was administered 8-12 h earlier or if only 1 sub-\\ncutaneous dose of enoxaparin has been administered, an IV dose of 0.3 mg/kg of enoxaparin should be given. If the last dose was\\nadministered within the previous 8 h, noadditional enoxaparin should be given.', 'For patients who have not received prior anticoagulant therapy, 0.5-0.75 mg/kg IV bolus.\\nn With ﬁbrinolytic therapy: If age <75 y, 30 mg IV bolus, followed in 15 min by 1 mg/kg subcutaneous every 12 h (maximum 100 mg for the\\nﬁrst 2 doses).\\nIf age$75 y: no bolus, 0.75 mg/kg subcutaneous every 12 h (maximum 75 mg for theﬁrst 2 doses).\\nRegardless of age, if CrCl<30 mL/min: 1 mg/kg subcutaneous every 24 h.\\nFondaparinux n Initial therapy: 2.5 mg subcutaneous daily.', 'n With ﬁbrinolytic therapy: 2.5 mg IV, then 2.5 mg subcutaneous daily starting the following day. Contraindicated if CrCl<30 mL/min.\\nn Fondaparinux should not be used to support PCI because of the risk of catheter thrombosis.\\n*Therapeutic aPTT range in setting ofﬁbrinolytic therapy is 50-70 s.\\nACS indicates acute coronary syndromes; ACT, activated clotting time; aPTT, activated partial thromboplastin time; CrCl, creatinine clearance; PCI, percutaneous coronary', 'intervention; PPCI, primary percutaneous coronary intervention; and UFH, unfractionated heparin.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2163\\ncontext of NSTE-ACS, bivalirudin was evaluated in the\\nACUITY (A Comparison of Angiomax Versus Heparin\\nin Acute Coronary Syndromes) trial, where bivalirudin\\nwas noninferior to UFH plus glycoprotein IIb/IIIa in-\\nhibitor for the risk of MACE and superior with respect', 'to 30-day major bleeding.\\n41 The bleeding de ﬁnition\\nused in the study was speci ﬁc to the ACUITY trial.\\nBivalirudin was also evaluated in the MATRIX (Mini-\\nmizing Adverse Hemorrhag ic Events by Transradial\\nAccess Site and Systemic Implementation of AngioX)\\ntrial where it was compared against UFH alone (ie,\\nwithout concomitant glycoprotein IIb/IIIa inhibitor).\\n42\\nNo signiﬁcant difference was observed between the 2\\narms with respect to 30-day ischemic or bleeding\\nevents.', 'events.\\n7. Intravenous enoxaparin compared with UFH reduces\\nthe risk for ischemic outcomes without a signi ﬁcant\\ndifference in bleeding in the setting of PPCI. In the\\nATOLL (Acute Myocardial Infarction Treated with\\nPrimary Angioplasty and Intravenous Enoxaparin or\\nUnfractionated Heparin to Lower Ischemic and\\nBleeding Events at Short- and Long-term Follow-up)\\ntrial,\\n24 which enrolled patients presenting with\\nSTEMI, the primary endpoint of 30-day incidence of', 'death, complication of MI, procedural failure, or major\\nbleeding occurred in 28% of patients with enoxaparin\\ncompared with 34% with UFH (P ¼ 0.06). Although the\\nincidence of primary endpoint was not signi ﬁcantly\\ndifferent between enoxaparin and UFH, the secondary\\nendpoint of 30-day death, recurrent ACS, or urgent\\nrevascularization was signi ﬁcantly lower in the\\nenoxaparin group (7% versus 11%; P ¼ 0.015). In\\naddition, a net clinical beneﬁt (death, complication of', 'MI, or major bleeding) was observed with enoxaparin\\ncompared with UFH (10% versus 15%; P ¼ 0.03). In a\\nmeta-analysis of 10,451 patients, intravenous enox-\\naparin was associated with a signiﬁcant reduction in\\ndeath and major bleeding.\\n26\\n8. Fondaparinux should not be used as the sole antico-\\nagulant to support PCI because of the risk of catheter\\nthrombosis.\\n5,27,31 In the OASIS-5 trial, an increase was\\nobserved in the rate of catheter-related thrombus with', 'fondaparinux compared with enoxaparin (0.9%\\nversus 0.4%).\\n5 Similar results were observed in the\\nOASIS-6 (The Safety and Ef ﬁcacy of Fondaparinux\\nversus Control Therapy in Patients with STEMI) trial\\nin which a higher rate of guiding-catheter thrombosis\\nand more coronary complications with fondaparinux\\nwere observed when used during PCI.\\n27\\n9. In patients with STEMI treated withﬁbrinolytic ther-\\napy, parenteral anticoagulation is recommended\\nbefore and after ﬁbrinolytic therapy to reduce', 'ischemic events. In studies of ﬁbrinolytic therapy\\nsuch as the GUSTO (Global Utilization of Streptoki-\\nnase and Tissue Plasminogen Activator for Occluded\\nCoronary Arteries) trial, t he ASSENT-3 (Assessment\\nof the Safety and Ef ﬁcacy of a New Thrombolytic\\nRegimen) trial, or the ExTRACT-TIMI 25 (Enoxaparin\\nand Thrombolysis Reperfusion for Acute Myocardial\\nInfarction Treatment-Thrombolysis In Myocardial\\nInfarction 25) study, intravenous heparin was\\nadministered for at least 48 hours.', '10,29,43 In the\\nExTRACT-TIMI 25 study, the UFH infusion was\\ngiven for at least 48 hours but could be continued\\nfor a longer period at the treating physician ’s\\ndiscretion, whereas the subcutaneous injections of\\nenoxaparin were continued until hospital discharge\\nor for a maximum of 8 days (whichever came\\nﬁrst).\\n10 Patients randomized to enoxaparin had a\\nlower risk of death or nonfatal recurrent MI through\\n30 days compared with UFH (9.9% versus 12.0%);', 'however, treatment with e noxaparin was associated\\nwith an increase in major bleeding (2.1% versus\\n1.4%).\\n10\\n10. In patients with STEMI who received ﬁbrinolytic\\ntherapy and who are not planned for an invasive\\napproach, enoxaparin is the preferred anticoagulant\\nover UFH.\\n9,10,28,29,44 In the ExTRACT-TIMI 25 study,\\nenoxaparin until hospital discharge or for a maximum\\nof 8 days (whichever came ﬁrst) was compared with\\nUFH administered for at least 48 hours (could be', 'continued for a longer period at the treating physi-\\ncian’s discretion) in 20,506 patients with STEMI\\nreceiving ﬁbrinolytic therapy.\\n10 The primary endpoint\\no fd e a t ho rn o n f a t a lr e c u r r e n tM It h r o u g h3 0d a y s\\noccurred in 12% in the UFH group compared with 9.9%\\nin the enoxaparin group. In a meta-analysis of 14\\nrandomized trials, UFH did not reduce reinfarction or\\ndeath in patients treated with ﬁbrinolytic therapy. In\\ncontrast, low-molecular-weight heparin reduced the', 'risk of reinfarction and death compared with placebo\\nand the risk of reinfarction.\\n45\\n11. In patients with STEMI who are not likely to undergo\\nan invasive approach, fondaparinux is an alternate\\nanticoagulant that can be used. In the OASIS-6 trial of\\npatients with STEMI who were treated with throm-\\nbolytic agents (predominantly streptokinase), fonda-\\nparinux signi ﬁcantly reduced the risk of the primary\\nendpoint of death or reinfarction at 30 days, including', 'as i g n iﬁcant reduction in mortality, reinfarction, and\\nsevere bleeding when compared with placebo or\\nUFH.\\n27,30\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2164\\n4.5. Lipid Management\\nSynopsis\\nThe current recommendations focus on patients with\\nrecent (ie, within 12 months) ACS. The 2023 AHA/ACC/\\nACCP/ASPC/NLA/PCNA CCD guideline provides more\\ndetailed recommendations on long-term management of', 'lipids in patients with prior ACS.\\n14 ASCVD event rates are\\nsubstantially higher in patients with recent ACS than\\nthose with CCD, with 1-year rates of cardiovascular\\ndeath, MI, and ischemic stroke estimated at 10% to 15%\\nafter an ACS hospitalization.\\n15,16 Higher risk among pa-\\ntients with ACS supports more aggressive LDL-\\ncholesterol (LDL-C) target si np a t i e n t sw i t hr e c e n tA C S\\nc o m p a r e dw i t ht h o s ew i t hC C D(Figure 5).\\n14-16 RCTs have', '14-16 RCTs have\\ndemonstrated ASCVD event reduction with multiple\\ndifferent pharmacological approaches to LDL-C level\\nlowering, with the magnitude of bene ﬁt proportional to\\nt h ed e g r e eo fL D L - Cl e v e ll o w e r i n g .17 In patients with\\nACS, RCTs have demonstrated incremental bene ﬁtw i t h\\nhigh- compared with moderate-intensity statin therapy\\nin regard to reduction in MACE.\\n1-4 For patients who do\\nnot reach LDL-C treatment goals on maximally tolerated', 'statin therapy, or who are intolerant to statins, several\\nnonstatin therapies, including ezetimibe, monoclonal\\nantibodies to proprotein convertase subtilisin/kexin\\ntype 9 (PCSK9), and bempedoic acid, can both lower\\nLDL-C levels and improve ASCVD outcomes across\\ndiverse populations.\\n5-10 Inclisiran also lowers LDL-C\\nlevels by preventing translation of PCSK9 mRNA, but\\nclinical outcomes studies are not yet available (Table 12).\\nNonetheless, the relative bene ﬁto fL D L - C–lowering', 'therapies is expected to be proportional to the observed\\nr e d u c t i o ni nL D L - Cl e v e l s(Tables 11 and 12 ).\\n5-11 A lipid\\nproﬁle is recommended as soon as feasible after pre-\\nsentation with ACS ( Figure 5 ), because LDL-C levels\\ndecrease modestly beginning 24 hours from symptom\\nonset.\\n18 Lipid management after hospital discharge is\\ndiscussed in Section 11.2 , “Reassessment of Lipid Levels\\nPostdischarge. ”\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t', '1. High-intensity statin regimens lower LDL-C concen-\\nt r a t i o nb ya na v e r a g eo f$50% (Table 11 ). The CTT\\n(Cholesterol Treatment Tri alists) meta-analysis of 5\\nRCTs showed that LDL-C concentration lowering with\\nhigh-intensity statins compared with moderate-\\nintensity statins reduces major vascular events by\\napproximately 15% in patients with coronary artery\\ndisease (CAD).\\n4 An individual participant meta-\\nanalysis of the A to Z (Aggrastat to Zocor) and PROVE', 'IT (Pravastatin or Atorvastatin Evaluation and Infec-\\ntion Therapy)-TIMI 22 trials, both of which were per-\\nformed in patients stabilized early after ACS,\\ndemonstrated signi ﬁcant reductions in cardiovascular\\nand all-cause death with more intensive versus less\\nintensive statin regimens.\\n19 The bene ﬁto fah i g h -\\nintensity statin regimen appears early after ACS and\\npersists over time. 3 The beneﬁt of high-intensity sta-\\ntins after ACS appears to be independent of baseline', 'Recommendations for Lipid Management\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1A\\n1. In patients with ACS, high-\\nintensity statin therapy is rec-\\nommended to reduce the risk of\\nMACE. *,1-4\\n1A\\n2. In patients with ACS who are\\nalready on maximally tolerated\\nstatin therapy with low-density\\nlipoprotein cholesterol (LDL-\\nC) ‡70 mg/dL (‡1.8 mmol/L),\\nadding a nonstatin lipid-lowering\\nagent is recommended to further', 'reduce the risk of MACE.†\\n5-7\\n1 B-R\\n3. In patients with ACS who are\\nstatin intolerant, nonstatin lipid-\\nlowering therapy is recom-\\nmended to lower LDL-C and\\nreduce the risk of MACE.\\n8-10\\n2a B-R\\n4. In patients with ACS who are\\nalready on maximally tolerated\\nstatin therapy with LDL-C 55 to\\n69 mg/dL (‡1.4 to <1.8 mmol/L),\\nadding a nonstatin lipid-lowering\\nagent is reasonable to reduce the\\nrisk of MACE.*\\n5-7,11-13\\n2b B-R\\n5. In patients with ACS, the con-\\ncurrent initiation of ezetimibe in', 'combination with maximally\\ntolerated statin may be consid-\\nered to reduce the risk of MACE.\\n5\\n*Modiﬁed or †adapted from the“2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for\\nthe Management of Patients With Chronic Coronary Disease.”14\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2165\\nLDL-C concentration. No indication was observed of\\nany safety concerns from achieving very low LDL-C', 'concentrations on statins or other lipid-lowering ther-\\napies; therefore, high-inten sity statin therapy should\\nnot be de-escalated during follow-up in patients who\\nare tolerating treatment.\\n13\\n2. Multiple therapeutic options are now available to add\\nto maximally tolerated statin therapy to achieve\\nd e s i r e dL D L - Cg o a l si np a t i e n t sw i t hA C S(Table 12). In\\nIMPROVE IT (Improved Reduction of Outcomes;\\nVytorin Efﬁcacy International Trial), addition of ezeti-', 'mibe to simvastatin 40 mg daily in patients <10 days\\nafter ACS led to a modest but signiﬁcant reduction in\\nMACE, over a median follow-up of 6 years.\\n5 Clinical\\ntrials of PCSK9 inhibitors have demonstrated a 15%\\nrelative risk reduction in MACE over a median of 2 to 3\\nFIGURE 5 Management of Lipid-Lowering Therapy for Patients With ACS\\nColors correspond to Class of Recommendation inTable 2. *Nonstatin LDL-lowering therapy: ezetimibe, PCSK9 inhibitor (eg, alirocumab, evolocumab and inclisiran),', 'and/or bempedoic acid. ACS indicates acute coronary syndromes; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; and PCSK9, proprotein\\nconvertase subtilisin/kexin type 9.\\nTABLE 11 Nonstatin Treatment Options for LDL-C Lowering in Patients With ACS Who Are Not at LDL-C Goal on Maximally\\nTolerated Statin Therapy\\nDrug Mechanism of Action\\nLDL-C Lowering\\n(%)\\nOutcomes Study Performed\\nin Patients With Recent ACS? Potential Adverse Effects', 'Ezetimibe* Blocks NPC1L1 cholesterol absorption 15-25 Yes ( <10 d post ACS) Liver function test abnormalities\\nEvolocumab Monoclonal antibody to PCSK9 w60 Established ASCVD ( >1 mo post ACS) Injection site reaction\\nAlirocumab Monoclonal antibody to PCSK9 w60 Yes (1-12 mo post ACS) Injection site reaction\\nInclisiran Inhibitor of PCSK9 synthesis (small\\ninterfering RNA)\\nw50 Clinical outcomes trials in ASCVD are\\nongoing\\nInjection site reaction\\nBempedoic\\nacid†', 'Bempedoic\\nacid†\\nATP-citrate lyase inhibitor w20 With or at high risk for CVD ( >90 d post\\nACS)\\nGout; gallstones; liver function test\\nabnormalities\\nAll agents are approved by the FDA.\\n*The LDL-C lowering potency of ezetimibe is greater when used in combination with statin therapy (approximately 25% LDL-C reduction) than when used as monotherapy (15%-20%).', '†Coadministration of bempedoic acid with simvastatin at a dose>20 mg and pravastatin at a dose>40 mg is not recommended due to the increased risk of muscle-related adverse\\neffects from statins.\\nACS indicates acute coronary syndromes; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; FDA, U.S. Food and Drug Administration; LDL-C, low-density\\nlipoprotein cholesterol; NPC1L1, Niemann-Pick C1-Like 1 protein; and PCSK9, proprotein convertase subtilisin/kexin type 9.', 'Rao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2166\\nyears including patients >1 month after ACS. 6,7,20\\nGreater absolute bene ﬁt with PCSK9 inhibitors has\\nbeen demonstrated in those patients enrolled closer to\\ntheir ACS event.\\n20,21 Evolocumab effectively reduces\\nLDL-C levels early after ACS and has demonstrated\\nfavorable changes on plaque components by intra-\\ncoronary imaging in patients with NSTEMI.\\n22-24 Greater', '22-24 Greater\\nplaque regression has also been reported by intra-\\ncoronary imaging for patients treated with alirocumab\\nafter AMI. 25 Inclisiran is a small interfering RNA tar-\\ngeting synthesis of the PCSK9 protein that is adminis-\\ntered at 6-month intervals after an initial 3-month\\ndose. Inclisiran lowers LDL-C levels by approximately\\n50% and is well tolerated,\\n26 but clinical outcome\\nstudies are not yet available. Bempedoic acid works\\nupstream from statins in the liver and leads to', 'approximately 20% reduction in LDL-C levels. It re-\\nduces MACE by 13% in statin-intolerant patients when\\nstarted >90 days after ACS.\\n10\\n3. Statin intolerance is frequent in clinical practice and\\nthe most commonly reported cause is statin-associated\\nmuscle symptoms. 27 To consider a patient as having\\nstatin intolerance, a minimum of 2 statins should be\\nattempted, including at least 1 at the lowest approved\\ndaily dose.\\n28 Currently available options for patients', 'with complete or partial intolerance to statin therapy\\ninclude ezetimibe, PCSK9 inhibitor monoclonal anti-\\nbodies, inclisiran, and bempedoic acid. Ezetimibe and\\nPCSK9 inhibitors have been demonstrated to be safe\\nand well tolerated and improve lipid parameters in\\nstatin-intolerant patients.\\n8,9 However, outcomes\\ns t u d i e su s i n gt h e s ea g e n t sa sm o n o t h e r a p yo ri nc o m -\\nbination in statin-intolerant patients are not available.', 'Bempedoic acid is an ATP citrate lyase inhibitor that\\nreduces LDL-C levels by 15% to 25% with low rates of\\nmuscle-related adverse effects.\\n29,30 A combination\\nproduct that combines bempedoic acid with ezetimibe\\nlowered LDL-C levels by approximately 35%.\\n31 In the\\nCLEAR Outcomes (Cholesterol Lowering via Bempe-\\ndoic Acid, an ACL-Inhibiting Regimen) trial, bempedoic\\nacid was compared with placebo in statin-intolerant\\npatients with or at high risk for ASCVD. Patients with', 'ACS within 90 days prior to randomization were\\nexcluded from this trial. Mean LDL-C level was\\n139 mg/dL at enrollment and was reduced by 29 mg/dL\\nwith bempedoic acid compared with placebo. MACE\\nwas reduced by 13% in the bempedoic acid arm. Bem-\\npedoic acid raised uric acid levels in a small subset of\\npatients, and rates of abnormal liver function tests,\\ngout, and gallstones were increased with its use in the\\ntrial.\\n10\\n4. IMPROVE IT randomized patients post-ACS with', 'LDL-C levels of $50 mg/dL and #125 mg/dL\\n(#100 mg/dL if on lipid-lowering therapy) to the\\ncombination of simvastatin (40 mg) and ezetimibe (10\\nmg) or simvastatin (40 mg) and placebo (simvastatin\\nmonotherapy), with median LDL-C level at enrollment\\nof 69.5 mg/dL. The addition of ezetimibe reduced the\\nrelative risk of MACE by 6.4% compared with placebo.\\n5\\nBeneﬁt was similar among patients with baseline\\nL D L - C5 0t o7 0m g / d Lv e r s u s$70 mg/dL.32 FOURIER', '(Further Cardiovascular Outcomes Research With\\nPCSK9 Inhibition in Subjects With Elevated Risk) and\\nODYSSEY OUTCOMES (Evaluation of Cardiovascular\\nOutcomes After an Acute Coronary Syndrome During\\nTreatment With Alirocumab) enrolled patients with\\nLDL-C $70 mg/dL and thus did not speciﬁcally assess\\noutcomes associated with adding PCSK9 inhibitor\\ntherapy among patients with LDL-C levels 55 to\\n70 mg/dL.\\n6,7 However, secondary analyses of both\\ntrials demonstrated better outcomes in patients with', 'achieved LDL-C <50 mg/dL versus those with ach-\\nieved LDL-C levels $50 mg/dL, with monotonic\\nrelationships, suggesting b etter outcomes with pro-\\ngressively lower LDL-C even well below 50 mg/dL.\\n11,12\\nRates of neurocognitive and muscle events, including\\nhemorrhagic stroke, were not increased among\\npatients who achieved very low LDL-C levels with\\nPCSK9 inhibition.\\n11,12 Longer term follow-up studies\\nsupport continued bene ﬁt and safety associated with', 'achieving and maintaining very low LDL-C levels in\\nsecondary prevention with a PCSK9 inhibitor over\\nseveral years.\\n33 The beneﬁts of ezetimibe and PCSK9\\ninhibitors appear to be greater among higher risk\\npatients with prior ACS and diabetes or more\\nadvanced coronary or polyvascular disease or\\nelevated biomarkers.\\n20,34-41\\n5. Ezetimibe reduces LDL-C levels by 15% to 25% by\\nblocking its absorption from the gastrointestinal tract\\nvia the Niemann-Pick C1-Like 1 protein (NPC1L1). The', 'IMPROVE IT trial studied the combination of simva-\\nstatin (40 mg) and ezetimibe (10 mg) (simvastatin-\\nTABLE 12 Statin Classi ﬁcation\\nStatin Classi ﬁcation by Expected LDL-C Reduction\\nHigh-Intensity\\nTherapy*\\nModerate-Intensity\\nTherapy†\\nLow-Intensity\\nTherapy‡\\nAtorvastatin\\n40-80 mg\\nRosuvastatin\\n20-40 mg\\nAtorvastatin 10-20 mg\\nRosuvastatin 5-10 mg\\nSimvastatin 20-40 mg\\nPravastatin 40-80 mg\\nLovastatin 40 mg\\nFluvastatin XL 80 mg\\nFluvastatin 40 mg BID\\nPitavastatin 1-4 mg\\nSimvastatin 10 mg', 'Simvastatin 10 mg\\nPravastatin 10-20 mg\\nLovastatin 20 mg\\nFluvastatin 20-40 mg\\nModiﬁed with permission from Grundy et al.42 Copyright 2018 American Heart Asso-\\nciation, Inc., and American College of Cardiology Foundation.\\n*Expected LDL-C reduction$50%.\\n†Expected LDL-C reduction$30% to 49%.\\n‡Expected LDL-C reduction<30%.\\nBID indicates twice daily; LDL-C, low-density lipoprotein cholesterol.\\nJACC VOL. 85, NO. 22, 2025 Rao et al', 'JUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2167\\nezetimibe) to simvastatin (40 mg) and placebo (sim-\\nvastatin monotherapy) in patients hospitalized with an\\nACS in the past 10 days. The median time from ACS to\\nrandomization was 5 days, and 34% of patients were\\nalready on a statin at the time of the ACS event. The\\naddition of ezetimibe reduced the relative risk of\\nMACE by 6.4% compared with placebo (hazard ratio,', '0.936 [95% CI, 0.89-0.99]) over a median of 6 years ’\\nfollow-up. Ezetimibe was well-tolerated without any\\nclear imbalances in adverse events compared with\\nplacebo.\\n5\\n4.6. Beta-Blocker Therapy\\nSynopsis\\nBeta blockers decrease myocardial oxygen demand by\\nreducing the heart rate, blood pressure, and myocardial\\ncontractility. 1,3 The clinical bene ﬁt of beta blockers in\\npatients with left ventricular ejection fraction\\n(LVEF) <40% and stabilized HF is well established,\\nincluding patients post-MI.', '3-5 Most of the RCT data per-\\ntaining to early use of beta-blocker therapy in STEMI were\\nconducted in the pre-reperfusion era.\\n3 No adequately\\npowered RCTs have been done that examine the clinical\\nbeneﬁt of beta blockers during hospitalization among\\npatients exclusively wit h NSTE-ACS. Although most\\nstudies were conducted in pa tients with STEMI, early\\nhospital initiation of beta-blocker therapy (within 24\\nhours) is recommended among most patients with ACS', 'and without contraindications (eg, acute HF [Killip class\\nII-IV], evidence of low cardiac output state or at risk for\\ncardiogenic shock, PR interval >0.24 milliseconds, sec-\\nond- or third-degree heart block without a cardiac pace-\\nmaker, severe bradycardia, active bronchospasm).\\n1,2,6\\nPatients with an initial contraindication to beta-blocker\\ntherapy on presentation can be reassessed after 24 hours\\nand initiated on oral beta-blocker therapy if the initial', 'contraindication has resolved. Further study is warranted\\nto examine the beneﬁt in those patients with NSTE-ACS.\\nAlthough an open-label randomized trial has raised\\nquestions about the bene ﬁt of long-term beta-blocker\\ntherapy following hospital discharge in patients with ACS\\nwho have undergone coronary revascularization and have\\npreserved left ventricular (LV) function,\\n7 this area re-\\nmains under study.\\nRecommendation-Speci ﬁc Supportive Text', '1. RCTs from both the pre-reperfusion era and in the\\nearly reperfusion era have shown that early initiation of\\nbeta-blocker therapy reduces the risk of reinfarction\\nand ventricular arrhythmias among patients with\\nSTEMI.\\n1-3 The COMMIT (Clopidogrel and Metoprolol in\\nMyocardial Infarction) trial included 45,852 patients\\n(approximately 50% received ﬁbrinolytic therapy and\\n7% having NSTE-ACS) and showed that early initiation\\nof high doses (ie, up to 15 mg intravenously then 200', 'mg orally daily) of metoprolol reduced the risk of\\nreinfarction an dv e n t r i c u l a rﬁbrillation compared with\\nplacebo but increased the risk of cardiogenic shock that\\noccurred mainly during the ﬁrst 24 hours.\\n1 In a small\\nopen-label trial of 801 patients with STEMI who un-\\nderwent PPCI, carvedilol did not reduce MACE over 3\\nyears, but the trial was underpowered to detect a dif-\\nference.\\n8 Overall, the weight of the evidence suggests\\nthat a low dose of oral beta blocker should be initiated', 'in patients without contraindication early after diag-\\nnosis of ACS (<24 hours) with slow dose escalation as\\nb l o o dp r e s s u r ea n dh e a r tr a t ep e r m i t .U s es h o u l db e\\ndiscontinued in those with new or worsening HF\\nsymptoms or signs of cardiogenic shock. In hemody-\\nnamically stable patients with STEMI who do not have\\nacute HF, intravenous beta blockers can be adminis-\\ntered prior to reperfusion if there are ongoing symp-\\ntoms or a clinical indication for administration. The', 'weight of the evidence does not support the routine use\\nof intravenous beta blocker s prior to PPCI because of\\ninconsistent results as to whether it has any favorable\\neffect on infarct size or clinical outcomes.\\n9,10 The\\noptimal duration of beta-blocker use remains unclear in\\npatients with preserved LVEF. Although a randomized\\ntrial did not conﬁrm long-term beneﬁt from continued\\nuse of a beta blocker after hospital discharge in lower\\nrisk patients with preserved LV function who had un-', 'dergone coronary revascularization,\\n7 additional studies\\nare ongoing in this space.\\nR e c o m m e n d a t i o nf o rB e t a - B l o c k e rT h e r a p y\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nRECOMMENDATION\\n1A\\n1. In patients with ACS without\\ncontraindications, early (<24 hours)\\ninitiation of oral beta-blocker therapy\\nis recommended to reduce risk of\\nreinfarction and ventricular\\narrhythmias.\\n1-5\\nRao et al JACC VOL. 85, NO. 22, 2025', '2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2168\\n4.7. Renin-Angiotensin-Aldosterone System Inhibitors\\nSynopsis\\nOral ACE inhibitors reduce all-cause death and MACE\\nin patients with STEMI or NSTEMI, particularly when\\nassociated with high-risk features (LVEF #40%, hyper-\\ntension, diabetes mellitus, or STEMI with anterior\\nlocation).\\n1-4,6 Even in AMI without high-risk features,\\nuse of an oral ACEi confers a modest survival bene ﬁt.4', 'Compared with ACEi, the beneﬁts of an ARB in patients\\nwith AMI with HF or LV systolic dysfunction are\\nsimilar.\\n5 Thus, in the absence of contraindications,\\neither an oral ACEi or ARB should be initiated in\\nappropriate patients with AMI.\\n5,8 In patients with AMI\\nwith LVEF #4 0 % ,a n dw i t hH Fs y m p t o m sa n d / o rd i a -\\nbetes mellitus, the addition of a mineralocorticoid re-\\nceptor antagonist reduced all-cause death and MACE\\nand should be given in the absence of advanced', 'chronic kidney disease, hyperkalemia, or other\\ncontraindication.\\nIn patients with symptomatic HF and reduced LVEF,\\nsacubitril-valsartan has been demonstrated to be superior\\nto an ACEi for reducing cardiovascular death or HF hos-\\npitalization; however, the trial excluded patients within 3\\nmonths of ACS.\\n9 In a trial of patients early after MI with\\nLVEF #40% and/or pulmonary congestion, sacubitril-\\nvalsartan did not signi ﬁcantly reduce cardiovascular', 'd e a t ho ri n c i d e n tH Fc o m p a r e dw i t ha nA C E i .H y p o t e n -\\nsive events were more common with sacubitril-valsartan,\\nbut no other safety concerns were observed. Therefore, if\\ntreatment with sacubitril-valsartan for HF with reduced\\nejection fraction is planned, initiation of this combination\\nagent instead of an ACEi or ARB early after MI appears\\nsafe.\\n10\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. Randomized controlled trials have demonstrated a', 'reduction in all-cause death and MACE with the addi-\\ntion of an oral ACEi in patients with AMI with\\nLVEF #40%\\n1,3 and in patients with anterior STEMI.2 An\\nindividual-patient meta-analysis of 98,496 patients\\nwith AMI also showed a survival beneﬁtw i t hA C E iu s e ,\\nwith the greatest absolute beneﬁt in patients with hy-\\npertension, diabetes, and STEMI of anterior location.\\n4\\nIn the VALIANT (Valsartan in Acute Myocardial\\nInfarction) trial of patien ts with AMI with LV systolic', 'dysfunction and/or HF symptoms, the use of an ARB\\nwas statistically noninferior to an ACEi, and rates of all-\\ncause death were similar between the 2 treatment\\narms.\\n5 Concomitant initiation of both an ACEi and ARB\\nin patients with AMI should be avoided due to an in-\\ncrease in adverse events without added bene ﬁt\\nc o m p a r e dw i t he i t h e rd r u ga l o n e .5,8\\n2. In the EPHESUS (Eplerenon eP o s t - A c u t eM y o c a r d i a l\\nInfarction Heart Failure Ef ﬁcacy and Survival Study)', 'trial, the mineralocorticoid receptor antagonist\\neplerenone reduced both all-cause death and MACE\\nduring a mean follow-up of 16 months in patients\\nwith AMI with LVEF #40% who also had symptoms\\nof HF and/or diabetes mellitus. The use of evidence-\\nbased therapies for this population was relatively\\nhigh, including 86% use of ACEi or ARB and 75% use\\nof a beta blocker at enrollment.\\n7 Patients with\\nadvanced chronic kidney disease (serum creatinine\\n>2.5 mg/dL) or hyperkalemia (serum potassium >5.0', 'mmol/L) were excluded from enrollment.\\n7 In a trial\\nof 1,012 patients with acute STEMI and without a\\nhistory of HF, the use of eplerenone reduced the\\nprimary endpoint compared with placebo, but the\\nbeneﬁt was largely driven by a reduction in natri-\\nuretic peptides.\\n11\\nRecommendations for Renin-Angiotensin-Aldosterone\\nSystem Inhibitors\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1A\\n1. In high-risk patients with ACS', '(LVEF £40%, hypertension, dia-\\nbetes mellitus, or STEMI with\\nanterior location), an oral\\nangiotensin-converting enzyme\\ninhibitor (ACEi) or an angiotensin\\nreceptor blocker (ARB) is indi-\\ncated to reduce all-cause death\\nand MACE.\\n1-6\\n1 B-R\\n2. In patients with ACS and\\nLVEF £40%, and with HF symp-\\ntoms and/or diabetes mellitus, a\\nmineralocorticoid receptor\\nantagonist is indicated to reduce\\nall-cause death and MACE.\\n7\\n2a A\\n3. In patients with ACS who are not\\nconsidered high risk, an oral ACEi', 'or an ARB is reasonable to reduce\\nMACE.\\n4\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2169\\n3. The ACE Inhibitor Myocardial Infarction Collaborative\\nGroup meta-analysis of 98,496 patients with AMI re-\\nported a 30-day mortality rate of 7.1% in AMI patients\\nt r e a t e dw i t ha nA C E ic o m p a r e dw i t h7 . 6 %r e c e i v i n g\\nplacebo (proportional reduction, 7% [95% CI, 2%-11%];', 'P ¼ 0.004), and the beneﬁt appeared to be irrespective\\nof baseline risk.\\n4 The use of an ACEi also reduced\\nnonfatal cardiac failure compared with placebo.4\\n5. STEMI MANAGEMENT: REPERFUSION\\nSTRATEGIES\\n5.1. Regional Systems of STEMI Care\\nSynopsis\\nThe goal of optimizing outcomes after STEMI depends\\nnot only on the ef ﬁcient execution of STEMI care pro-\\ncesses but also on the seamless communication and\\ncoordination of care among the teams caring for the', 'patient. The goal of each community is therefore to\\nensure a coordinated response to every patient with\\nSTEMI, regardless of physical location at presentation, to\\nhelp minimize total ischemic time. The creation and\\nmaintenance of successful systems of STEMI care\\nrequire detailed mapping of care for all possible routes\\nby which a patient with S TEMI could present for\\ndiagnosis and receive de ﬁnitive reperfusion therapy at\\nboth PCI-capable and non –PCI-capable facilities, as well', 'as access to cardiac surgical care and other advanced\\ncare modalities ( Figure 6 ). The many stakeholders of\\nregional systems of STEMI care (including hospitals,\\nEMS companies, regional public health departments, and\\nlocal governments) must ensure that all components of a\\nSTEMI system of care function in a coordinated way\\nwith no gaps in care processes to help optimize STEMI\\noutcomes in the community.\\nRecommendation-Speci ﬁc Supportive Text\\n1. The establishment of coord inated regional systems', 'of STEMI care is associated with reduced time to\\nreperfusion and increased survival in STEMI in\\nseveral pre- versus postimplementation comparison\\nstudies throughout the world.\\n1-6 Over the past 15\\nyears, considerable gains have been made in\\nreducing FMC to reperfusion times in patients with\\nSTEMI and these improvements in reperfusion times\\nhave been associated with improved outcomes.\\n5,7\\nUnfortunately, recent declines have been reported\\nin the rates of achieving established STEMI perfor-', 'mance measures,\\n8 in part due to the COVID-19\\npandemic and related challenges in ensuring\\nadequate resourcing and staf ﬁng of EMS agencies\\nand hospitals. Therefore , all communities should\\ncontinue to establish, reinvigorate, and maintain\\nregional systems of STEMI care to improve outcomes\\nof patients with STEMI globally. The collection of\\nhigh-quality data at every stage of care is an insep-\\narable component of a STEMI system of care. Suc-\\ncessful STEMI systems have robust mechanisms for:', '1) educating the public of the need to immediately\\ncall 9-1-1 (or other appropriate local emergency ser-\\nvices) for ischemic symptoms and not driving them-\\nselves to the nearest hospital; 2) data collection that\\nbalances the need for adequate data capture without\\nintroducing data overburden; 3) data sharing within\\nhospital departments (eg, ED and cardiology) or be-\\ntween hospitals and EMS agencies; and 4) meetings\\nto review and discuss shared data at local and sys-', 'tem levels to drive process improvement.\\nRecommendation for Regional Systems of STEMI Care\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n1 B-NR\\n1. All communities should create\\nand maintain regional systems of\\nSTEMI care that coordinate pre-\\nhospital and hospital-based\\nSTEMI care processes with the\\ngoal of reducing total ischemic\\ntime and improving survival in\\npatients with STEMI.\\n1-6\\nRao et al JACC VOL. 85, NO. 22, 2025', '2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2170\\nFIGURE 6 Care System Pathway for Patients Experienc ing Ischemic Symptoms Suggestive of ACS\\nSystems of STEMI care, and the most common routes by which patients present for diagnosis and deﬁnitive reperfusion therapy for STEMI. Best clinical practice consists', 'of patients calling 9-1-1 (or other emergency services) to activate EMS; EMS obtaining a prehospital ECG, activating the cardiac catheterization laboratory from theﬁeld\\nfor suspected STEMIs, and transporting the patient to the nearest PCI center when possible; and achieving a system goal of FMC-to-device time within 90 minutes.\\nColors correspond to Class of Recommendation inTable 2. *Patients with chest tightness or other symptoms indicative of a heart attack. ACS indicates acute coronary', 'syndromes; ED, emergency department; EMS, emergency medical services; FMC,ﬁrst medical contact; PCI, percutaneous coronary intervention; PPCI, primary\\npercutaneous coronary intervention; and STEMI, ST-segment elevation myocardial infarction.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2171\\n5.2. Reperfusion at PCI-Capable Hospitals\\n5.2.1. PPCI in STEMI\\nSynopsis\\nTimely PPCI confers improved survival compared with', 'ﬁbrinolytic therapy as primary reperfusion therapy for\\npatients with STEMI. 6,7 Systems of care designed to\\nreduce the time to PPCI for patients with STEMI have\\nbeen consequential in reducing risk of early death. 19,20\\nT h eg o a li st op r o v i d eP P C Ia ss o o na sp o s s i b l ea f t e rt h e\\ndiagnosis of STEMI is made with ﬁrst device activation\\nwithin 90 minutes from FMC among walk-in and EMS-\\ntransported patients and 120 minutes for transfer pa-\\ntients from non –PCI-capable facilities.', '1-7 The bene ﬁto f\\nPPCI begins to diminish for those >12 hours from symp-\\ntom onset, but there appears to be continued beneﬁtf o r\\nPPCI through appro ximately 24 hours. 12,13 In stable\\nasymptomatic patients with an occluded artery>48 hours\\nafter symptom onset, routine PCI has not been shown to\\nbe bene ﬁcial in the absence of ongoing ischemia; the\\nrelative utility of routine PCI for asymptomatic patients\\nwith STEMI between 24 to 48 hours from symptom onset\\nis less rigorously tested.', '14,15 However, coronary revascu-\\nlarization should be considered for patients with late\\npresentations with continued signs and symptoms of\\nischemia, including cardiogenic shock, acute severe HF,\\npersistent angina, and life-threatening arrhythmias.\\nRecommendation-Speci ﬁc Supportive Text\\n1. PPCI is the recommended reperfusion therapy in pa-\\ntients with STEMI and ischemic symptoms when\\nperformed #90 minutes (FMC –to–ﬁrst-device activa-\\ntion) or #120 minutes in transfer patients to improve', 'survival.\\n1-7 The success of PPCI in achieving these goals\\nwas facilitated by the introduction in 2006 of the\\nAHA’s Mission: Lifeline programs involving EMS and\\nclinicians (eg, emergency medicine, cardiology,\\nnursing) with practiced drill-down programs and\\nregionalization of care\\n21 that have improved myocar-\\ndial salvage, as well as reduced risk of death and\\nadverse outcomes.\\n4,22,23 PPCI is superior toﬁbrinolytic\\nt h e r a p y ,w h i c hi su s e dw h e nt h ep a t i e n ti si nan o n–', 'PCI-capable hospital and transfer time to a PCI-capable\\nhospital is anticipated to be >120 minutes. Compared\\nwith ﬁbrinolytic therapy with a similar treatment\\ndelay, PPCI offers higher rates of infarct-related artery\\npatency, and restoring TIMI 3 epicardialﬂow grade, as\\nwell as lower rates of recurrent ischemia, reinfarction,\\nemergency repeat revascularization procedures, intra-\\ncranial hemorrhage, and death.\\n6,7 Radial access for\\nPPCI has further reduced death, decreased access site', 'bleeding, decreased the need for transfusion, and\\nreduced acute kidney injury when compared with\\nfemoral access (Section 7.1, “Vascular Access Approach\\nfor PCI”).\\n24,25\\n2. In the SHOCK (Should We E mergently Revascularize\\nOccluded Coronaries for Cardiogenic Shock) trial, 9 re-\\nported in 1999, patients with AMI and cardiogenic\\nshock were randomized to medical therapy or\\nRecommendations for PPCI in STEMI\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .', 'COR LOE RECOMMENDATIONS\\n1A\\n1. In patients with STEMI present-\\ning <12 hours after symptom\\nonset, PPCI should be performed\\nwith a goal of FMC to device\\nactivation of £90 minutes,\\nor £120 minutes in patients\\nrequiring hospital transfer, to\\nimprove survival.\\n1-7\\n1 B-R\\n2. In patients with ACS and cardio-\\ngenic shock or hemodynamic\\ninstability, emergency revascu-\\nlarization of the culprit vessel by\\nPCI or CABG is indicated to\\nimprove survival, irrespective of\\ntime from symptom onset.\\n8-11\\n2a B-NR', '8-11\\n2a B-NR\\n3. In patients with STEMI present-\\ning 12 to 24 hours after symptom\\nonset, PPCI is reasonable to\\nimprove clinical outcomes. *\\n12-15\\n2a C-LD\\n4. In patients with STEMI present-\\ning >24 hours after symptom\\nonset with the presence of\\nongoing ischemia or life-\\nthreatening arrhythmia, PPCI is\\nreasonable to improve clinical\\noutcomes. †\\n12,14\\n3: No Beneﬁt B-R\\n5. In patients who are stable with\\nSTEMI who have a totally\\noccluded infarct-related artery\\n>24 hours after symptom onset', 'and are without evidence of\\nongoing ischemia, acute severe\\nHF, or life-threatening\\narrhythmia, PPCI should not be\\nperformed due to lack of\\nbeneﬁt.†\\n16,17\\n*Reproduced or†modiﬁed from the“2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”18\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2172\\nemergency revascularization. Among the patients\\nrandomized to revascularization, 64% of patients were', 'referred for PCI and 36% for CABG surgery. The median\\ntime from randomization to revascularization was 0.9\\nhours for PCI and 2.7 hours for CABG surgery. Despite\\nlack of a signiﬁcant difference in the primary endpoint\\nof mortality at 30 days, emergency revascularization\\nwith either PCI or CABG surgery reduced mortality at 6\\nmonths,\\n9 and the mortality rate bene ﬁtw a sm a i n -\\ntained through 1 and 6 years.26,27 In an observational\\nanalysis from the FITT-STEMI (Feedback Intervention', 'and Treatment Times in ST-Elevation Myocardial\\nInfarction) trial, for every 10-minute delay in PPCI after\\n60 minutes from FMC, there were an additional 3 to 4\\ndeaths per 100 with>8 0 %m o r t a l i t yb e y o n d6h o u r so f\\ndelay from FMC for patients with cardiogenic shock.\\n8\\nTherefore, it is recommended that PPCI should be\\nperformed in patients with STEMI and cardiogenic\\nshock as soon as possible, ideally within 90 minutes, to\\nreduce the mortality rate. Observational studies sug-', 'gest that emergency CABG surgery remains a treatment\\noption in patients with cardiogenic shock who are not\\namenable to primary reperfusion with PCI\\n10,11 or when\\nPCI is not successful.11,28\\n3. The beneﬁt of PCI for asymptomatic patients present-\\ning 12 to 24 hours after symptom onset is not well\\nstudied. Small randomized trials of patients 12 to 48\\nhours after symptom onset in STEMI have demon-\\nstrated that PPCI reduces infarct size and improves the\\nLVEF.', 'LVEF.\\n12,14 These ﬁndings are further supported by\\nobservational data. 13,15\\n4. No dedicated trials have been done that examine the\\nbeneﬁt of PPCI in patients with STEMI presenting late\\n>24 hours after symptom onset who have clinical evi-\\ndence of ongoing ischemia, acute severe HF, or life-\\nthreatening arrhythmias. Observational data and\\nsmall trials suggest that PCI in patients with STEMI\\nwith delayed presentations is reasonable and is asso-\\nciated with improved outcomes.\\n12,14,15', '12,14,15\\n5. PCI is not recommended for an occluded infarct-\\nrelated artery if the patient is asymptomatic and has\\na completed infarct. MACE outcomes were similar in\\nthose with an occluded infar ct-related artery versus\\nthose who underwent PCI 3 to 28 days after an MI\\n(Occluded Artery Trial [OAT])\\n16 and results were no\\ndifferent at 7 years follow-up.29 Similar ﬁndings were\\nn o t e di nt h eD E C O P I( D e s o b s t r u c t i o nC o r o n a i r ee n', 'Post-Infarctus) trial, which enrolled patients with an\\noccluded artery and Q waves on the ECG presenting 2\\nto 15 days after symptom onset.\\n17\\n5.2.2. Urgent CABG Surgery\\nSynopsis\\nTrials that evaluated the ef ﬁcacy and safety of CABG\\nsurgery in STEMI are limited.4 When PCI is not possible\\nfor anatomic reasons or in the presence of complex\\ndisease, CABG surgery can be performed as the primary\\nreperfusion strategy. After successful reperfusion of the\\ninfarct-related artery, CABG surgery can also be', 'important when managing patients with more extensive\\nnoninfarct-related artery disease ( Section 7.4.1 , “Man-\\nagement of Multivessel CAD in STEMI ”). The appro-\\npriate timing of CABG surgery in patients with STEMI\\nshould be determined on an individual basis, taking\\ninto consideration the hemodynamic stability of the\\npatient, the presence of ongoing ischemia, and extent\\nof myocardium at risk. After failed PPCI, emergency\\nCABG surgery is not recommended in the absence of a', 'large area of myocardium at risk or if surgical targets\\nare poor and if surgery may be associated with an\\nincreased risk of death and adverse cardiovascular\\noutcomes compared with nonsurgical management.\\n5 For\\nrecommendations regarding CABG surgery in patients\\npresenting with cardiogenic shock or mechanical com-\\nplications, please refer to Section 8.1 , “Revasculariza-\\ntion in ACS With Cardiogenic Shock ” and Section 9.1 ,\\n“Mechanical Complications. ”', 'Recommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. No RCTs have been done that compare PPCI with sur-\\ngical revascularization in the setting of STEMI. For pa-\\ntients with STEMI who are hemodynamically stable\\nwith anatomy of the infarct-related artery that is not\\namenable to PPCI, or if PPCI is unsuccessful, CABG\\nRecommendation for Urgent CABG Surgery\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n2a B-NR', '2a B-NR\\n1. In patients with STEMI in whom\\nPCI is not feasible or successful,\\nwith a large area of myocardium\\nat risk, emergency or urgent\\nCABG surgery can be effective to\\nimprove clinical outcomes. *\\n1,2\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”3\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2173\\nsurgery can be useful if there is a large area of', 'myocardium at risk. In such patients, particularly in the\\npresence of ongoing ischemia or if a large area of\\nmyocardium is at risk, CABG surgery may be effectively\\nperformed as a primary reperfusion strategy or after\\nPPCI.\\n1,2 D e s p i t ea ni n c r e a s ei nt h ea c u i t yo fp r e s e n t a -\\ntion and the burden of comorbidities, the in-hospital\\nmortality rate after CABG surgery in patients with\\nSTEMI continues to decrease.\\n1,4\\n5.3. Reperfusion at Non–PCI-Capable Hospitals\\nSynopsis', 'Synopsis\\nA large proportion of patients globally live >1h o u r\\ndriving time to a PCI-capable hospital. 14-17 At non–PCI-\\ncapable hospitals, transfer for PPCI is recommended if\\ndevice activation can be rea sonably predicted to occur\\nin <2 hours from FMC. If this cannot be achieved and\\nsymptoms have been present <12 hours, ﬁbrinolytic\\ntherapy is recommended to reduce the risk of recurrent\\nMACE. Patients with STEMI who present to a non –PCI-', 'capable facility $12 hours after onset of symptoms should\\nbe transferred to a PCI-capable facility when possible.\\nHowever, if the patient has associated hemodynamic\\ninstability or a large infarct territory at risk, they are at\\nvery high risk for morbidity and death, and in this situa-\\ntion where timely PPCI is not possible, the bene ﬁts of\\nﬁbrinolytic administration likely outweigh the bene ﬁto f\\nprolonged transfer for PPCI.\\nRecommendation-Speci ﬁc Supportive Text', '1. PPCI is recommended to reduce the risk of MACE when\\nFMC to PPCI can be achieved within 120 minutes. A\\npatient who presents to a non –PCI-capable hospital\\nwith STEMI should be transferred to a PCI-capable\\nhospital when this intervention can be accomplished\\nwithin 120 minutes.\\n1,2,18 System delays related to\\ntransfer are frequently underestimated, and a case-by-\\ncase approach should be calculated for each patient\\nwith STEMI prior to transfer for PPCI.19-21', '2. The use ofﬁbrinolytic therapy in STEMI in the United\\nStates is driven by patients who are unable to receive\\ntimely PPCI (<120 minutes FMC to device activation).\\nNumerous RCTs and meta-analyses have demonstrated\\nsuperiority to PPCI over ﬁbrinolytic therapy. However,\\nthe bene ﬁts of PPCI versus ﬁbrinolytic therapy\\ndiminish with increasing PCI-related time delay such\\nthat after 120 minutes, the bene ﬁts are no longer as\\nclear when compared with more timely ﬁbrinolytic\\ntherapy administration.', '19 In these patients, when\\ntimely PPCI cannot be performed, meta-analyses of\\nRCTs and observational studies show statistically\\nsimilar morbidity and mortality rates for a pharmaco-\\ninvasive approach (eg, ﬁbrinolytic therapy followed\\nby PCI within 2 to 24 hours) when a patient does not\\nhave timely access to PPCI.\\n4,5 The STREAM (Strategic\\nReperfusion Early After Myocardial Infarction) trial,\\nwhich randomized 1,892 early presenters (symptoms\\n<3 hours) with STEMI unable to receive PCI within 1', 'hour of FMC, found that both a 30-day composite\\n(eg, death, shock, CHF, or reinfarction) and 1-year\\nmortality rates were similar for prehospital ﬁbrino-\\nlysis versus transfer for PPCI.\\n10,22\\n3. Small studies suggest that PPCI continues to offer\\nclinical bene ﬁt in patients 12 to 24 hours after symp-\\ntoms onset; therefore, transfer to a PCI-capable hos-\\npital is reasonable.\\n11,12 Late presenters with STEMI who\\nhave associated hemodynamic instability or large', 'infarct size are at very high risk for acute deterioration\\nRecommendations for Reperfusion at Non –PCI-Capable\\nHospitals\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1A\\n1. In patients with STEMI and an\\nestimated time from FMC to de-\\nvice activation of£120 minutes or\\nthose with a contraindication to\\nﬁbrinolytic therapy, transfer to a\\nPCI-capable hospital for PPCI is\\nrecommended to reduce MACE.\\n1-3\\n1A\\n2. In patients with STEMI and', 'symptom onset of <12 hours and\\nanticipated delay to PPCI >120\\nminutes from FMC, ﬁbrinolytic\\ntherapy should be administered\\nin patients without contraindica-\\ntion to reduce MACE.4-10\\n2a B-NR\\n3. In patients with STEMI and\\nsymptom onset of 12 to 24 hours,\\ntransfer to a PCI-capable hospital\\nfor PPCI is reasonable to reduce\\ninfarct size and MACE.\\n11,12\\n3: Harm B-R\\n4. In patients with only ST-segment\\ndepression, except when true\\nposterior STEMI is suspected,\\nﬁbrinolytic therapy should not be', 'administered due to risk of\\nhemorrhagic stroke and major\\nnoncerebral bleeding. 13\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2174\\nand long-term morbidity. In this situation, ﬁbrinolytic\\nadministration may outweigh potential risks when\\ntimely PPCI is not possible. Fibrinolysis in this setting\\nshould be followed by transfer to a PCI-capable center\\nas soon as feasible.\\n4. There is no beneﬁto fﬁbrinolysis and there is potential', 'harm (eg, hemorrhagic stroke and major noncerebral\\nbleeding) in administering ﬁbrinolytic therapy to pa-\\ntients who present with symptoms concerning for ACS\\nwithout ST-segment elevation or suspected true pos-\\nterior STEMI.\\n13\\n5.3.1. Timing and Choice of Agent for Fibrinolytic Therapy\\nSynopsis\\nPPCI remains the reperfusion modality of choice when\\nit can be rapidly achieved in a patient with STEMI. In\\ninstances where this is not possible or cannot be achieved', 'in a timely manner, the beneﬁts of coronary reperfusion\\nwith ﬁbrinolytic therapy in patients with STEMI are well\\nestablished, with a time-dependent reduction in both\\nmortality and morbidity rates during the initial 12 hours\\nafter symptom onset, especially in those who present\\nearly after symptom onset with low bleeding risk and\\nlarge anterior infarctions.\\n1-7 The bene ﬁto f ﬁbrinolytic\\ntherapy in patients who present>12 hours after symptom\\nonset has not been established, 8-10 although consider-', 'ation should be given to administering aﬁbrinolytic agent\\nin symptomatic patients presenting >12 hours after\\nsymptom onset of STEMI with a large area of myocardium\\nat risk or hemodynamic instability, if PCI is unavailable.\\nFibrin-speci ﬁc ﬁbrinolytic therapies are preferred over\\nnon–ﬁbrin-speci ﬁc agents due to superior patency rates\\nand less immunogenicity (Table 13).\\n11-16 Tenecteplase is a\\ngenetically engineered version of alteplase with higher', 'speci ﬁcity for ﬁbrin. In a large randomized trial of pa-\\ntients with AMI, tenecteplase and alteplase were equiva-\\nlent for 30-day mortality rates, but tenecteplase was\\nassociated with reduced noncerebral bleeding.\\n17\\nReteplase (recombinant plasminogen activator) has not\\nbeen shown to improve survival compared with alteplase\\nin patients with MI, but its convenient bolus dosing al-\\nlows for greater ease of use.\\n18 Adjunctive antiplatelet and/', 'or anticoagulant therapies are indicated, regardless of the\\nchoice of ﬁbrinolytic agent ( Sections 4.3.2 ., “Oral P2Y12\\nInhibitors During Hospitalization, ” and 4.4, “Parenteral\\nAnticoagulation ”). Absolute and relative contraindica-\\ntions for ﬁbrinolytic therapy are listed in Table 14.\\nPatients should be transferred to a PCI-capable hospital\\nafter initiation of ﬁbrinolytic therapy for routine coronary\\nangiography ( Section 5.3.2 ., “Coronary Angiography and', 'PCI After Fibrinolytic Therapy ”). Signs of failed reperfu-\\nsion are discussed in Section 5.3.2.\\nTABLE 13 Fibrin-Speci ﬁc Fibrinolytic Agents for STEMI\\nFibrinolytic Agent Dose\\nTenecteplase\\n(TNK-tPA)\\nSingle IV weight-based bolus*\\nReteplase (rPA) Two 10-unit IV boluses given 30 min apart (administered\\nover 2 min)\\nAlteplase (tPA) 90-min weight-based infusion †\\nStreptokinase is no longer available in the United States.\\n*30 mg for weight<60 kg; 35 mg for 60-69 kg; 40 mg for 70-79 kg; 45 mg for 80-89', 'kg; and 50 mg for$90 kg.\\n†Adults $67 kg: 100-mg total dosage administered as a 15-mg IV bolus, followed by\\n50-mg IV infused over 30 min, and then 35-mg IV infused over the next 60 min.\\nAdults <67 kg: 15-mg IV bolus, followed by 0.75 mg/kg IV (not to exceed 50 mg)\\ninfused over 30 min, and then 0.5 mg/kg IV (not to exceed 35 mg) over the next 60 min.\\nrPA indicates reteplase plasminogen activator; TNK-tPA, tenecteplase tissue-type\\nplasminogen activator; and tPA, tissue-type plasminogen activator.', 'TABLE 14 Absolute and Relative Contraindications for\\nFibrinolytic Therapy in STEMI *\\nAbsolute Contraindications\\nn Any prior ICH\\nn Known structural cerebral vascular lesion (eg, arteriovenous\\nmalformation)\\nn Known malignant intracranial ne oplasm (primary or metastatic)\\nn Ischemic stroke within 3 mo except acute ischemic stroke†\\nn Suspected aortic dissection\\nn Active bleeding or bleeding diathesis (excluding menses)\\nn Signi ﬁcant closed-head or facial trauma within 3 mo', 'n Intracranial or intraspinal surgery within 2 mo\\nn Severe uncontrolled hypertension (unresponsive to therapy)\\n(SBP >180 mm Hg or DBP>110 mm Hg)\\nRelative Contraindications\\nn History of chronic, severe, poorly controlled hypertension\\nn Signi ﬁcant hypertension on presentation (SBP >180 mm Hg or\\nDBP >110 mm Hg)\\nn History of prior ischemic stroke >3m o\\nn Dementia\\nn Known intracranial pathology not covered in absolute contraindications\\nn Traumatic or prolonged (>10 min) CPR\\nn Major surgery (<3w k )', 'n Recent (within 2 to 4 wk) internal bleeding\\nn Noncompressible vascular punctures\\nn Pregnancy\\nn Active peptic ulcer\\nn Oral anticoagulant therapy\\n*Viewed as advisory for clinical decision-making and may not be all-inclusive or\\ndeﬁnitive.\\n†Acute ischemic stroke within 4.5 h of onset.\\nCPR indicates cardiopulmonary resuscitation; DBP; diastolic blood pressure; ICH,\\nintracranial hemorrhage; SBP, systolic blood pressure; and STEMI, ST-segment elevation\\nmyocardial infarction.', 'JACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2175\\n5.3.2. Coronary Angiography and PCI After Fibrinolytic Therapy\\nSynopsis\\nFailure of reperfusion and risk of reocclusion after\\nsuccessful ﬁbrinolytic therapy are important limitations\\nof ﬁbrinolytic therapy. For this reason, all patients\\nreceiving ﬁbrinolytic therapy should be transferred to a\\nPCI-capable hospital to facilitate immediate or early', 'catheterization depending on the clinical circumstances.\\nHospitals should have transfer protocols in place to allow\\nfor a seamless transfer to the PCI-capable facility as soon\\nas it is safe to do so. A detailed assessment of clinical\\nstatus is critical to determine the timing of angiography. A\\nlack of improvement in ischemic symptoms, persistent\\nST-segment elevation ( <50% resolution of ST-segment\\nelevation in the anterior leads or <70% in inferior leads', '[measured either from the lead with maximal baseline ST\\nelevation or as the sum of ST-segment deviation across\\nleads]),\\n13 or hemodynamic or electrical instability can\\nindicate incomplete reperfusion by ﬁbrinolytic therapy. 14\\nWhen there are signs of failed reperfusion, patients\\nshould undergo immediate coronary angiography and\\nrescue PCI. For the remaining patients, routine coronary\\nangiography within 2 to 24 hours after ﬁbrinolytic\\ntherapy with coronary revascularization as needed is', 'recommended.\\nRecommendation-Speci ﬁc Supportive Text\\n1. Numerous clinical trials have evaluated a strategy of\\nearly coronary angiography with possible PCI after\\nﬁbrinolytic therapy. This strategy of immediate trans-\\nfer and angiography has been associated with lower\\nrates of recurrent ischemic events as compared with\\nusual care.\\n1-5 Regardless of the timing of angiography,\\nimmediate transfer enables earlier access to specialized\\ncenters, providing critical care services and on-site', 'catheterization laboratory teams that can facilitate\\nclinical assessments to determine the likelihood of\\nreperfusion and enable earlier angiography for the\\nunstable patient.\\n2. Rescue PCI is associated with improved outcomes in\\npatients with clinical signs of failed reperfusion after\\nﬁbrinolytic therapy. Severa l trials have demonstrated a\\nt r e n dt o w a r dl o w e rm o r t a l i t ya n ds i g n iﬁcantly lower\\nrates of recurrent MI and HF when rescue PCI is per-\\nformed for failed ﬁbrinolysis.', '6,7 The REACT (Rapid\\nEarly Action for Coronary Treatment) trial 6 enrolled\\n427 patients with failed reperfusion at 90 minutes after\\nﬁbrinolysis to 1 of 3 treatment arms, including rescue\\nPCI, conservative care, or repeat ﬁbrinolytic therapy.\\nRescue PCI signi ﬁcantly reduced the composite pri-\\nmary endpoint of death, reinfarction, stroke, or severe\\nHF at 6 months compared with either conservative care\\nor repeat ﬁbrinolytic therapy. Meta-analyses also sup-', 'port lower rates of death or reinfarction when rescue\\nPCI is performed in this setting.\\n8,9 Minor and major\\nbleeding and rates of stroke were signiﬁcantly higher\\nwith rescue PCI. 6-8 These studies were performed in\\nthe era of femoral artery access, with fewer options for\\nantiplatelet and anticoagulant therapy. The use of\\nradial artery access\\n15 and the elimination of the routine\\nuse of glycoprotein IIb/ IIIa inhibitors has reduced\\nbleeding. For this reason, the balance of beneﬁtf r o m', 'rescue PCI outweighs the risks for most patients with\\nevidence of failed reperfusion after ﬁbrinolysis.\\n3. Routine early angiography with the intent to perform\\nPCI after ﬁbrinolysis reduces MACE in comparison to\\nusual care (delayed coronary angiography and/or an\\nischemia-guided strategy of revascularization).\\n1-5,11,16\\nIn these studies, >80% of patients who were trans-\\nferred underwent PCI to treat a signi ﬁcant residual\\nstenosis or suboptimal ﬂow of the infarct-related ar-', 'tery. Meta-analyses of the RCTs showed a reduction in\\nRecommendations for Coronary Angiography and PCI\\nAfter Fibrinolytic Therapy\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1A\\n1. In patients with STEMI, transfer\\nto a PCI-capable center immedi-\\nately after ﬁbrinolytic therapy is\\nrecommended. 1-5\\n1 B-R\\n2. In patients with STEMI with sus-\\npected failed reperfusion after\\nﬁbrinolytic therapy, immediate\\nangiography with rescue PCI is', 'recommended to reduce the risk\\nof death or recurrent MI.*\\n6-9\\n1 B-R\\n3. In patients with STEMI treated\\nwith ﬁbrinolytic therapy, early\\nangiography between 2 and 24\\nhours with the intent to perform\\nPCI is recommended to reduce the\\nrates of death or MI.*\\n1-5,10,11\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”12\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2176', '2176\\nthe combined endpoint of death or reinfarction with\\nan early invasive approach after ﬁbrinolytic ther-\\napy.10,17,18 In a network meta-analysis evaluating\\nclinical outcomes with different modes of reperfusion\\nfor STEMI, a pharmaco-invasive strategy (de ﬁned as\\nan interval between lysis and PCI $2h o u r s )w a s\\nassociated with a 21% reduction in the mortality rate\\nwhen compared with a strategy ofﬁbrinolysis alone.\\n18\\nFurthermore, contemporary registries have shown an', 'association between a pha rmaco-invasive approach\\nand improved outcomes compared with PPCI when\\ntransfer times are long.\\n19 The optimal timing of angi-\\nography and PCI after ﬁbrinolytic therapy has not\\nbeen clearly deﬁned but a similar beneﬁti ni s c h e m i c\\ne n d p o i n t si se v i d e n ta c r o s st h es p e c t r u mo ft i m e s\\nincluded in the clinical trials.\\n17,20 Although earlier\\nstudies raised concerns for increased bleeding with\\nvery early catheterization (mean time, 2.2 hours),\\n21', '21\\nmore contemporary data suggest similar rates of\\nbleeding even if cardiac catheterization is performed\\nvery early after ﬁbrinolytic therapy.\\n17,20\\n6. NSTE-ACS: ROUTINE INVASIVE OR SELECTIVE\\nINVASIVE INITIAL APPROACH\\n6.1. Rationale and Timing for a Routine Invasive or Selective\\nInvasive Approach\\nSynopsis\\nA routine invasive approach refers to a strategy of\\nperforming coronary angiography with the intent to\\nperform coronary revascularization by PCI or CABG (as', 'appropriate) in patients with NSTE-ACS. This approach\\nprovides important prognostic information, including\\ndelineating the extent and severity of CAD. Several RCTs\\nhave demonstrated that a routine invasive approach in\\npatients with NSTE-ACS reduces the risk of MACE when\\ncompared with a selective invasive approach.\\n1-3 Notably,\\nthese strategy trials were conducted in an era prior to the\\navailability of hs-cTn assays, routine use of radial\\napproach for coronary angiography, newer generation', 'drug-eluting stents, and contemporary evidence-based\\nantiplatelet therapies. Pati ents who are at prohibitively\\nhigh risk from angiography or who have known coronary\\nanatomy or preferences that preclude revascularization\\n(PCI or CABG) may be managed noninvasively.\\n13 In addi-\\ntion, some low-risk patients, particularly those who have\\nnormal cardiac biomarkers and in whom a diagnosis of an\\nACS is questioned, should be considered for a “selective', 'invasive ” approach that includes further noninvasive risk\\nstrati ﬁcation prior to considera tion of coronary angiog-\\nraphy, because they derive less bene ﬁt from a routine\\nRecommendations for Rationale and Timing for a\\nRoutine Invasive or Selective Invasive Approach\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\nRoutine Invasive Versus Selective Invasive Strategy\\n1A\\n1. In patients with NSTE-ACS who', 'are at intermediate or high risk of\\nischemic events and are appro-\\npriate candidates for revascular-\\nization, an invasive approach with\\nthe intent to proceed with\\nrevascularization is\\nrecommended during\\nhospitalization to reduce\\nMACE. *\\n1-6\\n1A\\n2. In patients with NSTE-ACS who\\nare at low risk of ischemic events,\\neither a routine invasive or se-\\nlective invasive approach is rec-\\nommended to help identify\\nthose who may require revascu-\\nlarization and to reduce\\nMACE.\\n1-4,7', 'MACE.\\n1-4,7\\n(continued in the next column)\\nContinued\\nCOR LOE RECOMMENDATIONS\\nTiming of Coronary Angiography for Those in Whom an Invasive\\nApproach Is Planned\\n1 C-LD\\n3. In patients with NSTE-ACS who\\nhave refractory angina or hemo-\\ndynamic or electrical instability,\\nan immediate invasive strategy\\nwith intent to perform revascu-\\nlarization is indicated to reduce\\nMACE. †\\n8-11\\n2a B-R\\n4. In patients with NSTE-ACS who are\\nat high risk‡ of ischemic events, it\\nis reasonable to choose an early', 'invasive strategy (within\\n24 hours) to reduce\\nMACE. †\\n8,9,11,12\\n2a B-R\\n5. In patients with NSTE-ACS who\\nare not at high risk and are\\nintended for an invasive strategy,\\nit is reasonable to perform angi-\\nography before hospital\\ndischarge to reduce MACE.*\\n8,11\\n*Reproduced or†modiﬁed from the“2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”7 ‡Predictors of risk are outlined inFigure 8.\\nJACC VOL. 85, NO. 22, 2025 Rao et al', 'JUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2177\\ninvasive approach. 4,7,13 These low-risk patients should\\nstill undergo noninvasive stress testing or coronary CT\\nangiography prior to hospit al discharge. Patients with\\nhigher risk ﬁndings on noninvasive testing or who have\\nrecurrent ischemic symptoms should be referred for\\ninvasive coronary angiograph y prior to hospital discharge\\nin the absence of contraindication (Figure 7).', 'Recommendation-Speci ﬁc Supportive Text\\n1. In patients with NSTE-ACS, a routine invasive\\napproach improves clinical outcomes, including lower\\nrates of recurrent MI and recurrent ischemia, compared\\nwith a selective invasive approach that involves\\nfurther noninvasive risk strati ﬁcation prior to consid-\\neration of angiography.\\n1-3 In a collaborative meta-\\nanalysis of RCTs, a routine invasive approach reduced\\ndeath or MI by 18% (OR, 0.82 [95% CI, 0.72-0.93]),', 'including a 25% reduction in MI (OR, 0.75 [95% CI,\\n0.65-0.88]) when compared with a selective invasive\\napproach.\\n5 The beneﬁt was more apparent in higher\\nrisk patients with elevated biomarkers. 4 The studies\\nthat established the bene ﬁt of a routine invasive\\napproach were conducted in the late 1990s and early\\n2000s, and it is unknown whether contemporary\\nFIGURE 7 Selection of a Routine Invasive Versus Selected Invasive Strategy in Patients With NSTE-ACS', 'Colors correspond to Class of Recommendation inTable 2. *AHA Scientiﬁc Statement on MINOCA.17 CABG indicates coronary artery bypass grafting; CCTA,\\ncardiac CT angiography; MINOCA, myocardial infarction with nonobstructive coronary artery disease; NSTE-ACS, non–ST-segment elevation acute coronary\\nsyndromes; and PCI, percutaneous coronary intervention.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2178', '2178\\ntherapies and advances in interventional methods\\nwould yield different results . Similarly, elevated car-\\ndiac biomarkers (CK-MB and older generation troponin\\nassays) identify those who beneﬁt more from a routine\\ninvasive strategy; however, it remains unknown\\nwhether hs-cTn assays that detect smaller degrees of\\nmyonecrosis are as useful for identifying those who\\nbeneﬁt from routine coronary angiography. Although\\nwomen are less likely to have obstructive coronary', 'disease at angiography, they derive as much bene ﬁt\\nfrom a routine invasive approach in the presence of\\nsimilar risk predictors.\\n4 The GRACE 2.0 risk calculator\\nand TIMI Risk Score for unstable angina/NSTEMI may\\nhelp identify patients at increased risk of MACE who\\nbeneﬁt more from a routine invasive approach\\n(Table 5 ).\\n1 Relative contraindications to coronary\\nangiography that merit furt her consideration of the\\nrelative risks and bene ﬁts of a routine invasive', 'approach are outlined in Table 15.\\n2. Although some trials have demonstrated a reduction\\nin MACE with a routine invasive approach in NSTE-\\nACS,\\n1-3 others have not demonstrated a signi ﬁcant\\nbeneﬁt when compared with a selective approach that\\ninvolves further risk strati ﬁcation. 4,7 Although a\\npooled analysis of 3 randomized trials suggested that\\nthe beneﬁt of a routine invasive approach was inde-\\npendent of baseline risk,\\n6 other meta-analyses across', 'studies have suggested that lower risk patients may\\nderive less beneﬁt.4,5,14 In addition, some low-risk pa-\\ntients, particularly those who have normal cardiac\\nbiomarkers in whom a diagnosis of an ACS is suspect,\\nmay have improved outcomes with a selective invasive\\napproach.\\n4,5 These patients should preferentially un-\\ndergo noninvasive stress testing or coronary CT angi-\\nography prior to hospital discharge to help determine\\nthe need for coronary angiography; however, patients', 'with suspected ongoing ischemic symptoms should be\\nconsidered for coronary angiography.\\n3. Patients with NSTE-ACS who are unstable (eg, re-\\nfractory or recurrent angina [despite optimal medical\\ntherapy, hemodynamic or electrical instability, acute\\npulmonary edema or HF, worsening mitral regurgita-\\ntion]) have been largely excluded from RCTs. Despite a\\nrelative paucity of clinical trial data, these patients are\\nat heightened risk of adverse outcomes, and an im-', 'm e d i a t ei n v a s i v es t r a t e g y(<2h o u r sf r o mh o s p i t a l\\nadmission) with intention to perform revascularization\\nis recommended.\\n8,15 If patients with ACS and unstable\\nfeatures are at a non–PCI-capable hospital, they should\\nbe immediately transferred to a PCI-capable facility\\nwith a goal of immediate angiography. Clinical features\\nthat support immediate coronary angiography with\\nintent to revascularize are listed inFigure 8.', '4. For patients with NSTE-ACS for whom the decision has\\nbeen made to proceed with coronary angiography, the\\nbeneﬁt of an early invasive versus a delayed invasive\\napproach is unclear.\\n8,9,11,12 In the TIMACS (Timing of\\nIntervention in Acute Coronary Syndromes) trial, 11\\npatients were enrolled within 24 hours of symptoms\\nand randomized to early angiography within 24 hours\\nversus delayed angiography $36 hours from time of\\nrandomization. In the VERDICT (Very Early vs Deferred', 'Invasive Evaluation Using Computerized Tomography)\\ntrial,\\n12 patients were randomized to early angiography\\nwithin 12 hours versus delayed between 48 to 72 hours\\nfrom time of diagnosis. Both studies reported no sig-\\nniﬁcant difference in MACE between an earlier versus\\ndelayed invasive approach in the overall study pop-\\nulations, but there was si gnal toward a reduction in\\nMACE with an earlier invasive approach in the higher\\nrisk patients with a GRACE risk score >140.\\n11,12 In a', '11,12 In a\\nmeta-analysis of RCTs that compared an early versus\\ndelayed approach, a mortality bene ﬁtw a sn o ts e e n\\nwith earlier angiography. However, factors that\\nfavored an earlier invasive approach included a GRACE\\nrisk score >140, diabetes, age >75 years, and elevated\\ncardiac biomarkers (althou gh formal tests for interac-\\ntion were not signiﬁcant).\\n8 Although not evaluated in\\nRCTs, a continuing steep rise in cardiac biomarkers,\\nlikely due to ongoing ischemia and myonecrosis', 'despite optimized medical therapy, may also favor\\nearlier coronary angiography.\\n5. In intermediate- or low-risk patients for whom angi-\\nography is planned in NSTE-ACS, timing does not\\nappear to be critical, and a delayed invasive strategy\\nwithin 48 to 72 hours does not appear to increase\\nfuture risk of MACE.\\n8,10-12 ,15 Randomized trial data\\nhave not demonstrated an overall signi ﬁcant differ-\\nence in death or MI between an earlier versus delayed\\ninvasive approach in nonselected patients with', 'NSTEMI.\\n8,11,12,16\\nTABLE 15 Relative Contraindications for a Routine\\nInvasive Approach in ACS\\nn High risk for bleeding on DAPT\\nn Severe thrombocytopenia (platelet count <50 /C2 109/L)\\nn Advanced kidney disease (not on dialysis)\\nn Acute renal failure\\nn Limited (<1-2 y) life expectancy\\nn Advanced dementia\\nn Known coronary anatomy that precludes PCI and/or CABG surgery\\nn Patient preference\\nACS indicates acute coronary syndromes; CABG, coronary artery bypass grafting; DAPT,', 'dual antiplatelet therapy; and PCI, percutaneous coronary intervention.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2179\\n7. CATHETERIZATION LABORATORY\\nCONSIDERATIONS IN ACS\\n7.1. Vascular Access Approach for PCI\\nSynopsis\\nThe radial artery has become the preferred vascular\\naccess site for patients undergoing cardiac catheterization\\nand PCI. 8,9 T r a n s r a d i a la c c e s si sa s s o c i a t e dw i t hl o w e r', 'mortality, bleeding, and vascular complications in pa-\\ntients treated for ACS.\\n5 In addition, patients prefer radial\\naccess because it allows earlier ambulation and causes\\nless discomfort than femoral access. 9 Ac a v e a ti sm o s t\\ntrials comparing radial versus femoral access had very low\\ncrossover rates because they required operators with\\nexpertise in radial access.\\n3 T h ec h o i c eo fr a d i a la c c e s sh a s\\nto be weighed against the possibility that the radial artery', 'could be used as a bypass conduit for CABG surgery.\\n10 In\\nsites where surgeons routinely utilize the radial artery as\\na bypass conduit, consideration should be given on the\\nchoice of vascular access and future use of radial artery\\nfor the cardiovascular surgical team. Although the radial\\nartery is the most widely studied wrist access site, the use\\nof alternative sites in the upper extremity, including the\\nulnar and distal radial arteries have yielded similar', 'FIGURE 8 Selection and Timing of an Invasive Strategy in NSTE-ACS\\nFigure 8summarizes the recommendations in the 2025 ACS Guideline for a routine or selective invasive approach in NSTE-ACS. It is not meant to encompass every\\npatient scenario or situation, and clinicians are encouraged to use a Heart Team approach when care decisions are unclear and to see the accompanying supportive text', 'for each recommendation. Colors correspond to Class of Recommendation inTable 2. GRACE indicates Global Registry of Acute Coronary Events; HF, heart failure; NSTE-\\nACS, non–ST-segment elevation acute coronary syndromes; Tn, troponin; TIMI, Thrombolysis In Myocardial Infarction; VF, ventricularﬁbrillation; and VT, ventricular\\ntachycardia. Adapted with permission from Lawton et al.18 Copyright 2022 American Heart Association, Inc., and American College of Cardiology Foundation.', 'Recommendation for Vascular Access Approach for PCI\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n1A\\n1. In patients with ACS undergoing\\nPCI, a radial approach is preferred\\nto a femoral approach to reduce\\nbleeding, vascular complications,\\nand death.*\\n1-6\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”7\\nRao et al JACC VOL. 85, NO. 22, 2025', '2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2180\\noutcomes. 11,12 Transfemoral access, preferably with the\\nuse of ultrasound guidance, should be considered in pa-\\ntients in whom temporary MCS is planned and is the\\ndefault alternative access site among patients in whom\\nthe radial artery cannot be used due to clinical, anatom-\\nical, or technical reasons.\\n13\\nRecommendation-Speci ﬁc Supportive Text\\n1. RCTs have consistently demonstrated the bene ﬁto f', 'radial access in comparison with femoral access among\\npatients treated for ACS. A meta-analysis using indi-\\nvidual patient data from 7 high-quality RCTs (48.6%\\nwith NSTE-ACS; 46.2% with STEMI) demonstrated that\\nradial access was independently associated with a sig-\\nniﬁc a n t2 4 %a n d5 1 %r e l a t i v er i s kr e d u c t i o no fa l l - c a u s e\\ndeath and major bleeding, respectively, when\\ncompared with femoral access.\\n3 The magnitude of the\\nmortality bene ﬁt was greater among patients with', 'lower baseline hemoglobin levels. The beneﬁto fr a d i a l\\naccess toward reducing bleeding was driven by a sig-\\nniﬁcant reduction in access-site bleeding. Vascular\\ncomplications were signi ﬁcantly reduced by 62%. The\\nMATRIX trial\\n6 demonstrated a signi ﬁcantly lower rate\\nof the coprimary endpoints of MACE and net adverse\\nclinical events (composites of death, MI, and stroke at\\n30 days, and MACE plus non-CABG major bleeding)\\namong patients with ACS randomized to the transradial', 'approach compared with the transfemoral approach.\\nThis is consistent with prior meta-analyses that have\\nreported lower mortality and bleeding with radial ac-\\ncess in patients with ACS.\\n4,14 The SAFARI-STEMI\\n(Safety and Ef ﬁcacy of Femoral Access versus Radial\\nfor Primary Percutaneous Intervention in ST-Elevation\\nMyocardial Infarction) trial showed no difference in\\n30-day mortality rates between radial and femoral ac-\\ncess; however, the trial stopped early and therefore was', 'underpowered to detect a mortality beneﬁt.\\n15\\n7.2. Use of Aspiration Thrombectomy\\nSynopsis\\nDespite restoration of coro nary patency, suboptimal\\nmyocardial perfusion resulting from distal embolization\\nor microvascular obstruction is frequent and is associated\\nwith larger infarct size, impairment of LV function, and\\nexcess mortality rates.\\n6,7 Removing coronary artery\\nthrombus prior to balloon angioplasty, stent deployment,\\nor both is an intuitive adjunct to PPCI that may yield', 'putative clinical bene ﬁts. Routine manual thrombus\\naspiration performed via low pro ﬁle catheters improved\\nelectrocardiographic and angiographic markers of\\nm y o c a r d i a lp e r f u s i o ni nseveral clinical studies\\n8,9 and\\nreduced adverse events in a single-center trial.10,11 How-\\never, subsequent trials of manual aspiration thrombec-\\ntomy have not demonstrated a clinical bene ﬁt.1,2,4,12,13\\nSimilarly, results from a po oled analysis showed that', 'mechanical thrombectomy during STEMI was not superior\\nto conventional PCI alone.\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. Results from several RCTs have shown that routine\\nmanual aspiration thrombectomy prior to PCI does not\\nreduce MI size or improve clinical outcomes as\\ncompared with PCI alone.\\n1,2,4,12,13 In a patient-level,\\npooled analysis comprising 3 RCTs, aspiration throm-\\nbectomy did not reduce the primary endpoint of car-\\ndiovascular death at 30 days among patients with', 'STEMI undergoing PPCI (n ¼ 18,306).\\n3 Similarly, aspi-\\nration thrombectomy did not lower risks for recurrent\\nMI, target vessel revascularization, stent thrombosis, or\\nHF at 30 days or 1 year. With respect to safety, the\\nincidence of stroke or transient ischemic attack at\\n30 days and 1 year was numerically higher, albeit\\nnot statistically signi ﬁcant, among patients who\\nunderwent aspiration thrombectomy. Reductions in\\ncardiovascular death were lower while risks for stroke', 'or transient ischemic attack were higher among those\\nwith a large thrombus burden treated with aspiration\\nthrombectomy. Dedicated studies are warranted to\\nevaluate the role of selective aspiration thrombectomy\\nin those high-risk patients most likely to beneﬁtf r o m\\nthrombus removal prior to PCI. Manual aspiration\\nthrombectomy may be performed as a bailout proced-\\nure to remove thrombus that persists after balloon\\nangioplasty or stent deployment, particularly with', 'concomitant no-re ﬂow. Estimates from RCT cohorts\\nindicate that 4% to 7% of patients with STEMI under-\\ngoing PPCI will require bailout aspiration\\nthrombectomy.\\n1,2,10\\nRecommendation for Use of Aspiration Thrombectomy\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n3: No beneﬁtA\\n1. Among patients with STEMI un-\\ndergoing PPCI, manual aspiration\\nthrombectomy should not be\\nperformed routinely prior to PCI\\ngiven lack of clinical beneﬁt.*', '1-4\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”5\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2181\\n7.3. Use of Intracoronary Imaging\\nSynopsis\\nIntracoronary imaging serves as a valuable tool for\\nguiding the placement of coronary stents, particularly in\\ncases involving the left main artery or complex lesions,\\nresulting in greater stent expansion, less stent malap-', 'position, and fewer coronary dissections.\\n1,2,4,13 IVUS\\nprovides a comprehensive view of the vessel wall,\\nallowing for the evaluation of plaque burden, calci ﬁca-\\ntion extent, lesion length, and external elastic lamina\\ndiameter before stent placement. It also facilitates the\\nassessment of minimum stent area, malapposition,\\nunderexpansion, tissue protrusion, edge disease, and\\nedge dissection after stent deployment.\\n14 OCT utilizes\\ninfrared light to produce high-resolution images of the', 'vessel wall, offering speci ﬁca d v a n t a g e si na s s e s s i n g\\ncalcium thickness, lipid presence, thrombus formation,\\nﬁbroatheroma, and plaque rup ture, which is particularly\\nhelpful in patients with ACS. It is also useful for\\nexamining stent strut neointimal thickness, apposition,\\nand edge dissections. However, it has limitations\\nregarding imaging depth and requires the injection of\\ncontrast to clear blood, limiting its utility in cases of', 'ostial left main disease. Both IVUS and OCT play\\nessential roles in evaluating the necessity for lesion\\npreparation, choosing the appropriate stent size,\\nreducing the likelihood of geographical errors,\\nconﬁrming proper stent expansion, identifying compli-\\ncations, and determining the underlying reasons for\\nstent failure.\\n14,15\\nRecommendation-Speci ﬁc Supportive Text\\n1. Randomized trials including patients with ACS have\\nshown that intracoronary imaging guidance is associ-', 'ated with lower risk of target vessel failure (cardiac\\ndeath, target vessel MI, or ischemia-driven target\\nvessel revascularization) in patients undergoing PCI.\\n1-4\\nThe advantages of intracoronary imaging are sustained\\nover time and can be extended to less complex lesions.5\\nRenovate-Complex PCI (Randomized Controlled Trial\\nof Intravascular Imaging Guidance versus Angiography-\\nGuidance on Clinical Outcomes after Complex Percu-\\ntaneous Coronary Intervention) demonstrated a sig-', 'niﬁcant reduction in target vessel failure with\\nintracoronary guidance (IVUS or OCT) versus angio-\\ngraphic guidance after a median follow-up of 2.1 years.\\n1\\nThe OCTOBER (Optical Coherence Tomography Opti-\\nmized Bifurcation Event Reduction) trial showed a\\nsigni ﬁcant reduction in target vessel failure at 2 years\\nwith OCT versus angiographic guidance in bifurcation\\nlesions, including left main bifurcations.\\n4 Randomized\\ntrials directly comparing OCT versus IVUS have', 'demonstrated that OCT is noninferior to IVUS for PCI-\\nguidance.\\n6-8,10 However, the ILUMIEN IV: Optimal PCI\\n(OCT Guided Coronary Stent Implantation Compared\\nwith Angiography) trial, the largest trial testing the\\nstrategy of imaging guidance with OCT, did not reveal a\\ndifference in target vessel failure with OCT in high-risk\\npatients or patients with hi gh-risk lesions; however,\\nthe coprimary endpoint of minimal stent area was\\nsigni ﬁcantly larger with OCT guidance compared with', 'angiography guidance.\\n2 The rates of deﬁnite or prob-\\nable stent thrombosis were also signiﬁcantly lower with\\nOCT-guided PCI compared with angiography-guided\\nPCI. A minimum stent area of<4.5 to 5.0 mm2 by OCT\\nis considered to be an independent predictor of\\nMACE.\\n16,17 Two large network meta-analyses showed\\nthat, in aggregate, intracoronary imaging guidance\\n( w i t he i t h e rI V U So rO C T )f o rP C Id e c r e a s e sc a r d i a c\\ndeath, target vessel MI, target lesion revascularization,', 'and stent thrombosis.\\n11,18\\nRecommendation for Use of Intracoronary Imaging\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n1A\\n1. In patients with ACS undergoing\\ncoronary stent implantation in\\nleft main artery or in complex\\nlesions, intracoronary imaging\\nwith intravascular ultrasound\\n(IVUS) or optical coherence to-\\nmography (OCT) is recommended\\nfor procedural guidance to\\nreduce ischemic events. *\\n1-11', '1-11\\n*Adapted from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”12\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2182\\n7.4. Management of Multivessel CAD in ACS\\n7.4.1. Management of Multivessel CAD in STEMI\\nSynopsis\\nSeveral randomized trials of hemodynamically stable\\npatients with STEMI have demonstrated that a strategy\\nof multivessel PCI of signi ﬁcantly stenosed nonculprit', 'v e s s e l si ss a f ea n dr e d u c e sr i s ko fM A C Ew h e n\\ncompared with PCI of the infarct-related artery alone.\\n1-8\\nThese trials enrolled a select group of patients with\\nanatomy suitable for PCI and without clinical factors\\nprecluding further invasive therapies. Recent studies\\nsuggest a lower risk of MACE (predominantly driven by\\na lower rate of recurrent ischemia and recurrent MI)\\nwhen multivessel stenting occurs as a single procedure\\nas opposed to when staged.', '10-12 The decision to proceed\\nwith multivessel stenting and the timing of the pro-\\ncedure should take into account the patient ’s clinical\\na n dh e m o d y n a m i cs t a t u s ,t h ed u r a t i o na n dc o m p l e x i t y\\nof the infarct-related artery PCI, the complexity of dis-\\nease in the noninfarct-related artery, the amount of\\nmyocardium in jeopardy, and the presence of comor-\\nbidities that might favor a conservative approach to\\ncare. Few studies of multivessel PCI have directly', 'compared the ef ﬁcacy of a physiologic-guided PCI\\nversus an angiographic-guided PCI approach.\\n17,18 A\\nmeta-analysis across trials did not suggest any differ-\\nential bene ﬁt for complete revascularization based on\\nwhether the approach was guided by fractional ﬂow\\nreserve (FFR) or angiography alone.\\n3\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. Over the past decade, numerous trials have reported a\\nsigni ﬁcant reduction in MACE with complete revas-', 'cularization. 1,2,4-8 These studies have demonstrated\\nbeneﬁts to complete revascularization either at the\\ntime of PPCI 2,5-8 or as a staged procedure. 1,2,4,6 The\\nPRAMI (Preventive Angioplasty in Acute Myocardial\\nInfarction) trial,\\n8 one of the earliest trials of multi-\\nvessel PCI, randomized 465 patients with STEMI and\\nMVD to a strategy of complete revascularization\\nversus culprit artery only rev ascularization. The trial\\nwas stopped early due to a signiﬁc a n tr e d u c t i o ni nt h e', 'primary composite endpoint (cardiovascular death,\\nnonfatal MI, or refractory angina) with complete\\nrevascularization, with signi ﬁcant reductions in\\nnonfatal MI and refractory angina and a trend in\\nreduction in the rates of cardiovascular death. The\\nCOMPLETE (Complete versus Culprit-Only Revascu-\\nlarization Strategies to Trea t Multivessel Disease after\\nEarly PCI for STEMI) trial\\n1 randomized 4,041 patients\\nwith STEMI and signi ﬁcant MVD to a strategy of', 'Recommendations for Management of Multivessel CAD in\\nSTEMI\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1A\\n1. In selected, hemodynamically\\nstable patients with STEMI and\\nmultivessel disease (MVD), after\\nsuccessful PCI of the infarct-\\nrelated artery, PCI of signiﬁcantly\\nstenosed * noninfarct-related ar-\\nteries is recommended to reduce\\nthe risk of death or MI and\\nimprove angina-related quality of\\nlife (QOL).†\\n1-9\\n2a C-EO', '1-9\\n2a C-EO\\n2. In appropriate patients with\\nS T E M Ia n dc o m p l e xM V D ,a f t e r\\nsuccessful PCI of the infarct-\\nrelated artery, elective CABG\\nsurgery for signiﬁcantly stenosed\\nnoninfarct-related arteries\\ninvolving the left anterior\\ndescending artery or left main\\nd i s e a s ei sr e a s o n a b l et or e d u c e\\nthe risk of cardiovascular\\nevents. †\\n2b B-R\\n3. In selected hemodynamically\\nstable patients with STEMI and\\nlow-complexity MVD (those not\\nintended for CABG surgery),', 'multivessel PCI of signiﬁcantly\\nstenosed noninfarct-related ar-\\nteries at the time of PPCI may be\\npreferred over a staged approach\\nto reduce the risk of cardiovas-\\ncular events.\\n10-12\\n3: Harm B-R\\n4. In patients with STEMI compli-\\ncated by cardiogenic shock,\\nroutine PCI of a noninfarct-\\nrelated artery at the time of PPCI\\nshould not be performed\\nbecause of the higher risk of\\ndeath or renal failure.*\\n13-15\\n*Signiﬁcantly stenosed refers to lesions that are severely diseased as deﬁned by the', '“2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization” as a visually\\nestimated diameter stenosis severity of$70% for non–left main disease and$50% for\\nleft main disease.16 †Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary\\nArtery Revascularization.”16\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2183\\nstaged PCI of the non –infarct-related artery (per-\\nformed up to 45 days post MI) or culprit vessel–only', 'revascularization with PCI reserved for patients with\\nrefractory symptoms. At a median follow-up of 3\\nyears, multivessel PCI reduced cardiovascular death\\nor MI and cardiovascular death, MI, or ischemia-\\ndriven revascularization. This bene ﬁtw a sc o n s i s t e n t\\nacross all subgroups. Angina-related QOL was also\\nsigni ﬁcantly improved with multivessel PCI, with a\\ngreater proportion of patients in the complete\\nrevascularization arm who were angina-free in long-\\nterm follow-up.', 'term follow-up.\\n9 In a meta-analysis, complete revas-\\ncularization reduced cardi ovascular death in patients\\nwith STEMI. 19 The bene ﬁts of complete revasculari-\\nzation with multivessel PCI should not be extrapo-\\nlated to patients with disease more suited to CABG\\nsurgery, because they were excluded from these\\ntrials.\\n2. The trials examining the beneﬁto fm u l t i v e s s e lP C Ii n\\npatients with STEMI and MVD excluded patients\\nintended for CABG surgery. Furthermore, few pa-', 'tients with complex disease, such as chronic total\\nocclusions or involvement of the left main artery,\\nwere included in these trials. For this reason, the\\nbeneﬁts of a strategy of multivessel PCI cannot be\\nextrapolated to patients with more complex non-\\ninfarct-related artery disease. In patients with CCD\\nand complex CAD, including complex left main dis-\\nease, or in patients with diabetes who have MVD\\ninvolving the left anterior descending artery, CABG', 'surgery is associated with improved event-free sur-\\nv i v a lw h e nc o m p a r e dw i t hP C I .\\n20-24 As such, a similar\\nbeneﬁto fC A B Go v e rP C Im i g h tb ee x p e c t e df o rp a -\\ntients with STEMI and complex non –infarct-related\\nartery disease involving the left main or left anterior\\ndescending artery or in patients with diabetes and\\nMVD involving the left anterior descending artery,\\nwho are stable and remote from their acute infarct,\\nalthough the optimal timing of CABG is unclear in', 'this setting and needs to take into account increased\\nbleeding risk from DAPT.\\n3. Performing multivessel PCI at the time of PPCI offers\\nthe convenience of a single procedure, allowing for\\nfaster recovery, without the risk of repeated arterial\\naccess, or the potential for recurrent ischemia before\\nthe staged PCI. The BIOVASC (Direct Complete Versus\\nStaged Complete Revascularization in Patients Pre-\\nsenting With Acute Coronary Syndromes and Multi-\\nvessel Disease) trial', '10 randomized 1,525 patients with\\nACS (w40% with STEMI) and MVD to a strategy of a\\nsingle setting immediate multivessel PCI or staged\\nm u l t i v e s s e lP C I .A t1y e a r ,i m m e d i a t em u l t i v e s s e lP C I\\nwas noninferior to staged multivessel PCI for the\\nprimary endpoint all-cause death, MI, unplanned\\nischemia-driven revasculari zation, or cerebrovascular\\ne v e n t s .W h e nc o m p a r e dw i t hs t a g e dP C I ,as i n g l e\\nprocedure multivessel PCI was associated with lower', 'rates of recurrent MI and lower rates of unplanned\\nischemia-driven revascularization. The MULTISTARS\\nAMI (Multivessel Immediat e Versus Staged Revascu-\\nlarization in Acute Myocardial Infarction) study\\n11\\ncompared a strategy of a single procedure multi-\\nv e s s e lP C Iw i t hs t a g e dm u l t i v e s s e lP C Ii n8 4 0p a -\\ntients with STEMI and MVD. Immediate multivessel\\nPCI was noninferior and superior to staged multi-\\nvessel PCI for the primary endpoint of death, rein-', 'f a r c t i o n ,s t r o k e ,u n p l a n n e di s c h e m i a - d r i v e n\\nrevascularization, or hospitalization for HF at 1 year.\\nThis was largely driven by a lower rate of recurrent\\nischemia and recurrent in farction in the immediate\\ngroup. In a network meta-analysis comparing all\\nstrategies for managing the non –infarct-related ar-\\ntery, a single procedure approach for immediate\\nmultivessel PCI was preferred followed by staged\\nmultivessel PCI.\\n12 Patients ideally suited for imme-', 'd i a t ec o m p l e t er e v a s c u l a r i z a t i o ni n c l u d et h o s ew i t h\\nuncomplicated PCI of the infarct-related artery and\\nlow complexity noninfarct-related artery disease with\\nstable hemodynamics, normal LV ﬁlling pressures,\\nand normal renal function.\\n4. In patients with STEMI complicated by cardiogenic\\nshock and MVD, a strategy of multivessel PCI is\\nassociated with worse outcomes.\\n13-15 The CULPRIT-\\nSHOCK (Culprit Lesion Only PCI versus Multivessel', 'PCI in Cardiogenic Shock) trial\\n13 randomized 706 pa-\\ntients with AMI, approximately 60% with STEMI, and\\ncardiogenic shock to a strategy of complete multi-\\nvessel PCI or culprit vessel –only PCI. At 30 days and\\n1 year, the rates of death or need for renal replace-\\nment therapy were signi ﬁcantly higher in the group\\nof patients randomized to multivessel PCI.\\n13,14\\nImportantly, the CULPRIT-SHOCK trial only\\npermitted enrollment if there was an identi ﬁable', 'culprit lesion. In situations where an unstable-\\nappearing nonculprit artery lesion was observed, or\\nin those patients with an uncertain culprit lesion, the\\ndecision to proceed with multivessel PCI may be\\nmore nuanced.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2184\\n7.4.2. Management of Multivessel CAD in NSTE-ACS\\nSynopsis\\nMultivessel coronary disease, de ﬁned as angiograph-', 'ically signiﬁcant stenosis ($50%) in$2 epicardial arteries,\\nis present in up to 40% to 70% of patients with NSTE-ACS.\\nIdenti ﬁcation of the culprit artery in these situations\\nmight be challenging.\\n13 Several subsets of patients,\\nincluding those with complex left main disease, complex\\n3-vessel disease, and diabetes with left anterior\\ndescending artery involvement, might be appropriate for\\nCABG surgery.\\n12 A Heart Team approach is recommended', 'to consider CABG surgery versus multivessel PCI based on\\nthe complexity of CAD, technical feasibility, patient ’s\\nsurgical risk, and the potential for rehabilitation after\\nCABG surgery. Dedicated RCTs comparing multivessel PCI\\nversus culprit-only PCI exclusively among hemodynami-\\ncally stable patients with NSTE-ACS are lacking. A large\\nsubgroup analysis from an RCT that included both pa-\\ntients with STEMI and NSTE-ACS and several observa-\\ntional studies have suggested that multivessel PCI among', 'selected patients not intended for CABG reduces risk of\\nMACE.\\n1-4,6,14 Angiographic assessment might over-\\nestimate the severity of a nonculprit lesion. 15 In one\\nstudy, routine integration of physiological assessment of\\na nonculprit artery stenosis in NSTE-ACS led to change in\\nmanagement (ie, from revascularization to medical\\ntreatment only) in 38% of the cases.16\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. Studies evaluating the bene ﬁt of multivessel PCI', 'among patients with NSTE-ACS and MVD excluded\\npatients planned for CABG. The potential bene ﬁto f\\nmultivessel PCI cannot be extrapolated to patients\\nwith complex CAD. Indeed, certain subsets of patients\\nmight derive a survival beneﬁt from CABG, including\\nthose with diabetes and disease involving the left\\nanterior descending artery, left main with high\\ncomplexity, MVD with complex or diffuse CAD, and\\nthose with severe LV dysfunction ( Table 16 ).\\n17-20', '17-20\\nAccordingly, a Heart Team approach is recommended\\nto consider CABG surgery versus multivessel PCI based\\non the complexity of the CAD, technical feasibility,\\npatient ’s surgical risk, and the potential for rehabili-\\ntation after CABG surgery in these situations. In pa-\\ntients who are deemed appropriate for CABG, surgery\\ncould be considered prior to hospital discharge. Several\\nobservational studies have suggested that early CABG\\n(performed within 3 days of presentation) may be', 'associated with similar outcomes compared with\\ndelayed CABG.\\n21-23\\n2. The FIRE (Functional Assessment in Elderly MI Pa-\\ntients With Multivessel Dis ease) trial enrolled 1,445\\nelderly patients (median age, 80 years) with multi-\\nvessel disease (ie, nonculprit artery with minimum\\nvessel diameter >2.5 mm and angiography estimated\\nstenosis 50% to 99%) and ACS (w65% with NSTE-ACS).\\nMultivessel PCI reduced the risk of MACE, as well as\\nreduced all-cause and cardiovascular mortality. The', 'beneﬁt was consistent between patients with NSTE-\\nA C Sv e r s u sp a t i e n t sw i t hS T E M I .\\n1 Several observa-\\ntional studies and a meta-analysis of observational\\nstudies demonstrated that multivessel PCI is associ-\\nated with a lower incidence of long-term MACE.\\n2,3,6\\nFew RCTs have evaluated the optimal timing of a\\nRecommendations for Management of Multivessel CAD in\\nNSTE-ACS\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS', '1 C-EO\\n1. In patients with NSTE-ACS with\\nMVD, the mode of revasculariza-\\ntion (CABG or multivessel PCI)\\nshould be based on the disease\\ncomplexity and patient ’s\\ncomorbidities.\\nMultivessel CAD and Candidates for PCI\\n1 B-R\\n2. In stable patients with NSTE-ACS\\nwith MVD but without left main\\nstenosis who are not intended for\\nCABG surgery and undergoing\\nculprit-lesion PCI, PCI of signiﬁ-\\ncant nonculprit lesions (at the\\ntime of the index procedure or as\\na staged procedure) is recom-', 'mended to reduce the risk of\\nMACE.\\n1-6\\n2b B-R\\n3. In patients with NSTE-ACS in\\nwhom multivessel PCI is being\\nconsidered, physiological\\nassessment of a nonculprit ste-\\nnosis may be considered to guide\\nrevascularization decisions.\\n7-9\\n3: Harm B-R\\n4. In patients with NSTE-ACS\\ncomplicated by cardiogenic\\nshock, routine PCI of a nonculprit\\na r t e r ya tt h et i m eo fi n d e xp r o -\\ncedure should not be performed\\nbecause of the higher risk of\\ndeath or kidney failure.*\\n10,11', '10,11\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”12\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2185\\nmultivessel PCI approach. The SMILE (Single Staged\\nVersus Multistaged PCI in Multivessel NSTEMI Pa-\\ntients) trial enrolled 584 patients and demonstrated\\nthat multivessel PCI conducted in a single procedure\\nreduces risk of MACE at 1 year driven by a lower risk of\\nrevascularization.', 'revascularization.\\n4 The BIOVASC trial randomized\\n1,525 patients with ACS ( w60% with NSTE-ACS) and\\nshowed that multivessel PCI in a single procedure was\\nnoninferior to staged PCI with respect to MACE at\\n1 year and without evidence of an interaction between\\npatients with NSTE-ACS versus patients with\\nSTEMI.\\n5,24\\n3. In a secondary analysis including 328 patients with\\nNSTE-ACS and MVD from the FAME (Fractional Flow\\nReserve Versus Angiography for Multivessel Evalua-', 'tion) trial that randomized patients to either\\nangiography-guided PC I (if diameter stenosis$50%) or\\nFFR-guided PCI (if FFR #0.80), FFR-guided PCI\\nreduced the number of stents and the incidence of\\nMACE at 2 years.\\n7 The FRAME-AMI (Fractional Flow\\nReserve vs. Angiography-Gu ided Strategy for Manage-\\nment of Non-Infarction Related Artery Stenosis in Pa-\\ntients with Acute Myocardial Infarction) trial enrolled\\n562 patients with ACS and MVD (w53% with NSTE-ACS)', 'and were randomized to FFR-guided PCI (if FFR#0.80)\\nor angiography-guided PCI (diameter stenosis of\\n>50%). FFR-guided PCI reduced the number of stents\\nand the risk of MACE at 3.5 years with no evidence of\\ninteraction between patients with NSTE-ACS and pa-\\ntients with STEMI. Of note, the trial was prematurely\\nterminated due to slow recruitment and enrolled<50%\\nof the planned 1,292 patients.\\n9 In the FAMOUS-NSTEMI\\n(Fractional Flow Reserve Versus Angiographically', 'Guided Management to Optimise Outcomes in Unsta-\\nble Coronary Syndromes) trial, which randomized\\n350 patients with NSTE-ACS and MVD to FFR-guided\\nPCI (if FFR #0.80) or angiography-guided PCI (diam-\\neter stenosis of >30%), FFR-guided PCI reduced the\\nnumber of revascularization procedures at 1 year.\\n8\\n4. In patients with NSTE-ACS complicated by cardiogenic\\nshock and MVD, multivessel PCI at the time of the in-\\ndex procedure is associated with worse outcomes.\\n10,11', '10,11\\nThe CULPRIT-SHOCK (Culprit Lesion Only PCI versus\\nMultivessel PCI in Cardiogenic Shock) trial randomized\\n706 patients with AMI and cardiogenic shock (approx-\\nimately 40% with NSTE-ACS) to multivessel PCI at the\\ntime of the index procedure or culprit-only PCI. Mul-\\ntivessel PCI was associated with higher rates of death\\nor need for renal replacement therapy at 30 days and at\\n1y e a r .\\n10,11 Notably, the CULPRIT SHOCK trial enrolled\\nonly patients with an identiﬁable culprit lesion. When', 'there is an unstable-appearing nonculprit, or uncertain\\nculprit, artery lesion, the decision to proceed with\\nmultivessel PCI will be based on the anatomic and\\nclinical circumstances.\\n8. CARDIOGENIC SHOCK MANAGEMENT\\n8.1. Revascularization in ACS With Cardiogenic Shock\\nTABLE 16\\nConsiderations for Choice of Coronary\\nRevascularization Strategy for Patients With\\nNSTE-ACS and MVD\\nIn patients with NSTE-ACS and MVD, CABG surgery may be preferred\\nover multivessel PCI in any of the following situations:', 'Signi ﬁcant left main coronary stenosis with high-complexity CAD\\nMultivessel CAD with complex or diffuse CAD\\nDiabetes mellitus and MVD with the involvement of the LAD\\nMultivessel CAD or complex left main CAD with severe left ventricular\\ndysfunction\\nAdapted from the“2021 ACC/AHA/SCAI Coronary Revascularization Guideline.”12\\nCAD indicates coronary artery disease; CABG, coronary artery bypass grafting; LAD,\\nleft anterior descending artery; MVD, multivessel disease; NSTE-ACS, non–ST-segment', 'elevation acute coronary syndromes; and PCI, percutaneous coronary intervention.\\nRecommendations for Revascularization in ACS With\\nCardiogenic Shock\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1 B-R\\n1. In patients with ACS and cardio-\\ngenic shock or hemodynamic\\ninstability, emergency revascu-\\nlarization of the culprit vessel by\\nPCI or with CABG is indicated to\\nimprove survival, irrespective of\\ntime from symptom onset.\\n1-4', '1-4\\n3: Harm B-R\\n2. In patients with ACS complicated\\nby cardiogenic shock, routine PCI\\nof a noninfarct-related artery at\\nt h et i m eo fP P C Is h o u l dn o tb e\\nperformed because of the higher\\nrisk of death or renal failure.*\\n5-7\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”8\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2186\\nSynopsis\\nIn patients with STEMI and hemodynamic instability,', 'treatment delays to PPCI are associated with worse sur-\\nvival.\\n1 In patients with cardiogenic shock, PCI of the\\nculprit vessel only is recommended. 5,6 Emergency CABG\\nis recommended in those patients in whom PCI is not\\nfeasible. 2,9 Immediate revascularization with PCI or CABG\\nis also recommended in high-risk patients with NSTEMI\\nwho are in cardiogenic shock.\\n2-5 The use of MCS devices in\\npatients with cardiogenic shock is covered inSection 8.2,\\n“MCS in Patients With ACS and cardiogenic shock.”', 'Recommendation-Speci ﬁc Supportive Text\\n1. In the SHOCK (Should We E mergently Revascularize\\nOccluded Coronaries for C ardiogenic Shock) trial, 2 re-\\nported in 1999, patients with AMI and cardiogenic shock\\nwere randomized to medical therapy or emergency\\nrevascularization. Among the patients randomized to\\nrevascularization, 64% of patients were referred for PCI\\nand 36% for CABG. The median time from randomiza-\\ntion to revascularization was 0.9 hours for PCI and 2.7', 'hours for CABG. Despite lack of a signiﬁcant difference\\nin the primary endpoint of mortality at 30 days, emer-\\ngency revascularization with either PCI or CABG\\nreduced the mortality rate at 6 months,\\n2 and the mor-\\ntality beneﬁt was maintained through 1 and 6 years.10,11\\nIn an observational analysis from the FITT-STEMI\\n(Feedback Intervention and Treatment Times in ST-\\nElevation Myocardial Infarction) trial, for every 10-\\nminute delay in PPCI after 60 minutes from FMC, there', 'were an additional 3 to 4 deaths per 100 with a>80%\\nmortality rate beyond 6 hours of delay from FMC.\\n1\\nTherefore, it is recommended that PPCI should be per-\\nformed in patients with STEMIa n dc a r d i o g e n i cs h o c ka s\\nsoon as possible, ideally within 90 minutes, to reduce\\nthe mortality rate.\\n1,2 Observational studies suggest that\\nemergency CABG remains a treatment option in patients\\nwith cardiogenic shock who are not amenable to primary', 'reperfusion with PCI3,4 or when PCI is unsuccessful.4,12\\n2. In patients with STEMI complicated by cardiogenic\\nshock and MVD, a strategy of multivessel PCI is asso-\\nciated with worse outcomes.\\n5-7 The CULPRIT-SHOCK\\ntrial 5 randomized 706 patients with AMI (approxi-\\nmately 60% with STEMI) and cardiogenic shock to a\\nstrategy of complete multive ssel PCI or culprit-only\\nPCI. At 30 days and 1 year, the rates of death or need for\\nrenal replacement therapy were signiﬁcantly higher in', 'the group of patients randomized to multivessel PCI.\\n5,6\\nImportantly, the CULPRIT SHOCK trial permitted\\nenrollment only if there was an identi ﬁable culprit\\nlesion. In situations where there is an unstable\\nappearing nonculprit artery lesion, or in those patients\\nwith an uncertain culprit, the decision to proceed with\\nmultivessel PCI may be more nuanced.\\n8.2. MCS in Patients With ACS and Cardiogenic Shock\\nSynopsis\\nCardiogenic shock is estimated to occur in approxi-', 'm a t e l y1 0 %o fp a t i e n t sw i t hS T E M Ia n di sa s s o c i a t e dw i t h\\nan early mortality rate of 40% to 50%.\\n10,11 Several types of\\ndevices for temporary MCS a re available and have been\\nstudied in patients with cardiogenic shock with variable\\nefﬁcacy and increased risk of vascular complications.\\nIABP counterpulsation improves coronary perfusion and\\nreduces cardiac afterload. It is relatively easy to use and\\nhas a smaller insertion pro ﬁle, which is associated with', 'lower rates of vascular access site complications when\\ncompared with other MCS devices.\\n12,13 Percutaneous\\nmicroaxial ﬂow pumps unload the LV by draining blood\\nfrom the LV and pumping it to the ascending aorta. They\\nare dependent on adequate right ventricular function to\\nﬁl lt h eL Va n dr e q u i r ea d e q u a t eo x y g e n a t i o no fb l o o d .V A -\\nECMO provides both blood ﬂow and oxygenation but in-\\ncreases afterload. Randomized trials of MCS devices', 'remain challenging to conduct due to relative lack of\\nequipoise on the part of treating physicians, leading to\\nselective patient enrollment and limiting the generaliz-\\nability of study results. Although small studies of micro-\\naxial ﬂow pumps did not demonstrate clinical beneﬁtf o r\\npatients with AMI and cardiogenic shock,\\n14-16 a\\nRecommendations for MCS in Patients With ACS and\\nCardiogenic Shock\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .', 'COR LOE RECOMMENDATIONS\\n2a B-R\\n1. In selected* patients with STEMI\\nand severe or refractory cardio-\\ngenic shock, insertion of a\\nmicroaxial intravascular ﬂow\\npump is reasonable to reduce\\ndeath.\\n1\\n2a B-NR\\n2. In patients with mechanical\\ncomplication of ACS, short-term\\nMCS devices are reasonable for\\nhemodynamic stabilization as a\\nbridge to surgery.\\n2-4\\n3: No beneﬁt B-R\\n3. In patients with AMI and cardio-\\ngenic shock, the routine use of\\nintra-aortic balloon pump (IABP)\\nor venoarterial extracorporeal', 'membrane oxygenation (VA-\\nECMO) is not recommended due\\nto a lack of survival beneﬁt.\\n5-9\\n*See supportive text.\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2187\\nrandomized trial at specialized centers in Europe\\ndemonstrated a mortality bene ﬁt with use of the micro-\\naxial ﬂow pump in selected patients, albeit with increased\\nrisk of complications, including limb ischemia and renal\\nreplacement therapy.', '1 Best practices for insertion of all\\nMCS devices, including the multimodality use of ﬂuo-\\nroscopy and ultrasound, shouldb eu t i l i z e dw h e nf e a s i b l e\\nfor obtaining femoral access.17-19\\nRecommendation-Speci ﬁc Supportive Text\\n1. The DanGer-SHOCK (Danish-German Cardiogenic\\nShock) trial enrolled patients with STEMI and cardio-\\ngenic shock of <24 hours duration, de ﬁned as hypo-\\ntension (SBP <100 mm Hg or vasopressor support), end-\\norgan hypoperfusion (arterial lactate $2.5 mmol/L and/', 'or SvO\\n2 <55% with a normal PaO2), and LVEF <45%.\\nP a t i e n t sw h ow e r ec o m a t o s e( G l a s g o wC o m aS c a l e\\nscore <8) after out-of-hospit al cardiac arrest and pa-\\ntients with overt right ventricular failure were\\nexcluded.\\n1 The study enrolled 360 patients at 14\\ns p e c i a l i z e dc e n t e r si nE u r o p ea n dr a n d o m i z e dt h e mt o\\nuse of a microaxialﬂow pump or standard of care. Use of\\na microaxial ﬂow pump signiﬁcantly reduced the risk of', 'all-cause mortality at 180 days by 26% (HR, 0.74 [95% CI,\\n0.55-0.99]; P ¼ 0.04; absolute risk reduction, 12.7%;\\nnumber needed to treat¼ 8 )c o m p a r e dw i t hs t a n d a r do f\\ncare. The absolute risk reduction seen in this trial is\\nsimilar to the absolute risk reduction in 6-month mor-\\ntality observed with emerge ncy revascularization in\\npatients with AMI and LV failure in the SHOCK (Should\\nWe Emergently Revascularize Occluded Coronaries for\\nCardiogenic Shock) trial.\\n1,20 However, given the', 'increased risks of serious complications like bleeding,\\nlimb ischemia, and renal replacement therapy with the\\nmicroaxial ﬂow pump seen in the DanGer Shock trial, the\\nCOR is based on the balance between these risks and the\\nreduction in death. Additionally, the timing of micro-\\naxial ﬂow pump placement was not dictated by the trial\\nprotocol; thus, the preferred timing of placement is\\nunclear. Based on these results, use of a microaxialﬂow\\npump is reasonable to reduce mortality in patients with', 'STEMI and cardiogenic shock who have clinical features\\nconsistent with the inclusion criteria of the DanGer-\\nSHOCK trial. In particular, patients with STEMI who\\npresent with SCAI shock stages C, D, or E, who are non-\\ncomatose and have adequate peripheral vasculature to\\naccommodate large-bore access are reasonable candi-\\ndates for the microaxialﬂow pump.\\n2. Although randomized trial data are lacking, MCS de-\\nvices can be considered as a bridge to surgery for pa-', 'tients with mechanical complications of AMI when\\nadequate clinical stabilization is required and may allow\\nfor further tissue stabilization at the injured site. A\\nsystemic review of patients treated with MCS as a bridge\\nto surgical treatment of ventricular septal rupture yiel-\\nded 111 studies (n ¼ 2,440) with almost all patients\\nreceiving initial IABP support (n ¼ 2,263).\\n2 Of the 129\\npatients who underwent additional MCS device place-\\nment (77.5% of whom were on VA-ECMO), the lowest in-', 'hospital mortality was observed in those treated with\\nVA-ECMO (29.2%) when compared with those treated\\nwith an IABP alone (52.0%). However, 2 database ana-\\nlyses that were not included in the systematic review\\ndemonstrated higher in-hospital death with use of VA-\\nECMO in patients with post-AMI mechanical complica-\\ntions.\\n3,4 Evaluation of the ECLS (Extracorporeal Life\\nSupport) Organizations Regi stry yielded 158 patients\\nwith post-AMI mechanical complications who under-', 'went VA-ECMO. 3 Survival to hospital discharge here\\nwas low at 37.3%, and complications related to VA-\\nECMO use occurred in 75.3% of patients. Evaluation of\\nthe National Inpatient Sample yielded 10,726 patients\\nwith post-STEMI mechanical complications, and the use\\nof VA-ECMO was associated with increased in-hospital\\nmortality (OR, 2.80 [95% CI, 1.92-4.04]), while the use\\nof an IABP was not associated with lower mortality.\\n4\\nBoth data sources included use of VA-ECMO at any', 'time during the hospitalization for post-AMI mechani-\\ncal complications, including use of VA-ECMO post-\\nsurgery, a cohort at highest risk of in-hospital mortality.\\n3. The IABP-SHOCK II (Intraaortic Balloon Pump in\\nCardiogenic Shock II) trial randomized patients with\\nAMI and severe or refractorycardiogenic shock in whom\\nearly revascularization was planned to IABP or no IABP.\\n5\\nAt 30 days and long-term follow-up, no differences were\\nobserved in the primary outcome of all-cause death or', 'the secondary biomarker or measures of disease severity\\nendpoints.\\n6,7 VA-ECMO has not been shown to reduce\\ndeath compared with medical therapy alone in patients\\nwith cardiogenic shock in the setting of MI but increases\\nmajor bleeding and vascular complications.\\n21 The\\nECMO-CS (Extracorporeal Membrane Oxygenation in\\nthe Therapy of Cardiogenic Shock) trial randomized\\npatients with rapidly deteriorating or severe cardiogenic\\nshock to immediate or no immediate VA-ECMO.\\n8 At 30', '8 At 30\\ndays, no differences were observed in the primary\\ncomposite endpoint of all-ca use death, resuscitated\\ncardiac arrest, and implementation of another MCS de-\\nvice with results consistent in the 74 patients with\\ncardiogenic shock related to MI and in the as-treated\\nanalysis. The ECLS-SHOCK (Extracorporeal Life\\nSupport in Infarct-Related Cardiogenic Shock) trial\\nrandomized patients with AMI and severe or refractory\\ncardiogenic shock in whom early revascularization was', 'planned to early ECLS or no ECLS.\\n9 No differences were\\nobserved in the primary outcome of the 30-day mortality\\nrate or secondary outco mes. Moderate or severe\\nbleeding and peripheral vascular complications\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2188\\nrequiring intervention were higher in the ECLS versus\\nno ECLS group. Overall, these studies do not support\\nroutine use of IABP and VA-ECMO in patients with AMI', 'and cardiogenic shock.\\n9. ACS COMPLICATIONS\\n9.1. Mechanical Complications\\nSynopsis\\nTimely reperfusion therapy has reduced the incidence\\nof mechanical complications (ventricular septal rupture,\\nmitral valve insufﬁciency due to papillary muscle infarc-\\ntion or rupture, or free wall rupture) after AMI\\n(Figure 9 ).\\n3,4 Although occasionally found incidentally,\\nmechanical complications commonly present with recur-\\nrent or refractory chest pain or a new murmur accompa-', 'nied by disproportionate HF, cardiogenic shock, or\\nsudden cardiac death on clinical presentation within the\\nﬁrst week after an AMI. Medical therapy alone is associ-\\nated with high risk of early death\\n5,6;d eﬁnitive surgical\\ncorrection is frequently the treatment of choice. 7,8 Mor-\\ntality rates with surgery are highest in subjects with\\ncardiogenic shock and in those requiring early emer-\\ngency/urgent intervention after AMI.\\n9,10 Observed mor-', '9,10 Observed mor-\\ntality rates following delayed surgery (>7 days) are lower\\nbut patient selection and survivor bias contribute to this\\nobservation.\\n11,12 The availability of temporary MCS de-\\nvices has led to increasing trends for delayed surgery due\\nto concerns for the initial degree of extensive tissue\\ndestruction.\\n13,14 Delayed surgical intervention may enable\\nhemodynamic stabilization, l ead to recovery of end-organ\\ninjury, and promote infarct tissue healing and maturation', 'that could facilitate de ﬁnitive repair. Percutaneous ap-\\nproaches toward repair have been used in patients with\\nprohibitive surgical risk or contraindications to surgery as\\na primary or temporizing opti on in the setting of acute\\nmitral regurgitation and ventricular septal rupture and\\nremain an evolving area of investigation.\\n15,16 Select pa-\\ntients with mechanical complications of ACS may be\\nconsidered for cardiac transplantation or durable left', 'ventricular assist device as a primary or bailout treatment\\nstrategy to improve survival.\\n17\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. No RCTs evaluate the role of transfer of patients with\\nmechanical complications after MI to dedicated centers\\nwith cardiac surgical expertise. Although overall surgi-\\ncal mortality is approximately 40%, it remains the\\ntreatment strategy of choice. Hemodynamic deteriora-\\ntion is unpredictable and can be precipitous in previ-', 'ously stable subjects. Consequently, transfer to a Level 1\\ncardiac intensive care unit (CICU)\\n18 with access to\\nvarious temporary MCS devices and multidisciplinary\\nexperienced teams of surgical, interventional, HF, and\\npalliative care specialists is recommended. Emerging\\ndata following the creation of shock teams supports the\\ntransfer of hemodynamically unstable patients from\\ncommunity hospitals to centers with multidisciplinary\\nexpertise.\\n19,20 Although the exact timing remains un-', 'certain, early corrective surgery is the treatment of\\nchoice for mechanical complications of MI.\\n7,8,12 The risk\\nof surgical correction is highest when performed in the\\nsetting of cardiogenic shock\\n9,21,22 and appears lower\\nwhen surgery is delayed. The early hazard with surgery\\nis attributed to patient acuity, end-organ injury, and\\nlack of tissue integrity to promote deﬁnitive and lasting\\nrepair. Selected subjects may be candidates for either\\ndeﬁnitive or temporizing percutaneous structural', 'intervention as a bridge to deﬁnitive surgical interven-\\ntion.\\n15,16,23 Given the complexity of decision making, a\\nHeart Team approach to guide feasibility, timing, and\\nnature of corrective intervention as well as the need and\\nselection of MCS support is recommended as soon as a\\nmechanical complication is diagnosed.\\n2. No RCTs have evaluated the role of MCS in improving\\nclinical outcomes in the setting of mechanical compli-\\nc a t i o n s .T h ec h o i c eo fs p e c iﬁc MCS should be individ-', 'ualized and guided by patient characteristics, nature of\\nthe mechanical complication, and the hemodynamic\\nproﬁle. In patients with ventricular septal rupture, the\\nuse of an IABP has been shown to reduce left-to-right\\nshunting and improve hemodynamics in patients with\\nand without shock.\\n24 Favorable hemodynamic effects\\nwith IABP are also noted with acute ischemic mitral\\nregurgitation. Various devices have been utilized when\\nIABP fails or if hemodynamic instability remains pro-\\nfound.', 'found.\\n1 The use of MCS devices has enhanced hemo-\\ndynamic stabilization to allow the opportunity for\\nconsideration of delayed corrective strategy. 13,14\\nRecommendations for Mec hanical Complications\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1 C-EO\\n1. Patients with a mechanical\\ncomplication of ACS should be\\nmanaged in a facility with cardiac\\nsurgical expertise.\\n2a B-NR\\n2. In patients with a mechanical', 'complication of ACS, short-term\\nMCS devices are reasonable for\\nhemodynamic stabilization as a\\nbridge to surgery.\\n1-3\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2189\\n9.2. Electrical Complications and Prevention of Sudden Cardiac\\nDeath After ACS\\nFIGURE 9 Clinical Characteristics of Mechanical Complications of Acute Myocardial Infarction', 'Contained rupture is the preferred term for an entity sometimes referred to as pseudoaneurysm. HF indicates heart failure; LA, left atrium; LV, left ventricle; and MR,\\nmitral regurgitation. Modiﬁed with permission from Damluji et al.25 Copyright 2025 Devon Medical Art.\\nRecommendations for Electrical Complications and\\nPrevention of Sudden Cardiac Death After ACS\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\nVentricular Arrhythmias', '1A\\n1. In patients post MI, implantable\\ncardioverter-de ﬁbrillator (ICD)\\nimplantation is recommended in\\nselected patients with an\\nLVEF £40% (Table 17) at least 40\\ndays post MI and at least 90 days\\npostrevascularization to reduce\\ndeath. *\\n1-4\\n2a C-EO\\n2. In patients post ACS, ICD implan-\\ntation is reasonable in patients with\\nclinically relevant ventricular\\narrhythmias >48 hours and within\\n40 days post MI to improve\\nsurvival.*\\n5,6\\n(continued in the next column)\\nContinued\\nCOR LOE RECOMMENDATIONS', '2b B-R\\n3. In patients early after MI, use-\\nfulness of a temporary wearable\\ncardioverter-de ﬁbrillator is un-\\ncertain in patients with an\\nLVEF £35% to improve survival.\\n7\\nBradyarrhythmias\\n1 B-NR\\n4. In patients presenting with an AMI\\nwith sustained evidence of second-\\ndegree Mobitz type II atrioventric-\\nular block, high-grade atrioven-\\ntricular block, alternating bundle-\\nbranch block, or third-degree\\natrioventricular block (persistent\\nor infranodal), permanent pacing is\\nindicated.†\\n8,9', 'indicated.†\\n8,9\\n*Adapted from the “2017 AHA/ACC/HRS Guideline for Management of Patients With\\nVentricular Arrhythmias and the Prevention of Sudden Cardiac Death.”† Adapted from\\nthe “2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With\\nBradycardia and Cardiac Conduction Delay.”\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2190\\nSynopsis\\nElectrical complications in patients with ACS may', 'create challenges in clinical management due to consid-\\neration for the need of anticoagulant therapy in patients\\nwho develop atrial ﬁbrillation (AF) or ﬂutter and possible\\nneed for antiarrhythmic therapy and electrophysiologic\\ninterventions. Many of these considerations have been\\naddressed in depth in separate guideline documents.\\n10\\nGenerally, arrhythmic complications increase both\\nmorbidity and mortality rates in patients after ACS. Pa-\\ntients who present with AMI with reduced LVEF (#40%)', 'have increased risk of new-onset AF, bradyarrhythmias,\\nand ventricular arrhythmias.\\n11,12 This risk appears to be\\nincreased in those patients who are not revascularized or\\nreceive ﬁbrinolytic therapy compared with those who\\nundergo PCI.11\\nRecommendation-Speci ﬁc Supportive Text\\n1. Ventricular arrhythmia sa r ec o m m o na f t e rA C Sa n d\\nmore common in patients with reduced LVEF. MADIT\\nII (Multicenter Automatic De ﬁbrillator Implantation\\nTrial) demonstrated a 31% reduction in all-cause', 'mortality (HR, 0.69 [95% CI, 0.51-0.93]) for prophy-\\nlactic implantation of a cardiac deﬁbrillator in patients\\nwith an LVEF#30% who were at least 30 days after MI\\nor 3 months after revascularization for MI and had an\\nanticipated life expectancy longer than 1 year.\\n2 A\\nmortality beneﬁt for prophylactic ICD implantation has\\nalso been shown in patients with an LVEF #35% and\\nNew York Heart Association class II or III HF symp-\\ntoms,\\n1,3 as well as in patients with inducible ventricu-', 'lar tachycardia or ventricular ﬁbrillation and an\\nLVEF #40%1,4,13 (Table 17).\\n2. The risk of ventricular arrythmias and sudden cardiac\\nd e a t hi sh i g h e s te a r l ya f t e rM I ,a l t h o u g ht h er o u t i n e\\nimplantation of a deﬁbrillator (for primary prevention)\\nin patients with LV dysfunction early after MI or CABG\\nhas not been associated with improved survival.\\n14-16 In\\nDINAMIT (Deﬁbrillator in Acute Myocardial Infarction\\nTrial), ICD implantation led to a 58% reduction in', 'arrhythmic deaths within 6 to 40 days post MI with\\nejection fraction #35%; however, this was offset by an\\nincrease in nonarrhythmic deaths.\\n16 Sustained epi-\\nsodes of ventricular tachycardia or ventricular ﬁbrilla-\\ntion occurring >48 hours after reperfusion are\\nassociated with an increased risk of death,12,17 and the\\nrisk of sudden cardiac death is highest in the ﬁrst\\nmonth. 5 Patients with ventricular arrhythmias should\\nﬁrst be managed with beta blockers and/or antiar-', 'rhythmic therapy. The bene ﬁt of ICD implantation in\\npatients with persistent or sustained ventricular ar-\\nrhythmias and who are <40 days post MI remains un-\\nclear.\\n15,16,18 A single-center observational study\\nenrolled patients post STEMI (median, 9 days) and\\nreferred those with an LVEF #40% for electrophysio-\\nl o g i ct e s t i n ga n di m p l a n t e da nI C Do n l yi nt h o s ew i t h\\ninducible ventricular tachycardia. Although a ran-\\ndomized comparator arm was unavailable, 22% of', 'those who underwent ICD implantation had ventricu-\\nlar tachycardia terminated by the device during the\\nﬁrst 12 months.\\n6 The effects of ICD implantation on\\nmortality cannot be de ﬁnitely ascertained, and more\\nresearch is required. Radiofrequency catheter ablation\\nshould be considered in patients with recurrent ven-\\ntricular tachycardia or ventricular ﬁbrillation followed\\nby ICD implantation.\\n19 Earlier ICD implantation can be\\nconsidered in patients who have an indication for a', 'permanent pacemaker prior to hospital discharge and\\nin whom LVEF is not expected to recover, but no evi-\\ndence was observed to de ﬁnitively demonstrate the\\nsafety of this approach.\\n10,20\\n3. In the VEST (Vest Prevention of Early Sudden Death)\\nt r i a l ,t h er o u t i n eu s eo fat e m p o r a r yw e a r a b l e\\ncardioverter-de ﬁbrillator did not signi ﬁcantly reduce\\nthe primary endpoint (composite of sudden death or\\ndeath from ventricular tachyarrhythmias at 90 days) in', 'patients with AMI and LVEF #35% (relative risk, 0.67\\n[95% CI, 0.37-1.21]).\\n7,21 The secondary endpoint of\\ndeath from any cause was lower in the wearable vest\\ngroup compared with the no-device group (relative\\nrisk, 0.64 [95% CI, 0.43-0.98]); only 12 of 48 patients\\nwere wearing the device at the time of death.\\n7 Greater\\nbeneﬁt was demonstrated in those who were compliant\\nwith the device. 21 As such, use of a wearable\\ncardioverter-de ﬁbrillator could be considered in high-', 'risk patients with reduced LVEF as a bridge to\\nconsideration for the need for an ICD.\\n4. Patients with STEMI with second- or third-degree\\natrioventricular block have higher in-hospital mortal-\\nity than those without high-degree atrioventricular\\nblock.\\n22,23 Patients who present with ACS with com-\\np l e t eh e a r tb l o c kh a v eah i g h e ri n c i d e n c eo fc a r d i o -\\ngenic shock, ventricular arrhythmia, and death.\\n24,25 In\\na contemporary cohort of patients with AMI, the\\nTABLE 17', 'TABLE 17\\nLVEF and Patient Characteristics De ﬁning an\\nIndication for Prophylactic ICD Implantation for\\nPrimary Prevention in Ischemic Heart Disease\\nLVEF\\nPatient Category: All Patients Should\\nHave Expected Survival of $1y\\n#30% NYHA class I, II, or III 2\\n31%-35% NYHA class II or III 1,3\\n#40% Inducible VT 1,4,13\\nICD indicates implantable cardioverter-de ﬁbrillator; LVEF, left ventricular ejection\\nfraction; NYHA, New York Heart Association; and VT, ventricular tachycardia.', 'JACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2191\\nincidence of high-degree atrioventricular block has\\ndecreased from 4.2% to 2.1%; however, increased\\nmorbidity and mortality remain despite reperfusion\\ntherapy in those with high-degree atrioventricular\\nblock.\\n26,27 A pooled analysis of 30,000 patients found\\nthat high-degree atrioventricular block, asystole, and\\nelectromechanical dissociation are infrequent compli-', 'cations of NSTEMI but are associated with increased\\nshort-term mortality. High-degree atrioventricular\\nblock is not considered to be responsible for the\\nincreased mortality but is a surrogate marker of larger\\ninfarct size.\\n28 Temporary pacemaker insertion in the\\nsetting of ACS in patients with high-degree atrioven-\\ntricular block and other pacer indications has been\\nfound to improve postdischarge survival. 8,9,29 Perma-\\nnent pacemaker insertion is recommended with unre-', 'solved high-degree atrioventricular block that persists\\n>72 hours.\\n20\\n9.3. Pericarditis Management After MI\\nSynopsis\\nThe diagnostic criteria for post-MI pericarditis are dis-\\nplayed in Table 18. Pericarditis that occurs early after MI\\ntypically arises 1 to 3 days after a transmural event and is\\npresumed to be inﬂammatory in nature due to adjacent\\nmyocardial necrosis. These cases of early pericarditis are\\ntypically transient, lasting several days, and will resolve', 'with conservative therapy. Acetaminophen can be given\\nfor symptomatic relief. A second form of pericarditis may\\noccur weeks after MI (Dressler ’ss y n d r o m e )a n di s\\nbelieved to be immune-mediated as a response to peri-\\ncardial irritation or damage, such as in the setting of any\\ndegree of hemopericardium.\\n1,2 These cases of late peri-\\ncarditis often require additional therapy (Table 19). Given\\nthe rarity of post-MI pericarditis (0.1%-0.5%) in the era of\\nearly coronary reperfusion therapy,', '3 dedicated RCTs of\\nh i g h - d o s ea s p i r i na r el a c k i n g ,a n dd a t aa r ee x t r a p o l a t e d\\nfrom studies of the heterogeneous diagnosis of acute\\npericarditis.\\n4 Furthermore, RCTs of colchicine were per-\\nformed on a background of high-dose aspirin therapy.5-7 If\\nsymptoms persist despite standard supportive therapy in\\nearly pericarditis and in any l ate pericarditis, high-dose\\naspirin may be used to reduce symptoms.\\n4 The use of', '4 The use of\\ncolchicine should also be considered to reduce symptoms\\nand decrease risk of recurrence\\n8,9; suggested dosing is\\nsummarized in Table 19. The value of a loading dose of\\ncolchicine in this setting is unclear. Routine use of high-\\ndose aspirin or colchicine is not indicated for the man-\\nagement of asymptomatic pericardial effusions. 10,11 Glu-\\ncocorticoids and nonsteroidal anti-in ﬂammatory drugs\\n(other than aspirin) are potentially harmful due to', 'possible increase in risk of recurrent MI or impaired\\nmyocardial healing and risk of rupture.\\n12,13\\n9.4. Management of LV Thrombus After MI\\nSynopsis\\nLV thrombus typically occurs in the setting of large\\nanterior STEMI and can lead to thromboembolic compli-\\ncations, including stroke and systemic embolization. In\\nthe era of PCI, the incidence of LV thrombus after ACS has\\ndecreased and is estimated to be<5% to 10% in the post-\\nMI population.\\n1-3 Limited RCT data are available on the', 'contemporary management of LV thrombus, and current\\nmanagement is based mostly on retrospective and\\nobservational data and expert consensus. Patients at\\nhighest risk for LV thrombus include those with anterior\\nSTEMI involving the left anterior descending artery,\\nLVEF <30% (especially in the presence of an LV aneu-\\nrysm), and longer times to reperfusion. An echocardio-\\ngram is the recommended imaging modality for diagnosis,\\ngiven its wide accessibility and low cost.\\n4 Cardiac MRI is', '4 Cardiac MRI is\\nmore sensitive for detection of LV thrombus and may be\\nconsidered when there is high clinical suspicion and\\nechocardiogram results are inconclusive. LV thrombus\\nmay form later during hospitalization or after discharge;\\ntherefore, repeat imaging can sometimes detect LV\\nthrombus in high-risk patients.\\n5 Because DAPT is recom-\\nmended for most patients early after ACS, the addition of\\nan anticoagulant for LV thrombus needs to be considered', 'in the context of the patient’s overall bleeding risk versus\\ntheir risk of an embolic event. Most patients with LV\\nthrombus will warrant anticoagulation for a period of 3\\nmonths, at which time the presence of residual thrombus\\ncan be assessed by repeat imaging to help determine\\nwhether a more prolonged course is warranted.\\n1 Although\\ndirect oral anticoagulants (DOAC) are routinely used in\\nTABLE 18 Clinical Criteria for Diagnosis of Pericarditis', 'Diagnosis Is Made With Presence of Pleuritic Chest Pain and‡1 of the Following\\nCriteria:\\nn Friction pericardial rub on auscultation\\nn Electrocardiographic evidence such as classic PR-segment depression or\\ndiffusive concave ST-segment elevations, or in the setting of MI,\\npersistent ST-segment elevations or dynamic T-wave changes\\nn New or growing pericardial effusion on echocardiography\\nMI indicates myocardial infarction.\\nTABLE 19 Additional Therapy for Persistent/Late\\nPericarditis Symptoms', 'Medical Therapy Dosing Schedule\\nHigh-dose aspirin 500-1,000 mg every 6-8 h until symptoms improve\\nColchicine 0.5-0.6 mg once * or twice daily for 3 mo\\n*Daily dosing should be used in patients who weigh<70 kg and further adjusted in\\npatients with stage 4-5 kidney disease, severe hepatic impairment, or with concomitant\\nP-glycoprotein and/or moderate and severe CYP3A4 inhibitors.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2192', '2192\\nclinical practice, there are limited data comparing the\\nefﬁcacy of a DOAC versus vitamin K antagonist in the\\nsetting of LV thrombus. Observational studies and small\\nRCTs have suggested that DOAC may be noninferior to\\nvitamin K antagonist with respect to mortality, stroke, or\\nLV thrombus resolution, and DOACs may offer an\\nimproved bleeding proﬁle.\\n6 The practical management of\\nLV thrombi is more completely addressed in other\\ndocuments.\\n1,6\\n10. IN-HOSPITAL ISSUES IN THE MANAGEMENT\\nOF ACS', 'OF ACS\\n10.1. Cardiac Intensive Care Unit\\nSynopsis\\nThe nurse-to-patient ratio in the CICU should be sufﬁ-\\ncient to provide (1) continuous electrocardiographic\\nrhythm monitoring, (2) frequent assessment of vital signs\\nand mental status, and (3) ab ility to perform rapid car-\\ndioversion and de ﬁbrillation for arrhythmias. 1,2 Some\\nhospitals may not have a dedicated CICU but rather care\\nfor patients with MI within a general multipurpose ICU;\\nthis approach requires trained providers with suf ﬁcient', 'expertise in the care of cardiac patients.\\nRecommendation-Speci ﬁc Supportive Text\\n1. Admission to the CICU and optimal length of stay in the\\nCICU after an MI should be based on patients ’ risk\\nproﬁles and clinical stability, while considering the\\npatient ’s baseline cardiac risk and comorbidities. Pa-\\ntients with ACS with continuing/ongoing angina, he-\\nmodynamic instability, uncontrolled arrhythmias, or a\\nlarge MI with HF, cardiogenic shock, or both, should be\\nadmitted to a CICU.', 'admitted to a CICU.\\n1,2 Patients with ongoing ischemic\\nsymptoms should be preferent ially triaged for cardiac\\ncatheterization whenever possible. Stable patients with\\nACS and without recurrent ischemia, signi ﬁcant ar-\\nrhythmias, pulmonary edema, or hemodynamic insta-\\nbility do not need CICU admission and can be admitted\\nto an intermediate care or telemetry unit. Clinical pre-\\ndictors may be useful for helping identify patients who\\nwill require CICU care. For example, the ACTION ICU', 'risk score for CICU admission integrates 9 variables on\\npresentation to the ED including: signs or symptoms of\\nH F ,i n i t i a lh e a r tr a t e ,i n i t i a lS B P ,i n i t i a lt r o p o n i n ,i n i t i a l\\nserum creatinine, prior revascularization, chronic lung\\ndisease, ST-segment depression, and age >70 years.\\n3\\n10.2. Management of Anemia in ACS\\nSynopsis\\nAnemia is common in patients with ACS and is associ-\\nated with worse short- and long-term outcomes. 2-4 Ane-', 'mia is associated with adverse outcomes irrespective of\\nwhether the anemia is chronic and due to comorbid con-\\nditions, or acute and the result of bleeding related to\\nantithrombotic therapy and/o r invasive procedures. The\\nadverse effects of anemia may be due to decreased\\nmyocardial oxygen delivery, increased myocardial oxy-\\ngen demand due to increased cardiac output, or the\\navoidance of potentially bene ﬁcial antithrombotic drugs\\nand/or procedures. In observational studies, blood', 'transfusion has been associated with worse clinical out-\\ncomes.\\n5-8 Randomized trials in medically ill patients and\\nthose undergoing cardiac surgery have demonstrated\\ns i m i l a ro rb e t t e ro u t c o m e sw i t har e s t r i c t i v et r a n s f u s i o n\\nstrategy (targeting a blood hemoglobin level around\\n8 g/dL) than with a liberal transfusion strategy (targeting\\na blood hemoglobin level around 10 g/dL).\\n9-11 However,\\nrandomized trial evidence for populations with ACS sug-', 'gests possible clinical bene ﬁtf o ram o r el i b e r a l\\nRecommendation for CICU\\nCOR LOE RECOMMENDATION\\n1 C-EO\\n1. Patients with ACS and with\\nongoing angina, hemodynamic\\ninstability, uncontrolled arrhyth-\\nmias, suboptimal reperfusion, or\\ncardiogenic shock should be\\nadmitted to a CICU to reduce\\ncardiovascular events.\\nRecommendation for Management of Anemia in ACS\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n2b B-R', '2b B-R\\n1. In patients with ACS and acute or\\nchronic anemia, blood trans-\\nfusion to achieve a hemoglobin\\nlevel ‡10 g/dL may be reasonable\\nto reduce cardiovascular events.\\n1\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2193\\ntransfusion strategy targeting a hemoglobin level above\\n10 g/dL compared with targeting a hemoglobin level\\nabove 7 g/dL to 8 g/dL.\\n1,12,13\\nRecommendation-Speci ﬁc Supportive Text', '1. The MINT (Myocardial Ischemia and Transfusion) trial\\nrandomly assigned 3,504 patients with acute STEMI or\\nNSTEMI and anemia with a blood hemoglobin level\\nof <10 g/dL (13% with recent bleeding) to a restrictive\\ntransfusion strategy (transfusing if the hemoglobin\\nlevel was <7-8 g/dL) or a liberal transfusion strategy\\n(transfusing if the hemoglobin level was <10 g/dL).\\n1\\nPatients were ineligible for enrollment if they had un-\\ncontrolled bleeding, were r eceiving palliative treat-', 'ment, or were scheduled to have cardiac surgery.\\nTransfusion could be delayed for patients with volume\\noverload or until day of dialysis in patients with end-\\ns t a g er e n a ld i s e a s e .T h ep r i m a r yo u t c o m eo f3 0 - d a y\\ndeath or recurrent MI occurred in 16.9% of patients in\\nthe restrictive strategy and 14.5% of patients in the\\nliberal strategy (relative risk, 1.15 [95% CI, 0.99-1.34];\\nP ¼ 0.07). Death occurred in 9.9% of patients in the', 'restrictive strategy and 8.3% of patients in the liberal\\nstrategy (relative risk, 1.19 [95% CI, 0.94-1.49]), and\\ncardiac death occurred in 5.5% of patients in the\\nrestrictive strategy and 3.2% of patients in the liberal\\nstrategy (relative risk, 1.74 [95% CI, 1.26-2.40]).\\nAlthough the MINT trial did not demonstrate a statis-\\ntically signiﬁcant reduction in its primary endpoint, the\\nresults suggest that a liberal blood transfusion strategy\\ntargeting a hemoglobin level around 10 g/dL may pro-', 'vide short-term clinical bene ﬁt over a restrictive\\ntransfusion strategy targeting a hemoglobin level above\\n7 g/dL or 8 g/dL in patients with AMI and anemia.\\n10.3. Telemetry and Length of Stay\\nSynopsis\\nAdvances in vascular access methods, coronary revas-\\ncularization, and concomitant medical therapies have\\ncontributed to shortening length of stay and further\\nfacilitated changes in discharge patterns after PCI in the\\nsetting of ACS. There remainslimited evidence regarding', 'the optimal length of stay after MI. Patients with STEMI\\nrepresent a higher risk cohort who may require longer\\nlength of stay. Available data suggest that an early\\ndischarge strategy of <3 days from admission is not\\nassociated with increased mortality for low-risk patients\\nafter STEMI who have undergone PCI.\\n3-8 T h eZ w o l l es c o r e\\nhas been recommended as a clinical tool to help identify\\npatients after PPCI in STEMI at low risk of death (low-risk', 'patients, score #3) who can potentially be discharged\\nearlier from the hospital (48 to 72 hours). Predictors of\\nmortality in the Zwolle score include age, Killip class,\\npostprocedural TIMI Flow Grade, 3-vessel disease, ante-\\nrior infarction, and ischemic time.\\n3 Optimal length of stay\\nin the setting of NSTE-ACS has been less rigorously\\nstudied. Small retrospective studies have suggested\\nsafety of very early or same-day discharge after PCI for', 'patients with ACS, with most (71%) of same-day discharge\\nbeing troponin-negative.\\n9 Patients being considered for\\nearly discharge should be clinically stable without evi-\\ndence of ongoing ischemia, acute kidney injury, LV\\ndysfunction, HF, and procedural complications and with\\nadequate postdischarge support.\\n8 Hospitals and care\\nproviders should ensure that patients have access to\\npostdischarge prescriptio n medications and adequate\\nfollow-up.\\nRecommendation-Speci ﬁc Supportive Text', '1. The number of studies addressing telemetry duration\\nare few and the focus has been on arrhythmia moni-\\ntoring, not continuous ST-segment monitoring.\\nContinuous ST-segment monitoring can be considered\\nfor higher-risk patients, including those with suspected\\nischemia who are not yet revascularized.\\n1,10-14 Patients\\nwith ACS who are at low risk for cardiac arrhythmias\\nrequire rhythm monitoring for #24 hours or until cor-\\nonary revascularization (whichever comes ﬁrst) in a', 'telemetry unit, while individuals at intermediate to\\nhigh risk for cardiac arrh ythmia may require rhythm\\nmonitoring for >24 hours in a telemetry unit or in an\\nintermediate care unit, depe nding on the clinical pre-\\nsentation, degree of revascularization, and early\\nRecommendation for Telemetry and Length of Stay\\nCOR LOE RECOMMENDATION\\n1 C-LD\\n1. In patients with ACS, telemetry\\nmonitoring is recommended to\\nreduce cardiovascular events\\nwith duration determined by\\ncardiac risk.\\n1,2', 'cardiac risk.\\n1,2\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2194\\npostrevascularization course with input from the\\ntreating cardiologist. 10,12-14\\n10.4. Noninvasive Diagnostic Testing Prior to\\nHospital Discharge\\nSynopsis\\nIn patients with ACS, LV function should be routinely\\nevaluated in patients prior to hospital discharge to help\\nguide therapy and for risk stratiﬁcation.\\n1-3 Transthoracic', '1-3 Transthoracic\\nechocardiography is generally the preferred modality\\nbecause it is noninvasive and can provide a comprehen-\\nsive assessment of ventricular and valvular function, as\\nwell as possibly detect LV thrombus or mechanical\\ncomplications. Transthoracic echocardiography is there-\\nfore strongly preferred for all patients hospitalized with\\nSTEMI because complications may be more likely to be\\npresent. In patients where transthoracic echocardiogra-', 'phy is nondiagnostic, cardiac magnetic resonance imag-\\ning is a reasonable alternative in clinically stable patients.\\nAlternatively, LV function and some mechanical compli-\\ncations can be assessed invasively with left ventriculog-\\nraphy in the cardiac catheterization laboratory, but other\\ndata regarding valvular function and wall motion are best\\nevaluated with noninvasive methods like transthoracic\\nechocardiography or cardiac magnetic resonance imaging.', 'LV function may also be estimated noninvasively by\\nmyocardial perfusion imaging testing, but this will also\\nprovide incomplete information regarding the presence or\\nabsence of other complications of MI. For patients in\\nwhom LV function is found to be reduced, a repeat\\nechocardiogram should be performed in 6 to 12 weeks to\\nfurther guide treatment decisions and for consideration of\\nneed for an ICD.\\n4,5\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t', '1. LV function should be routinely evaluated in patients\\nwith ACS prior to hospital discharge because LVEF\\nguides therapeutic interventions and facilitates risk\\nstrati ﬁcation. The diagnosis of LV dysfunction is\\nimportant because it may trigger consideration for the\\ninitiation or optimization of guideline-directed thera-\\npeutic interventions for patients with HF or depressed\\nLV function. It also helps identify patients with\\nreduced LVEF who may require consideration for', 'future primary prevention implantation of an ICD. Be-\\nsides LVEF, transthoracic echocardiography facilitates\\nthe assessment of regional wall motion abnormalities,\\nvalvular function, mechanical complications,\\n4 and LV\\nthrombus. 5 In cases in which LV function cannot be\\nadequately assessed despite the use of contrast echo-\\ncardiography, cardiac magnetic resonance is the\\npreferred imaging modality for clinically stable pa-\\ntients.\\n6-9\\n10.5. Discharge Planning\\n10.5.1. Patient Education\\nSynopsis', 'Synopsis\\nPatient education is universally valued and aims to\\ndeliver information from clinicians to patients to\\nimprove health behavior and long-term health-related\\noutcomes. Clinicia n sa r ew e l lp o s i t i o n e dt oe n g a g ei n\\nmeaningful dialogue with patients who have experi-\\nenced an ACS event about secondary prevention\\nand building self-care skills to manage their condition\\n(Table 20 ). Recovery represents a teachable moment to', 'provide structured educatio n, including priming the pa-\\ntient to attend cardiac rehabilitation (CR). Systematic\\nreviews of educational interventions targeting secondary\\nprevention in patients with coronary heart disease, many\\nof whom have ACS, have demonstrated effectiveness in\\nimproving disease-related knowledge, healthy behaviors\\n(eg, smoking cessation, physical activity, healthy dietary\\nbehavior), and medication adherence.\\n1-3 The magnitude', '1-3 The magnitude\\nof the effect on each of these outcomes varies by study.\\nBeyond improved knowledge and behavior change, the\\nimpact of individualized education for patients with ACS\\non morbidity and mortality is less clear. A shortcoming\\nof published educational intervention studies to date is\\nthat the interventions are markedly heterogeneous but\\nvary in intensity, duration, delivery mode, resources\\nneeded, and outcomes measured. Currently, insuf ﬁcient', 'Recommendation for Noninvasive Diagnostic Testing\\nPrior to Hospital Discharge\\nCOR LOE RECOMMENDATION\\n1 C-LD\\n1. In patients with ACS, an assess-\\nment of LVEF is recommended\\nprior to hospital discharge to\\nguide therapy and for risk strati-\\nﬁcation.\\n1-3\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2195\\ncomparative data are available to guide clinicians about\\nwhich speci ﬁc educational interven tions are best. How-', 'ever, evidence supports the use of individualized goal\\nsetting that demonstrates respect for the patient and\\ntheir circumstances, structu red content that is culturally\\nappropriate, and clearly de ﬁned outcomes.\\n4 Table 20\\nlists the components that should be discussed with ACS\\npatients at the time of hospital discharge.\\n10.5.2. Postdischarge Follow-Up and Systems of Care\\nCoordination\\nSynopsis\\nTransition from the hospital to home is a critical period', 'for patients with ACS because approximately 1 in 5 pa-\\ntients are readmitted within 30 days of discharge.\\n1-6\\nWomen, individuals from traditionally underrepresented\\nracial and ethnic groups, and patients who require ICU\\nservices during their index hospitalization are particularly\\nat risk for readmission. 3 Quality improvement programs\\nsuch as the Hospital to Home Initiative 7 or the AMI\\nToolkit 8 provide resources to assist clinicians decrease\\nreadmission rates and improve medication and CR', 'adherence through increase d provider communication\\nand care coordination. Transitional care interventions\\nthat leverage different typ es of support (eg, hospital-\\ninitiated support, patient and family education deliv-\\nered before and after discharge, or community-based or\\nchronic disease management models of care) are exam-\\nples of ways to reduce risk of readmission.\\n9 Hospital-\\ninitiated support interventions are associated with\\nreduced mortality rates at 3 months and 1 year as well as a', 'reduction in 30-day readmission rates among patients\\nwith AMI.\\n9,10 Multicomponent integrated care ($2q u a l i t y\\nimprovement strategies targeting different domains of\\nthe health care system, health care professionals, or pa-\\ntients) as compared with usual care has been associated\\nwith reduction of all-cause death, cardiovascular mortal-\\nity, and all-cause hospitalization.\\n11 Emerging digital\\nhealth interventions hold promise to improve the transi-', 'tion from hospital to home. For additional recommenda-\\ntions on nutrition, physical activity, smoking cessation,\\nand alcohol and substance use, refer to the “2023 AHA/\\nACC/ACCP/ASPC/NLA/PCNA Guideline for Management\\nof Patients With Chronic Coronary Disease. ”\\n12 Table 21\\nsummarizes the recommended guidance for hospital\\ndischarge.\\nTABLE 21 Guidance for ACS Discharge: Best Practices\\nCommunication n Patient centered, verbally and in writing in pa-\\ntient/caregiver preferred language', 'n Shared decision-making regarding assessment of\\ngoals and preferences should be discussed with\\npatient/caregiver\\nClinical assessment n Address comorbidities and risk factors for recur-\\nrent events\\nn Assess for presence of ongoing ischemic symp-\\ntoms, using standardized instrument ideally\\nembedded into EHR\\nn Assess risk for bleeding related to medications or\\nprocedural site\\nn Assess need for additional testing (eg, repeat\\nechocardiogram, staged PCI)', 'n Assess whether vaccinations are current (eg,\\ninﬂuenza)\\nn Perform medication reconciliation, including a\\nprescription for sublingual nitroglycerin, unless\\ncontraindicated\\nPatient/caregiver\\nassessment\\nn Assess capacity for patient/caregiver for self-care\\n(eg, secondary prevention, symptom monitoring,\\nfollowing plan of care, lifestyle changes, contact\\ninformation for continuing care team)\\nn Provide verbal and written educational informa-\\ntion related to self-care', 'n Use teach-back method to conﬁrm understanding\\nof self-care\\nn Use teach-back method for patient/caregiver\\nunderstanding of medication adherence and\\ntreatment regimen\\nReferrals\\nn Conﬁrm referral to CR\\nn Provide educational materials related to CR\\nincluding contact information\\nSocial determinants\\nof health\\nn Assess and address barriers to obtaining and\\ntaking prescribed medications, to include referral\\nto pharmacy assistance programs or social worker\\nas appropriate', 'as appropriate\\nn Assess and address barriers to attending CR,\\nincluding viability of home-based or hybrid CR\\nACS indicates acute coronary syndromes; CR, cardiac rehabilitation; EHR, electronic\\nhealth record; and PCI, percutaneous coronary intervention.\\nTABLE 20 Essential Components of Patient Education\\nn Reason for hospitalization (expla in reason for admission, diagnostic\\ntests, procedural results)\\nn Tailored discussion of lifestyle modi ﬁcations (AHA’sL i f e’sE s s e n t i a l8 )5', 'n Medications (written and verbal instructions including purpose, dose,\\nfrequency, potential adverse effects of each medication; reﬁll in-\\nstructions; changes to prehospital r egimen; importance of adherence)\\nn Symptom management (what to monitor for and actions to take should\\nsymptoms recur, including whom to call)\\nn Returning to daily routine (when to resume physical activity, sexual\\nactivity, work, and travel)\\nn Psychosocial considerations (open dialogue about symptoms of', 'depression and anxiety)\\nn Follow-up care (future appointments with cardiology, CR, additional\\ntesting postdischarge)\\nAHA indicates American Heart Association; and CR, cardiac rehabilitation.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2196\\n10.5.3. Cardiac Rehabilitation\\nSynopsis\\nCR is a multifaceted and comprehensive outpatient\\nintervention that is considered the standard of care for', 'secondary prevention of CVD. The primary goals of CR are\\nmodifying CVD risk factors and improving patient func-\\ntional capacity and QOL with the goal of reducing subse-\\nquent morbidity and mortality. Through a combination of\\nmonitored exercise training, health and nutrition educa-\\ntion, psychological support, and personalized patient\\nassessment, including me dication optimization\\n(Figure 10), CR has been shown to lower the risk of car-\\ndiovascular and all-cause death, reduce hospital read-', 'missions, and to be cost-effective.\\n10,11 Despite its proven\\nbeneﬁts, CR is underutilized and referral rates to CR are\\nlow, especially for women and members of traditionally\\nunderrepresented groups.\\n8 Factors that contribute to this\\noverall low enrollment rate include a poor utilization of a\\ncentralized method for referral via the electronic health\\nrecord, inadequate communication between treatment\\nteams, and perceived inconvenience as well as associated\\ncosts for the patient.', '8 To increase the utilization of CR,\\npatients should be referred to CR during hospitalization\\nfor ACS and prior to discharge.\\n12 To improve access for\\npatients who live in rural locations and in areas with no\\ncenter-based CR, home-based CR options should be\\nconsidered. These home-based CR programs have similar\\nshorter-term safety and clinical outcomes (eg, improve-\\nments in exercise capacity, QOL, blood pressure, choles-\\nterol) as center-based CR.\\n13-15 More intensive CR programs', 'FIGURE 10 Core Components of Cardiac Rehabilitation\\nAdapted with permission from Sandesara et al.30 Copyright 2015 American College of Cardiology Foundation.\\nRecommendations for CR\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\n1A\\n1. Patients with ACS should be\\nreferred to an outpatient CR\\nprogram prior to hospital\\ndischarge to reduce death, MI,\\nhospital readmissions, and\\nimprove functional status and\\nQOL.\\n1-4\\n2a B-R', 'QOL.\\n1-4\\n2a B-R\\n2. In patients with ACS, a home-\\nbased CR program is a reasonable\\nalternative to a center-based CR\\nprogram to improve functional\\nstatus and QOL.\\n5-9\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2197\\nhave been developed with a goal of expanding the bene-\\nﬁts of traditional CR programs through additional exer-\\nc i s ea n de d u c a t i o ns e s s i o n s ,a sw e l la sp l a c i n gag r e a t e r', 'focus on diet and lifestyle factors.\\n16-18 Although improved\\noutcomes have been described with an intensive pro-\\ngram, 16,19 the studies are observational in nature. Both\\ntraditional and intensive CR programs remain underutil-\\nized, so the primary emphasis should be on enrollment\\nand adherence to any CR program.\\n20\\nRecommendation-Speci ﬁc Supportive Text\\n1. Exercise-based CR programs are associated with\\nimproved survival and reduced risk of reinfarction in', 'patients after AMI. 1-4 CR can be enhanced as a\\ncomponent of a multifactorial rehabilitation program\\nwith risk factor education and counseling. Patients\\nwith ACS who participate in CR have signi ﬁcantly\\nbetter outcomes compared with those who do\\nnot.\\n1,21,22 In a meta-analysis of 85 RCTs of exercise-\\nb a s e dC Ri np a t i e n t sw i t hc o r o n a r yh e a r td i s e a s e ,\\nthe intervention reduced risk of MI, reduced all-cause\\nhospitalization, reduced health care costs, and', 'improved health-related QOL outcomes over 12\\nmonths of follow-up.\\n1 Longer follow-up suggested\\nreductions in cardiovascular mortality. 1,4 CR is\\nparticularly bene ﬁcial in older patients with CAD, a\\ngroup that is at a higher risk of losing independence\\nand functioning.\\n23-26\\n2. To overcome challenges that have prevented greater\\npatient participation, new strategies and innovative\\nmodels that utilize digital health tools are emerging to\\nmeet the evolving needs of CR patients. CR programs', 'have traditionally been delivered via center-based CR.\\nThese programs require patients to be physically pre-\\nsent at a facility located in a hospital or outpatient\\ncenter, which limits access for many patients, espe-\\ncially women and some racial and ethnic groups.\\n9,27,28\\nA review of 23 RCTs of home- and center-based CR\\nfound that these programs tend to implement the same\\ncore components.\\n13 These include patient assessment\\nof current medical history, e xercise training, dietary', 'counseling, risk factor management (eg, smoking,\\nlipids, blood pressure, weight, diabetes), and psycho-\\nlogical intervention. Comparison of studies in home-\\nand center-based CR indicate a similar improvement in\\nQOL and no statistically signi ﬁcant difference in the\\nall-cause mortality rate up to 12 months after the\\nintervention.\\n5,6 However, more RCTs are needed with\\nhome-based CR in patients with ACS because of an\\nevidence gap (especially in high-risk patients) in', 'assessing the safety of home-based CR in patients at\\nhigh risk for recurrent ischemic events, as well the\\nimpact of a home-based rehabilitation strategy on\\nclinical outcomes such as cardiovascular death,\\nrecurrent MI, and rehospitalization.\\n29 Advances in\\ntechnology and remote monitoring may help to\\nimprove the ef ﬁcacy and safety of this approach.\\nHybrid models that combine elements of both center-\\nand home-based programs may also offer beneﬁts.\\n11. DISCHARGE: LONG-TERM MANAGEMENT AND', 'SECONDARY PREVENTION\\n11.1. DAPT Strategies in the First 12 Months Postdischarge\\nRecommendations for DAPT Strategies in the First\\n12 Months Postdischarge\\nReferenced studies that support recommendations are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATIONS\\nDefault Duration of DAPT\\n1A\\n1. In patients with ACS who are not\\nat high bleeding risk, DAPT with\\naspirin and an oral P2Y12 inhibi-\\ntor should be administered for at\\nleast 1 year to reduce MACE.\\n1-6\\nBleeding Reduction Strategies\\n1A', '1A\\n2. In patients with ACS who have\\ntolerated DAPT with ticagrelor,\\ntransition to ticagrelor\\nmonotherapy ‡1 month post PCI\\nis useful to reduce bleeding\\nrisk.\\n7-11\\n1A\\n3. In patients at high risk of\\ngastrointestinal bleeding, a pro-\\nton pump inhibitor (PPI) is rec-\\nommended in combination with\\nDAPT, oral anticoagulants, or\\nboth to reduce risk of\\nbleeding.\\n12-15\\n2b B-R\\n4. In patients with ACS undergoing\\nPCI, de-escalation of DAPT\\n(switching from ticagrelor or\\nprasugrel to clopidogrel) after 1', 'month may be reasonable to\\nreduce bleeding risk.\\n16-20\\n2b B-R\\n5. In patients with ACS undergoing\\nPCI who are at high bleeding risk,\\ntransition to single antiplatelet\\ntherapy (aspirin or P2Y12 inhibi-\\ntor) after 1 month may be\\nreasonable to reduce bleeding\\nrisk.\\n21\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2198\\nSynopsis\\nThe addition of an oral P2Y12 inhibitor to aspirin\\n(DAPT) reduces the risk of early and late thrombotic', 'events among patients with ACS regardless of whether\\nthey are managed with an invasive strategy.\\n1-3 Notwith-\\nstanding these salutary bene ﬁts, prolonged exposure to\\nDAPT results in excess bleeding that may lead to DAPT\\ninterruption,\\n22 which in turn may increase the risk of\\nrecurrent ischemic events. 23 Identifying individuals most\\nlikely to realize a net clinical beneﬁto rh a r mf r o mp r o -\\nlonged DAPT has emerged as an important clinical prior-', 'ity. Several tools have been developed that predict the\\nrisk of ischemic and/or bleeding events and may be useful\\nwhen considering how best to personalize care for an in-\\ndividual patient.\\n24-27 Moreover, alternative antiplatelet\\nstrategies have been compare dw i t hc o n v e n t i o n a lD A P T\\nwith the intent to reduce bleeding while maintaining\\nischemic ef ﬁcacy. Growing evidence suggests that a\\nstrategy of aspirin discontinuation with ticagrelor mono-\\ntherapy reduces bleeding.', '7-11 Although clopidogrel mon-\\notherapy has been studied,28,29 interpatient variability in\\npharmacodynamic response to clopidogrel is substantial30\\nand may increase thrombotic risk in certain individuals.\\nTo that end, a strategy of clopidogrel monotherapy may\\nincrease risk of MACE in patients after ACS when\\ncompared with more prolonged DAPT.\\n29 Additional ap-\\nproaches include aspirin monotherapy31,32 or a strategy of\\n“de-escalation ” (ie, switching from ticagrelor or prasugrel', 'to clopidogrel), 16-20 although the safety of these strategies\\nin terms of their effects on risk of MACE is less ﬁrmly\\nestablished. Efﬁcacy and safety of shorter DAPT strategies\\nhave not been rigorously studied in patients not under-\\ngoing PCI. Figure 11 summarizes the guideline recom-\\nmendations for DAPT management in patients with ACS\\nduring the ﬁrst 12 months post discharge.\\nRecommendation-Speci ﬁc Supportive Text\\n1. Patients with ACS are characterized by a sustained\\nprothrombotic state,', '33 thus highlighting the need for\\ncontinued antithromboti c therapy beyond the index\\npresentation. The double-blind placebo-controlled\\nCURE (Clopidogrel in Unstable Angina to Prevent\\nRecurrent Events) trial (n ¼ 12,562) demonstrated that\\nDAPT with clopidogrel yields a consistent reduction in\\nboth early and late composite ischemic events as\\ncompared with aspirin alone among patients with\\nNSTE-ACS who were primarily managed medically.\\n3,34\\nThe treatment effect was consistent among those', 't r e a t e dw i t ho rw i t h o u tr e v a s c u l a r i z a t i o n .4 Subsequent\\nstudies showed that DAPT with prasugrel or ticagrelor\\nadministered for 1 year provides incremental re-\\nductions in ischemic events, albeit with excess\\nbleeding, as compared with clopidogrel.\\n1,2 Although\\nconcordant bene ﬁts were also observed among trial\\nparticipants requiring surgical revascularization, the\\nsafety and efﬁcacy of DAPT should be considered in the', 'context of CABG as a postrandomization event and the\\nhigh proportion of patients who did not resume study\\ndrug after surgery.\\n4-6 An important consideration in\\nextending the results of clinical trials that established\\nthe beneﬁts of DAPT to contemporary cohorts is that\\npatients at elevated risk for bleeding were typically\\nexcluded in early studies. Therefore, the default\\nstrategy for a minimum DAPT duration of 1 year is most\\napplicable to those patients without high bleeding risk', 'presenting with ACS. Moreover, the choice of P2Y12\\ninhibitor may vary in relation to treatment approach,\\nas described in Section 4.3.2 , “Oral P2Y12 Inhibitors\\nDuring Hospitalization. ” In select patients who have\\ntolerated DAPT, it may be reasonable to extend treat-\\nment beyond 1 year after considering risks for long-\\nterm bleeding and thrombosis.\\n35-37\\n2. Results from several randomized trials have consis-\\ntently shown that aspirin withdrawal followed by', 'ticagrelor monotherapy after 1 to 3 months of\\nticagrelor-based DAPT resu lts in less bleeding without\\nclear excess in MACE, as compared with continued\\nDAPT among patients with ACS undergoing PCI.\\n7-11\\nAlthough studies examining this strategy were char-\\nacterized by relatively low rates of ischemic events,\\nstudy-level\\n38 and individual patient data pooled ana-\\nlyses 39-41 have yielded similar results. Although data\\nwith clopidogrel have been mixed, concerns have been', 'raised that a strategy of clopidogrel monotherapy\\nstarted 1 to 2 months after PCI may increase risk of\\nMACE in patients with ACS when compared with longer\\nDAPT.\\n29 It remains unknown whether this may be\\nexplained by excess thrombotic risk in patients dis-\\nplaying inadequate platelet inhibition to clopidogrel,\\nobserved in 30% to 40% of patients after PCI.\\n30,42 Re-\\nsults from a randomized trial showed that a strategy of\\nP2Y12 inhibitor discontinuation followed by aspirin', 'alone after 6 months of DAPT resulted in excess\\nthrombotic risk among patients with ACS undergoing\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2199\\nPCI (n ¼ 2,712; 38% STEMI), albeit with less bleeding.32\\nSimilar ﬁndings were observed with earlier P2Y12 in-\\nhibitor discontinuation 3 months after PCI. 31,43\\nAlthough the on-treatment pharmacodynamic effects\\nof ticagrelor and prasugrel are similar, the safety of', 'prasugrel monotherapy has not been established in\\npatients $1 month post ACS; low-dose prasugrel mon-\\notherapy (3.75 mg daily) in Japanese patients very early\\nafter PCI with ACS or at high bleeding risk may increase\\n30-day MACE compared with DAPT.\\n44\\n3. PPIs reduce the risk of gastrointestinal bleeding among\\npatients receiving aspirin, 14 DAPT, 13 or an oral antico-\\nagulant. 12,15 Because the conversion of clopidogrel to\\nits active metabolite and the metabolism of certain', 'PPIs depend on some common hepatic enzymes (eg,\\nC Y P 2 C 1 9 ) ,t h ep o t e n t i a lf o rad r u g - d r u gi n t e r a c t i o n\\nexists when both agents are coadministered. The re-\\nsults of several ex vivo studies found that clopidogrel-\\ninduced platelet inhibition is attenuated with use of\\ncertain PPIs, a pharmacodynamic effect that is most\\npronounced with omeprazole.\\n45,46 Nonetheless, results\\nfrom a double-blind, placebo-controlled randomized', 'trial showed no signi ﬁcant differences in ischemic\\nevents between omeprazole versus placebo among\\npatients treated with clopidogrel, but PPI use markedly\\ndecreased the risk of gastrointestinal bleeding.\\n13\\nMoreover, post hoc analyses from several randomized\\ntrials have shown that ischemic risk is not increased\\nwhen a clinically indicated PPI is used with clopidog-\\nrel.\\n47,48 Importantly, the antipla telet effects and clin-\\nical ef ﬁcacy of ticagrelor and prasugrel are not', 'appreciably modi ﬁed with concomitant PPI use. 48-50\\nTherefore, it is recommended to administer a PPI in\\npatients with ACS at elevated bleeding risk treated\\nwith DAPT or oral anticoagulant.\\n4. De-escalation implies modulating DAPT intensity by\\nswitching from ticagrelor or prasugrel to clopidogrel.\\n51\\nDe-escalation can be guided by the results of platelet\\nfunction assays that quantify the degree of platelet\\ninhibition among patients treated with clopidogrel.', 'Patients with adequate response may continue to\\nreceive clopidogrel, whereas nonresponders are\\nswitched to a more potent P2Y12 inhibitor. Clopidogrel\\nresponsiveness may also be inferred with use of gen-\\notyping assays that identify polymorphisms in genes\\ninvolved in clopidogrel metabolism.\\n52 Clinical trials\\nexamining guided de-escalation after PCI have either\\nshown a lack of bene ﬁt,16 noninferiority, 20 or re-\\nductions in minor bleeding 17 versus conventional', 'DAPT. By contrast, unguided de-escalation is per-\\nformed without antecedent knowledge of platelet\\nresponsiveness. Randomized trials have suggested that\\nunguided de-escalation 1 month after PCI reduces\\nbleeding without incurring ischemic risk as compared\\nwith longer term prasugrel- or ticagrelor-based\\nDAPT.\\n18,19 Pooled analyses ha ve shown that de-\\nescalation (guided or unguided) yields comparable ef-\\nﬁcacy to DAPT with respect to ischemic events while\\nreducing bleeding.', 'reducing bleeding.\\n53,54 However, trials of ticagrelor\\nand prasugrel have suggested that the beneﬁto fm o r e\\npotent P2Y12 inhibitor therapy extends beyond the\\nearly phase post ACS, but with increased bleeding.\\n1,2,55\\n5. In the MASTER DAPT (Management of High Bleeding\\nRisk Patients Post Bioresorbable Polymer Coated Stent\\nImplantation With an Abbreviated Versus Standard\\nDAPT Regimen) trial, patients at high risk of bleeding\\nwho had completed a 4-week course of DAPT after', 'successful PCI with drug-eluting stents were randomly\\nallocated to single antiplatelet therapy or more pro-\\nlonged DAPT ($2 additional months).\\n21 In the absence\\nof oral anticoagulant use, the choice of discontinuing\\na s p i r i no rP 2 Y 1 2i n h i b i t o ra n dt h ec h o i c eo fP 2 Y 1 2\\nTABLE 22 Academic Research Consortium High Bleeding Risk\\nCriteria After PCI\\nMajor Criteria 26 Minor Criteria\\nAge $75 y\\nAnticipated use of long-term oral\\nanticoagulation (Section 11.1.1,', '“Antiplatelet Therapy in Patients on\\nAnticoagulation Postdischarge”)\\nSevere or end-stage CKD\\n(eGFR <30 mL/min)\\nModerate CKD (eGFR 30-59 mL/min)\\nHemoglobin level<11 g/dL Hemoglobin level 11-12.9 g/dL for men and\\n11-11.9 g/dL for women\\nSpontaneous bleeding requiring\\nhospitalization or transfusion in the past\\n6 mo or at any time, if recurrent\\nSpontaneous bleeding requiring\\nhospitalization or transfusion within the\\npast 12 mo not meeting the major\\ncriterion\\nModerate or severe baseline', 'thrombocytopenia (platelet\\ncount <100 /C2 10\\n9/L)\\nChronic bleeding diathesis\\nLiver cirrhosis with portal hypertension\\nLong-term use of oral NSAIDs or steroids\\nActive malignancy (excluding nonmelanoma\\nskin cancer) within the past 12 mo\\nPrevious spontaneous ICH (at any time)\\nPrevious traumatic ICH within the past 12 mo\\nPresence of a brain arteriovenous\\nmalformation\\nModerate or severe ischemic stroke within\\nthe past 6 mo\\nAny ischemic stroke at any time not meeting\\nthe major criterion', 'the major criterion\\nNondeferrable major surgery on DAPT\\nRecent major surgery or major trauma within\\n30 d before PCI\\nThe presence of at least 1 major or 2 minor criteria helps to identify those at increased risk of\\nbleeding. Modiﬁed with permission from Urban et al.26 Copyright 2019 American Heart Association,\\nInc.\\nCKD indicates chronic kidney disease; DAPT, dual antiplatelet therapy; eGFR, estimated\\nglomerular ﬁltration rate; NSAID, nonsteroidal anti-inﬂammatory drugs; ICH, intracranial hemor-', 'rhage; and PCI, percutaneous coronary intervention.\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2200\\ninhibitor was at the discretion of the treating physi-\\nc i a n .A no r a la n t i c o a g u l a n tw a su s e di n3 6 . 4 %o fp a -\\ntients, and clopidogrel monotherapy was selected in\\n53.9% of patients randomized to abbreviated DAPT.\\nCompared with standard therapy, an abbreviated an-', 'tiplatelet strategy demonstrated noninferiority with\\nrespect to composite ischemic events and superiority\\nregarding clinically rele vant bleeding over 1 year.\\nAmong patients with ACS (n ¼ 1,780; 30% STEMI)\\nallocated to an abbreviated strategy, clinicians selected\\na potent P2Y12 inhibitor with ticagrelor use in\\napproximately 25% of patients.\\n56 Results in the ACS\\ncohort were qualitatively consistent with the overall\\ntrial results with respect to both ischemic and bleeding', 'o u t c o m e s .A l t h o u g ht h et r i a ld e m o n s t r a t e dn o n -\\ninferiority for abbreviated DAPT with respect to MACE\\nin patients at high bleeding risk, it was underpowered\\nto determine the relative safety of discontinuing\\naspirin versus P2Y12 inhibitor. Multiple studies have\\nidenti ﬁed clinical and laboratory predictors of bleeding\\nand/or ischemic risk.\\n24-27 The Academic Research\\nConsortium determined 20 correlates of bleeding and\\nproposed a consensus-based de ﬁnition of high', 'bleeding risk as the presence of having at least 1 major\\nor 2 minor criteria at time of PCI (Table 22).\\n26\\n11.1.1. Antiplatelet Therapy in Patients on Anticoagulation\\nPostdischarge\\nFIGURE 11 DAPT Strategies in the First 12 Months Postdischarge\\nColors correspond to Class of Recommendation inTable 2. *High bleeding risk discussed inSection 11.1, “Recommendation-Speciﬁc Supportive Text” item 5, and', 'outlined inTable 22. ACS indicates acute coronary syndromes; DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; and\\nSAPT, single antiplatelet therapy.\\nRecommendation for Antiplatelet Therapy in Patients on\\nAnticoagulation Postdischarge\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n1 B-R\\n1. In patients with ACS who require\\noral anticoagulant therapy,\\naspirin should be discontinued', 'after 1 to 4 weeks of triple\\nantithrombotic therapy, with\\ncontinued use of a P2Y12 inhibi-\\ntor (preferably clopidogrel) and\\nan oral anticoagulant to reduce\\nbleeding risk. *\\n1-5\\n*Modiﬁed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery\\nRevascularization.”6\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2201\\nSynopsis\\nPatients after ACS may frequently have indications\\nfor anticoagulant therapy, including AF, venous', 'thromboembolism, and prosthetic heart valves.\\nBleeding risks are increased in the setting of triple\\ntherapy with the combination of aspirin, P2Y12 in-\\nhibitor, and anticoagulant. Therefore, the bene ﬁts of\\nthese therapies must be weighed against the risk of\\nbleeding. A growing number of studies have demon-\\nstrated the overall safety of a strategy of aspirin\\ndiscontinuation 1 to 4 weeks after ACS or PCI in pa-\\ntients who require anticoagulation after ACS.\\n1-5 For', '1-5 For\\nmost patients, a DOAC will be preferred over a\\nvitamin K antagonist due to their favorable ef ﬁcacy\\nand safety pro ﬁle.7 Trials of more potent P2Y12 in-\\nhibitors (ie, prasugrel and ticagrelor) excluded patients\\nrequiring long-term anticoag ulation; therefore, clopi-\\ndogrel is generally favored as the P2Y12 inhibitor in\\nthis setting for most patients. The decision whether to\\ncontinue anticoagulant with or without antiplatelet\\ntherapy >12 months after ACS is addressed in the', '“2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for\\nthe Management of Patients with Chronic Coronary\\nDisease. ”\\n8\\nRecommendation-Speci ﬁc Supportive Text\\n1. Several RCTs have demonstrated that the discontinua-\\ntion of aspirin 1 to 4 weeks after PCI reduces the risk of\\nbleeding in patients with AF with an indication for\\nDAPT and an oral anticoagulant.1-5 Although individual\\nstudies were not powered for ischemic endpoints,', 'm e t a - a n a l y s e sa c r o s sr a n d o m i z e dt r i a l ss u g g e s tn o\\ndifference in mortality, stroke, and overall MACE when\\naspirin is discontinued for patients on an oral antico-\\nagulant, albeit with a marginal apparent increase in MI\\nand stent thrombosis.\\n9-14 An analysis of stent throm-\\nbosis rates suggested that 80% of events occurred\\nwithin 30 days of PCI, with stent thrombosis events\\nnumerically less frequent in those receiving aspirin', '(randomization was approximately 1 week after PCI)\\nc o m p a r e dw i t hp l a c e b oi nt h eA U G U S T U S( A n t i t h -\\nrombotic Therapy After Acute Coronary Syndrome or\\nPCI in Atrial Fibrillation) trial.\\n15,16 Therefore, in pa-\\ntients with a high risk of stent thrombosis, aspirin for\\nup to 30 days after PCI could be considered. P2Y12 in-\\nhibitor therapy should be continued for at least 12\\nmonths after PCI following aspirin discontinuation but', 'could be discontinued earlier in those with multiple\\nrisk factors for bleeding.\\n17,18\\n11.2. Reassessment of Lipid Levels Postdischarge\\nSynopsis\\nAggressive LDL-C lowering is an important component\\nof secondary CVD prevention. For every 1.0-mmol/L (w39\\nmg/dL) reduction of LDL-C, an approximate 22% relative\\nreduction in cardiovascular events is observed over a\\nperiod of 4 to 5 years.\\n2 Despite the growing number of\\nlipid-lowering therapies currently available, many', 'patients with ACS do not achieve target LDL-C levels.\\n4,5\\nThe reasons are varied but include underprescribing by\\nproviders, cost or insuf ﬁcient coverage by medical in-\\nsurance companies, and intolerance to therapies. Many\\npatients are also unwilling or unable to readily ﬁll pre-\\nscriptions at pharmacies or patients self-discontinue\\ntherapy early. Providers are not always aware of the bar-\\nriers that patients may be experiencing; therefore, a', 'conversation between clinician and patient is important\\nto help improve adherence. If adverse effects are experi-\\nenced, consideration should be given to subsequent\\nrechallenge at each visit or changing to a different type of\\nstatin or class of lipid-lowering therapy. Statin intoler-\\nance requires exposure to at least 2 different statins with 1\\nprescribed at the lowest available dose. Because risk of\\nMACE is elevated in the early months after ACS, early', 'follow-up visits are important for making appropriate\\nchanges to lipid-lowering therapy to help achieve desired\\nLDL-C targets ( Section 4.5 , “Lipid Management ”).\\nImportantly, lipid-lowering therapies should not be\\ndowntitrated in response to very low LDL-C concentra-\\ntions, because current evidence supports that those with\\nvery low LDL-C concentrations are at lowest risk of MACE\\nwithout any clear safety concern.\\n6-9\\nRecommendation-Speci ﬁc Supportive Text', '1. Use of high-potency statin therapy has been shown to\\nreduce MACE with the beneﬁt appearing early after ACS\\nand persisting with time.10 To date, evidence suggests\\nthe beneﬁt of lowering LDL-C concentrations may be\\nRecommendation for Reassessment of Lipid Levels\\nPostdischarge\\nCOR LOE RECOMMENDATION\\n1 C-LD\\n1. In patients after ACS, a fasting\\nl i p i dp a n e li sr e c o m m e n d e d4t o\\n8 weeks after initiation or dose\\nadjustment of lipid-lowering\\ntherapy to assess response or', 'adherence to therapy. *\\n1,2\\n*Modiﬁed from the“2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/\\nNLA/PCNA Guideline on the Management of Blood Cholesterol.”3\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2202\\nirrespective of whether it is achieved through high-\\npotency statins or other lipid-lowering therapies;\\nhowever, the largest body of evidence exists with statin\\ntherapies. As such, early intensi ﬁcation of lipid-', 'lowering therapy after ACS is justi ﬁed. In clinical\\npractice, statin-eligible patients remain undertreated\\nor untreated.\\n1,11 Early and frequent follow-up,\\nincluding lipid testing, is associated with improved\\nadherence to lipid-lowering therapies.\\n1 In the PALM\\n(Provider Assessment of Lipid Management) registry,\\nless than one-half of adults were on the statin intensity\\nrecommended by the guidelines.\\n12 In a study of U.S.\\nveterans with a history of ACS or coronary revascular-', 'ization, less than one-half of patients received inten-\\nsiﬁcation of lipid-lowering therapy (41.9% at 3 months\\nversus 47.3% at 1-year postdischarge). 5 High patient\\ncopays and poor coverage of newer lipid-lowering\\ntherapies by some prescription plans are factors\\ncontributing to suboptimal LDL target attainment. To\\nthat end, out-of-pocket costs should be veri ﬁed and\\ndiscussed with patients before they ﬁll a prescription\\nfor a new lipid-lowering therapy. Education about the', 'importance of lipid-lowering therapies should be dis-\\ncussed with patients at visits to allow them the op-\\nportunity to ask questions and review potential\\nbarriers. For the management of lipid-lowering therapy\\ninitiated prior to discharge and continued after hospital\\ndischarge, refer to Section 4.5, “Lipid Management. ”\\n11.3. SGLT-2 Inhibitors and GLP-1 Receptor Agonists\\nSynopsis\\nThe cardiovascular bene ﬁts of both sodium glucose\\ncotransporter-2 (SGLT-2) inhibitors and glucagon-like', 'peptide-1 (GLP-1) receptor ag onists are well documented\\nin stable patients with ASCVD and type 2 diabetes,\\n1-6 as\\nwell as in patients with HF regardless of diabetes\\nstatus.\\n7-11 GLP-1 receptor agonists may lead to weight loss\\nin many patients, and semaglutide has been shown to\\nr e d u c et h er i s ko fM A C Ei no v e r w e i g h to ro b e s ep a t i e n t s\\nwith stable ASCVD but has not been studied early after\\nACS.\\n12 SGLT-2 inhibitors may increase the risk of urinary', 'tract infection, genital myco tic infection, hypovolemia,\\nand acute kidney injury (while offering longer term renal\\nbeneﬁt in patients with diabetes). Due to a higher risk of\\ndiabetic and euglycemic ketoacidosis in the perioperative\\nperiod, canagli ﬂozin, dapagli ﬂozin, and empagli ﬂozin\\nshould be stopped$3d a y sa n de r t u g l iﬂozin $4d a y sp r i o r\\nto scheduled surgery, including CABG.\\n13-15\\nThe efﬁcacy and safety of SGLT-2 inhibitors have now', 'been studied in 2 large trials of patients after MI. In pa-\\ntients without diabetes or HF, dapagli ﬂozin was not\\nshown to reduce the risk of cardiovascular death or HF\\nhospitalization in patients with AMI and impaired LV\\nsystolic function.\\n16 Similarly, empagli ﬂozin did not\\nsigni ﬁcantly reduce all-cause death or ﬁrst HF hospitali-\\nzation in patients without prior HF who were hospitalized\\nwith AMI and found to have impaired LV systolic function', 'with or without signs of congestion. However, empagli-\\nﬂozin did reduce HF hospitalizations in this population.\\n17\\nNo new safety concerns were identiﬁed. Therefore, use of\\nan SGLT-2 inhibitor does not need to be deferred in pa-\\ntients with an indication for its use at hospital discharge.\\n11.4. Use of Chronic Colchicine\\nSynopsis\\nColchicine is a botanical-derived anti-in ﬂammatory\\nagent that has been used for millennia in the treatment of\\ngout. Colchicine reduces neutrophil adhesion to endo-', 'thelial cells and platelets and has been shown to reduce\\nhigh-sensitivity C-reactive protein concentration and\\nlow-attenuation plaque volume in patients already on\\naspirin and statin therapy.\\n6-9 Colchicine is associated with\\na lower risk of MI in patients with gout, as well as in pa-\\ntients with CAD, including those with prior MI.\\n1,4,5,10,11\\nAlthough gastrointestinal events were historically re-\\nported at a higher rate in patients on colchicine, this rate', 'does not differ from placebo at the lower once daily\\ndosing.\\n5 A meta-analysis of the studies examining\\ncolchicine in patients with CAD reported no difference in\\nall-cause death with colchicine versus placebo, but a\\nnonsigni ﬁcant trend was observed toward an increased\\nrisk of noncardiovascular death that requires further\\nstudy.\\n5 To date, no potential pathogeneses of the non-\\ncardiovascular deaths have been consistently shown to\\nexplain the numerical differences in noncardiovascular\\ndeath.\\n5', 'death.\\n5\\nRecommendation-Speci ﬁcS u p p o r t i v eT e x t\\n1. COLCOT (Colchicine Cardiovascular Outcomes Trial)\\nrandomized patients #30 days (median, 14 days) after\\nMI to low-dose colchicine versus placebo. 2 Colchicine\\nreduced the primary outcome of cardiovascular death,\\nRecommendation for Use of Chronic Colchicine\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n2b B-R\\n1. In patients after ACS, low-dose', 'colchicine may be reasonable to\\nreduce risk of MACE.\\n1-5\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2203\\nresuscitated cardiac arrest, MI, stroke, or urgent coro-\\nnary revascularization by 32% (median follow-up, 22.6\\nmonths). Although directional consistency was seen\\nacross individual components, this bene ﬁtw a sd r i v e n\\nby a reduction in hospitalizations for angina requiring\\nrevascularization and stroke. The smaller COPS', '(Colchicine in Patients With ACS) study randomized\\npatients during their index hospitalization of ACS to\\ncolchicine versus placebo.\\n3 The primary endpoint of all-\\ncause death, ACS, unplanned ischemia-driven urgent\\nrevascularization, and noncardioembolic ischemic\\nstroke was numerically, but not signiﬁcantly, lower for\\npatients on colchicine (P ¼ 0.09). Although deaths were\\ninfrequent, more deaths occurred for patients on\\ncolchicine than on placebo (8 versus 1; P ¼ 0.017) due', 'to more noncardiovascular deaths. In a post hoc\\nanalysis, the composite outcome of cardiovascular\\ndeath, ACS, stroke, or urgent revascularization was\\nlower for colchicine than placebo. The LoDoCo2 (Low-\\nDose Colchicine-2) trial enrolled patients with stable\\n(>6 months) coronary disease, demonstrating a\\nreduction in the composite of cardiovascular death,\\nMI, ischemic stroke, or ischemia-driven coronary\\nrevascularization with col chicine (median follow-up,', '28.6 months); ﬁndings were consistent in the 84% of\\npatients with prior ACS.\\n4,12 Pooled data from these\\nlarge trials con ﬁrmed a reduction in the incidence of\\nMACE with colchicine versus placebo. 5 Colchicine\\nshould not be administered in patients with blood\\ndyscrasias, renal failure (creatinine clearance <15 mL/\\nmin), severe hepatic impairment, or with concomitant\\nP-glycoprotein and/or st rong CYP3A4 inhibitors.\\nAlthough the trials studied a dose of 0.5 mg daily,', 'daily dosing of 0.5 mg or 0.6 mg may be considered.\\nThere are ongoing trials studying the ef ﬁcacy of\\ncolchicine in patients after MI.\\n11.5. Immunization\\nSynopsis\\nInﬂuenza infection is associated with increased risks of\\ncardiovascular morb idity and mortality.\\n5 Previous studies\\nhave shown that in ﬂuenza infection may contribute to\\natherogenesis and plaque destabilization, thereby\\nprecipitating the occurrence of ACS. 6,7 Inﬂuenza vaccine\\nhas been shown to reduce the risk of death and MACE in', 'patients after ACS and ASC V Da n ds h o u l dt h e r e f o r eb e\\nadministered in patients without contraindication.\\n1-3,5,8\\nO t h e ri l l n e s s e ss u c ha sC O V I D - 1 9a n dp n e u m o c o c c a l\\npneumonia increase risk of cardiovascular events and\\ndeath in patients with ASCVD. However, randomized trial\\ndata are lacking to support routine administration of\\nother vaccines for patients at time of hospitalization for\\nACS. As such, regular immunization schedules are sup-', 'ported for all patients per the U.S. Centers for Disease\\nControl and Prevention recommendations in the absence\\nof contraindication.\\n9\\nRecommendation-Speci ﬁc Supportive Text\\n1. In the FLUVACS (Flu Vaccination in Acute Coronary\\nSyndromes and Planned Percutaneous Coronary In-\\nterventions) study, cardiovascular death was lower in\\npatients who received inﬂuenza vaccination compared\\nwith the control group at both 6-month (2% versus 8%)\\nand 1-year follow-up (6% versus 17%). The triple com-', 'posite endpoint of cardiovascular death, nonfatal MI,\\nand rehospitalization for severe recurrent ischemia at 1\\nyear was signi ﬁcantly lower in the vaccine group\\nc o m p a r e dw i t hc o n t r o l s .\\n2,10 Among patients admitted\\nwith MI or high-risk coronary heart disease, inﬂuenza\\nvaccine administered within 72 hours of an invasive\\ncoronary procedure or hospitalization resulted in a\\nlower risk of the composite primary outcome of all-\\ncause death, MI, or stent thrombosis and a lower risk', 'of cardiovascular death compared with placebo at 1\\nyear.\\n1\\n12. EVIDENCE GAPS AND FUTURE DIRECTIONS\\nThe treatment of ACS has been the subject of thousands of\\nclinical trials comprising very large numbers of patients.\\nAs such, its management is guided by the largest evidence\\nbase in clinical medicine. Despite this, there are\\nnumerous unanswered questions, evidence gaps, and\\nareas for further study. Some of these areas have been\\naddressed by observational studies but were not included', 'in this guideline because the LOE was insuf ﬁcient to\\nguide clinical practice. Other areas were not included\\nbecause they are less well de ﬁned and require more\\ndetailed study. This section summarizes some higher\\npriority evidence gaps and areas for future study.\\nRecommendation for Immunization\\nReferenced studies that support recommendation are\\nsummarized in the Evidence Table .\\nCOR LOE RECOMMENDATION\\n1A\\n1. In patients with ACS without a\\ncontraindication, annual in ﬂu-', 'enza vaccination is recommended\\nto reduce the risk of death and\\nMACE. 1-4\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2204\\nINITIAL EVALUATION AND MANAGEMENT\\nAlthough the 2025 ACS guideline recognizes the value of\\nrisk scores in estimating the risk of death or recurrent MI,\\nlimited prospective randomized data are available as to\\nwhether risk scores should be used to determine treat-', 'ment strategies. The highest risk patients are those who\\npresent after a cardiac arrest. Although the data support\\nan invasive approach in patients who have been resusci-\\ntated and who have evidence of ST-segment elevation on\\nthe postarrest ECG, any potential bene ﬁto fc o r o n a r y\\nangiography may be attenuated in those who are coma-\\ntose. Similarly, it is less clear whether reperfusion with\\neither ﬁbrinolysis or primary PCI provides clinical beneﬁt', 'in patients with ST-segment elevation who present late\\nafter symptom onset (12 to 48 hours) but who are no\\nlonger symptomatic. Further research is needed to deﬁne\\nthe role of coronary angiography and revascularization in\\nthese patient subgroups.\\nIn-Hospital Management of ACS\\nPatients with ACS are placed on telemetry to monitor for\\nlife-threatening arrhythmias or for rhythm disturbances\\nthat may require further the rapy (eg, atrioventricular', 'block, AF). Given the length of stay for most patients with\\nACS has decreased signiﬁc a n t l y ,t h eo p t i m a ld u r a t i o no f\\ntelemetry monitoring with contemporary management is\\nunclear. The increasingly rapid triage and timing of\\ninvasive risk strati ﬁcation also calls into question the\\nvalue of “preloading ” of oral P2Y12 inhibitors, with pre-\\nloading deﬁned as administering the loading dose prior to\\ncoronary angiography. As ou tlined in this document,', 'clinical trials of preloading have not shown a compelling\\nbeneﬁt when coronary angiography occurs rapidly after\\nthe patient ’s clinical presentation. Nonetheless, the\\npharmacodynamic effects of clopidogrel are delayed due\\nto its need to be metabolized to its active metabolite, and\\nthere are reports that the antiplatelet effects of all P2Y12\\ninhibitors may be delayed in patients with STEMI. In this\\ncontext, parenteral P2Y12 inhibition could be considered', 'but has not yet been compared to a strategy of more\\npotent oral P2Y12 inhibitor administration. Other drug\\ntherapies in need of further evaluation in the ACS setting\\ninclude the utility of sacubitril-valsartan, nonstatin lipid-\\nlowering therapies (including clinical outcome studies for\\nPCSK9 inhibitors early after ACS), and GLP-1 receptor\\nagonists for reducing short- and long-term MACE after\\nACS. The clinical beneﬁt of beta blockers in the setting of', 'patients with NSTE-ACS requires further study, as well as\\nthe optimal duration of their use after ACS.\\nFor patients with MVD found during coronary angiog-\\nraphy, there are several remaining gaps in evidence. In\\npatients with NSTEMI, the role of multivessel PCI versus\\nculprit-only PCI needs further supportive data. As a cor-\\nollary, whether multivessel PCI in the ACS setting should\\nbe guided by angiography or physiology is still a matter of\\ndebate. Finally, as noted in this guideline, the recom-', 'mendations for PCI of nonculprit arteries in patients with\\nSTEMI are for patients who are not intended for CABG,\\nwhich is a qualiﬁer based on the inclusion criteria of the\\nrandomized trials. The optimal strategy for patients who\\nhave more complex anatomy is less clear.\\nThe 2025 ACS guideline includes a new recommenda-\\ntion regarding the management of cardiogenic shock us-\\ning the microaxial ﬂow pump MCS device. Because the\\nbeneﬁt of this device was offset by an increase in serious', 'complications, more data are needed to guide the selec-\\ntion of patients for MCS, the timing of MCS placement and\\nduration of support, and strategies to reduce the risks of\\nvascular complications, ble eding, and limb ischemia.\\nDISCHARGE STRATEGIES AND\\nSECONDARY PREVENTION\\nOne of the most important areas needing further clariﬁ-\\ncation is the timeline deﬁning the transition of a patient\\nfrom ACS to chronic coronary syndrome. The 2025 ACS\\nguideline does not de ﬁne this largely because no data', 'exist to guide any recommendations. Moreover, it is likely\\nthat this transition is highly individualized and accounts\\nfor the patient’s risk at initial presentation, the status of\\nresidual unrevascularized CAD, control of cardiovascular\\nrisk factors, and bleeding risk with continued antith-\\nrombotic therapy. Once a patient is deemed to have\\nJACC VOL. 85, NO. 22, 2025 Rao et al\\nJUNE 10, 2025:2135 – 2237 2025 Acute Coronary Syndromes Management Guideline\\n2205', '2205\\ntransitioned to having a “chronic coronary syndrome, ”\\nthe question of how to or whether to de-escalate anti-\\nplatelet therapies is unclear. These decisions may also be\\ninﬂuenced by complications of ACS requiring additional\\nantithrombotic therapy such as LV thrombus from a large\\nanterior wall MI. The role of DOACs in this setting appears\\nprudent but is not supported by a robust body of data.\\nOther complications such as post-MI pericarditis now', 'have several therapeutic options, but no comparative data\\nare available to help determine which approach is\\noptimal.\\nWith respect to long-term secondary prevention, more\\nresearch is needed to determine whether home-based CR\\nprovides the same beneﬁt as facility-based programs and\\nresults in higher rates of adherence. Randomized trials of\\nGLP-1 receptor agonists post MI will be important to un-\\nderstand the role of these agents in reducing long-term', 'risk in patients with diabetes or those who are over-\\nweight or with obesity. Finally, data are lacking on the use\\nof high-dose aspirin in those with post-MI pericarditis,\\na n da d d i t i o n a ld a t aw o u l db eu s e f u lt oc o nﬁrm the efﬁ-\\ncacy of colchicine post ACS.\\nPRESIDENTS AND STAFF\\nAmerican College of Cardiology\\nCathleen Biga, MSN, FACC, President\\nCathleen C. Gates, Chief Executive Ofﬁcer\\nRichard J. Kovacs, MD, MACC, Chief Medical Ofﬁcer', 'Justine Varieur Turco, Divisional Vice President, Scientiﬁc\\nPublications and Guidelines\\nMindy J. Saraco, MHA, Director, Clinical Policy and\\nGuidelines\\nG r a c eD .R o n a n ,S e n i o rP r o d u c t i o na n dO p e r a t i o n s\\nManager, Clinical Policy Publications\\nLeah Patterson, Project Manager, Clinical Content\\nDevelopment\\nAmerican College of Cardiology/American Heart Association\\nThomas S.D. Getchius, National Senior Director,\\nGuidelines', 'Guidelines\\nAbdul R. Abdullah, MD, Director, Guideline Science and\\nMethodology\\nAmerican Heart Association\\nKeith Churchwell, MD, FAHA, President\\nNancy Brown, Chief Executive Ofﬁcer\\nMariell Jessup, MD, FAHA, Chief Science and Medical\\nOfﬁcer\\nNicole Aiello Sapio, EdD, Executive Vice President,\\nOfﬁce of Science Strategies and Operations\\nR a d h i k aR a j g o p a lS i n g h ,P h D ,S e n i o rV i c eP r e s i d e n t ,\\nOfﬁce of Science and Medicine\\nPrashant Nedungadi, BPharm, PhD, National Vice', 'President, Science and Medicine, Clinical Guidelines\\nP a u lS t .L a u r e n t ,D N P ,R N ,N a t i o n a lV i c eP r e s i d e n t ,\\nOfﬁce of Science and Medicine\\nJody Hundley, Senior Production and Operations\\nManager, Scienti ﬁcP u b l i c a t i o n s ,O fﬁce of Science\\nOperations\\nRao et al JACC VOL. 85, NO. 22, 2025\\n2025 Acute Coronary Syndromes Management Guideline JUNE 10, 2025:2135 – 2237\\n2206'], 'uris': None, 'included': ['metadatas', 'documents'], 'data': None, 'metadatas': [{'start_index': 0, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 471, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 938}, {'start_index': 1404, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 1872}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 2365}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 2809}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 3294}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 3784}, {'start_index': 4273, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 4771}, {'start_index': 5257, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 5728, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 6194, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 6693, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 7137}, {'start_index': 7598, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 8073}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 8461}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 8810}, {'start_index': 9166, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 9525}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 9930}, {'start_index': 10423, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 10867}, {'start_index': 11314, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 11765, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 12246}, {'start_index': 12712, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 13211, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 13685}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 14181}, {'start_index': 14669, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 15165, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 15630}, {'start_index': 16105, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 16492, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 16971, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 17422, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 17897, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 18300, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 18794, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 19156, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 19637, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 20088, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 20571}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 21027}, {'start_index': 21509, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 21979, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 22447, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 22927}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 23393}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 23886}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 24373}, {'start_index': 24869, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 25352, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 25832}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 26326}, {'start_index': 26793, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 27270}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 27756}, {'start_index': 28243, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 28742}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 29211}, {'start_index': 29700, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 30148, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 30591, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 31078}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 31577}, {'start_index': 32048, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 32544}, {'start_index': 33023, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 33487, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 33960, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 34451}, {'start_index': 34930, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 35385}, {'start_index': 35835, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 36312, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 36807, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 37306, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 37751}, {'start_index': 38196, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 38651}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 39139}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 39596}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 40092}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 40578}, {'start_index': 41033, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 41479}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 41975}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 42456}, {'start_index': 42936, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 43422, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 43902}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 44243}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 44677}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 45139}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 45617}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 46091}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 46577}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 47044}, {'start_index': 47520, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 48019}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 48513}, {'start_index': 49008, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 49479, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 49936, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 50428}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 50921}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 51416}, {'start_index': 51909, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 52405}, {'start_index': 52891, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 53358}, {'start_index': 53855, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 54327, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 54787}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 55242}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 55699}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 56181}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 56645}, {'start_index': 57139, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 57590, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 58071, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 58512, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 58947}, {'start_index': 59437, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 59936}, {'start_index': 60420, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 60864}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 61338}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 61788}, {'start_index': 62263, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 62675, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 63147}, {'start_index': 63613, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 64103}, {'start_index': 64599, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 65086}, {'start_index': 65537, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 65980, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 66446, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 66907}, {'start_index': 67402, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 67884}, {'start_index': 68383, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 68875, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 69335}, {'start_index': 69764, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 70225, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 70725}, {'start_index': 71208, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 71669, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 72164}, {'start_index': 72621, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 73119, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 73595, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 74061}, {'start_index': 74540, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 75030}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 75488}, {'start_index': 75959, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 76417}, {'start_index': 76890, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 77367}, {'start_index': 77857, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 78349, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 78806, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 79265}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 79720}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 80190}, {'start_index': 80643, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 81115, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 81591, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 82086, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 82562}, {'start_index': 83054, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 83519}, {'start_index': 83980, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 84425}, {'start_index': 84893, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 85382, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 85844}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 86341}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 86813}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 87305}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 87783}, {'start_index': 88266, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 88732}, {'start_index': 89180, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 89680, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 90129, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 90588}, {'start_index': 91086, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 91515}, {'start_index': 91921, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 92390}, {'start_index': 92855, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 93320}, {'start_index': 93801, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 94268}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 94730}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 95199}, {'start_index': 95659, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 96151, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 96637}, {'start_index': 97092, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 97559, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 98052, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 98514, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 98982, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 99432, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 99899, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 100383, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 100851}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 101323}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 101801}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 102281}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 102771}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 103222}, {'start_index': 103699, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 104195}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 104655}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 105098}, {'start_index': 105455, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 105947}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 106419}, {'start_index': 106907, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 107372}, {'start_index': 107823, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 108297}, {'start_index': 108767, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 109229, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 109725, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 110180}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 110663}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 111130}, {'start_index': 111558, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 112006, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 112502, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 112963, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 113422}, {'start_index': 113870, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 114349, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 114848, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 115346, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 115837}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 116319}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 116785}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 117268}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 117722}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 118199}, {'start_index': 118680, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 119172, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 119669, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 120154}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 120647}, {'start_index': 121103, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 121557}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 122040}, {'start_index': 122539, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 123032}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 123526}, {'start_index': 123996, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 124484, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 124825, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 125319, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 125804}, {'start_index': 126304, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 126791}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 127283}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 127775}, {'start_index': 128264, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 128757, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 129241, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 129730, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 130207, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 130694}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 131183}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 131637}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 132115}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 132569}, {'start_index': 133069, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 133546, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 134002}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 134466}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 134927}, {'start_index': 135409, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 135853, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 136322}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 136784}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 137281}, {'start_index': 137777, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 138239, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 138738}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 139229}, {'start_index': 139728, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 140189}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 140689}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 141141}, {'start_index': 141587, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 142050, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 142550, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 143049, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 143523, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 144023, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 144498}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 144964}, {'start_index': 145423, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 145914, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 146401}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 146901}, {'start_index': 147360, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 147851, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 148330}, {'start_index': 148830, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 149295, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 149772, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 150269, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 150733, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 151227, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 151675}, {'start_index': 152142, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 152604}, {'start_index': 153093, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 153534}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 153997}, {'start_index': 154458, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 154916, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 155383, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 155855}, {'start_index': 156321, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 156778, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 157260, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 157725, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 158174, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 158651, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 159122, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 159608}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 160106}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 160581}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 161067}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 161551}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 162014}, {'start_index': 162404, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 162885, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 163327, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 163811}, {'start_index': 164310, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 164791, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 165269, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 165750}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 166206}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 166701}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 167177}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 167646}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 168144}, {'start_index': 168621, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 169111, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 169563}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 170039}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 170519}, {'start_index': 170988, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 171471, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 171966, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 172427, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 172899, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 173375, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 173864}, {'start_index': 174323, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 174816, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 175275, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 175752, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 176236}, {'start_index': 176728, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 177226, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 177693}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 178173}, {'start_index': 178629, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 179129}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 179601}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 180098}, {'start_index': 180576, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 181066, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 181537, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 181995}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 182444}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 182889}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 183389}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 183860}, {'start_index': 184310, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 184796}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 185280}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 185778}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 186259}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 186727}, {'start_index': 187204, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 187672}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 188133}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 188598}, {'start_index': 189058, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 189554, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 190053}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 190545}, {'start_index': 191034, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 191533, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 192033}, {'start_index': 192502, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 192980}, {'start_index': 193428, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 193910, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 194379}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 194864}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 195327}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 195814}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 196314}, {'start_index': 196787, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 197286}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 197759}, {'start_index': 198259, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 198756, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 199222, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 199715, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 200190, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 200667}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 201156}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 201627}, {'start_index': 202105, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 202591}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 203059}, {'start_index': 203487, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 203971, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 204423}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 204895}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 205383}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 205879}, {'start_index': 206376, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 206857}, {'start_index': 207331, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 207739, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 208238}, {'start_index': 208734, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 209207}, {'start_index': 209687, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 210184, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 210677}, {'start_index': 211161, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 211650}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 212125}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 212614}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 213096}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 213571}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 214046}, {'start_index': 214529, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 215003}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 215489}, {'start_index': 215964, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 216432, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 216931, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 217368}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 217830}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 218314}, {'start_index': 218784, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 219241, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 219690}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 220184}, {'start_index': 220678, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 221167}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 221666}, {'start_index': 222132, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 222619, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 223091, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 223577, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 224061, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 224535}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 225005}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 225490}, {'start_index': 225949, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 226444}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 226920}, {'start_index': 227377, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 227824, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 228311}, {'start_index': 228788, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 229253, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 229699}, {'start_index': 230156, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 230614}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 231068}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 231543}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 232030}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 232474}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 232905}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 233364}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 233848}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 234302}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 234798}, {'start_index': 235293, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 235748}, {'start_index': 236233, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 236687}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 237154}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 237608}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 238097}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 238577}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 239034}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 239529}, {'start_index': 240011, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 240496}, {'start_index': 240965, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 241447}, {'start_index': 241908, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 242390}, {'start_index': 242882, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 243366, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 243836, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 244327}, {'start_index': 244819, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 245314, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 245811, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 246266, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 246753}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 247235}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 247731}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 248221}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 248670}, {'start_index': 249155, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 249616}, {'start_index': 250087, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 250562, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 251045, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 251522, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 251975}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 252453}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 252915}, {'start_index': 253381, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 253838}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 254313}, {'start_index': 254792, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 255278, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 255744}, {'start_index': 256243, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 256699}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 257175}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 257671}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 258070}, {'start_index': 258564, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 259056, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 259515, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 260001}, {'start_index': 260421, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 260881, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 261334, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 261801}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 262248}, {'start_index': 262706, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 263168, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 263651}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 264144}, {'start_index': 264625, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 265103, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 265591, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 266067}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 266522}, {'start_index': 266972, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 267467, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 267929}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 268418}, {'start_index': 268887, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 269387}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 269866}, {'start_index': 270325, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 270795, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 271292, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 271774, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 272263, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 272757}, {'start_index': 273244, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 273718, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 274173}, {'start_index': 274630, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 275075, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 275543, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 276001, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 276456}, {'start_index': 276956, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'start_index': 277442, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 277937}, {'start_index': 278394, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 278847}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 279299}, {'start_index': 279755, 'source': '/content/extracted/data/files/no_take_home/doc1.pdf'}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 280190}, {'source': '/content/extracted/data/files/no_take_home/doc1.pdf', 'start_index': 280684}]}\n"]}]},{"cell_type":"code","source":["def experiment_2(model, tokenizer, vector_db, doc_dir, k):\n","  results = []\n","  doc_names = os.listdir(doc_dir)\n","  doc_names = [doc.split(\".\")[0] for doc in doc_names]\n","\n","  qa_objects = os.listdir(QA_DIR)\n","  for doc in doc_names:\n","    print(doc)\n","    qa_object = [qa for qa in qa_objects if doc + \".json\" in qa][0]\n","    with open(os.path.join(QA_DIR, qa_object), \"r\") as f:\n","      data = json.load(f)\n","\n","    questions = data[\"questions\"]\n","    answers = data[\"answers\"]\n","\n","    # delete the relevant doc out of the RAG\n","    chunks = delete_doc_from_vector_db(vector_db, doc + \".pdf\")\n","\n","    for i, question in enumerate(questions):\n","      print(f\"Question {i+1}/{len(questions)}\")\n","      prompt = create_prompt(question, k, vector_db)\n","      generated_text, logprobs_list = get_answer_and_token_probs(model, tokenizer, prompt)\n","\n","      results.append({\n","          \"id\": f\"{doc}_question_{i}\",\n","          \"response\" : generated_text,\n","          \"answer\": answers[i],\n","          \"logprobs\": logprobs_list\n","      })\n","    # reinsert the doc after\n","    insert_chunks_into_vector_db(vector_db, chunks)\n","\n","  df = pd.DataFrame(results).set_index(\"id\")\n","  return df"],"metadata":{"id":"Ws_hspX6SB03","executionInfo":{"status":"ok","timestamp":1764634288143,"user_tz":300,"elapsed":5,"user":{"displayName":"Laurens Ludovicus Michielsen","userId":"01001837259802933183"}}},"execution_count":27,"outputs":[]},{"cell_type":"code","source":["df = experiment_2(model, tokenizer, vs, DATA_DIR, 3)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"GYABpnMSZjaP","outputId":"7bac6267-a5fd-4bb9-c880-ca25887f1450"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["doc7\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc2\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc1\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc8\n","Question 1/5\n","Question 2/5\n","Question 3/5\n","Question 4/5\n","Question 5/5\n","doc5\n","Question 1/5\n","Question 2/5\n"]}]},{"cell_type":"code","source":["df.to_csv(\"/content/drive/MyDrive/held_out_rag_results.csv\")"],"metadata":{"id":"-Zh62qV5Zqu9"},"execution_count":null,"outputs":[]},{"cell_type":"markdown","source":["#TODO\n","#TODO\n","#TODO SAVE TO CSV IN DRIVE"],"metadata":{"id":"ofzI7OoirE58"}},{"cell_type":"markdown","source":["# Experiment 3: Wrong RAG\n","## Step 1: setup wrong RAG"],"metadata":{"id":"PQkTLPjnoY_K"}},{"cell_type":"code","source":["DERM_DIR = \"/content/dermatology/\""],"metadata":{"id":"VKVS6Y-GqUxf"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["zip_path = \"/content/drive/MyDrive/dermatology.zip\"        # path to your zip file\n","extract_path = DERM_DIR  # where to extract\n","\n","with zipfile.ZipFile(zip_path, 'r') as zip_ref:\n","    zip_ref.extractall(extract_path)"],"metadata":{"id":"W8p5jqKDp4-M"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["DERM_DIR = os.path.join(DERM_DIR, \"dermatology/dermatology\")\n","print(os.listdir(DERM_DIR))"],"metadata":{"id":"3DNmKBKMqdl9"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["PERSIST_DIR = \"./RAG_DERMATOLOGY\"\n","COLLECTION = \"hallucination_eval\"\n","CHUNK_SIZE = 500\n","CHUNK_OVERLAP = 20"],"metadata":{"id":"PbdTDxALqzyU"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["documents = []\n","for d in os.listdir(DERM_DIR):\n","    path = os.path.join(DERM_DIR, d)\n","    loader = PyPDFLoader(path)\n","    pages = loader.load()\n","\n","    # merge pages into one big Document\n","    full_text = \"\\n\".join([p.page_content for p in pages])\n","    documents.append(Document(page_content=full_text, metadata={\"source\": path}))\n","\n","print(len(documents), \"combined documents\")\n"],"metadata":{"id":"zB47JMSQrBty"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["splitter = RecursiveCharacterTextSplitter(\n","    chunk_size=CHUNK_SIZE,\n","    chunk_overlap=CHUNK_OVERLAP,\n","    add_start_index=True,\n",")\n","chunks = splitter.split_documents(documents)\n","print(f\"Created {len(chunks)} chunks\")"],"metadata":{"id":"917BwBOTrPnl"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["vs_derm = Chroma.from_documents(\n","    documents=chunks,\n","    embedding=emb,\n","    persist_directory=PERSIST_DIR,\n","    collection_name=COLLECTION,\n","    collection_metadata={\"hnsw:space\": \"cosine\"}\n",")\n","vs_derm.persist()\n","print(\"Persisted at:\", os.path.abspath(PERSIST_DIR))\n","print(\"Vector count:\", vs_derm._collection.count())"],"metadata":{"id":"pUjjVyuKrQv5"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["df = experiment_1(model, tokenizer, vs_derm, DATA_DIR, 3)"],"metadata":{"id":"YMcUHGQyrZ8T"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["df.to_csv(\"/content/drive/MyDrive/derm.csv\")"],"metadata":{"id":"xPR272VQZzzo"},"execution_count":null,"outputs":[]}]}